<SEC-DOCUMENT>0001628280-19-014001.txt : 20191112
<SEC-HEADER>0001628280-19-014001.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112171309
ACCESSION NUMBER:		0001628280-19-014001
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		191210757

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exdx-20190930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2019 Workiva--><!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074,d:2565452a47ef4d43a9ad4561bcf5edd8--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:exdx="http://www.exagen.com/20190930" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzMtMS0xLTEtMTAzODc_6c71be27-2680-4eb5-8a0a-c175a9ee488c">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzQtMS0xLTEtMTA0MDM_bba7ce84-9a5c-4074-a7a2-3110169862a7">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzUtMS0xLTEtMTA0MDU_01c9fe00-d15f-437f-b71c-b3bd1f5b7197">2019</ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzYtMS0xLTEtMTA0MDc_85206b4e-e8eb-41e9-a62a-db846ae997a3">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzctMS0xLTEtMTA0MDk_770a3f70-a30e-4a23-8428-811181de1fbc">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjEwMDA_c43a2b30-47ae-46c0-8186-19be08bba125">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzU_c6825e11-0fc3-4e9f-9041-6ef37ef4651d">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODA_bc7e3512-1d71-474f-a1f3-d50463190609">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i92647d4518404696ab919e985542dc23_D20190101-20190930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NDg_b98a8d34-8542-45c3-b460-7428b1e5f9cc">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="exdx-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i698b14fde74d48c986bc7722d2a47d8e_I20191108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9e798451cd564d85a050ce8581db466a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1618f264237473e8438081b30871740_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d776fef836147e8aa9fca48608805fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29630b56e3742939a0bdba1189a6cbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a482197c34d44c3ae90623f48d4b912_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5aac5ad5ae438abb53532ed876958a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c8f49f4ea54bc58629c4cf906e85ac_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i594311f90cd64628a3d0aa29e07f0898_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a1c50a126f4905ba75a973e1a3e682_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e681c5c446e4f03a7abffd537dd5352_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3229df7dacf74fca997f4b0f45d5bb9b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia414d6d243b647818871ad407f657257_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ae889f40dd442a96d1fcd4f3335f02_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822fcb2995c1470cb62140417fcb6f90_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iececa9bd8c374f448e2c8c12d96a1d37_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e5197af80646e69a15779b9738a368_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21b9dac09b37446fb247a953a02f8cfd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a5c654aa4fe4cd2af17f3785df2fe7b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f4bdb7e8bdd41f98f110e1f34540e3e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c321aea67a4b76bb1d06797b32516f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355fab1a4851405d964d3ce01c25e0cb_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40961c268efa4e669f1ab85e0e151e85_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e60ced97b104c0abfde5ea44bf688d1_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4c6d0140a2430f9e5cc852e998ada7_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice03cdba22334e48a533d94a025d010e_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf8495c14984c22b8ce5f6c41ee86e8_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad03575f3844523a836225bd6a1ff75_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f39641f06e425987e31b75e8435957_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd86c6fc3a247958775687c6c9081f7_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15803c46e4214e129bb899b341202df8_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce8694d9ba647108d4ea5ab8b905c1b_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337919a6832e4104bc0864899a13424e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f88d3ad0c564ab193266b222933588d_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a450e5a552453fa6bac61e4872ceba_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee63a714e044b14bee48842ecfb743b_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae2f6600a9cd41b7908364073cd2f4b1_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd81548cfe74374b9b0ab13f94caa0a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d80c008209c426a814d7dd70f19e32f_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30025f8cbc5f45baa8876d50bde62fe7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-23</xbrli:startDate><xbrli:endDate>2019-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdf719c7a7e4723b6692faeb9eec292_I20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-23</xbrli:startDate><xbrli:endDate>2019-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfb3b43b3d643db9c0aa9a4cf494dc2_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0a93f41a20455ebdd1ecf05f3d71f1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f42ba8fdddf43508fe432039d3bea83_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5a1b65ea2e4772af6730adb19a219b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c397043b0a4757a1ab205b9203c35c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bf1ae302d841fc97de1f33e7991b73_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84325f36965b4db489f07aff6f65377b_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48533d3983e8456cbeabafad30dbeb68_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9910315e8ba4f9ebdbc616cfe66741f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d86bef637f5439da150d6607648998b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2569645c6b438594320c445bd2f7df_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b6a2a4f7464d0c962375e478a9a57f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4b9180e4b54309b12c8bde22fbd406_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf3daa4d6ce48df96adce7481138367_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife08467e105c4ca290a3a0fa3636d3ea_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412a4bc0981e429bb2c3c5e64c8588b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe4f91b3fec4fef9d89209d8df0145a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb9a3f35ed44889b3becb647aad758d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc18586b25674689a55653cbc6ba01fd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a849e120d8a4d0e8a2192315f7f1d31_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab7fdcf6ea44e4196147db770e82818_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfbb7c25a64494dbfebb530261307a8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ead417360294b46b273d3316cc3ac11_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2db87ab7524a10b5714856382436dc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e71d7bdf8b4e58ab63f9e4492e3a24_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7491bc1715c402c87c11f837d462f25_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d50576626ca4bb09058ce09556f99f6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7d07ac43134c56bd65c32a20842780_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3c7dcf56ca41a4b105284483e7e373_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117917342465407baf079c005b0dfcb3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0986e73045a14160ba73146b0023d069_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a60fb4a5d5d4f5289b1f4c0113fe3e8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d1f81cc6e84b5494d096638cfd9d83_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e975d35170436cab761c1a79d6a68f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d1b13bd06f4289b57c9968d5a5034f_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d710d634904421a501a1631a9070fa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e26ceee4414fc2ab3a53e749e41b4a_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ae2ebb8e184bd395a0b6b0997eb389_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc7396f4e6249ecafc16cddc8b813e2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cd8526aa4f4a2897a2f2d8cdd90fa4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9774db8f05cb4b99b9d4806cbefe7bbe_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0717d7c677d6448da99afc8400886103_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2036583b6802432094a2445756a97d97_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0d3ee1297444fc9aa08f456ef2c9c7_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50eedc9033db402abed9620d44e35700_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c30c3ce04a84e4d874b74595bca6d56_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c143e96ac9b4806bef7c462dd041d9e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199eae29222f49ccbbc2f5f8369952de_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77e882cd1974313a78b7279282ccfd2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717f3fbc203143a2b2caad2a58d2a79d_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c29ece949cf4a19a46b6de69ea06eb8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67896f9ab6ed4543aecbdd23e5c897fc_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3ed9cee3e94243840bca963f193791_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c087d67dc248d6a8b02fc4a43f742c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6060eadd8f24bc1be3eb453cc22ca19_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8542a7dabeb54160bf0ca8be742e9212_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i349270c037f94e44af2351837279531e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efe7f934c0047d1bd2ce2d9c861261e_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbce37a02d245539b9bcdbbdeea57b7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1132f9c16d4dc1af50508da38762d4_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260086f6c68e4de8b8f8f51fc380212a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec80ab26441a4e79a659a24f2e383d48_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621ecaf0fe824109be7c5edd830fcf40_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a81e346b614153977eb22e41d41635_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ef04b2fcfa49d582c1daa128336b09_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705ad45db6ea4e2195c730551dac08dc_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9c9599bc1a428cac54f6b6233b42a7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99b30654d864c038634ae1e2765c0e4_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40e030b64dea4330b9962390e9b32038_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167c8bf3e14242d4b6b0b5533837f6e1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1fa1729eb34b299178d8caf2161699_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i321e9cae976c4953b8b700e620bfb3ce_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69188b3f953943e8857feda39af6a513_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879c70b4b5494742ae2de43311dee3aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83471b6a9094305b6ad8430295ff5cc_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7547ba12aab74508ae6730cee6b11777_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f8b0aeca3d46d185477b020a4cad1f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c9982c73979435b8b18653fef66b69e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67a92bb4ee44f42b31178b35355abc0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ca50f81cf04570bc17e8f427844a2e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55d1a24be2548af9b0dd677741eb14f_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie724734be96b41eb9f3acb00203b7563_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784c198f85794d068e262abe227f7399_D20181207-20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-07</xbrli:startDate><xbrli:endDate>2018-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida1326b9e5734d61880de0e289e849bb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19b52fc68724d4c9866d0bbfa02eb24_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593387046d9c4d19baf524fd531f341c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84146f62f914258a7de7f505ec8dae3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f42b4e0da004e11a3d759fb51a524c2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57cc12cbbd74a1ca2bdcab1be975050_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id95d3234e4504a759f6d486b2d115f8d_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9edfc62e2b4d1bad85e451eacf5407_I20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iece3f21b80234006a7c103426a2665ce_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15176551c5942c6996c700737062eb7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">exdx:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d71efa9a85b42ea9b589b656b2491e8_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">exdx:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b232544b0e4c3982a50c01fa3beedd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia072d734c1074dffafc2727ff7d43637_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbbd59a27b684af7ad1433a642355d7b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49e177a5bc240e58f5c1feec55322b0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep82024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbe833388254c769b6515006ac2d21a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0b712c3e3658431f99e266dbcbea25a3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="leaseextention"><xbrli:measure>exdx:leaseExtention</xbrli:measure></xbrli:unit><xbrli:context id="i049fe228926f4c9398df1295ac08300c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88479b12a8647d596f63546f0bbdd6e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba0cb4c451d417dbe3f4f8dfab39b44_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec9d6e18a8246b99def6548100abbca_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97157708442344caa00fafca0fbb5704_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdbf37439b04f6980d34a5eb0f08877_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2cf5de0966423685b89de08ef5d10f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aeb522a5a804c1ab10f04b766c6d235_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cdfd7d55d447c6a6ba587c0fb72778_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8396f778183403a8b3d18137e1d7154_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b7d6be4807402181770f969bd3b3c8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc77115ea38400ebaa8de4fdf3c7cd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c4da20970f49bab695c3ca35f9f79a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202d9a2d99d343aeb330da6b95303d98_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578d8c5006254318b4ecbd98581f9308_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib206ca9a730640ff880db0ca2948c48f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48be9f8c11ab46a0a2b04915df9f4383_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife24fcb5063e4bf2a8ca790bfd29a229_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cb01ea319e4dcf9a9ae2d18095b29c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib871a4638845441c862fde06e4cc74f2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6de603a8d9482782ee114aee3bf819_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c74d0be6304b29b0107390ce9abeec_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51991cbb9983403c883bb01e0ecacfe4_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76ec7383c01495aa62e382bd4f709f7_I20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac11f467d4a414d8b4dc99e134c6b38_I20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3012c64b3841629d97963b5c65859a_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd111bb967164dd1b749064f44fe4ace_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6821094327564f7ba91627dc90eeb669_D20180131-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-31</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id07edc4e5b92475b8e47bad4f0b1c23f_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4fe828275f44fdbff0acdc8da1a56f_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ecfcc3c27f94cccbdb02d3266aed9c6_D20180101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34cec7509c0b444690051ce059a40fc2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a943c5b22a147a0a01ed7c2ddc3799b_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d7a070fb6e417cbecca982fcd80243_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1936657650f8443fb7d623789b65864b_I20190923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6966cf5374bc41b5875121d7c8d99c81_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:StockOptionPlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief83568c465c465ab430cf56fab8b518_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:StockOptionPlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie73e694807f84cd394cbd47d74001ce4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae39458ccf0d427992cbe4b9527b3bf2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebae713e20d543688dfbdbe7e08cf864_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5dcfbeb31e4eb58cbd0c160cec9a94_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c70eba81b941949fd1d670216abba6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ecd63e9c5f4460db504293975df2da0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda4e23b775541d98dd6601b0687861c_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8317e42cca1547e9993f03b3818b96f3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23dea42dd5f74d579f2d9bf2d1dd0899_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58c1033dd94444781da3f845ffefc22_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icefda7fbf4b24e1c95147ec5fc5fbd6a_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c606ae405a1436dae303d8eb1512adc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99104c1c22ba4f62b010859df135eb14_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b3ab090ddd4194a42e7530e862e17f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156a4580a77d4e07840641d780bf4cf0_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0fd8531c4e483bb241496bd66cde52_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98b0d24446a4951aa7a1010ab0bfe0a_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029c39ddb96e43e7add282e21e47eeb1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c8b9c0ae1445a795a53d86906d1dc1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5daf739bda4ce99c2faed14eefff7e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5649d541959437c953f9b7daa0a171d_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23243689232c443f8220af8eb34ad150_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61985dc8dff1424b8c09ade62daae302_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92647d4518404696ab919e985542dc23_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c33b5d4543e4472a07114c686f5e1ba_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36ac713957946c8b6ec9a842cee9f1b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcaca6cf8313483db51df9c1afdb0e41_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb1b252737849b5896adb5e69e39207_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050d48ebbcd24210b1475a4d33bb14c6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6525292a42e544c98b6b7fe58ef7a0b2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f237a8b0314f22ba9545b209899f19_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:16pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:16pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:16pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8xMzc0Mzg5NTM2MzU3Mw_a62eb45b-a768-45cb-808f-7969cadef007">10-Q</ix:nonNumeric></span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:115%;">(Mark One) </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:1pt;font-weight:400;line-height:115%;">&#65279;</span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:0.1%;"></td><td style="width:1.874814%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:94.125186%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#65279;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8xLTAtMS0xLTEwNDI4_bb7f4575-6214-424b-be6b-76fedfe28d92">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:115%;">For the quarterly period ended <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8yLTAtMS0xLTEyODA2L3RleHRyZWdpb246YmFkNTVmYjk2YjM3NDJmNDhkZTRmYzM2ZjgwZWVhMzlfNjA0NzMxMzk1MjgwMw_ca5f8fee-1a39-4b6d-929e-bf2ab84140f3">September&#160;30, 2019</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8zLTAtMS0xLTEyODE1_9c0a2a14-fcf2-4d45-ae2d-fc308bbba25a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:700;line-height:115%;">Commission File Number: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzM2_55ca7dbd-0042-4b09-be0e-4fd0eb700bfb">001-39049</ix:nonNumeric></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:22pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzI1_d915f38d-b123-4eb7-97ab-ecc87a8027da">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:87.719298%;"><tr><td style="width:0.1%;"></td><td style="width:1.966667%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.333333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.333333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.166667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.166667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.833333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.166667%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.833333%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8wLTAtMS0xLTEyOTEz_64febce5-29be-413d-8aa0-81156c67853a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8wLTYtMS0xLTEyOTE1_58ebcf91-110c-40ba-9b5c-2f5b1cdac513">20-0434866</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8zLTEtMS0xLTEyOTE5_23862ce3-e889-4c21-912f-cdc267de4a76">1261 Liberty Way,</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8zLTItMS0xLTEyOTIx_4c9b52b8-974c-44c4-8ba9-bad22e727a3b">Suite C</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTEtMS0xLTEyOTIz_d7fe719b-db04-418b-91db-77a3333557cf">Vista</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTItMS0xLTEyOTI1_5c7d9cd7-c36f-4ca6-9f5b-30a1dd2d7605">California</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTYtMS0xLTEyOTE3_d818aa6a-7b47-48c5-98f8-082620d004f1">92081</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.766082%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6YzUyMDUxMWRjZTJlNDVlYjgyMTgxZjNkYzUyNDE5NWIvdGFibGVyYW5nZTpjNTIwNTExZGNlMmU0NWViODIxODFmM2RjNTI0MTk1Yl8wLTAtMS0xLTEyODk2_5d121edd-c9a7-4c28-8258-41c1bcd0c0c2">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6YzUyMDUxMWRjZTJlNDVlYjgyMTgxZjNkYzUyNDE5NWIvdGFibGVyYW5nZTpjNTIwNTExZGNlMmU0NWViODIxODFmM2RjNTI0MTk1Yl8wLTEtMS0xLTEyODk4_9675ac26-2219-4d6d-a8ce-6aa6dcfe495f">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Registrant's Telephone Number, Including Area Code)</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.520468%;"><tr><td style="width:1.0%;"></td><td style="width:35.060703%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.918211%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.642173%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.918211%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:35.060703%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTAtMS0xLTExMjM5_608ad7a5-6913-4335-8cdf-054f4837e12c">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTItMS0xLTExMjQy_22438200-b287-41eb-9f15-78e5843bf9e8">XGN</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTQtMS0xLTExMjQ0_0e265523-cb3e-417d-bc9d-e82bc6c55825">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODgy_271fdced-9585-44c3-9d37-932628115452">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODg3_6f788aee-053b-4799-bdb1-99fdcfd43cce">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:115%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934. </span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.959064%;"><tr><td style="width:1.0%;"></td><td style="width:19.621622%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.621622%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.062003%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.073132%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.621622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Large accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF8yLTAtMS0xLTExMjQ2_ff25061b-d9ee-42e1-806e-06ae402479c4">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller reporting company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF8yLTQtMS0xLTExMjQ5_00bbb45d-5c68-4efc-922c-45e36f9dd6f7">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF80LTQtMS0xLTExMjUx_d074640a-508e-46aa-90e9-ad63399a9034">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzYx_4bc867c1-4b96-4a5e-9ab0-c5140a432cfd">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODc5_9301bfcb-2bf1-4fb7-9cbf-6b1d93320443">&#9744;</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:400;line-height:120%;"> &#9746;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">Total shares of common stock outstanding as of the close of business on November&#160;8, 2019 was <ix:nonFraction unitRef="shares" contextRef="i698b14fde74d48c986bc7722d2a47d8e_I20191108" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5Nzgz_0d85ba27-4895-4ac5-b502-4640cda3c9db">12,560,990</ix:nonFraction>.</span></div><div id="i_0_4"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:9.403509%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:75.192982%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.403509%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Part I.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Information</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Balance Sheets as of September 30, 2019 and December 31, 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Condensed Statements of Operations for the Three and Nine Months ended September 30, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_34">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Nine Months ended September 30, 2019 and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_34">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Statements of Cash Flows for the Nine Months ended September 30, 2019</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31"> and 2018</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_701">Notes to Unaudited Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_701">Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_701">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_7">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_7">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_740">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_740">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_749">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_749">33</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Part II.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other Information</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_762">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_762">34</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_771">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_771">34</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_777">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_777">69</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_783">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_783">70</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_789">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_789">70</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_795">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_795">70</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_801">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_801">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_807">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_807">73</a></span></div></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div id="i_0_668"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_22"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Part I. Financial Information</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 1. Condensed Financial Statements</span></div><div id="i_0_25"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Condensed Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:74.169591%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964912%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNS00LTEtMS0w_59fd1148-cd35-407c-a76f-fcc72eb91147">77,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNS02LTEtMS0w_73ab613d-1a06-4723-afe4-fd7debb1fd64">13,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNi00LTEtMS0w_0639af98-dc0e-48b1-b784-21e63e61d178">6,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNi02LTEtMS0w_0645d0f3-d82e-4af2-8ab6-28e7bd41be04">5,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNy00LTEtMS0w_cccb441d-e6d8-470a-923d-2c60a665c0ff">1,686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNy02LTEtMS0w_ac302b74-5c18-4321-9ad2-939e165b0e27">2,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOC00LTEtMS0w_5b03f385-e290-4937-b6a9-1101b0947539">85,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOC02LTEtMS0w_f21d50ba-9cde-4da6-969e-abd0f97d1799">21,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOS00LTEtMS0w_e74bcdca-124e-402d-9e0c-653a892da247">1,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOS02LTEtMS0w_bf9eeaf1-5a82-4aed-972a-475e6a6f289e">1,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTEtNC0xLTEtMA_8f115615-7552-4eaf-903f-7d1dc41abb8a">5,506</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTEtNi0xLTEtMA_af452212-f1fc-4460-9b9e-acdac7e20e90">5,506</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTItNC0xLTEtMA_6a648440-14fd-44f0-8a75-6eccadcbbe2e">172</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTItNi0xLTEtMA_3454effe-7f86-4378-979f-acb2f50b7ab1">503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTMtNC0xLTEtMA_565b14bf-50c5-42a7-886c-a4fa236e54ec">92,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTMtNi0xLTEtMA_917b66fe-35d2-4c2e-ac07-c9e835b50f92">28,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTYtNC0xLTEtMA_81f519ab-8c81-4ea0-b01a-5d9fd4d06ba9">1,213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTYtNi0xLTEtMA_4a4bc050-0169-47e8-b2f0-5ca0707b1b01">1,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTctNC0xLTEtMA_4895def9-945e-412e-97e7-c54caab42039">6,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTctNi0xLTEtMA_60815fec-41f0-4b2f-833b-0f94871a590a">3,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds received prior to issuance of Series&#160;G redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:zerodash" name="exdx:TemporaryEquityProceedsReceivedPriorToIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTgtNC0xLTEtMA_997c99e3-8c0e-4122-aa7d-e24895d65aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityProceedsReceivedPriorToIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTgtNi0xLTEtMA_20fde7d5-79ba-49b4-9fcd-881fd65e049e">3,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTktNC0xLTEtMA_875f2ea1-eddc-4634-a144-9570fcf266fe">7,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTktNi0xLTEtMA_be2ce0ff-6379-447f-9415-f2abdad4c432">8,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjAtNC0xLTEtMA_56c0c002-d9e7-40da-8159-e97c45de03e9">25,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjAtNi0xLTEtMA_1065f92c-de9a-4103-851e-a68b9785755d">24,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:zerodash" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjEtNC0xLTEtMA_8d19661d-c58d-45c9-a9c0-9b8d03bc5f5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjEtNi0xLTEtMA_4028dbe6-ee8d-4567-9be6-ebd3047ecfff">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjItNC0xLTEtMA_63eccde2-fda2-4be9-8d29-90d9e533470d">245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjItNi0xLTEtMA_123732da-7756-462a-a82a-7da8102ddea0">245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNC0xLTEtMA_aab6eea5-b571-45d1-bf20-d42ca896652d">510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNi0xLTEtMA_360ad91e-506a-41f5-adfb-42cf80387312">304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtNC0xLTEtMA_9a81ef19-7428-4759-908d-2d9b6ecbdb25">34,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtNi0xLTEtMA_0952e222-0973-4184-a791-950a3025b98f">35,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNC0xLTEtMTEzMDQ_e9d9644b-e274-4eb4-88d7-76b87b59f0a9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNi0xLTEtMTEzMDU_177c1d25-e6b4-447d-9ec9-88c056b3bb08"></ix:nonFraction></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Redeemable convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg2Mw_b186f830-ba20-4179-84cf-a409963b7efb"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg2Mw_d099f148-dac4-4529-a534-7e43ee59a55f">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc1MA_435243fb-83fc-4c01-8b40-125e5ba41ef9"><ix:nonFraction unitRef="shares" contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc1MA_8698a61f-5096-44ca-ba21-9407addea36f">750,300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg1Mw_45143215-4def-479d-a573-d5c89d92e86b">none</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc3NQ_3336f3b8-c4c2-4740-a427-c5ba4c26b03f">532,606,084</ix:nonFraction> shares issued and outstanding at September 30, 2019 (unaudited) and December 31, 2018, respectively; liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc5MQ_a533e801-b631-4a9e-a1ab-b7ad0a9229bb">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTgwNA_f842bea5-a276-46a1-8404-822876a5ecdf">163,316</ix:nonFraction> at September 31, 2019 (unaudited) and December 31, 2018, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNC0xLTEtMA_d76cabf8-6006-41fb-971b-9b36493c0b12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNi0xLTEtMA_689c2bf6-ee36-4425-a301-98bceca84859">105,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI4Mg_07d8efb4-d2b8-400e-a541-82c533697fbb"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI4Mg_a1e6580d-fe7e-46a1-bed2-68e0368b3c45">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI5NA_7d746f79-da97-40c6-ae12-90ef2d1944fc">10,000,000</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4Mg_2a0eb5cc-2662-42e5-a650-7c3568edca9e"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4Mg_990a6f3c-3388-4102-baf6-ebd0c0896061">no</ix:nonFraction></ix:nonFraction> shares issued or outstanding at September 30, 2019; <ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_17e08aa1-01ef-410a-8128-1e679834b892"><ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_7711eac3-3786-4118-b378-8d303fa945fe"><ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_cc9ac07d-9bba-490a-ae94-9a464ae65b15">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued or outstanding at December 31, 2018</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNC0xLTEtMTEzMTQ_a8c5ffa1-b444-456d-86b9-68157eb83030">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNi0xLTEtMTEzMTY_d4cb6bd2-4b8b-426d-85d6-20b2bac337a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzcw_6faec5c5-28f2-4150-a071-a36ca7ec1bbd"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzcw_fc964da7-d1c7-4657-bfd7-5e56b6c3e6ca">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzgz_b8435cd8-3603-459d-971a-62c49b46cc72">200,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzk4_504c8c78-fc46-4197-a098-acebb64e80d7">1,470,000,000</ix:nonFraction> shares authorized at September 30, 2019 (unaudited) and December 31, 2018, respectively; <ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDEw_2362ef11-c285-45f7-9ca2-5eb9a377a29b"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDEw_46241b5e-15b0-4cad-803f-8f8f7035ec9e">12,559,492</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDE4_1296ac2a-25b3-4ef8-8e43-264d5d5412e6"><ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDE4_c0c3c104-f742-42d1-8917-b5ab710ba78e">63,005</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2019 (unaudited) and December 31, 2018, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjgtNC0xLTEtMA_6dfc4131-3a69-4895-9912-982533109201">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjgtNi0xLTEtMA_0932ef0d-b71f-4c40-a1eb-39af62abd954">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjktNC0xLTEtMA_487852d1-3afe-4f45-a017-5f16e3bdad46">219,831</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjktNi0xLTEtMA_ba8ed7de-af8e-4ee3-8a75-0e3e2e605f82">40,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzAtNC0xLTEtMA_ff3575f1-06ef-4da8-afa6-7f03aeb97c5c">161,194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzAtNi0xLTEtMA_3f4b2fb8-a508-4ce2-9192-442f013b1bfa">152,564</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzEtNC0xLTEtMA_5891ef5f-6407-4e4b-b4d7-b5f0d4881124">58,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzEtNi0xLTEtMA_417208a8-b207-459a-b18b-1ed60d243a15">111,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzItNC0xLTEtMA_dde0924c-61e1-4233-a5d5-3b5829fa9a3c">92,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzItNi0xLTEtMA_34aabcc0-8e95-443e-a7da-89a849d45c2a">28,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_28"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Unaudited Condensed Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.953216%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy0yLTEtMS0w_a8a2284f-6350-4c5a-8440-f3595b9a6e0e">10,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy00LTEtMS0w_8872cb29-5274-40da-9a77-c1d82d379183">8,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy02LTEtMS0w_d0df24b3-f5d9-4840-974d-b0c9cabdbb12">30,173</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy04LTEtMS0w_03602f4e-6c7d-4e95-ab3b-d9e93d9132b4">22,799</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs of revenue (excluding amortization of purchased technology)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS0yLTEtMS0w_463104be-bfcc-4f81-9689-570200faf362">4,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS00LTEtMS0w_22ea699d-5a99-49a2-8d73-cc2be9125b88">3,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS02LTEtMS0w_30b1f38e-585c-443c-b17b-12e068fdca90">14,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS04LTEtMS0w_91ab12fe-9ea0-4241-a3aa-f6ff9c324c89">11,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi0yLTEtMS0w_0ac21535-f4fd-4bfc-82d5-932bf065ae64">7,306</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi00LTEtMS0w_004741e8-7191-4186-9ba7-9dbcbc977dda">4,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi02LTEtMS0w_4093c0f9-446c-467b-a137-07c713e13d12">20,787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi04LTEtMS0w_209a613f-28af-4bf8-a27e-289ef5103967">14,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy0yLTEtMS0w_a8fc2934-5fb3-45c4-b773-9b6cc26bd23b">507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy00LTEtMS0w_e4454e44-fcf5-4086-a83a-c9ef80b681d3">525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy02LTEtMS0w_f2c67ecd-4a01-424c-bcf1-7840e2592cd5">1,610</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy04LTEtMS0w_c753d07c-6907-4a8f-abfa-3e14f4cf940c">1,592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC0yLTEtMS0w_be54e756-a8bf-4030-87c4-1335c758cfbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC00LTEtMS0w_2328de9a-1b77-49fa-80b2-95fcda623fdc">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC02LTEtMS0w_7e80b49b-8e66-4dda-bd97-f94dba5c7778">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC04LTEtMS0w_0ebf8802-adb1-473a-a237-c4f0efae63b6">141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtMi0xLTEtMA_ea1c552f-78ca-4a1d-bbb8-929f9da449e9">12,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtNC0xLTEtMA_65b52c6a-11e7-4fa6-9729-586556cd540c">9,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtNi0xLTEtMA_460f5834-a7df-4a48-bae8-52e2c77a7872">36,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtOC0xLTEtMA_82a66b48-fd03-4a5e-b6ee-4f5e522c04dc">27,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtMi0xLTEtMA_6ea9c481-ba36-4cb5-82e5-fe2729c972c1">2,157</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtNC0xLTEtMA_d24650e9-fff3-4704-b079-68d39e2825c8">1,133</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtNi0xLTEtMA_9b884f58-8d7f-43c4-83af-6d8b1644e172">6,441</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtOC0xLTEtMA_68c84378-5363-4310-88c3-25ac4dcf1e7d">4,729</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItMi0xLTEtMA_1ddb19ac-c494-4022-a8f5-006714f9e69c">909</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItNC0xLTEtMA_2a46c5cf-9321-4c57-aeee-2dbf535a7417">704</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItNi0xLTEtMA_d8d9adda-8329-408d-9196-eecc2fc3a105">2,720</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItOC0xLTEtMA_d4744acd-3ead-4954-abd5-b19da3352c6d">2,098</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtMi0xLTEtMA_e8d48045-0cca-49a1-9021-0cce663521be">200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtNC0xLTEtMA_73b98443-9074-4045-9491-6996d1384dda">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtNi0xLTEtMA_8cc36ea5-dbd1-434f-8599-3f497fb5cc43">267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtOC0xLTEtMA_e1412c4a-f4e4-4f72-8827-1fdb50618cff">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtMi0xLTEtMA_acd2c5d3-92b9-4d90-aa0f-7aee91e64f3c">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtNC0xLTEtMA_5d7b4720-8628-4eb0-bfe4-9295f8d324a4">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtNi0xLTEtMA_c10a2d6c-dbca-4f6f-8742-80d36fe6d1e1">264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtOC0xLTEtMA_210f907e-cd9b-4271-ae8e-d9772ebe2107">77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtMi0xLTEtMA_64d4d0ac-faa4-4cbe-bd50-17f49d24bd30">3,141</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtNC0xLTEtMA_21676f79-e4c8-4110-8b30-9923ee49d568">1,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtNi0xLTEtMA_b67f621a-f2c3-4dc2-8254-b6ddc26789dd">8,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtOC0xLTEtMA_d9203870-9135-4339-a733-c2bd53754772">6,695</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctMi0xLTEtNzcyNA_b810634e-e566-4852-abf6-27c69f950ec9">338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctNC0xLTEtNzczMw_444283a8-c2ab-4876-834a-21db13ca2e5f">2,768</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctNi0xLTEtNzc0Mg_3a80ab05-d278-4db6-868f-2594a8fd2163">4,640</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctOC0xLTEtNzc1Mg_34784d88-cc3d-4c59-8b99-e44ce70d70c6">6,462</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend recorded in connection with financing transactions</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtMi0xLTEtNzcyNA_9fd9f5fd-e1be-41a7-93c1-f52e7b435c9c">13,601</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtNC0xLTEtNzczMw_c29a6b83-22d1-406d-9e8a-489d698b6e6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtNi0xLTEtNzc0Mg_cb7d9d61-8eed-49d6-9601-d8aaf55589cb">13,601</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPreferredStockDividendsAndAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtOC0xLTEtNzc1Mg_b508a1d2-a891-49d3-bfd4-a55acee0d887">1,152</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktMi0xLTEtNzcyNA_181dc7c5-edaa-4eae-8981-935f8fefa6da"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktMi0xLTEtNzcyNA_cbd7e9b5-0135-4b64-b979-8cc1747302ff">17,080</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNC0xLTEtNzczMw_4b1e9849-4ee5-4dcf-83df-6094a1b0a5c4"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNC0xLTEtNzczMw_5f849cd8-84a9-488e-a974-16ae0c5e4527">4,524</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNi0xLTEtNzc0Mg_82f8f703-a13d-484f-8d8e-3c2dbd3e1b4e"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNi0xLTEtNzc0Mg_e2002487-8a70-4cb7-9319-28364ef321a9">26,871</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktOC0xLTEtNzc1Mg_3e80886f-c16a-4365-8328-732d6b8789db"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktOC0xLTEtNzc1Mg_90654e60-da46-4300-9c0e-145112c66735">14,309</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItMi0xLTEtMA_4953527d-740c-480c-9c7e-5757ac56502d">11.29</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItNC0xLTEtMA_94d1339a-a346-4728-9110-6ecd00d5e4b2">71.80</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItNi0xLTEtMA_8e13b226-631b-4a3a-9678-efe93344a1aa">48.70</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItOC0xLTEtMA_fea77e01-5f91-45aa-a78f-5ce6239cf9e4">227.11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtMi0xLTEtMA_872b2a12-90e3-4d6e-813a-8217656a8b2f">1,513,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtNC0xLTEtMA_c76f355f-bc6f-430f-b4cf-86102a83d0ec">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtNi0xLTEtMA_6c12c11e-612e-4e10-b6e2-35f572b974cb">551,730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtOC0xLTEtMA_58e8e734-ea22-4df1-86af-9e27effe8570">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div id="i_0_34"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"> Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share amounts)</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:30.547865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.518409%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.805596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.603829%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.743741%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.805596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.836524%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.983800%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable<br/>Convertible<br/>Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:6pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2018 (as revised)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMi0xLTEtMA_e5b579bb-56aa-4a3a-a55b-133d234fcc58">532,606,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctNC0xLTEtMA_72a36863-588a-44f5-90da-25d7f8d9adcd">105,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia29630b56e3742939a0bdba1189a6cbc_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctNi0xLTEtMA_2a84dea4-857b-4d30-9394-95117527450d">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia29630b56e3742939a0bdba1189a6cbc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctOC0xLTEtMA_ef7eeccb-fcc9-45bc-8ef0-15b042f89199">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a482197c34d44c3ae90623f48d4b912_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTAtMS0xLTA_bbff4071-2ac2-4fa0-8099-68c403002053">40,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9b5aac5ad5ae438abb53532ed876958a_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTItMS0xLTA_c6d52c80-1590-45a2-a134-4679fcb6fcfc">152,564</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTQtMS0xLTA_50894b7e-b5cd-452f-9070-30c7302e67e3">111,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Accretion of redeemable convertible preferred stock</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMA_45ab147b-3216-42f0-91b5-2d4dbc3c93aa">2,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTA_f6152f23-ea18-418c-8e80-731df06f5da0">2,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTA_ba2f39eb-c4fc-402f-8f2c-e55884b0eb0c">2,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktNi0xLTEtMA_85d77469-29ad-4e11-9e5f-9ef6b61eafdf">24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktOC0xLTEtMA_28ff4586-3237-4eac-a7ac-79aeb38b25f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktMTQtMS0xLTA_20971da1-d829-426f-8127-3db55f909236">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjAtMTAtMS0xLTA_47240be0-1395-4f79-8168-b037cc9bbbfd">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjAtMTQtMS0xLTA_10242731-7460-46f0-b29f-3e03f897bafd">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfNi0wLTEtMS0xMjA5My90ZXh0cmVnaW9uOmQxMzllMTA0NGNiNzQyMmVhMGY2MTA5ZWI3MjViYjBkXzE5MjQxNDUzNDg3MDY3_bc99a97e-0822-4a67-a338-3ec1c4aa9f25">0.078</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfNi0wLTEtMS0xMjA5My90ZXh0cmVnaW9uOmQxMzllMTA0NGNiNzQyMmVhMGY2MTA5ZWI3MjViYjBkXzE5MjQxNDUzNDg3MDcy_b4f79016-0f38-48de-a2a4-16fb894c5680">96</ix:nonFraction> (Note 8)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjEtMi0xLTEtMA_68ab703a-b086-402d-a6cf-c45c43373da4">97,646,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjEtNC0xLTEtMA_808a63d0-937b-49ff-b5b6-21e858a97cf5">7,520</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i64c8f49f4ea54bc58629c4cf906e85ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjItMTItMS0xLTA_e185cbd6-1a63-4e41-af6e-749da6cc4064">2,704</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjItMTQtMS0xLTA_64691d8e-886c-4a2b-aaae-045cce868796">2,704</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at March&#160;31, 2019 (as revised)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMi0xLTEtMA_e61b02de-076a-4be1-98c1-664a3a3f2eac">630,252,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtNC0xLTEtMA_c5f68f04-24eb-47f7-b919-b16e913dc822">114,866</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i594311f90cd64628a3d0aa29e07f0898_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtNi0xLTEtMA_4f167beb-576c-44c6-abfe-a92d9861d4c8">63,029</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i594311f90cd64628a3d0aa29e07f0898_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtOC0xLTEtMA_ca15f2b5-7d5a-4af4-9711-0db9136d92e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20a1c50a126f4905ba75a973e1a3e682_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTAtMS0xLTA_0af00cd4-f20f-49f3-8826-6b6e82432d10">38,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8e681c5c446e4f03a7abffd537dd5352_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTItMS0xLTA_27cbd050-3feb-4863-851f-090bfc866aa5">155,268</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTQtMS0xLTA_07b87e35-243e-4d86-8f65-0b98d0b77db5">116,772</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Accretion of redeemable convertible preferred stock</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtNC0xLTEtMA_320c5665-e3c9-493f-b413-740bf834839e">2,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtMTAtMS0xLTA_7f2f31d5-b5d8-477b-9253-ce1c166e5432">2,188</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtMTQtMS0xLTA_8bb33174-fc26-4fdf-9d4a-e17feaa4d795">2,188</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtNi0xLTEtMTAyMjM_ce862728-aeee-4480-80a1-fb693e095d26">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtOC0xLTEtMTAyMjM_eced59e2-465c-4ae2-aab4-93daf943f087">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTQtMS0xLTEwMjIz_bc68caab-1cf3-4fc5-bc73-8c18b423300a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTAtMS0xLTA_7a44620b-210d-4dd1-aeb0-ad837994c258">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTQtMS0xLTA_b046af1d-2124-4059-a58b-81cdd9595f07">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTItMC0xLTEtMTIxMDYvdGV4dHJlZ2lvbjozMzMxOTg0Mjk2OTA0M2IyYWVlYmJhN2JiMWRiMWMzNl8xOTI0MTQ1MzQ4NzA1MQ_f9192df9-f12b-47e1-8ea0-83a19ca8d9fd">0.078</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTItMC0xLTEtMTIxMDYvdGV4dHJlZ2lvbjozMzMxOTg0Mjk2OTA0M2IyYWVlYmJhN2JiMWRiMWMzNl8xOTI0MTQ1MzQ4NzA1Ng_e2b11e3a-9bc9-4de2-9899-fc86cd29dae0">28</ix:nonFraction> (Note 8)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjctMi0xLTEtMA_877a2590-7272-4582-bc5b-8dc3417e9fc6">51,282,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjctNC0xLTEtMA_9928c8a9-c695-4e76-9b87-5758f7f0aa46">3,972</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3229df7dacf74fca997f4b0f45d5bb9b_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjgtMTItMS0xLTA_b0fb038d-6866-41b3-92a1-d0217063d705">2,785</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjgtMTQtMS0xLTA_bad3457a-38cc-4835-a1e8-a94fa2a3f6ba">2,785</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia414d6d243b647818871ad407f657257_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMi0xLTEtMA_fffdd48f-1867-4e73-8d2d-ee7cc172ed54">681,534,421</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia414d6d243b647818871ad407f657257_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktNC0xLTEtMA_f08a72d2-5c0f-4b5f-ac4b-86a61172fa98">121,026</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i23ae889f40dd442a96d1fcd4f3335f02_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktNi0xLTEtMA_a47ee016-2b80-4507-b33d-ce25657d42f2">63,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23ae889f40dd442a96d1fcd4f3335f02_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktOC0xLTEtMA_5e25db9b-fcd7-4944-a155-03d9351645c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i822fcb2995c1470cb62140417fcb6f90_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTAtMS0xLTA_c6545230-e270-40ce-9c59-0865237a99a9">36,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iececa9bd8c374f448e2c8c12d96a1d37_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTItMS0xLTA_d6a3de22-8446-4caf-8e29-1fa200521501">158,053</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia414d6d243b647818871ad407f657257_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTQtMS0xLTA_e6a91d69-b762-4f2f-8ace-2c538aaa0ef2">121,734</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtNC0xLTEtMTAyNzI_ff9ea939-4876-4f20-b54c-b2aa4828c4df">338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtMTAtMS0xLTEwMjc0_4c7324b4-469e-42bc-9084-ee00048bb91e">338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtMTQtMS0xLTEwMjc0_09e622c7-403c-4d8b-961f-eb93dbef7161">338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzItMTAtMS0xLTgxNw_288a4146-194f-488c-a0ad-582b4d28ece5">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzItMTQtMS0xLTgyMw_d0ac2d39-5057-47a9-81d6-68ae0d4142d5">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMC0xLTEtMTIwOTAvdGV4dHJlZ2lvbjo4YmExYTY2YjhmMjM0Y2I0ODhjODE3NTA3ZjMzNDM1Zl8xOTI0MTQ1MzQ4NjIzMg_5b7c59c2-5f25-4f16-8dbf-bd3f13b3ec34">0.047</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMC0xLTEtMTIwOTAvdGV4dHJlZ2lvbjo4YmExYTY2YjhmMjM0Y2I0ODhjODE3NTA3ZjMzNDM1Zl8xOTI0MTQ1MzQ4NjIzOA_71733499-97d7-408a-b5dd-a377889d4316">318</ix:nonFraction> (Note 8)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMi0xLTEtODQx_c1ffec1b-b53b-483d-8237-9443e22e9215">233,446,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNC0xLTEtODQ4_5ebb3e49-70c0-4a80-ab07-cdebe7f1f551">3,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTAtMS0xLTg1Nw_91f32a09-4125-4ce8-ab19-cc182dbeb88f">6,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTQtMS0xLTg2Mw_2228671d-c0f8-4c07-96b8-a1cce94a7151">6,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMTIwNTU_b94751f8-691f-4889-834f-2f86657fccd0">6,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTEyMDY0_ead279b3-1992-4204-873c-84f0943dd803">6,741</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTEyMDcw_2635f8d4-a75e-44ae-82b1-7ef3a6f8225d">6,741</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMi0xLTEtMTAzMTg_1d90bd93-a052-4f81-bf54-60299bf387b6">97,592,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMTAzMTg_6888fd43-29fa-4501-9384-276c67feb5d5">6,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTEwMzI2_5e8d3c7e-41ef-41e4-8473-c801bb4fd110">6,860</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTEwMzI2_42502f57-3fa2-46ce-bf35-5c410a2d6961">6,860</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of preferred stock to common stock in connection with initial public offering (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesRedeemedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMi0xLTEtODA2_2b7c3eb8-c80d-43ab-9c97-53b10f122575">1,012,573,679</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesRedeemedUponConversionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNC0xLTEtODA4_c6a28de7-a6ed-40cb-aa71-6860cf008d0a">138,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNi0xLTEtODEx_277e8f64-6240-4c9e-89ca-43d8763b20d4">7,816,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtOC0xLTEtODE0_c12aa759-293a-4cef-8f33-35511fe088a0">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTAtMS0xLTgxNw_ff218580-5672-488a-87b2-4624c57726f7">138,898</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTQtMS0xLTgyMw_21c42f2c-de06-476c-8ac8-8b3ca8856c7f">138,906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtNi0xLTEtODEx_27543035-9719-4ace-be40-947aacb3be71">4,140,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtOC0xLTEtODE0_a44f5072-fee6-40ef-b040-9a39bde9a47c">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtMTAtMS0xLTgxNw_a0ca11a0-d4cb-4588-b8b3-93a4679fc597">50,514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtMTQtMS0xLTgyMw_b169358f-25a4-4b9c-93cb-b62c47dfe286">50,518</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of common and preferred stock warrants</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtNi0xLTEtODEx_f2adf6a1-4644-4c71-aee3-10dcaf0c5d14">539,794</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtOC0xLTEtODE0_8170e140-e652-4a4c-afd4-7a7cdfe7dbdd">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtMTAtMS0xLTgxNw_fe93595f-ae5e-4da2-be8b-4545e48a6175">510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtMTQtMS0xLTgyMw_51c004e6-63b7-46e3-b807-8abe8893b32b">511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzYtMTAtMS0xLTgxNw_dc8b6530-fec6-4193-a0cf-d3ecedb11f94">726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzYtMTQtMS0xLTgyMw_326e1f41-c3e7-45b4-b0f2-3af4d9d6082f">726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i25e5197af80646e69a15779b9738a368_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzctMTItMS0xLTgyMA_0ae360ce-5135-4b34-a572-871ee8470499">3,141</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzctMTQtMS0xLTgyMw_1769eb95-98db-4579-8b0d-49b6155b9f7a">3,141</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:zerodash" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMi0xLTEtODA2_5188fbdc-fb7d-4904-a0ba-c2ee1491c5c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtNC0xLTEtODA4_07f91d40-f4f4-4dce-83f0-fab60fb95cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i21b9dac09b37446fb247a953a02f8cfd_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtNi0xLTEtODEx_a15f7b03-3454-4c70-8702-eff24df3e960">12,559,492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21b9dac09b37446fb247a953a02f8cfd_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtOC0xLTEtODE0_04c2fc3c-618a-4966-9d53-7a013bde5b37">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a5c654aa4fe4cd2af17f3785df2fe7b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTAtMS0xLTgxNw_371a0507-f87f-4af0-b33c-1b753d945570">219,831</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4f4bdb7e8bdd41f98f110e1f34540e3e_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTItMS0xLTgyMA_a2ab7b04-df52-45fb-8aa0-6d33732cff39">161,194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTQtMS0xLTgyMw_323a8fa4-7457-4b8e-9010-db1d1bd932df">58,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share amounts)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:31.333333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.048458%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.607930%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.048458%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.957416%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.425844%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719530%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable<br/>Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Deficit</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0yLTEtMS0w_1cc042f1-18c1-47d5-85b2-d9d3eeac9fa6">497,691,757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi00LTEtMS0w_d057e8ff-006e-4366-bd21-8b625534b481">92,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i15c321aea67a4b76bb1d06797b32516f_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi02LTEtMS0w_ac7f8146-4c67-4196-b9aa-942a9ebb9cd8">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15c321aea67a4b76bb1d06797b32516f_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi04LTEtMS0w_a32f8eb0-3c1f-4514-8454-8f35637f8e84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i355fab1a4851405d964d3ce01c25e0cb_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xMC0xLTEtMA_0d1ab52c-f33a-4f4e-8630-572e9ab2fa35">50,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i40961c268efa4e669f1ab85e0e151e85_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xMi0xLTEtMA_69ec55e6-7e65-4a61-9b2d-7ce35cdfca56">147,638</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xNC0xLTEtMA_b3ed39eb-e0ae-4364-9eff-9cee2ecca36d">96,684</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect of changes in accounting principle related to revenue recognition</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e60ced97b104c0abfde5ea44bf688d1_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMy0xMi0xLTEtMA_41750987-ba09-464a-a2ad-92a4d8af818f">3,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4c6d0140a2430f9e5cc852e998ada7_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMy0xNC0xLTEtMA_fbae0162-be07-4eac-825c-619d3a5b2c6b">3,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC00LTEtMS0w_210032cc-8418-46a4-b84a-2dd24c0d1585">1,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC0xMC0xLTEtMA_6738e017-e1c4-4677-9651-8860a5c2e0c3">1,382</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC0xNC0xLTEtMA_ac921ea6-48e2-4316-98ab-671a671ce247">1,382</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNS0xMC0xLTEtMA_3ed851ed-ab7d-4c50-9b03-f6865bfa0c90">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNS0xNC0xLTEtMA_1e2df2c5-e715-4dbb-8dc6-a8634aa083b8">46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Issuance of Series F redeemable convertible preferred stock for aggregate proceeds of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331" decimals="INF" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0wLTEtMS0xMjExMi90ZXh0cmVnaW9uOmI1NThjZTMyZTgxNDRhMzJhYjZjOTM1OWY1ODk5MjQxXzE5MjQxNDUzNDg2Mjc3_4dc0e620-4b38-42c8-a64b-0b4b73b663d1">0.078</ix:nonFraction> per share, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331" decimals="-3" name="exdx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0wLTEtMS0xMjExMi90ZXh0cmVnaW9uOmI1NThjZTMyZTgxNDRhMzJhYjZjOTM1OWY1ODk5MjQxXzE5MjQxNDUzNDg2Mjgx_3e333982-9979-4c20-857d-59ef03745bfd">7</ix:nonFraction>, in the third tranche closing of the Series F financing</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0yLTEtMS0w_13ab34f9-de69-4e46-a2c6-fcc2a1183567">34,914,327</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi00LTEtMS0w_cadcc049-7fcf-4255-87fc-3716856edf55">3,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0xMC0xLTEtMA_192e454d-1bfb-41d7-bc78-e7d0af3f8ce9">1,152</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0xNC0xLTEtMA_936f3cb0-f78e-4e09-8998-c91752db651c">1,152</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibdf8495c14984c22b8ce5f6c41ee86e8_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNy0xMi0xLTEtMA_0deadfbb-2771-49aa-aa9f-36d4e655d8a6">2,793</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNy0xNC0xLTEtMA_89b747e6-5d28-4756-8b1f-43256345899c">2,793</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at March&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0yLTEtMS0w_6fcd6341-6ace-462e-80fa-c25ea6487b79">532,606,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC00LTEtMS0w_bf1045df-c01e-4b09-b887-60f25fd6ca71">97,296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC02LTEtMS0w_50e3302b-15ab-47cc-afe8-bc453f708491">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC04LTEtMS0w_31b5118d-782a-4c1b-87c2-5fcfb13b42fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0f39641f06e425987e31b75e8435957_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xMC0xLTEtMA_6aaafa89-e2fd-4a0f-9ede-ad0cc8516577">48,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5dd86c6fc3a247958775687c6c9081f7_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xMi0xLTEtMA_fa3eeb48-a957-4ebc-b6f6-dd9c06e36317">147,345</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xNC0xLTEtMA_afc3d9cb-a7b8-4b27-b10b-d67bf8b33bf2">98,879</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS00LTEtMS0w_9d2319c7-e66e-4257-adf2-e4a2bd1395bd">2,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i15803c46e4214e129bb899b341202df8_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS0xMC0xLTEtMA_8a855c73-56c2-4847-9064-dfd74624fd83">2,312</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS0xNC0xLTEtMA_1c15454b-8a12-4d8b-a836-2a804c68d0c6">2,312</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15803c46e4214e129bb899b341202df8_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTAtMTAtMS0xLTA_37b432b2-7656-4385-8570-38874d78d414">44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTAtMTQtMS0xLTA_bbd87140-8863-4586-8df5-ead52707c835">44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ce8694d9ba647108d4ea5ab8b905c1b_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTEtMTItMS0xLTA_35fc10f4-277f-4221-a94a-375138f7e629">2,146</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTEtMTQtMS0xLTA_8a129509-7d90-4d28-8a55-41c06d87e128">2,146</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i337919a6832e4104bc0864899a13424e_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMi0xLTEtMA_df6d53dd-3600-4358-bd70-0d7052ce17c4">532,606,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i337919a6832e4104bc0864899a13424e_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItNC0xLTEtMA_5c2e366c-f63f-4e2a-9878-5dc411ed6e0d">99,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItNi0xLTEtMA_a29c3bb5-164a-45b5-b9c1-40ef090b6aa7">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItOC0xLTEtMA_1ca5fcf0-2236-4b6b-b9ac-7c1f35b7fba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f88d3ad0c564ab193266b222933588d_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTAtMS0xLTA_b503de28-8985-45fb-b606-8537d327e5f0">46,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic9a450e5a552453fa6bac61e4872ceba_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTItMS0xLTA_735c33e4-faef-4694-a23e-593651d6b3a5">149,491</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i337919a6832e4104bc0864899a13424e_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTQtMS0xLTA_26be3c9c-bfa4-43f8-8cd7-a88fd69c2a2e">103,293</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtNC0xLTEtNjAz_09c172b6-6cc8-471c-a051-f2f6a0ef1f41">2,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtMTAtMS0xLTY1NQ_76f122eb-35ea-4b6e-9ae7-184c72879f3a">2,768</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtMTQtMS0xLTY4MQ_73c05e23-3a63-4a9d-bf50-74312734f0c6">2,768</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTQtMTAtMS0xLTY1OA_c6902723-af59-4657-ac74-53552ecc30ea">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTQtMTQtMS0xLTY4NA_bc147af5-cc92-4f06-ab19-6a84409d5dc5">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifee63a714e044b14bee48842ecfb743b_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTUtMTItMS0xLTY3NQ_11ffdb71-14af-4bb8-8cda-54e363a123da">1,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTUtMTQtMS0xLTY4Nw_aea94060-a64e-43fd-9fd1-b5332ebb4f8c">1,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at September 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMi0xLTEtNjE1_e810d1fc-1668-475b-9b28-ad3d37bef819">532,606,084</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtNC0xLTEtNjI4_cc54d8e1-1f85-4234-aab1-fd8dc8ae61be">102,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idcd81548cfe74374b9b0ab13f94caa0a_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtNi0xLTEtNjQw_8bcf8b43-a527-41aa-bd05-58b9f668d578">63,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcd81548cfe74374b9b0ab13f94caa0a_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtOC0xLTEtNjUy_69c2683d-2c32-4047-9d21-683b62efd243">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5d80c008209c426a814d7dd70f19e32f_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTAtMS0xLTY2Ng_49c7277f-d9d9-4843-958e-066f6567f474">43,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i30025f8cbc5f45baa8876d50bde62fe7_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTItMS0xLTY3OA_3b67f36a-c0e6-4521-bb02-5edc12a85bb6">151,247</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTQtMS0xLTY5MA_e84c2687-f5ca-4bb5-8c01-b622b01fbe79">107,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div id="i_0_31"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:24.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"> Unaudited Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:76.688525%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.483060%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:7.972678%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.483060%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.972678%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNC02LTEtMS0w_b4604c2f-c887-4255-a3d7-c56abb79e747">8,630</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNC04LTEtMS0w_763f2b18-df5e-4d44-82fb-edc1dd0f41b8">6,695</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNy02LTEtMS0w_1de55166-d190-44b4-bff0-bffd43d79067">480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNy04LTEtMS0w_ee606bad-2b99-45d4-b9d3-cc1f4641b868">576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOC02LTEtMS0w_e976cc14-7b5e-4dac-a8d6-49378e65a724">575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOC04LTEtMS0w_2000c69a-7869-4741-ad5b-cc4ad15f1be0">425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7pt;font-weight:400;line-height:100%;">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOS02LTEtMS0w_22d5d2c9-bd12-42e9-a3fe-e7a819ed4d44">484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOS04LTEtMS0w_361e767b-6664-47f1-971f-e9051a849eac">380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revaluation of warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTAtNi0xLTEtMA_f790f476-fab7-4784-b9da-77239e8a52fd">267</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTAtOC0xLTEtMA_0ddd0ec7-0b86-405f-b79e-26dd60a251e7">55</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTQtNi0xLTEtMA_549487f6-15d0-4d6f-a528-e45f86407618">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTQtOC0xLTEtMA_223e6c4b-316b-4451-84eb-215c39b68323">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTUtNi0xLTEtMA_079a0391-f05c-4e69-bb5d-dada96b34c57">85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTUtOC0xLTEtMA_30de543d-ae01-4e23-8ef7-5fceb95eea26">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTctNi0xLTEtMA_83352eb8-5ab1-4988-8093-9b43c35fee76">286</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTctOC0xLTEtMA_af5224a2-cdaf-4ff2-acb7-aad045d6d9f1">1,168</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTgtNi0xLTEtMA_5adf8750-fa99-4595-9b47-056bdac5e851">510</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTgtOC0xLTEtMA_f329a4e8-460e-4bab-8ebd-167398387a4b">590</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTktNi0xLTEtMA_523321f4-b75a-4063-b46c-630e958c4d2a">24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTktOC0xLTEtMA_016f55ff-aa72-4441-bae1-b1a48c60e5f6">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjAtNi0xLTEtMA_4bfbbcc9-b55b-4fac-9f01-058e4b1bd53e">174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjAtOC0xLTEtMA_6e6c4a7f-d4f5-4ef4-b82f-8b15fd323a29">392</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjEtNi0xLTEtMA_6e34744f-021c-4713-9f9e-707f538003fb">1,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjEtOC0xLTEtMA_92edf028-841e-4a9f-8b64-982f3768bed2">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjMtNi0xLTEtMA_54e8d784-c569-49ce-b052-3225e78a7d14">5,784</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjMtOC0xLTEtMA_228a8085-34b6-4f9f-b6fd-4852bd8a1eac">7,432</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjUtNi0xLTEtMA_6c9a99eb-0d11-4a40-a042-9e5c99c559d2">377</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjUtOC0xLTEtMA_0423d888-a862-4e69-b5e1-55ce11cdd4b6">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjYtNi0xLTEtMA_ddc21455-01ae-4766-bdb8-58b196b4add6">300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjYtOC0xLTEtMA_2e44ff01-ae59-442d-912b-c6ee326b8e21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjctNi0xLTEtMA_61aa537d-0c80-4fd9-9a21-003227e64d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjctOC0xLTEtMA_d820b6a6-2153-4ff1-b92b-9b76aa5ed851">2,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjgtNi0xLTEtMA_4d689497-06ec-4e4e-8059-9a0ff455f0a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjgtOC0xLTEtMA_62f82e08-e9de-40d8-a15d-3d2e2c95b354">1,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjktNi0xLTEtMA_7bf2028f-81b0-4deb-83b1-6557fe67cbb0">77</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjktOC0xLTEtMA_0f538156-92c6-4710-8c51-946996a15fdf">1,128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Principal payment on capital lease obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzEtNi0xLTEtMA_a6a12dbd-f553-49bb-8474-5a61155f3c25">94</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzEtOC0xLTEtMA_ef2594a5-7b8b-42ca-91d2-8c0478decd09">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from initial public offering, net of issuance costs and offering costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtNi0xLTEtODgw_acb656d5-3887-4827-8aa7-4917bb9b3048">52,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtOC0xLTEtODgz_d97669db-318b-40b5-bec9-06010f65bd76">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from the issuance of Series F redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtNi0xLTEtMA_51524781-7782-4e62-bded-32c72d0a6df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtOC0xLTEtMA_c2febd6d-c9be-4caf-80cc-14dc8dcebe4d">2,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of Series G redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzYtNi0xLTEtMA_229aae6f-60a4-4812-9f6f-2fdbf9f88330">7,742</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzYtOC0xLTEtMA_b86ba959-fc4c-4056-9a87-260e0a6f1b64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of Series H redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzctNi0xLTEtODcy_3f2346a8-f795-471a-9d9d-a190111bf8c9">10,682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzctOC0xLTEtODc1_905804f2-8236-4ad5-ad8b-81e099d2158d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzgtNi0xLTEtMA_46c8f352-863b-44d2-9896-719d3ff7cc74">70,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzgtOC0xLTEtMA_fcf49680-07e4-49f0-b624-561e0fa71cc3">2,699</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzktNi0xLTEtMA_b329d939-feaa-4090-a2a9-f23f5071d0e8">64,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzktOC0xLTEtMA_68e2e55b-9625-4748-9bf8-0fbf8bc7df21">5,861</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDAtNi0xLTEtMA_a28e00d1-4b04-46dc-add7-fa36c10c469d">13,264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDAtOC0xLTEtMA_e9a3b39b-5812-44a7-ae64-0c7f7f394d61">11,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDEtNi0xLTEtMA_31e50641-df0b-4502-93e6-938146c6e2ac">77,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDEtOC0xLTEtMA_9338cd2e-931e-4952-96cc-38f090099489">5,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDMtNi0xLTEtMA_7843ddb2-48f9-4d6f-8eb0-72a4824b5460">1,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDMtOC0xLTEtMA_0a0709f8-fdf3-4894-b904-2bfe6f7caf0f">1,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion to redemption value of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDUtNi0xLTEtMA_74d08688-b7e7-4045-a109-f5c4238d0111">4,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDUtOC0xLTEtMA_802197dc-71fd-4883-be99-21d2c0e487d1">6,462</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Equipment purchased under capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDYtNi0xLTEtMA_0dd0f6d9-cc10-43d5-abc1-92ab37e04b63">412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDYtOC0xLTEtMA_a2901b11-3103-405c-8bcd-be036a5d6f86">289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDgtNi0xLTEtMA_89e8838c-45d9-474d-8308-3242c005201d">71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDgtOC0xLTEtMA_25b6fc66-45a0-44f0-addb-b8e3f1c867de">207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTEtNi0xLTEtODk0_745c8f49-ba4f-46df-b1ac-27e0e964edef">138,906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTEtOC0xLTEtODk3_e645aaf5-5c69-4a1f-9016-295b608408cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of common and preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="exdx:NoncashExerciseOfStockPurchaseWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtOTE0_53677b33-764f-4692-8555-e7d5efd081ea">511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:NoncashExerciseOfStockPurchaseWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtOTE3_9af7d675-35b1-4e8b-9780-ae178c1fffd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance costs included in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDktNi0xLTEtMA_f826d6dd-7b7f-46b0-8228-8e7e9d637ea3">1,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDktOC0xLTEtMA_d1ad5c5b-da40-40ee-873f-0f1d41b93d4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtNi0xLTEtMTAxNTE_b9634752-cc25-4fe7-90bd-279056671b64">726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtOC0xLTEtMTAxNTY_89fc7ca9-591e-4bde-9ed0-d3d31df089b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtMA_0c3e6589-d274-4369-a8a3-60db08cd2a2f">6,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtMA_06951f5d-aa5f-4910-a8ff-81184d88e2cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtNi0xLTEtMA_fc525851-9fe5-4a5e-b103-1ce8ace317d5">6,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtOC0xLTEtMA_6d86f9fb-96e5-4d9a-ba89-4b96fb8c4830">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of Series G to Series H redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:ConversionOfTemporaryEquityAmountConverted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtMTAzNTY_815d30b9-5b32-4623-8557-8d7e2b8501a3">11,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="exdx:ConversionOfTemporaryEquityAmountConverted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtMTAzNjM_348596b5-8423-4ab8-acb0-ac28a5f1260a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Deemed dividend from issuance of Series F redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="exdx:DeemedDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtNi0xLTEtMTIyMjY_0734d0fe-d0a1-4046-b9cd-0173be985607">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="exdx:DeemedDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtOC0xLTEtMTIyMzU_73179499-8db4-4a92-9f8c-5621086e2238">1,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment upon adoption of Topic 606</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="exdx:OtherNoncashTransactionChangeInAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtNi0xLTEtMA_d7f6fe41-5377-448f-a4de-7cd770dd10b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="exdx:OtherNoncashTransactionChangeInAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtOC0xLTEtMA_e9359f91-c4ad-41e9-b086-eedd69cb714a">3,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these financial statements</span></div><div id="i_0_701"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:24.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_37"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Exagen Inc.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Notes to Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:center;"><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 1. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMTQyOTM2NTExODM5NTI_af5709fa-311b-48a2-ab1e-363e5556b248" continuedAt="i747ca583b4d64dc080776cfd4a7ead9b" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i747ca583b4d64dc080776cfd4a7ead9b"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Exagen Inc. (the Company) was incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, Exagen Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the Company changed its name to Exagen Diagnostics, Inc. In January 2019, the Company changed its name to Exagen Inc. The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On September 23, 2019, the Company closed its initial public offering (the IPO) of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIwMA_b8321d76-8995-4279-a50a-73c1a113baa3">4,140,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIxNw_3209b701-bb95-48c2-81c4-ee5613ad1f19">14.00</ix:nonFraction> per share, including the exercise in full by the underwriters of their option to purchase <ix:nonFraction unitRef="shares" contextRef="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIwOQ_77f6876f-b2ee-4618-9a3b-45939a8cb794">540,000</ix:nonFraction> additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $<ix:nonFraction unitRef="usd" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIyNA_364a8089-7538-4213-82d3-06878d33c6e3">50.5</ix:nonFraction> million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923" decimals="-3" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIzMA_38d94116-98ba-41f4-9d8a-fc03f372f8ca">7.5</ix:nonFraction> million. In addition, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjI5MQ_caee41ab-e6c5-409e-9933-5421f380e683">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying condensed financial statements and notes to the condensed financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has suffered recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2019, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMTA4Ng_2fdd5b0b-10b8-479d-b3be-dacf95ff633e">77.8</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcwNDkwMw_566eb885-a069-4a17-a3d0-ce6bb51f166d">161.2</ix:nonFraction> million, respectively. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least the next twelve months.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:12pt;"><span><br/></span></div><div id="i_0_40"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTY_8cc66151-f680-4681-8f24-32bb2aa61ba7" continuedAt="i47b8c43afc5a4306829dfd0f777e812c" escape="true">Note 2. Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i47b8c43afc5a4306829dfd0f777e812c" continuedAt="i4a1001f57f38415ca65db7b47359742a"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Use of Estimates</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim condensed balance sheet as of September&#160;30, 2019, the condensed statements of operations and the condensed statements of redeemable convertible preferred stock and stockholders' equity (deficit) for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2019 and its results of operations for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 in accordance with GAAP. The results for the nine months ended September&#160;30, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2018, included in its Prospectus dated September 18, 2019 filed with the SEC on September 20, 2019.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTc_656dbc4b-fe27-4981-87ea-64e37492ba99" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Significant payers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzI_12f83e59-5c88-487e-8754-96a601a22efb" continuedAt="i34971614a89742028f169a4bf952b94e" escape="true">For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i34971614a89742028f169a4bf952b94e" continuedAt="i7c316f380ee14ed9b840155e53e031a7"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:51.147877%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980966%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980966%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980966%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.980966%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy0yLTEtMS0w_5f391e68-0971-46bd-8cf8-b59d94e55a00">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9cfb3b43b3d643db9c0aa9a4cf494dc2_D20180701-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy00LTEtMS0w_852adbac-5f15-4167-9b46-d70173538eab">30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1f0a93f41a20455ebdd1ecf05f3d71f1_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy02LTEtMS0w_305586f7-9ec6-4bf8-b439-76448d32e6cc">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5f42ba8fdddf43508fe432039d3bea83_D20180101-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy04LTEtMS0w_8ab7bc4d-d31c-4d55-9880-fa59d2433439">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3a5a1b65ea2e4772af6730adb19a219b_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC0yLTEtMS0w_ca70529f-cb12-425d-bd89-79c234d0553b">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id6c397043b0a4757a1ab205b9203c35c_D20180701-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC00LTEtMS0w_67a7777b-937b-451f-aa26-3e068cd11aad">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie6bf1ae302d841fc97de1f33e7991b73_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC02LTEtMS0w_34352076-90ff-4c1f-8a0b-12dc9ae08c45">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i84325f36965b4db489f07aff6f65377b_D20180101-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC04LTEtMS0w_7d3f4fd5-f3ab-441d-8f0c-776c4ddcceef">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i48533d3983e8456cbeabafad30dbeb68_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS0yLTEtMS0w_cd3361e9-9823-4c63-9603-ad0823f2f3a3">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie9910315e8ba4f9ebdbc616cfe66741f_D20180701-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS00LTEtMS0w_2650dae6-d152-4302-a2c0-99553798fd21">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8d86bef637f5439da150d6607648998b_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS02LTEtMS0w_6e4754f6-e885-47b6-9e73-67a63549fbb6">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iec2569645c6b438594320c445bd2f7df_D20180101-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS04LTEtMS0w_2c9091b5-f4d2-4b6d-b0cd-5c0c9c1e8b45">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i42b6a2a4f7464d0c962375e478a9a57f_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi0yLTEtMS0w_bcff1661-b16b-4880-8e34-82d968942e12">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9f4b9180e4b54309b12c8bde22fbd406_D20180701-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi00LTEtMS0w_d695f6f6-5d92-4b99-907f-2bf774c99a73">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idbf3daa4d6ce48df96adce7481138367_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi02LTEtMS0w_3d6fc591-fe75-4c02-b3cf-41f2a07dbbb1">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ife08467e105c4ca290a3a0fa3636d3ea_D20180101-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi04LTEtMS0w_a90fbff6-eac2-46b3-b809-4ee66bf5ee14">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i4a1001f57f38415ca65db7b47359742a" continuedAt="i39511d2972bd473a9b19d3e88eb5ccd5"><div style="margin-bottom:6pt;"><ix:continuation id="i7c316f380ee14ed9b840155e53e031a7"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:69.491228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i412a4bc0981e429bb2c3c5e64c8588b0_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfMy00LTEtMS0w_e05346fc-03a7-4a32-b64a-12aa2b9959a4">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4fe4f91b3fec4fef9d89209d8df0145a_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfMy02LTEtMS0w_32a486fb-8842-4ac6-8a58-7a96eaed193e">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2bb9a3f35ed44889b3becb647aad758d_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNC00LTEtMS0w_bdbf9da7-4b1e-42c1-9def-d42a189254d7">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idc18586b25674689a55653cbc6ba01fd_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNC02LTEtMS0w_908db973-d948-455e-b5aa-e1a8e7f1709f">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4a849e120d8a4d0e8a2192315f7f1d31_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNS00LTEtMS0w_f68f3325-25fa-44c4-a302-21148e3b746a">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icab7fdcf6ea44e4196147db770e82818_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNS02LTEtMS0w_c90c0467-4e28-4ec5-a037-94f48c63e2b1">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6bfbb7c25a64494dbfebb530261307a8_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNi00LTEtMS0w_587e6c84-25f4-40e6-920c-0712eb5ab0bf">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5ead417360294b46b273d3316cc3ac11_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNi02LTEtMS0w_18d9de0a-6ec5-41ce-81d7-f06f07eb4c38">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019 and 2018, approximately <ix:nonFraction unitRef="number" contextRef="i0e2db87ab7524a10b5714856382436dc_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU4NQ_a2369ada-282c-433f-bbac-0754a4689145">83</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i82e71d7bdf8b4e58ab63f9e4492e3a24_D20180701-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5MA_771092da-1c87-44a8-9653-45b2f0e2cc66">86</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test. For the nine months ended September&#160;30, 2019 and 2018, approximately <ix:nonFraction unitRef="number" contextRef="if7491bc1715c402c87c11f837d462f25_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5Mg_7994eb01-e453-4bee-a6c0-e8c4f8915e95">83</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0d50576626ca4bb09058ce09556f99f6_D20180101-20180930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5OQ_61786279-5de9-48b4-bd44-1e2db04d309e">86</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is dependent on key suppliers for certain laboratory materials. An interruption in the supply of these materials would temporarily impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMQ_a8041187-c819-45d1-baa5-8ee948dc5fbc" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes the Company's revenues as disaggregated by payer category (in&#160;thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:43.374449%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.922173%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.922173%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.922173%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.922173%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac7d07ac43134c56bd65c32a20842780_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy0yLTEtMS0yODA4_d8fa5cd1-ac54-4f8b-8482-3ee037576995">6,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b3c7dcf56ca41a4b105284483e7e373_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy00LTEtMS0yODA4_47409f9c-e0ed-4545-8c80-5c308ecd2153">5,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i117917342465407baf079c005b0dfcb3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy02LTEtMS0yODA4_ee41354e-d7fc-4709-b3b5-eaf140a5a7da">17,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0986e73045a14160ba73146b0023d069_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy04LTEtMS0yODA4_e82e17d8-58c7-4055-af8c-3b5e00ba38f4">15,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Government</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a60fb4a5d5d4f5289b1f4c0113fe3e8_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC0yLTEtMS0yODA4_18ebab2e-dbe5-4b58-b573-451528763a90">2,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21d1f81cc6e84b5494d096638cfd9d83_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC00LTEtMS0yODA4_ad3b7f64-f156-47f5-b30d-5fb3463bbe05">2,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24e975d35170436cab761c1a79d6a68f_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC02LTEtMS0yODA4_86a94e7d-38df-4093-a203-16aee5405437">7,964</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92d1b13bd06f4289b57c9968d5a5034f_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC04LTEtMS0yODA4_5945d73e-7ae2-4c34-b632-e0793a2aa48d">7,013</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Client</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9d710d634904421a501a1631a9070fa_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS0yLTEtMS0yODA4_c6192efe-282a-43c0-af74-3948259fec27">1,007</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7e26ceee4414fc2ab3a53e749e41b4a_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS00LTEtMS0yODA4_0de4960d-706a-4a45-82d9-b7f310d29c70">171</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35ae2ebb8e184bd395a0b6b0997eb389_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS02LTEtMS0yODA4_533ea587-ed15-47ef-b6a2-3d9295631c53">3,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iebc7396f4e6249ecafc16cddc8b813e2_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS04LTEtMS0yODA4_fb208e19-042e-47f7-a700-62dd12fc8262">428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05cd8526aa4f4a2897a2f2d8cdd90fa4_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi0yLTEtMS0yODA4_163ae80b-f8e8-467d-9591-471be1b836c5">148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9774db8f05cb4b99b9d4806cbefe7bbe_D20180701-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi00LTEtMS0yODA4_af99fa29-e940-49cc-bb1d-ad1ebf52be72">120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0717d7c677d6448da99afc8400886103_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi02LTEtMS0yODA4_98801171-d8e7-4ff1-8c8f-a5b34cc4fa9f">458</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2036583b6802432094a2445756a97d97_D20180101-20180930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi04LTEtMS0yODA4_34feb2bd-8077-402a-a7c5-885aba2d1442">335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Janssen (SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy0yLTEtMS0yODA4_a5f89a9c-4c8f-490b-b849-1190a9573e91">431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c0d3ee1297444fc9aa08f456ef2c9c7_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy00LTEtMS0yODA4_9ed39587-7a94-4ec2-b8ad-5710d8ae7950">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy02LTEtMS0yODA4_732fa9b8-ef69-4ca3-9fc3-fbd27b60f159">835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50eedc9033db402abed9620d44e35700_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy04LTEtMS0yODA4_cef17009-421e-4fc2-a5c4-7eb5e008a5e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC0yLTEtMS0yODA4_213c0832-a7a0-4511-9584-53789095fff8">10,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC00LTEtMS0yODA4_563cf0bf-08e8-4946-bc8d-35d929aea3ed">8,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC02LTEtMS0yODA4_409c7967-a29f-4131-9705-b5fc03ae2d3a">30,173</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC04LTEtMS0yODA4_a61a18c3-3e49-4639-85e8-657f9a45f4cb">22,799</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt;">Includes patient self-pay that is immaterial</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTg_0858a99c-acbf-447a-b94b-c370751a5e7f" continuedAt="i0cd5eda183ac436ab4cacdd5eb29bd3c" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The carrying value of the Company's cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 1 -&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 2 -&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 3 -&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i39511d2972bd473a9b19d3e88eb5ccd5" continuedAt="i72bd4eeaaa2a40479a220fc5c8daa386"><ix:continuation id="i0cd5eda183ac436ab4cacdd5eb29bd3c"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div></ix:continuation><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTk_13a561dd-2ca3-4daf-a0c5-9f036dc5cf7f" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $<ix:nonFraction unitRef="usd" contextRef="i6c30c3ce04a84e4d874b74595bca6d56_I20190930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDc5NDA5NQ_c193bd11-63a0-4d7f-8966-43cf356ccd41">0.1</ix:nonFraction> million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMg_5e97c874-c7d1-467e-8129-57b740282013" escape="true"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMg_b93c812d-7ff9-4f45-92ce-3fd64c30a0eb" escape="true"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:71.099415%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMi00LTEtMS0w_8f338b8d-9997-4cb9-b463-2132d0587d8f">77,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMi02LTEtMS0w_cc52f9fb-9290-4242-90cd-0e2347229cca">13,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMy00LTEtMS0w_be95251e-1b58-4619-8087-b551a627829f">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMy02LTEtMS0w_22cbd258-94df-4f5f-a8f3-0e73e8d1d3b7">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfNC00LTEtMS0w_22594496-0bda-4030-a844-07a20290ed65">77,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfNC02LTEtMS0w_a9f5901c-e1d0-47d7-ae90-2b35074558f9">13,264</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Offering Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2018, the Company deferred offering costs of $<ix:nonFraction unitRef="usd" contextRef="i9c143e96ac9b4806bef7c462dd041d9e_I20181231" decimals="-5" name="us-gaap:DeferredOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfNTQ5NzU1ODIxMTE0Ng_8642ce5d-2069-4caa-9ce1-26924c2c4e37">0.4</ix:nonFraction> million consisting of legal, accounting and other fees and costs directly attributable to its IPO, which are recorded within other assets in the accompanying condensed balance sheet. As of September&#160;30, 2019, the deferred offering costs were offset against the proceeds received upon the completion of the IPO.</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjI_28ed81ac-c992-4615-b336-c8c730a1dcbb" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying condensed balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfNTQ5NzU1ODIxMjA4OQ_caee41ab-e6c5-409e-9933-5421f380e683">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversions. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock Warrants</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#8217; equity.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 5 for further discussion on the remaining warrants.</span></div></ix:continuation><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i72bd4eeaaa2a40479a220fc5c8daa386" continuedAt="ia16798470e6b44d6abd0c9f2f9bd38d4"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjM_a395a152-372f-4922-a3b8-cd0ea3df9dc7" continuedAt="i0cf23c8954cb49988cb911142ac8b51f" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Payers are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payer (i.e. each individual third-party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Collection of the Company's net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:12pt;"><ix:continuation id="i0cf23c8954cb49988cb911142ac8b51f" continuedAt="ie9c1932ffd9b4529a0bb7edd3c315e30"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Codification (ASC) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie9c1932ffd9b4529a0bb7edd3c315e30"> (Topic 606) as of January&#160;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="i199eae29222f49ccbbc2f5f8369952de_I20180101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTY4MDM_43bb16fb-9dcc-4d7a-8bf7-4aaf5082777f">3.1</ix:nonFraction> million.</ix:continuation> </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Janssen Promotion Agreement</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a co-promotion agreement with Janssen (the Janssen agreement) to co-promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in the United States. The Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTkzNzM_385d9723-dc75-4413-b59d-ee70a27f9341">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMzg1MA_fa371903-3029-446c-95c8-4197be8c5513">0.8</ix:nonFraction> million during the three and nine months ended September&#160;30, 2019, respectively. The related expenses for marketing SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjQ_195e2b5c-22d7-4063-ac43-daeccc4189ce" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjU_b8c25b19-306c-4559-9f75-b274850807c5" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Advertising and Marketing Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzI4Nw_768e1949-04ec-4706-b6e6-f85d95af7815"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzI4Nw_fa4e4aff-2dec-467e-aabb-352627ff339b">0.4</ix:nonFraction></ix:nonFraction> million for the three months ended September&#160;30, 2019 and 2018, and $<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzM4Mw_08258d60-10b6-40f9-8b55-a92e5c931727"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzM4Mw_a04bfe38-0575-460e-af96-c4195f8ce12b">1.1</ix:nonFraction></ix:nonFraction> million for the nine months ended September&#160;30, 2019 and 2018, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Shipping and Handling Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ic77e882cd1974313a78b7279282ccfd2_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1Mzg_6930372f-5a80-445f-ab78-277d6a099770">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i717f3fbc203143a2b2caad2a58d2a79d_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NDI_2e7202c6-6722-4834-ad79-d5493c5b3398">0.3</ix:nonFraction> million for the three months ended September&#160;30, 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4c29ece949cf4a19a46b6de69ea06eb8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NDY_65364ec7-132b-4634-a187-2f4c87be05fb">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67896f9ab6ed4543aecbdd23e5c897fc_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NTQ_856fce7e-21f2-4a45-9050-072092dc3889">0.9</ix:nonFraction> million for the nine months ended September&#160;30, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjY_a060e9c2-9db5-42d2-a229-7af17a4466c6" continuedAt="i4da8efa5db464965935fe6ca48d5a429" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ia16798470e6b44d6abd0c9f2f9bd38d4" continuedAt="i4c586ed50d1e4b0f8805c61bb9e0df5c"><ix:continuation id="i4da8efa5db464965935fe6ca48d5a429" continuedAt="i2384236c3aef45b6b18b9f4653a23406"><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">period) on a straight-line basis. The fair value of stock options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2384236c3aef45b6b18b9f4653a23406">Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).</ix:continuation> </span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjc_29fd5c82-6523-47fe-88f4-8fc57c5ac0aa" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjk_9561fa53-d8d3-4d0b-afcb-8deceb749c05" escape="true"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and options outstanding under the Company's stock option plans. For the three and nine months ended September&#160;30, 2019 and 2018, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwNA_e0dd30b5-1da4-48c0-8f8b-e6dd688d55cd" escape="true"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:35.647059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.852941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.852941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.852941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.852941%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ica3ed9cee3e94243840bca963f193791_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi0yLTEtMS0w_859a22ce-2770-4902-9a58-6550753ef9bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c087d67dc248d6a8b02fc4a43f742c_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi00LTEtMS0w_637642bc-6aeb-4e29-a68f-5978a4caa231">5,202,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia6060eadd8f24bc1be3eb453cc22ca19_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi02LTEtMS0w_34551175-56f9-401d-89f2-7af9e3ccd5bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8542a7dabeb54160bf0ca8be742e9212_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi04LTEtMS0w_c11a8112-a403-445e-83e5-50fe939028a6">5,202,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i349270c037f94e44af2351837279531e_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy0yLTEtMS0w_e36dad0d-0c12-4434-833d-c18f21591433">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1efe7f934c0047d1bd2ce2d9c861261e_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy00LTEtMS0w_f9af6606-d846-4c80-8734-8fbf6f4f13a8">203,549</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fbce37a02d245539b9bcdbbdeea57b7_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy02LTEtMS0w_ff51e5fd-2d92-4ec6-b1a5-0b09b5bdd50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0f1132f9c16d4dc1af50508da38762d4_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy04LTEtMS0w_01461da0-9a60-465e-99f9-868fc8886edb">203,549</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i260086f6c68e4de8b8f8f51fc380212a_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC0yLTEtMS0w_7f22147e-3d2b-4bdd-ada6-47bebbad9cd1">461,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec80ab26441a4e79a659a24f2e383d48_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC00LTEtMS0w_209ebcc5-f978-4abd-a5d6-339b1142b3a4">934,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i621ecaf0fe824109be7c5edd830fcf40_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC02LTEtMS0w_c7ce0bca-d064-40af-a723-9658b55c9805">461,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i85a81e346b614153977eb22e41d41635_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC04LTEtMS0w_09ce97a2-e88d-4220-9b35-dee89b0830b8">934,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i25ef04b2fcfa49d582c1daa128336b09_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS0yLTEtMS0w_747862ce-ba05-4dc2-b92c-4147a1c8b605">1,475,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i705ad45db6ea4e2195c730551dac08dc_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS00LTEtMS0w_465584ca-cd51-4f16-86e6-eecd5a2ff9ae">69,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ife9c9599bc1a428cac54f6b6233b42a7_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS02LTEtMS0w_9a0a76ba-c15f-4f37-b09a-ad90b5fac0b1">1,475,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib99b30654d864c038634ae1e2765c0e4_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS04LTEtMS0w_24a36c2a-5e90-475e-a9ab-fdd58317871c">69,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi0yLTEtMS0w_b02fae05-2496-493d-b7e4-2084c0565b62">1,936,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi00LTEtMS0w_965ea2b6-3460-4424-a4dd-a4fbbc644713">6,411,163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi02LTEtMS0w_55df4d4d-22fb-4089-8f37-82a9c8877022">1,936,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi04LTEtMS0w_dc08f489-43af-4e21-a9ea-b43896462658">6,411,163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzA_0c87d0a7-71c6-405b-be78-47a3a9c70828" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Reporting</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div></ix:nonNumeric><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzE_ae53b77c-bd38-482f-b084-16bf5ec867f9" continuedAt="ic353656dc14741a59e7c76baa9ec80d7" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:4pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i4c586ed50d1e4b0f8805c61bb9e0df5c"><ix:continuation id="ic353656dc14741a59e7c76baa9ec80d7"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Leases&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases: Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement: Disclosure Framework--Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&#160;2018-13 on its condensed financial statements.</span></div></ix:continuation></ix:continuation><div style="text-indent:24.75pt;"><span><br/></span></div><div id="i_0_46"></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQwNg_52625434-6f8f-4111-a40d-6f0832b74141" continuedAt="ifff69862a8ea4af9ad28c290b9a67739" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 3. Other Financial Information</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQwOQ_3bbb71f6-8b02-47f5-9d68-b8fbd6157e2d" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:64.520468%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMi0yLTEtMS0w_395d1867-1c49-4475-82b6-78cc22c704d3">916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMi00LTEtMS0w_dc0e4483-6f7d-4e82-8b46-1e9c830401da">1,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid product royalties</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMy0yLTEtMS0w_5d2b6566-6da3-4cc8-b922-3e514465f769">137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMy00LTEtMS0w_da89948b-136c-4dc3-bba7-1ff42e6e11e9">176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNC0yLTEtMS0w_22ab521c-a17d-44e9-9200-11de162aa8fb">619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNC00LTEtMS0w_ab159bab-3b3a-4078-b348-3a2d7c111345">698</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNS0yLTEtMS0w_14d263be-e73d-4092-bbcb-b8dcd6f297dd">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNS00LTEtMS0w_008c81cf-1a2d-4f97-aaaa-95d9bd610981">148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNi0yLTEtMS0w_a3cb1f59-ce45-421b-b6da-aa062961063d">1,686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNi00LTEtMS0w_a54bb4ab-314c-458c-b525-50507aabc8a5">2,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQxMA_9fb62717-3768-4502-a4ee-94978e4606d3" continuedAt="i458d0366626c4e24934bcdd8d149e74c" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ifff69862a8ea4af9ad28c290b9a67739"><div style="margin-bottom:6pt;"><ix:continuation id="i458d0366626c4e24934bcdd8d149e74c"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:64.520468%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40e030b64dea4330b9962390e9b32038_I20190930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMi0yLTEtMS0w_a832d563-376d-4713-9a7f-a68e7aae52b1">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i167c8bf3e14242d4b6b0b5533837f6e1_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMi00LTEtMS0w_879b14cc-4225-4dea-94fe-4b2e14cf4a08">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice1fa1729eb34b299178d8caf2161699_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMy0yLTEtMS0w_17d7c008-751e-4c10-b2e4-cad533a3b928">2,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i321e9cae976c4953b8b700e620bfb3ce_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMy00LTEtMS0w_1620fd23-3e4b-4cff-abdb-cdeed719068a">1,855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69188b3f953943e8857feda39af6a513_I20190930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNC0yLTEtMS0w_692847fa-71c3-47c3-bb82-b7b08f3502c0">851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i879c70b4b5494742ae2de43311dee3aa_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNC00LTEtMS0w_88a359e5-064f-44c7-97e2-afd1341391fb">796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib83471b6a9094305b6ad8430295ff5cc_I20190930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNS0yLTEtMS0w_7898111e-a384-4892-8c31-de8ef40b98cd">423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7547ba12aab74508ae6730cee6b11777_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNS00LTEtMS0w_a114f605-2e26-4e18-acaf-57220ec715f9">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3f8b0aeca3d46d185477b020a4cad1f_I20190930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNi0yLTEtMS0w_7814ac8f-2240-497f-917a-95841352ade1">71</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c9982c73979435b8b18653fef66b69e_I20181231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNi00LTEtMS0w_1dca02c9-83ee-4c45-ba51-91bcc053e237">310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNy0yLTEtMS0w_5a642cd1-cb6c-41b0-b54e-b6d71b057f02">3,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNy00LTEtMS0w_f4a41bee-6c8f-4c25-888d-c75c32a24dbf">3,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOC0yLTEtMS0w_d342c9f6-77be-40c8-8107-5852f010eefb">2,284</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOC00LTEtMS0w_b619ea02-91a2-47d1-8e78-2d9e482d8cfb">1,819</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOS0yLTEtMS0w_cd92a837-b9b7-40d5-94ec-4a09a2e6fd2b">1,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOS00LTEtMS0w_1fbb230d-c445-47fe-bdde-7a7676a77423">1,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense for the three months ended September&#160;30, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5NzkzNg_37c3ba03-d147-4a52-8f04-8948988c38f0">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5Nzk0Mw_a164068f-c77c-4059-9e8d-4b2512876c3e">0.2</ix:nonFraction> million, respectively, and for the nine months ended September&#160;30, 2019 and 2018, was approximately $<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODAyNw_654b3c4f-03b4-44df-97db-d43db163230a">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODAzNA_6c93327d-2cf0-41b4-8626-010e6815bbbc">0.4</ix:nonFraction> million, respectively. At September&#160;30, 2019 and December 31, 2018, the gross book value of assets under capital lease was $<ix:nonFraction unitRef="usd" contextRef="ie67a92bb4ee44f42b31178b35355abc0_I20190930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODIxMQ_7cbb2c88-6a2f-460c-9f88-8e0789f42822">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52ca50f81cf04570bc17e8f427844a2e_I20181231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODIyNw_b558ad34-a26b-4d08-b51a-5b70f34630f4">0.4</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQxMQ_c04401e8-af62-45b1-88a7-72f207580dbe" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:64.520468%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMi0yLTEtMS0w_8d43d4c3-af47-4c40-b148-c6c895f9d507">2,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMi00LTEtMS0w_079a4011-772f-4e43-8ca5-208f0d0c98d9">2,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued deferred offering costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:AccruedFinancingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMy0yLTEtMS0w_7ff43376-66d4-431c-b792-7af8464a29d5">1,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="exdx:AccruedFinancingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMy00LTEtMS0w_4656ffd3-10d3-41cc-a8bc-a64317e8c8da">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNC0yLTEtMS0w_b2aeda82-0fde-43c6-88fa-c572a48a77f2">182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNC00LTEtMS0w_09ecb0dd-2104-4888-b934-98f34be4548b">178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNS0yLTEtMS0w_c574f947-489f-44c0-b105-001cf4c97207">292</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNS00LTEtMS0w_9773d6c2-ae92-460f-8673-019e14b7d060">243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNi0yLTEtMS0w_7cdc6290-3e05-4944-9c34-a5fb7dd7b70c">708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNi00LTEtMS0w_03d0e924-65d3-48dd-9004-01c10b41aa1c">602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical study activity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNy0yLTEtMS0w_5436f410-16c2-4317-9f35-1254c38692bb">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNy00LTEtMS0w_e0bf1a07-00f0-4350-82d5-db11dd202854">146</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOC0yLTEtMS0w_50bea0c1-ba73-4cb2-a57c-d436d7904fe1">179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOC00LTEtMS0w_4343cbcf-1586-484c-ab6b-6254d9dc5d9d">81</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOS0yLTEtMS0w_041965c6-e88e-4017-aa92-c3d21bbbf9f2">597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOS00LTEtMS0w_2adce198-0f05-4800-a82d-1088be8185ff">207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMTAtMi0xLTEtMA_cf9c45fe-1246-4e22-83da-32c3fbe340ac">6,449</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMTAtNC0xLTEtMA_90820848-8f12-4fdc-b463-f26be1d2eb0c">3,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_52"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 4. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzI5ODUzNDg5NTcyOA_84e29150-e683-4752-a925-620ce1a07924" continuedAt="i09482817071b4366b9a0c1ea5191b7bb" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="i09482817071b4366b9a0c1ea5191b7bb" continuedAt="i93c7f78cb91f4f98babe22d2762af41e"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Term Loan</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $<ix:nonFraction unitRef="usd" contextRef="ia55d1a24be2548af9b0dd677741eb14f_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTk1_b9dfde4b-070f-4787-abd8-3e17ab89b72b">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie724734be96b41eb9f3acb00203b7563_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTk5_7036c096-0322-40f1-af00-30d8a980c265">17.8</ix:nonFraction> million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i784c198f85794d068e262abe227f7399_D20181207-20181207" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzgz_ffada748-0bb7-47c9-9cae-5451dc491e9f">5.0</ix:nonFraction> million under the 2017 Term Loan. At September&#160;30, 2019, no additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The interest rate on all borrowings under the 2017 Term Loan is <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTY1_ba2cb247-9819-477e-980e-85616d4127e1">11.0</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTc4_255ca4cd-99b4-4308-8061-a91a379ef83c">2.5</ix:nonFraction>% is paid in-kind in the form of additional term loans, or PIK Loans, until September of 2019, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNzI0_ba2cb247-9819-477e-980e-85616d4127e1">11.0</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfODE1_6c5758fb-0916-4c63-b985-7e2dec4a4490">14</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay PIK interest. The outstanding principal and accrued interest on the 2017 Term Loan will be repaid in twenty-four equal monthly installments commencing in October 2020. Upon repayment of the final installment under the 2017 Term Loan, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTE4Mw_96c2f5a8-336d-4821-9248-fe8900df3bd1">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of 2017 Term Loan using the effective interest method. For the three months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="id19b52fc68724d4c9866d0bbfa02eb24_D20190701-20190930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNjk0Ng_f739926d-ec72-44cd-8c07-d702f37c6e21">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i593387046d9c4d19baf524fd531f341c_D20180701-20180930" decimals="-3" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNjk2MQ_763ce2c4-f00b-41c1-8b06-874f85c3191c">0.1</ix:nonFraction> million, respectively. For the nine months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="ic84146f62f914258a7de7f505ec8dae3_D20190101-20190930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNzA2OA_858ea220-33b3-4ee8-a033-aadd7e73ea9d">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f42b4e0da004e11a3d759fb51a524c2_D20180101-20180930" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNzA4Mw_2aac5aa0-73a2-4024-8123-50fee9b4e90e">0.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i93c7f78cb91f4f98babe22d2762af41e" continuedAt="ibbffd61f49814b02af9295c752222286"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If the 2017 Term Loan is prepaid after September&#160;7, 2019, but before September&#160;7, 2020, the 2017 Term Loan requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjA0NzMxMzk2NTE3NA_b9a477c0-cc79-49af-b733-c3960e01be97">3</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="2" format="ixt:numdotdecimal" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMjAxMw_1d09830a-b580-434c-9130-f242a2ff7407">1</ix:nonFraction>% during each subsequent twelve-month period after September&#160;7, 2020.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The 2017 Term Loan is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Term Loan require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The affirmative covenants require that the Company achieve a specified level of revenue, and either (i)&#160;gross margins, or (ii)&#160;gross profits (collectively referred to as the Interest Only Milestones), as measured quarterly on a rolling twelve month basis, and commencing with the quarter ending December 31, 2017 (1)&#160;the interest rate on the 2017 Term Loan will increase by <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="3" format="ixt:numdotdecimal" name="exdx:DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzAzNQ_7bce2709-e0c7-4ed5-b8a3-5799ebe7b107">8</ix:nonFraction>%  and (2)&#160;repayment will commence on the date it is determined the Interest Only Milestones have not been met and over the following eighteen months in equal monthly installments. The consequences of failing to achieve the Interest Only Milestones will be waived if, within sixty days of failing to achieve the Interest Only Milestones, the Company issues additional equity securities or subordinated debt with net proceeds of at least $<ix:nonFraction unitRef="usd" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="-5" format="ixt:numdotdecimal" name="exdx:DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzQ3Mg_68622a63-cce5-41f4-8898-74989e1c9587">9.5</ix:nonFraction> million. In addition, the 2017 Term Loan requires that the Company maintain certain levels of minimum liquidity. If the Company has achieved the Interest Only Milestones, the Company is required to maintain an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzcwNg_6d973030-e262-45f1-994e-4f4e78cefe35">2.0</ix:nonFraction> million. If the Interest Only Milestones are not met, the Company must maintain unrestricted cash balances totaling at least the trailing four months cash used to fund operating activities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The 2017 Term Loan agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At September&#160;30, 2019, the Company was in compliance with all covenants of the 2017 Term Loan.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon an event of default in any of the 2017 Term Loan covenants, the repayment of the 2017 Term Loan may be accelerated and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTI1NQ_5efdf222-d271-4942-bf81-98e6f2e84bbe">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Term Loan due beyond twelve months of the balance sheet date as non-current.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the 2017 Term Loan, the Company paid issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if57cc12cbbd74a1ca2bdcab1be975050_I20170930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTY5OA_d8f841aa-821a-40fa-bf23-731dfd3910b5">0.4</ix:nonFraction> million to Innovatus and an additional $<ix:nonFraction unitRef="usd" contextRef="id95d3234e4504a759f6d486b2d115f8d_I20170930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTczMg_a5ced481-f8a7-4085-9dfd-8f8cf9e43810">0.1</ix:nonFraction> million to third parties. These fees were recorded as discounts to the carrying value of the 2017 Term Loan. The Company also issued Innovatus warrants (i)&#160;on the closing date of the 2017 Term Loan, to purchase <ix:nonFraction unitRef="shares" contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTkzOA_8bf4326e-74da-4188-a1ba-02179bda9b9c">15,384,615</ix:nonFraction> shares of Series F redeemable convertible preferred stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjAyMw_d07fb4be-a931-4de0-8cb8-e0cdb98e22fd">0.078</ix:nonFraction> per share and (ii) on December 7, 2018, to purchase <ix:nonFraction unitRef="shares" contextRef="i4f9edfc62e2b4d1bad85e451eacf5407_I20181207" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjA3OA_a17bfe43-0acb-4c10-8e8b-22a0cbbb57c2">3,846,154</ix:nonFraction> shares of Series F redeemable convertible preferred stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjE2Mw_d07fb4be-a931-4de0-8cb8-e0cdb98e22fd">0.078</ix:nonFraction> per share (Note 5). These warrants are immediately exercisable and will expire if unexercised seven years after their issuance. The fair value of the warrants on each of their dates of issuance, determined using BSM option pricing model, was recorded as a discount to long-term debt and an offsetting amount recognized as a liability. The resulting debt discount is being amortized to interest expense using the effective interest method over the term of the 2017 Term Loan. In connection with the completion of the IPO in September 2019, the Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwOTU2NA_63dd8fdd-32f3-465e-9036-aed16ccc0022">104,722</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Future Minimum Payments on the Outstanding Borrowings</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:4pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ibbffd61f49814b02af9295c752222286"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzI5ODUzNDg5NTcyOQ_e0f7fab8-8ceb-4617-a9d9-cb5648ce805b" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:81.333333%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.935673%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMS00LTEtMS0w_7f82b452-0c9a-4b66-8003-d5803c11fa54">725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMi00LTEtMS0w_475f52f5-a087-48cb-863d-2639e3cc8c11">6,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMy00LTEtMS0w_ec9af286-f992-494b-af36-c0adb606e2cb">14,937</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNC00LTEtMS0w_7e1b6234-9a33-4ca7-b862-1db15481e438">11,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtIncludingUndiscountedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNS00LTEtMS0w_8c6a0c66-8694-43f9-ba93-8dfcbdcf0780">33,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNy00LTEtMS0w_fd4f4dae-367f-4cee-aa24-e946c13c1546">484</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtUndiscountedInterestAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfOC00LTEtMS0w_0f5a537b-f3e5-4336-baa6-8462853b5cf4">6,876</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfOS00LTEtMS0w_56d1e1dd-a54b-45e3-b7ec-34309b7499ff">25,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_55"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 5. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:PreferredStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzI5ODUzNDkyNTk5NQ_e15b51a3-9f40-4dee-8548-44dcc7c09d24" continuedAt="idb516641fa6946289d4dd6be02a251e9" escape="true">Warrants to Purchase Common or Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="idb516641fa6946289d4dd6be02a251e9"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the completion of the Company's IPO in September 2019:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The remaining outstanding Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate <ix:nonFraction unitRef="shares" contextRef="iece3f21b80234006a7c103426a2665ce_I20170930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzg0ODI5MDcyNzk3Mw_02e8203f-48ee-45ba-98f4-5a47c533f223">104,722</ix:nonFraction> shares of common stock.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Warrants to purchase common stock for <ix:nonFraction unitRef="shares" contextRef="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:ClassOfWarrantOrRightExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1Nzk4OQ_8ed4d768-f15f-4948-ab4d-e647751da403">569,184</ix:nonFraction> shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODEwMw_5df86fba-59e4-4a27-adfd-6da0c1853053">512,363</ix:nonFraction> shares of common stock. Unexercised warrants to purchase common stock for <ix:nonFraction unitRef="shares" contextRef="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:ClassOfWarrantOrRightUnexercisedAndTerminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzg0ODI5MDcyNzQ5NA_8e3b5bad-d02a-48a2-9ff4-d395682db0ae">9,054</ix:nonFraction> shares were terminated prior to the completion of the IPO.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Warrants to purchase Series D and Series E redeemable convertible preferred stock for <ix:nonFraction unitRef="shares" contextRef="ia15176551c5942c6996c700737062eb7_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODIwNQ_ed22cc0e-fa1d-467c-8444-d0753e0fa4fe">119,771</ix:nonFraction> shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i7d71efa9a85b42ea9b589b656b2491e8_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODMxMQ_3cb7eb22-e02c-46f6-811a-5d372e462f70">27,431</ix:nonFraction> shares of common stock. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Outstanding Warrants</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzI5ODUzNDkyNTk5Ng_4cde7125-620a-4f17-8c90-ad13c82a8a07" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following warrants to purchase common stock were outstanding as of September&#160;30, 2019:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:27.532164%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.888889%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id6b232544b0e4c3982a50c01fa3beedd_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMS0xLTEtMS03Njgy_2c08f99f-33a9-4505-95c5-48abef22ec97">282,402</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id6b232544b0e4c3982a50c01fa3beedd_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMS0zLTEtMS0xMjYxMA_230448cd-a729-4242-a567-0210aa371fa8">1.84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia072d734c1074dffafc2727ff7d43637_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMi0xLTEtMS03Njgy_096ef89b-c065-4913-bb32-3d643488465a">74,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072d734c1074dffafc2727ff7d43637_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMi0zLTEtMS0xMjYxMA_890e50f2-5409-4681-895a-ca6a82507e42">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icbbd59a27b684af7ad1433a642355d7b_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMy0xLTEtMS03Njgy_85d2cb42-6ba5-494e-a754-d9e3894baf02">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icbbd59a27b684af7ad1433a642355d7b_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMy0zLTEtMS0xMjYxMQ_b7bb9948-ad74-40e0-a5f6-7e7ab540127d">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if49e177a5bc240e58f5c1feec55322b0_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNC0xLTEtMS03Njgy_8660d6fc-34cf-4fca-9e6a-db6c9f0b8549">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if49e177a5bc240e58f5c1feec55322b0_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNC0zLTEtMS0xMjYxMg_784442ea-65a7-4093-b369-9ff4ae156830">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2024</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2dbe833388254c769b6515006ac2d21a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNS0xLTEtMS03Njgy_c4abe3e5-a4a2-4e32-81cb-819381d74bbd">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i2dbe833388254c769b6515006ac2d21a_I20190930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNS0zLTEtMS0xMjYxMw_f2a4f14c-cfaf-4497-a3c6-32966227e791">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNi0xLTEtMS03Njgy_c28ca174-2a44-4f7c-888a-72f5eebc29c4">461,273</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1) Prior to the conversion upon IPO, the remaining warrants were for the purchase of Series F redeemable convertible preferred stock.</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The outstanding warrants to purchase shares of common stock are equity classified at September&#160;30, 2019.</span></div></ix:continuation><div style="text-indent:24.75pt;"><span><br/></span></div><div id="i_0_58"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 6. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzI5ODUzNDg5ODUzNw_41c06ae7-9020-4bd7-8667-dcf00a9a2146" continuedAt="i97d31f38b8b24c51b52dc94e2cfa8c17" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i97d31f38b8b24c51b52dc94e2cfa8c17" continuedAt="i2ebda99ada764a0b90072c2e32bee14c"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk4Ng_7735bdd5-03d3-437b-b3b1-466ce783b25c">14,000</ix:nonFraction> square feet of office and laboratory space in Vista, California, under a lease that expires in January 2021, with options to extend the lease for <ix:nonFraction unitRef="leaseextention" contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="exdx:NumberOfOperatingLeaseExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5ODc_61ca4be9-908e-44f2-8eea-b65bf8175c80">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk5OA_6f9226d5-d271-41a6-a73e-6537edc5578f">36</ix:nonNumeric>-month periods. In addition, the Company also leases approximately <ix:nonFraction unitRef="sqft" contextRef="i049fe228926f4c9398df1295ac08300c_I20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk5NA_b99cf219-0f2e-4013-843d-bfafbd9c2743">19,500</ix:nonFraction> square feet of office space in Vista, California, under a lease that expires in January 2021 with an option to extend the lease for an additional <ix:nonNumeric contextRef="i049fe228926f4c9398df1295ac08300c_I20190930" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2ODAwMg_2569ace1-3181-4ace-a1ef-2e6273a75aa3">24</ix:nonNumeric>-month period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019 and 2018, rent expense was $<ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzg0ODI5MDcwMjg2NA_f417e9d8-c01d-4840-86ea-e6fcad8071c1"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzg0ODI5MDcwMjg2NA_f9887a2f-5e89-4463-abb8-9dc6d8be3c78">0.1</ix:nonFraction></ix:nonFraction> million. For the nine months ended September&#160;30, 2019 and 2018, rent expense was $<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNzgx_479bd037-e70a-4c23-a343-6d6eccf13c01"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNzgx_b3317b01-1641-4b2f-9b51-590d9d39b03b">0.3</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i2ebda99ada764a0b90072c2e32bee14c" continuedAt="i28ed20dfa87647028a5c073ba416d518"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition-related liabilities</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $<ix:nonFraction unitRef="usd" contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODE0MA_2eef1817-e61f-462d-bc16-0e1d9dab1c4a">2.0</ix:nonFraction> million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be <ix:nonFraction unitRef="usd" contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5OTM_92b2015b-097a-415b-9f63-8cca0153636e"><ix:nonFraction unitRef="usd" contextRef="icba0cb4c451d417dbe3f4f8dfab39b44_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5OTM_afb8680a-c9d2-4910-bf24-e9553e9fbf46">zero</ix:nonFraction></ix:nonFraction> at September&#160;30, 2019 and December 31, 2018.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies ranging from <ix:nonFraction unitRef="number" contextRef="i7ec9d6e18a8246b99def6548100abbca_I20190930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODQzNA_85b4c558-50fd-4304-8477-9bf252d79d40">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i97157708442344caa00fafca0fbb5704_I20190930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODQ0MA_64c24cdf-f721-4b61-9977-0c7734a31b2c">7.5</ix:nonFraction>%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i97157708442344caa00fafca0fbb5704_I20190930" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDM5ODA0NjUyMzI4NA_6ec1ae53-750d-4bbd-a7e5-aca8ee8b83d9">4.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930" decimals="-5" format="ixt:numdotdecimal" name="exdx:AdvancePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDM5ODA0NjUyMzI5Ng_165e1f93-0e7a-46b1-a014-7a34147c418c">100,000</ix:nonFraction>) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Licensing Agreements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from <ix:nonFraction unitRef="number" contextRef="i9cdbf37439b04f6980d34a5eb0f08877_I20190930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDQ2MQ_830bb94e-b103-4573-9a81-18ce2cdaa4c9">3.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4d2cf5de0966423685b89de08ef5d10f_I20190930" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDQ2Nw_52734ee5-ba03-41ee-86f4-091984f256e7">20.0</ix:nonFraction>%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Supply Agreement</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into a supply agreement with one supplier for reagents which includes a minimum annual purchase commitment of $<ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDc0OQ_86be8b13-2784-47cf-b750-7381685ff23e">3.25</ix:nonFraction> million for each of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjEwMDA_c43a2b30-47ae-46c0-8186-19be08bba125">three</span> years covered by the agreement, which terminates in 2021.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i28ed20dfa87647028a5c073ba416d518">The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities.</ix:continuation> </span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div id="i_0_61"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 7. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3MA_8a4130a9-ec8a-48da-926b-5bd705388fd6" continuedAt="i4035329b8e0c47ac878412e63b513430" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i4035329b8e0c47ac878412e63b513430" continuedAt="i680f543ee78a4de0bf4925c4fff877ff"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3MQ_ab503b78-df80-4db5-9492-54ae853248f6" continuedAt="ib0923d2f09fe432abc2d7fe11c331f13" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:52.970760%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.526316%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aeb522a5a804c1ab10f04b766c6d235_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy0yLTEtMS0zMTQ2_43bc48ef-cbe1-4b66-8132-17fe7c65b384">71,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8cdfd7d55d447c6a6ba587c0fb72778_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy00LTEtMS0zMTQ2_b9606bf0-20c4-4872-af4f-122b0daae0c9">71,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8396f778183403a8b3d18137e1d7154_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy02LTEtMS0zMTQ2_633b4763-8094-484c-a14e-163e2891076c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5b7d6be4807402181770f969bd3b3c8_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy04LTEtMS0zMTQ2_abe971d1-bbc2-4788-9dee-ac9d0685232b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i680f543ee78a4de0bf4925c4fff877ff"><div style="margin-bottom:6pt;"><ix:continuation id="ib0923d2f09fe432abc2d7fe11c331f13"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:52.385965%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cc77115ea38400ebaa8de4fdf3c7cd9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC0yLTEtMS0w_db749146-3be9-4a75-93f5-4bec3420b172">8,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1c4da20970f49bab695c3ca35f9f79a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC00LTEtMS0w_21201df3-a915-45b3-a2a6-e093f4fb704e">8,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202d9a2d99d343aeb330da6b95303d98_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC02LTEtMS0w_4585ac9c-f6bd-46c8-83e2-baa039254853">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i578d8c5006254318b4ecbd98581f9308_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC04LTEtMS0w_93c582c3-7c94-41ea-8baf-f52e414b1218">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib206ca9a730640ff880db0ca2948c48f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi0yLTEtMS0w_378200f3-8a54-4182-8e8f-2277ba9b1ca5">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48be9f8c11ab46a0a2b04915df9f4383_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi00LTEtMS0w_7e5832f5-e2a4-4a5f-a226-a7985da67021">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife24fcb5063e4bf2a8ca790bfd29a229_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi02LTEtMS0w_a909122d-41f8-4abc-b425-8cedd4011469">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i08cb01ea319e4dcf9a9ae2d18095b29c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi04LTEtMS0w_aae0edc4-0a32-4bf6-9692-952876376589">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company's money market funds is based on quoted market prices.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3Mg_bf6701cf-17ab-4290-9a33-d07ddea0db20" escape="true"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes a roll-forward of the financial instruments measured on a recurring basis and classified within Level&#160;3 of the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:82.941520%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liability<br/>Classified<br/>Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib871a4638845441c862fde06e4cc74f2_I20171231" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS02LTEtMS0w_69d80e43-d036-4598-a389-82395e58372e">896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTAtNi0xLTEtMA_a4df30f9-af19-43b2-87d9-ea1377d5a19b">289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTEtNi0xLTEtMA_317c40dd-c68e-4554-a395-403103e9e42b">318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab6de603a8d9482782ee114aee3bf819_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTItNi0xLTEtMA_a03baf9e-3003-4cf0-9b32-ea3d3a7dd328">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOC00LTEtMS0zMTc1_4f80ca8e-f2c2-4779-b0e1-6cad46eb1e5d">267</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfNy00LTEtMS0xMzQ3Mg_0cefa240-7823-4a0f-bdf0-6497bebc7ccd">510</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of liability classified warrants to stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS00LTEtMS03Nzk5_77b62f9a-4663-4728-b141-b167c60a4db8">726</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18c74d0be6304b29b0107390ce9abeec_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS00LTEtMS0zMTc1_17520d47-ca91-4ff1-902e-d1f7700c60e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Changes in the fair value of the Company's liability classified warrants are recorded in the line item change in fair value of financial instruments in the accompanying condensed statement of operations.</span></div></ix:continuation><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_64"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 8. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="exdx:TemporaryEquityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzOTMxNjI4NTc2MzU_60f48b20-8620-4060-adfe-0be999ae79a2" continuedAt="i738cc03cc7af407792ff04ab50f8b632" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="i738cc03cc7af407792ff04ab50f8b632" continuedAt="i32e73d01c320488e8fc9a0ba5761c9a0"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of convertible preferred stock from <ix:nonFraction unitRef="shares" contextRef="i51991cbb9983403c883bb01e0ecacfe4_I20190101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMjkz_489e3bde-b127-4d90-b0f0-fec0adf9623a">750,300,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="if76ec7383c01495aa62e382bd4f709f7_I20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMjk5_87c506e7-4b58-479a-8a22-de85da1e3926">955,500,000</ix:nonFraction> shares, of which <ix:nonFraction unitRef="shares" contextRef="i6ac11f467d4a414d8b4dc99e134c6b38_I20190102" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzE4_3f1f5842-dc67-47b5-909a-9f343327cb60">205,200,000</ix:nonFraction> shares are designated as Series G convertible preferred stock and set forth the rights, preferences and privileges of the Series G convertible preferred stock.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On July 11, 2019, the Company amended and restated its restated certificate of incorporation to among other things, increase its authorized shares of convertible preferred stock from <ix:nonFraction unitRef="shares" contextRef="ia414d6d243b647818871ad407f657257_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTM5Mw_a2d0b798-b099-475b-b78d-77e8bacd8b80">955,500,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i9f3012c64b3841629d97963b5c65859a_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTQwOA_77997fcc-00fd-4dd5-8017-9822a1a1c9e3">1,038,667,059</ix:nonFraction> shares, of which <ix:nonFraction unitRef="shares" contextRef="ibd111bb967164dd1b749064f44fe4ace_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTQyMQ_dab42acd-c205-4111-941e-6fca7e7abc16">479,967,595</ix:nonFraction> shares are designated as Series H redeemable convertible preferred stock and set forth the rights, preferences and privileges of the Series H redeemable convertible preferred stock.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon completion of the Company's IPO in September 2019, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU1NzY2MQ_caee41ab-e6c5-409e-9933-5421f380e683">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of redeemable convertible preferred stock remain outstanding at September&#160;30, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series F Financing</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company's Board of Directors authorized a third tranche closing of the issuance to existing preferred stockholders in connection with the Company's Series F financing, which was completed between December 2017 and January 2018. In December 2017, a group of existing investors of the Company purchased <ix:nonFraction unitRef="shares" contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI3Mw_f72200ec-b2d7-4b40-9842-75d4505f72b4">54,246,756</ix:nonFraction> shares of Series F redeemable convertible preferred stock at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI4MQ_a379d07a-e67e-4da4-80c7-ab07d6708b2e">0.078</ix:nonFraction> for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231" decimals="-5" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI5NQ_9e2dcbba-86d3-4ac7-b797-65fe8d831799">4.2</ix:nonFraction> million. In early January 2018, a group of existing stockholders of the Company purchased an additional <ix:nonFraction unitRef="shares" contextRef="i6821094327564f7ba91627dc90eeb669_D20180131-20180131" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODMwNw_3285e295-619f-4c92-8fac-eca1c583d833">34,914,327</ix:nonFraction> shares of Series F redeemable convertible preferred stock at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id07edc4e5b92475b8e47bad4f0b1c23f_D20180101-20180131" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNTQ5NzU1ODIwNzY2Mg_1bbdcd43-3180-45e3-878c-16333b2fdd94">0.078</ix:nonFraction> for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i6821094327564f7ba91627dc90eeb669_D20180131-20180131" decimals="-5" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODMxMw_60cfdcab-ee22-42f0-98fa-3ff11976559a">2.7</ix:nonFraction> million.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the third tranche closing of the Series F preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series F redeemable convertible preferred stock, and </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i32e73d01c320488e8fc9a0ba5761c9a0" continuedAt="i4600a9f3877b488db7c4c49732e5305a"><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">the Company determined there were no embedded features requiring bifurcation in the shares of Series F redeemable convertible preferred stock issued in the third tranche closing. The Company accounted for the difference between the estimated fair value and the $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODM2MQ_a379d07a-e67e-4da4-80c7-ab07d6708b2e">0.078</ix:nonFraction> per share purchase price of shares of Series F redeemable convertible preferred stock issued in the third tranche closing as a deemed dividend since all investors in the third closing are existing preferred stockholders of the Company, and the Company did not identify any elements to the transaction which it believes were compensatory in nature. As a result, the Company recognized a deemed dividend in the amount of $<ix:nonFraction unitRef="usd" contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331" decimals="-5" name="exdx:TemporaryEquityDeemedDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODM2Nw_945240bc-24a3-4f33-b70c-46e80def7390">1.2</ix:nonFraction> million in the first quarter of 2018, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#8217; deficit.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series G Financing</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjExMw_7cccd428-1e4c-4776-a8bc-ada942cedbd2">0.078</ix:nonFraction> in each closing. Shares of Series G redeemable convertible preferred stock were issuable under the Series G preferred stock purchase agreement until the earlier of March 31, 2019 or the issuance of all authorized shares of Series G redeemable convertible preferred stock, as specified in the Company's amended and restated certificate of incorporation.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2019 and March 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzMjg_16566775-7c68-424b-84d5-5d9ff1be349e">88,030,905</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8b4fe828275f44fdbff0acdc8da1a56f_D20190301-20190331" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzMzU_2f8bc609-982c-4de3-929b-8e5035f6227f">9,615,384</ix:nonFraction> shares, respectively, of Series G redeemable convertible preferred stock for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i3ecfcc3c27f94cccbdb02d3266aed9c6_D20180101-20190331" decimals="-5" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU0NTc_37e04251-6f51-4bd3-bb37-776455c5313a">7.6</ix:nonFraction> million to new and existing investors, of which $<ix:nonFraction unitRef="usd" contextRef="i34cec7509c0b444690051ce059a40fc2_D20180101-20181231" decimals="-4" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU1MDA_485c5b1b-9738-4338-9e9b-21999dc6a738">3.75</ix:nonFraction> million of gross proceeds were received as of December 31, 2018 and are included in the accompanying December 31, 2018 balance sheet.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU2NDk_732b8536-825f-4520-b5bd-275ea2ffbde7">51,282,048</ix:nonFraction> shares of Series&#160;G redeemable convertible preferred stock for aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU3NTY_014010da-c715-4845-a003-28f18ace7449">4.0</ix:nonFraction> million to existing investors.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, in May 2019, the Series&#160;G preferred stock purchase agreement was amended to include the right of the Company to require certain holders of Series&#160;G redeemable convertible preferred stock to purchase an additional <ix:nonFraction unitRef="shares" contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquityRightsForMandatoryPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU5OTk_2a688f27-48b0-44c8-9cdb-1551bb12dd5a">32,051,280</ix:nonFraction> shares of Series&#160;G redeemable convertible preferred stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131" decimals="3" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjEyMg_7cccd428-1e4c-4776-a8bc-ada942cedbd2">0.078</ix:nonFraction> per share, for total aggregate proceeds of $<ix:nonFraction unitRef="usd" contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531" decimals="-5" name="exdx:TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjEyOA_cb71d366-4b45-406c-8f18-d3dab504e97c">2.5</ix:nonFraction>&#160;million, at any time after July&#160;31, 2019 and prior to May&#160;31, 2020. This right terminated in connection with the issuance of the Series H redeemable convertible stock in July 2019.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the closings of the Series G preferred stock purchase agreement in January and March 2019, contained a single freestanding financial instrument, shares of Series G redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company concluded the closing in May 2019 contained two freestanding financial instruments, shares of Series G redeemable convertible preferred stock and the Company call right, and the Company concluded there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company call right was deemed to have nominal value since it was with insiders with knowledge of the imminent closing of Series H redeemable convertible stock.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series H Financing</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731" decimals="5" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjI3Ng_ee9f048f-4f38-48a3-b9c8-828048f9a239">0.04712</ix:nonFraction>. Pursuant to the terms of the agreement, the new investor purchased <ix:nonFraction unitRef="shares" contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731" decimals="INF" format="ixt:numdotdecimal" name="exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjM0Nw_2ddc0804-88e9-4d53-bac7-964715217c95">233,446,519</ix:nonFraction> shares of Series H redeemable convertible preferred stock for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731" decimals="-5" name="exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjM5Mw_73c36e0c-5e6e-4bb4-a739-2e5a74894dad">11.0</ix:nonFraction> million. In connection with the Series H financing, the Company converted all of the <ix:nonFraction unitRef="shares" contextRef="i3a943c5b22a147a0a01ed7c2ddc3799b_D20190701-20190731" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesRedeemedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjQ4MQ_94c991e0-35d1-4b18-aabb-c8fa06142f68">148,928,337</ix:nonFraction> outstanding shares of the Company's Series G redeemable convertible preferred stock into <ix:nonFraction unitRef="shares" contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731" decimals="INF" format="ixt:numdotdecimal" name="exdx:TemporaryEquitySharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjU5Nw_9d1055af-d454-4f96-9431-3dd94111500e">246,521,076</ix:nonFraction> shares of Series H redeemable convertible preferred stock on a dollar-for-dollar basis.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the closing of the Series H preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series H redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series H redeemable convertible preferred stock issued at closing. The Company accounted for the difference between the effective conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731" decimals="5" name="exdx:SaleOfTemporaryEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzOTMxNjI4NTc2MjY_f3845e96-4442-4c1b-9fac-39fa7c1484b8">0.04712</ix:nonFraction> and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $<ix:nonFraction unitRef="usd" contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930" decimals="-5" name="exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU3MjM0Mw_4053e420-1d1f-43cc-a5ab-02a0852663c1">6.7</ix:nonFraction> million in the third quarter of 2019, that was </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4600a9f3877b488db7c4c49732e5305a">recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#8217; equity (deficit). Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-5" name="exdx:TemporaryEquityDeemedDividend" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDc2NjAwMQ_885e405c-b696-488a-ae05-8d1e0203c323">6.9</ix:nonFraction> million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders' equity (deficit).</ix:continuation>  </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_67"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 9. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTg_8819dbbe-2eb2-412d-8fd9-43cf0edaa1f5" continuedAt="i7fc1ee2a6d374e44bdbdc001b684c348" escape="true">Stockholders' Equity (Deficit)</ix:nonNumeric></span></div><ix:continuation id="i7fc1ee2a6d374e44bdbdc001b684c348" continuedAt="i5050d1fa612b4bd99bb39c1ef59aac99"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things,&#160;increase its authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTc_93e805e4-4437-43d5-8f0a-3779cd76531a">1,470,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i74d7a070fb6e417cbecca982fcd80243_I20190131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTY_3b37a05d-4bfb-4343-b64c-d75e609bd177">1,675,200,000</ix:nonFraction> shares.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On July 11, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="ia414d6d243b647818871ad407f657257_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDIzMw_1c8cbf1f-8ad0-4af7-9f7f-6396892c89d8">1,675,200,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i9f3012c64b3841629d97963b5c65859a_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDI0OA_ae42c846-c67d-4b27-9707-4b600793c81f">1,970,000,000</ix:nonFraction> shares.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company filed its amended and restated certificate of incorporation on September 23, 2019, authorizing <ix:nonFraction unitRef="shares" contextRef="i1936657650f8443fb7d623789b65864b_I20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDMwMg_2ca9b673-9635-4292-af91-8bb586dfbe9a">200,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i1936657650f8443fb7d623789b65864b_I20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDMxNA_024aaf19-c7f8-42c3-9e35-8f64a2f91e2f">10,000,000</ix:nonFraction> shares of preferred stock.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5050d1fa612b4bd99bb39c1ef59aac99">On September 23, 2019, the Company closed its IPO of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMzk5Mw_b8321d76-8995-4279-a50a-73c1a113baa3">4,140,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDA1MQ_3209b701-bb95-48c2-81c4-ee5613ad1f19">14.00</ix:nonFraction> per share, including the exercise in full by the underwriters of their option to purchase <ix:nonFraction unitRef="shares" contextRef="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDE0NA_77f6876f-b2ee-4618-9a3b-45939a8cb794">540,000</ix:nonFraction> additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $<ix:nonFraction unitRef="usd" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDMwNQ_364a8089-7538-4213-82d3-06878d33c6e3">50.5</ix:nonFraction> million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923" decimals="-3" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDQzOQ_38d94116-98ba-41f4-9d8a-fc03f372f8ca">7.5</ix:nonFraction> million. In addition, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfNTQ5NzU1ODE0NTI1NA_caee41ab-e6c5-409e-9933-5421f380e683">7,816,643</ix:nonFraction> shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.</ix:continuation> </span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div id="i_0_70"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 10. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTQ_edc7fbfa-b206-44fd-baa0-50ef41efcae2" continuedAt="i8ce0649b74cc41ea89148e0d80b41efd" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i8ce0649b74cc41ea89148e0d80b41efd" continuedAt="i26a7b06d838d4838ae14f2eb726422b4"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2012, the Company's Board of Directors adopted the 2013 Stock Option Plan (the Plan). Pursuant to the Plan, employees, consultants, and directors may be granted either incentive stock options or non-qualified stock options to purchase shares of the Company's common stock. In July 2019, the number of shares reserved for issuance under the Plan was increased from <ix:nonFraction unitRef="shares" contextRef="i6966cf5374bc41b5875121d7c8d99c81_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzY5NQ_69763633-f112-4260-842e-28ffeaa552fc">669,806</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="ief83568c465c465ab430cf56fab8b518_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzY5Mg_a88945ca-cd08-4666-9b0f-cc0b6881ada5">1,663,681</ix:nonFraction> shares. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total of (i) <ix:nonFraction unitRef="shares" contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzcwNg_07c4df66-acc0-4acc-98ff-d1e911de008f">2,011,832</ix:nonFraction> shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and will initially be reserved for issuance under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be increased annually on the first day of each fiscal year during the term of the 2019 Plan, beginning with the 2020 fiscal year, by an amount equal to <ix:nonFraction unitRef="number" contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzM_b180136c-fdac-4533-a06a-07713c24c758">4</ix:nonFraction>% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year or such smaller amount as the Board of Directors may determine. As of September&#160;30, 2019, <ix:nonFraction unitRef="shares" contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfNjA0NzMxMzk2NTE0NQ_9035e737-e784-4116-bdce-0abb8c47f9c2">1,199,631</ix:nonFraction> shares remained available for future awards.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The options generally expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzU_c6825e11-0fc3-4e9f-9041-6ef37ef4651d">ten</span> years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODA_bc7e3512-1d71-474f-a1f3-d50463190609">four</span> years from the date of grant.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODc_b1a71e7b-bc14-4108-9521-6df07456b2eb" continuedAt="i0d7b646791b541e88264519697887dc8" escape="true"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i26a7b06d838d4838ae14f2eb726422b4"><div style="margin-bottom:6pt;"><ix:continuation id="i0d7b646791b541e88264519697887dc8"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.953216%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.011696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi0yLTEtMS0w_593bdda1-e3f4-47e9-a19b-8dcf9961ec14">661,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi00LTEtMS0w_c6868840-b620-411b-8ed0-6dd18ab493ce">1.22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi02LTEtMS0w_fe8372ce-8b02-4b46-a9cf-4ad59422ff56">9.52</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi04LTEtMS0w_7f9d76c4-4f54-4c8b-bf51-020d76c84588">6,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNy0yLTEtMS0w_356d4ad1-40dc-460b-a856-7672fc0f64ff">814,339</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNy00LTEtMS0w_5f323241-b2a8-4f54-ac54-d4f470d7e590">13.99</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOC0yLTEtMS0w_a060b67f-7752-4423-adbf-6a4fc02feff3">50</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOC00LTEtMS0w_81d84c5d-db17-45a3-bd3a-847d1f676045">1.84</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOS0yLTEtMS0w_9c468134-4555-4769-90bc-ebb8831d9d77">310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOS00LTEtMS0w_88c9a771-d09f-4055-9688-a468d34d9196">5.75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTAtMi0xLTEtMA_5d55ff91-0d62-4cfa-ba61-c61e6befbb79">153</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTAtNC0xLTEtMA_c8e47e66-d80a-4c56-9a47-9e507d3c788d">37.20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Outstanding, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtMi0xLTEtMA_5baaab90-d896-40ce-855d-dd55e6775b26">1,475,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtNC0xLTEtMA_8229d58d-717a-4759-ba29-a825415ddf6a">8.26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtNi0xLTEtMA_18897431-ab51-4668-9fd4-99e6b3b1d57f">8.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtOC0xLTEtMA_f8fbbad7-fa94-4eb4-9d38-2286840a49da">10,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Vested and expected to vest, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtMi0xLTEtMA_61024eca-4da9-4570-a774-caf56ad669ea">1,475,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtNC0xLTEtMA_8512ff54-3ef8-4927-b973-8bc9552c5e9d">8.26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtNi0xLTEtMA_61d7f751-21e3-4fee-8d06-3ffb096bbaaf">8.89</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtOC0xLTEtMA_b807f8c3-8f33-481a-9113-f8742ad80224">10,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercisable, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtMi0xLTEtMA_315a4c3e-dd56-4c38-a046-6fbeef997046">20,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtNC0xLTEtMA_2db7bd32-ed4c-4387-9c7c-f23b28cb3055">30.74</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtNi0xLTEtMA_e434adf1-67cd-48e8-8a1a-ee7892a30428">4.56</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtOC0xLTEtMA_6dc55a55-afd3-477d-a436-7d0890811597">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODg_ebb95503-48c3-467d-a8e9-70d2f0a4b6af" escape="true"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:45.953216%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.280702%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi0yLTEtMS0w_83701106-3c52-4666-bada-d53c3101ed44">59</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi00LTEtMS0w_4a9052b4-f418-468b-a971-6519a1869c0c">70</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi02LTEtMS0w_f77d29c4-6903-4a95-b13c-27257805d39c">59</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi04LTEtMS0w_c743858e-0e20-4b4b-85ff-7a80955cca3a">70</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy0yLTEtMS0w_e9196aff-cde6-4dd4-84fd-58e991d6ffba">2.0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy00LTEtMS0w_c5fbb0d7-1b54-4595-8c13-65518098b07d">2.6</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy02LTEtMS0wL3RleHRyZWdpb246YjJjZmY2ODNhYTU1NGRjOGI1NDAzY2Y1Y2E2YmQ0MjBfMTUzOTMxNjI3ODg4Nzk_fa8452c9-5703-4abc-845c-bbb7cd43bc4a">2.0</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy02LTEtMS0wL3RleHRyZWdpb246YjJjZmY2ODNhYTU1NGRjOGI1NDAzY2Y1Y2E2YmQ0MjBfMTUzOTMxNjI3ODg4ODU_f27f4d2f-7986-4d7e-95e7-ea4f8745ef67">2.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy04LTEtMS0wL3RleHRyZWdpb246MjVkMmU4OWI3ZmZiNDU1Mzg4ZjljYTU4MjE5YjE4MWFfMTA5OTUxMTYyNzc4MA_1bfe4600-5c1b-41bc-b657-6780b57297e9">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy04LTEtMS0wL3RleHRyZWdpb246MjVkMmU4OWI3ZmZiNDU1Mzg4ZjljYTU4MjE5YjE4MWFfMTA5OTUxMTYyNzc4NQ_fbe19310-3d78-4924-8809-9b20e715f167">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC0yLTEtMS0w_a6db7bf5-6bff-485c-843d-eaf1504b1de0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC00LTEtMS0w_9790f6cc-9fc3-485b-9257-03da1e953398">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC02LTEtMS0w_656889a3-5f9f-4f4f-8839-634881dcdde0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC04LTEtMS0w_b3f33377-1ea4-4df4-a1b9-2a4e6d3d70ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="iae39458ccf0d427992cbe4b9527b3bf2_D20190701-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS0yLTEtMS0wL3RleHRyZWdpb246NGI0ZjE1MTA5NGU3NGI4NGEwMzI3Y2M5YWJjYzJiODhfMzI5ODUzNDg4MzM0NQ_6ab2c87b-9508-4e0b-9d69-4e0e1a092a67">5.75</ix:nonNumeric>-<ix:nonNumeric contextRef="iebae713e20d543688dfbdbe7e08cf864_D20190701-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS0yLTEtMS0wL3RleHRyZWdpb246NGI0ZjE1MTA5NGU3NGI4NGEwMzI3Y2M5YWJjYzJiODhfMzI5ODUzNDg4MzM1MA_856be53c-49dd-4e2f-8788-b0f42d91990a">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS00LTEtMS0w_0431d0bd-1044-4dde-be88-90a4d8f77d51">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i4c5dcfbeb31e4eb58cbd0c160cec9a94_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS02LTEtMS0wL3RleHRyZWdpb246ODE2MmE0YjVkODdjNGE4NGJhN2YxMTdkMGI5OTdmNGZfMzI5ODUzNDg4MzM0NQ_6e13a166-11d7-4a6a-bb5b-cada12f579bd">5.75</ix:nonNumeric>-<ix:nonNumeric contextRef="if0c70eba81b941949fd1d670216abba6_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS02LTEtMS0wL3RleHRyZWdpb246ODE2MmE0YjVkODdjNGE4NGJhN2YxMTdkMGI5OTdmNGZfMzI5ODUzNDg4MzM1MQ_e7e6e6e8-a965-40ab-bbc3-685f448b60d4">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS04LTEtMS0w_f61fe8d7-8157-46e9-a84b-645845cb939f">6.08</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODk_14c75341-20f7-46b6-978f-3bdb12a97170" escape="true"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock-based compensation expense recorded related to options granted in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:38.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.181287%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035088%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.181287%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.181287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ecd63e9c5f4460db504293975df2da0_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi0yLTEtMS0w_d50962a9-f713-4a74-b463-74232248a776">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icda4e23b775541d98dd6601b0687861c_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi00LTEtMS0w_cff0139d-26c5-4695-b8db-8db5a805f9a3">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8317e42cca1547e9993f03b3818b96f3_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi02LTEtMS0w_0a215f4c-25c0-47e7-81d7-cc266b339e38">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23dea42dd5f74d579f2d9bf2d1dd0899_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi04LTEtMS0w_07ab0461-d0ba-4420-b90b-66ed7e07209f">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie58c1033dd94444781da3f845ffefc22_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy0yLTEtMS0w_3cddd339-5418-4b82-8d24-7ec021e9a35c">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icefda7fbf4b24e1c95147ec5fc5fbd6a_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy00LTEtMS0w_77f7dec2-85c8-47d8-968e-41b642caabf7">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c606ae405a1436dae303d8eb1512adc_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy02LTEtMS0w_8e34afdc-4d90-447e-a70f-76b459ff977b">73</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99104c1c22ba4f62b010859df135eb14_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy04LTEtMS0w_428a01df-7f1e-479b-91e8-48f727302c91">83</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i39b3ab090ddd4194a42e7530e862e17f_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC0yLTEtMS0w_30635c04-d761-4024-b73e-3db00231d079">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i156a4580a77d4e07840641d780bf4cf0_D20180701-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC00LTEtMS0w_0a9a88e8-630b-41a3-82f2-571499c58b01">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c0fd8531c4e483bb241496bd66cde52_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC02LTEtMS0w_1626c82b-3ec9-42e9-830a-a6ec30236788">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib98b0d24446a4951aa7a1010ab0bfe0a_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC04LTEtMS0w_f4c14193-8248-44e9-9d5a-95c661389040">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS0yLTEtMS0w_82b8801f-c4c3-4337-8d85-a084ad75d91f">62</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS00LTEtMS0w_f3ffb0f8-7201-44b8-8ee7-c46e6dd042cc">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS02LTEtMS0w_c9b1b24c-82da-4ee1-8fb8-da72c842f1f8">85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS04LTEtMS0w_0128c1c1-86f9-419c-ac3c-7d7ed58baa06">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, total unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="i9e798451cd564d85a050ce8581db466a_I20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTk0NQ_80dc7e11-e82c-4385-9c6f-4a9a9f0d377a">6.4</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzgxMw_1e88240d-2f2e-4fe1-9bc4-81a13c394bf5">3.5</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODU_2cb89625-0456-486c-95f2-f795df54b107">20</ix:nonFraction>% of their eligible compensation. A total of <ix:nonFraction unitRef="shares" contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzgyMg_ea220c37-d4c2-433f-ba55-3e6271ea9376">120,000</ix:nonFraction> shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 fiscal year, by an amount equal to <ix:nonFraction unitRef="number" contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930" decimals="INF" format="ixt:numdotdecimal" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODY_d2f328de-7cf8-4f28-9350-96e2d2ea8657">1</ix:nonFraction>% of the total number capital stock outstanding on December 31 of the preceding calendar year or such smaller other amount as the Board of Directors may determine. There has been <ix:nonFraction unitRef="usd" contextRef="i88c8b9c0ae1445a795a53d86906d1dc1_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTM_52106542-6eb8-4016-83f6-41a74f08c674"><ix:nonFraction unitRef="usd" contextRef="ide5daf739bda4ce99c2faed14eefff7e_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTM_8346be50-9868-4906-93af-94a3b99dafb7">no</ix:nonFraction></ix:nonFraction> stock-based compensation expense incurred related to the ESPP for the three and nine months ended September&#160;30, 2019.</span></div></ix:continuation><div style="text-indent:24.75pt;"><span><br/></span></div><div id="i_0_76"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 11. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NTQ_6fc97e77-cb68-4e12-a884-cb13dfe9c9b7" continuedAt="i7ad13590f08842cfbeafb3313c052dde" escape="true">Related Parties</ix:nonNumeric></span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7ad13590f08842cfbeafb3313c052dde" continuedAt="idbe2807ff3d0440ebfc16acb39c5f2c4">The Company entered into a consulting services agreement, as amended, with a member of the Company's Board of Directors under which this board member provides certain scientific consulting services to the Company. Under this agreement, as amended in June 2018, this board member is compensated at a bi-weekly rate of $<ix:nonFraction unitRef="usd" contextRef="ic5649d541959437c953f9b7daa0a171d_D20180601-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfNTQ5NzU1ODE0NzUxMg_0e23f8cd-012c-4a40-8eea-1954054fa102">5,000</ix:nonFraction> </ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="idbe2807ff3d0440ebfc16acb39c5f2c4"><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(plus reimbursement for certain administrative and travel related expenses) and received options to purchase <ix:nonFraction unitRef="shares" contextRef="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTA3NQ_5c6763fa-0da2-4e15-8235-48ba8ca58fd3">544</ix:nonFraction> shares of common stock in November 2017, the commencement date of the agreement. Total amounts paid to this board member under this agreement for the three months ended September&#160;30, 2019 and 2018 and the nine months ended September&#160;30, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="i23243689232c443f8220af8eb34ad150_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM0NA_ba679deb-1295-4d62-9526-b00a31768d85">30,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i61985dc8dff1424b8c09ade62daae302_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM0OA_b8a52149-c47f-4ddb-9f78-e28eba859326">30,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i92647d4518404696ab919e985542dc23_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM1Mg_73ef0962-d01d-4db5-b49e-6bc1893531f2">95,000</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i2c33b5d4543e4472a07114c686f5e1ba_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM2MA_394e6665-2c34-490d-ba2c-47bd40b143cb">91,000</ix:nonFraction>, respectively, which was recorded in research and development expenses in the accompanying condensed statements of operations. The Company accounted for the grant of options as an award to a non-employee and measures compensation cost for this award based on the value of the award at the date the consulting services are complete. The options granted to this board member were granted at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfNDM5ODA0NjUxOTk4MQ_b180f53e-e7c5-4ae2-aa37-18fe44547de4">0.367</ix:nonFraction> (the estimated fair value of share of common stock on the grant date using an OPM model), and vests over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NDg_b98a8d34-8542-45c3-b460-7428b1e5f9cc">three</span>-year term expected to coincide with the period the board member is expected to provide consulting services to the Company. The estimated fair value of the awards and related compensation cost recognized during the three and nine months ended September&#160;30, 2019 and 2018 was immaterial. All compensation cost related to these awards is recorded in research and development expenses in the accompanying condensed statements of operations. Effective July 12, 2019, this consultant no longer serves on the Company's Board of Directors.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2011, the Company entered into a license agreement with the Company's Chief Scientific Officer, and a related company, De&#160;Novo Diagnostics, Inc. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by the Company's Chief Scientific Officer prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company's Chief Scientific Officer will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930" decimals="-3" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMzU5Mg_1b0c1e97-d9b4-4f2c-b8cf-11c0f28e4681">0.6</ix:nonFraction> million upon the achievement of certain sales milestones and an ongoing royalty of <ix:nonFraction unitRef="number" contextRef="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930" decimals="2" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMzY3MA_7f337a03-bbcf-49da-aa78-4b7607cbac9e">5</ix:nonFraction>% on sales.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The third tranche closing of the Series&#160;F financing and the closings of the Series&#160;G financing described in Note 8 were issued to existing holders of the Company's redeemable convertible preferred stock.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div id="i_0_82"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 12. <ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:AccountingChangesAndErrorCorrectionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RleHRyZWdpb246ZGMxYmQ2YmExNDM5NGZiYmI2YTJjNDk0ZjYzOGNjNmVfMTUzOTMxNjI3OTAwMjI_bc0ad587-6f76-423c-988c-9a4699f5efa2" continuedAt="i7398943304f14920b47789921b138329" escape="true">Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018 </ix:nonNumeric></span></div><ix:continuation id="i7398943304f14920b47789921b138329" continuedAt="i55e9315c19f44288892d05bab78dfead"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During 2019, Company management identified immaterial misstatements in the financial statements for the year ended December 31, 2018 related to the carrying value of redeemable convertible preferred stock warrant liabilities. Based on a quantitative and qualitative analysis of the error as required by authoritative guidance, management concluded that the correction, which decreased the carrying value of the redeemable convertible preferred stock warrant liabilities with a corresponding decrease in net loss, had no material impact on the Company's previously issued financial statements as of and for the year ended December 31, 2018. These amounts have been adjusted in the accompanying balance sheet and statement of operations.</span></div><ix:nonNumeric contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RleHRyZWdpb246ZGMxYmQ2YmExNDM5NGZiYmI2YTJjNDk0ZjYzOGNjNmVfMTUzOTMxNjI3OTAwMjM_838b7678-be99-45fd-ae8a-f657e26fdaf8" continuedAt="i678d04a66cda449c8dc0dd067d88f1ed" escape="true"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The revision to the Company's previously reported balance sheet are identified in the table below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:55.894737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.304094%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.304094%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.304094%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi0yLTEtMS0w_2a065fd8-181c-4043-9b59-edd3f3c98404">2,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi00LTEtMS0w_4fab0d68-f1c8-49f4-93b8-b06c6911963e">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi02LTEtMS0w_4056c081-2ba6-4be2-9764-905a52a30b5e">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy0yLTEtMS0w_c319df53-1a5d-4ea4-9c1a-3afbf0e94540">36,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy00LTEtMS0w_c993e047-f433-4590-a49f-20c521b9e968">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy02LTEtMS0w_8094ba2b-c47b-45d1-b172-a5d99914b394">35,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC0yLTEtMS0w_a91bcba7-80c9-4880-980a-929049e6ab28">153,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC00LTEtMS0w_f48f8c19-9e81-4664-a14a-be717e09850b">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC02LTEtMS0w_69b7fea1-6281-4357-bed4-22ec3d17f81e">152,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS0yLTEtMS0w_21e18bc2-b4e9-42ff-b4a8-e705f7a8ac54">113,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS00LTEtMS0w_b261ca1d-443a-45c1-9829-85bf76ecd602">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS02LTEtMS0w_c9372c8c-687d-43e7-9bba-3b645adc10a9">111,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A revised rollforward of the Company's warrant liabilities is as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="i55e9315c19f44288892d05bab78dfead"><ix:continuation id="i678d04a66cda449c8dc0dd067d88f1ed"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:52.239766%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bb1b252737849b5896adb5e69e39207_I20171231" decimals="-3" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS0yLTEtMS0w_5eed1c13-70e8-44a4-8c5b-70b1966ad861">896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i050d48ebbcd24210b1475a4d33bb14c6_I20171231" decimals="-3" format="ixt:zerodash" name="exdx:PreferredStockWarrantLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS00LTEtMS0w_79e42fae-6092-48ef-862e-700684c80f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231" decimals="-3" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS02LTEtMS0w_3d2a1b82-4b55-403a-8365-a78ec4317dbc">896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series&#160;F redeemable convertible preferred stock in connection with 2017 Term Loan (Note&#160;4)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi0yLTEtMS0w_9efe6db6-b180-4070-8bd7-38ff47f97c89">289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi00LTEtMS0w_94390932-3ca9-44e2-beeb-e63fc4111f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi02LTEtMS0w_be21fb9d-f2e7-4034-bac0-8726de18e04c">289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy0yLTEtMS0w_3ab793c0-bd87-4134-8115-9f478fa4342b">1,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy00LTEtMS0w_a0145611-3bb2-44d4-8847-d6a74c3b260c">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231" decimals="-3" name="exdx:IncreaseDecreaseInFairValueOfFinancialInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy02LTEtMS0w_ec6a17a0-7b3e-4cb9-a3d3-957deb260eb9">318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC0yLTEtMS0w_2664fa4a-cbf2-4e95-9246-6fbaed7e43d3">2,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC00LTEtMS0w_d80a524f-63f4-4025-b707-3068dac5b268">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1618f264237473e8438081b30871740_I20181231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC02LTEtMS0w_ce031d64-95bd-4b31-92e0-38575bce9638">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March&#160;31, 2019 (unaudited) (as revised)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6525292a42e544c98b6b7fe58ef7a0b2_I20190331" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS0yLTEtMS0w_897cb777-e81c-494b-afa4-141aa0f235d3">2,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i84f237a8b0314f22ba9545b209899f19_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS00LTEtMS0w_d8e79362-c118-476a-be67-35f64ca51b41">1,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331" decimals="-3" format="ixt:numdotdecimal" name="exdx:PreferredStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS02LTEtMS0w_385cd105-1866-4cbc-a84b-d781621bac72">1,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i_0_7"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-indent:24.75pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2018 included in our Prospectus dated September 18, 2019 filed pursuant to Rule 424(b) under the Securities Act with the Securities and Exchange Commission on September 20, 2019, or the Prospectus.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Forward Looking Statements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing and therapeutics strategy, the expected benefits from our partnerships or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_10"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> brand, several of which are based on our proprietary CB-CAPs technology. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We currently market nine testing products under our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD in 2012 and revenue from this product comprised 83% and 86% of our revenue for the nine months ended September&#160;30, 2019 and 2018, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. In order to advance our integrated testing and therapeutics strategy, in December 2018 we entered into the Janssen agreement to exclusively promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in the United States for the treatment of adult patients with moderate to severe RA and for other indicated rheumatic diseases. We began direct promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in January 2019 and expanded our salesforce from 31 representatives as of December&#160;31, 2018 to 55 representatives as of September&#160;30, 2019. We expect our SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> promotion efforts to contribute incremental revenue in 2019 with our quarterly tiered promotion fee based on the incremental increase in total prescribed units above a predetermined average baseline of approximately 29,000 prescribed units per quarter.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We also have additional agreements with other leading pharmaceutical companies, including GSK, Horizon Therapeutics and Corrona, that leverage our testing products and the information generated from such tests. We plan to pursue additional strategic partnerships with a focus on the commercialization of therapeutics that are synergistic with our testing products.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We perform all of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> tests in our approximately 8,000 square foot clinical laboratory, which is certified by CLIA and accredited by CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA. We are approved to offer our products in all 50 states. Our clinical laboratory reports all AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">testing product results within five business days.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We market our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> testing products using our specialized salesforce. Unlike many diagnostic salesforces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our salesforce coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using our portfolio of testing products.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Reimbursement for our testing services comes from several sources, including commercial third-party payers, such as insurance companies and health maintenance organizations, government payers, such as Medicare, and patients. Reimbursement rates vary by product and payer. We continue to focus on expanding coverage among existing contracted rheumatologists and to achieve coverage with commercial payers, laboratory benefit managers and evidence review organizations.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Since inception we have devoted substantially all our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of September&#160;30, 2019 we had an accumulated deficit of $161.2&#160;million. We incurred net losses of $8.6&#160;million and $6.7 million for the nine months ended September&#160;30, 2019 and 2018, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. Through the date of our initial public offering (IPO) in September 2019, our operations were financed primarily from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO of 4,140,000 shares of our common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of our common stock. Including the option exercise, the aggregate net proceeds to us from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. As of September&#160;30, 2019 we had $77.8&#160;million of cash and cash equivalents. </span></div><div id="i_0_13"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Factors Affecting Our Performance</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Continued Adoption of Our Testing Products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;Since its launch in 2012, we have grown the number of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests delivered at a compound annual growth rate of 87%, with limited incremental investment in our commercial infrastructure. Approximately 83,000 AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests were delivered in 2018, representing 18% growth over 2017, and the number of ordering healthcare providers reached 1,278 in the fourth quarter of 2018, representing 18% growth over the same quarter in 2017. Through the third quarter of 2019, 78,237 AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests were delivered, representing approximately 29% growth over the same period in 2018, and the number of ordering healthcare providers through the third quarter of 2019 reached 2,040. More than 360,000 AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests have been delivered since launch, and for the third quarter of 2019, we reached 575 adopting healthcare providers (defined as those who had prescribed at least 11 diagnostic tests in the corresponding period) compared to 475 in the same period in 2018. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Reimbursement for Our Testing Products</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;&#160;&#160;Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers such as Medicare. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payers will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payers, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;&#160;&#160;We only recently began promoting SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in the United States under the Janssen agreement. We may encounter difficulties in successfully promoting SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> and generating significant revenue under the agreement. Our ability to effectively promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> will require us to be successful in a range of activities, including training and deploying additional sales representatives and creating demand for SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> through our own sales activities as well as those of Janssen. Based on our estimate of the total U.S. addressable market for SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;'</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">s approved indications of $28&#160;billion, each incremental 1% market share we are able to capture for SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> above the predetermined baseline under the Janssen Agreement could result in incremental revenue to us of $84&#160;million. However, it may take longer to generate meaningful revenue than we currently expect and we may not be successful in materially increasing market share, which would cause us to continue to rely on our existing testing products to drive revenue growth.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Development of Additional Testing Products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;We rely on sales of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test to generate the significant majority of our revenue. We recently launched AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> Anti-CarP and AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> PC4d. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Margin Expansion</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;&#160;&#160;We believe growth in our promotion of therapeutics will meaningfully improve our margin profile and further support our goal of achieving profitability. We also expect an increase to our gross margins in January 2020 onwards upon the expiration of a 10% annual royalty on our CB-CAPs technology. In addition, we believe we are well positioned to drive further margin expansion through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payer coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. However, these potential margin increases may be partially offset by expected decreases in Medicare reimbursement rates as a result of the Protecting Access to Medicare Act of 2014, or PAMA.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">Timing of Our Research and Development Expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;&#160;&#160;Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt;">How We Recognize Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.&#160;&#160;&#160;&#160;We recognize revenue in accordance with the provisions of Accounting Standards Codification, or ASC, Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Customers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payer. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Janssen Promotion Agreement</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2018, we entered into a co-promotion agreement with Janssen, under which we are responsible for the costs associated with our sales force in promoting SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in the United States. Janssen is responsible for all other costs associated with our promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> under the Janssen agreement. In exchange for our sales and co-promotional services, we are entitled to a quarterly tiered promotion fee ranging from $750 to $1,250 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> for that quarter over a predetermined baseline. The predetermined average baseline for the initial term of 18 months is approximately 29,000 prescribed units per quarter, subject to adjustment under certain circumstances. The term of the agreement expires on June&#160;30, 2020, unless extended by us for an additional 18 months upon 180 days written notice prior to the end of the initial term. Janssen can terminate the agreement at any time for any reason upon 30 days' notice to us, and we can terminate the agreement for any reason at the end of any calendar quarter upon 30 days' notice to Janssen. Either party may terminate the agreement in the event of the other party's default of any of its material obligations under the agreement if such default remains uncured for a specified period of time following receipt of written notice of such default.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We recognized co-promotional revenue of approximately $0.8 million during the nine months ended September&#160;30, 2019 and expect to continue to recognize revenue as we perform co-promotional services based on the number of total prescribed units of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> over the predetermined baseline.</span></div><div id="i_0_16"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Financial Overview</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revision of Previously issued Financial Statements for Correction of Immaterial Errors</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During 2019, we identified immaterial misstatements in the financial statements for the year ended December&#160;31, 2018 related to the carrying value of redeemable convertible preferred stock warrant liabilities. These amounts have been adjusted in the accompanying financial statements. See Note&#160;12 of our notes to our unaudited condensed financial statements for a summary of the amounts and financial statement line items impacted by the revision. All amounts set forth in the discussion and year ended December&#160;31, 2018 have been adjusted to reflect these revisions.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services, or payers, consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payer. These assessments require significant judgment by management.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered, as well as our ability to successfully promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Costs of Revenue (Excluding Amortization of Purchased Technology)</span></div><div style="text-indent:24.75pt;margin-top:4pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Each payer, commercial third-party, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payers for each month's billings.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect that our selling, general and administrative expenses will increase in absolute dollars as we expand our sales and sales support functions, including expansion activities related to our promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">. We also expect our selling, general and administrative expenses will increase because of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations activities and other administrative and professional services such as accounting, legal, regulatory and tax.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect that our research and development expenses will increase in absolute dollars as we continue to invest in research and development activities related to our existing testing products and product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization of Intangible Assets</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Amortization of intangible assets represents the total amortization expense for our purchased technologies.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The intangible assets recorded as of December&#160;31, 2017 became fully amortized in 2018; accordingly, we do not expect any future amortization expense related to these assets.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our current loan agreement with Innovatus.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect interest expense to increase in 2019 due to the draws we made under our loan agreement and to decrease in years thereafter due to lower interest rates and lower outstanding principal balances.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of Financial Instruments</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of our IPO, we classified our outstanding warrants to purchase shares of our redeemable convertible preferred stock as liabilities on our balance sheets at their estimated fair value since the underlying redeemable convertible preferred stock was classified as temporary equity. At the end of each reporting period, changes in the estimated fair value during the period were recorded as a component of other income (expense).</span></div><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the completion of our IPO, all outstanding warrants to purchase shares of our redeemable convertible preferred stock either terminated or were converted into warrants to purchase shares of our common stock and accordingly, will no longer be subject to measurement.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Other income, net, consists primarily of interest income earned on our cash and cash equivalents.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_19"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three Months Ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:58.526316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.380117%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited, in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,216&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs of revenue (excluding amortization of purchased technology)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,852&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,306&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4,932&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(18)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">47&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,157)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,133)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,024)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(909)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(704)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(205)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(255)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,141)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,756)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,385)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue increased $2.2&#160;million, or 26.9%, for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018, primarily due to an increase in the number of diagnostic tests delivered. The number of AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests, which accounted for 83% and 86% of revenue in the three months ended September&#160;30, 2019 and 2018, respectively, increased to 27,159 tests delivered in the three months ended September&#160;30, 2019 compared to 21,090 tests delivered in the same 2018 period. The increase is primarily due to the increased adoption of the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test by rheumatologists as the number of ordering healthcare providers increased to 1,591 for the three months ended September&#160;30, 2019 as compared to 1,236 healthcare providers in the same 2018 period. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, we began co-promoting SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in early 2019 and recognized approximately $0.4 million of revenue during the three months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs of Revenue (excluding amortization of purchased technology)</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs of revenue increased $0.9&#160;million, or 24.2%, for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018. This increase was primarily due to increased direct costs such as materials and supplies and royalties associated with the increase in test volume in 2019 compared to 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses increased $2.4&#160;million, or 48.1%, for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018. This increase was primarily due to increased employee related expenses of $1.8 million as a result of increasing the size of our sales force from 30 as of September&#160;30, 2018 to 55 as of September&#160;30, 2019. The remaining increase relates primarily to increased audit and professional services.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses remained relatively consistent for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amortization of Intangible Assets</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our purchased intangible assets were fully amortized at December 31, 2018, therefore there is no amortization expense recorded for the three months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Interest expense increased $0.2&#160;million, or 29.1%, for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018. This increase was primarily due to higher principal amounts outstanding at September&#160;30, 2019 under our long-term borrowing arrangements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of Financial Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The change in fair value of financial instruments decreased $0.3&#160;million, or 463.6%, for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018. This decrease resulted from changes in the valuation of our redeemable convertible preferred stock warrant liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Other income, net, remained relatively consistent for the three months ended September&#160;30, 2019 compared to the three months ended September&#160;30, 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Nine Months Ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:62.035088%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited, in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,799&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs of revenue (excluding amortization of purchased technology)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,841&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general&#160;and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,592&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(141)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">27,528&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,441)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,729)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,712)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,720)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,098)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(8,630)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,935)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Revenue increased $7.4&#160;million, or 32.3%, for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018, primarily due to an increase in the number of diagnostic tests delivered and an increase in the average reimbursement per test. The number of AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD tests, which accounted for 83% and 86% of revenue in the nine months ended September&#160;30, 2019 and 2018, respectively, increased to 78,237 tests delivered in the nine months ended September&#160;30, 2019 compared to 60,605 tests delivered in the same 2018 period. The increase is primarily due to the increased adoption of the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test by rheumatologists as the number of ordering healthcare providers increased to 2,040 as of September&#160;30, 2019 as compared to 1,628 healthcare providers in the same 2018 period. In addition, our average reimbursement per AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test increased to approximately $318 per test delivered in the nine months ended September&#160;30, 2019 from approximately $315 per test delivered in the same 2018 period, an increase of approximately 1%.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, we began co-promoting SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in early 2019 and recognized approximately $0.8 million of revenue during the nine months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs of Revenue (excluding amortization of purchased technology)</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs of revenue increased $2.8&#160;million, or 25.0%, for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018. This increase was primarily due to increased direct costs such as materials and supplies, royalties, shipping and handling and labor associated with the increase in test volume in 2019 compared to 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Selling, general and administrative expenses increased $6.4&#160;million, or 44.2%, for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018. This increase was primarily due to increased employee related expenses of $5.0 million as a result of increasing the size of our sales force from 29 at March 31, 2018 to 55 at September&#160;30, 2019. The remaining increase relates primarily to increased audit and professional services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses remained relatively consistent for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amortization of Intangible Assets</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our purchased intangible assets were fully amortized at December 31, 2018, therefore there is no amortization expense recorded for the nine months ended September&#160;30, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Interest expense increased $0.6&#160;million, or 29.6%, for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018. This increase was primarily due to higher principal amounts outstanding at September&#160;30, 2019 under our long-term borrowing arrangements.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of Financial Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The change in fair value of financial instruments increased $0.2&#160;million, or 385.5%, for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018. This increase resulted from changes in the valuation of our redeemable convertible preferred stock warrant liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Other income, net, increased $0.2 million, or 242.9% for the nine months ended September&#160;30, 2019 compared to the nine months ended September&#160;30, 2018. This increase was due to the higher cash balance in our money market funds account during the nine months ended September&#160;30, 2019 compared to the prior year period.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception. For the nine months ended September&#160;30, 2019 and 2018, we incurred a net loss of $8.6 million and $6.7&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of September&#160;30, 2019, we had an accumulated deficit of $161.2&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Through the date of our IPO in September 2019, our operations were financed primarily from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of our common stock. Including the option exercise, the aggregate net proceeds to us from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. As of September&#160;30, 2019, we had $77.8&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2017, we entered into the loan agreement with Innovatus, under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. The loan term is for five years with a final maturity date of September 2022. The loan accrues interest at an annual rate of 11.0%, of which 2.5%, during the first 24 months, will be treated as paid in kind interest. Paid in kind interest is added to the principal balance each period. After the initial 24 months of the loan, the entire 11.0% will be paid in cash at the end of each period. We may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium, which expires in October 2020.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our obligations under the loan agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The loan agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels of minimum liquidity (in specified instances, is either $2.0&#160;million or the trailing four months of cash used to fund operating activities) and achieve certain minimum amounts of revenue and either gross margins or gross profits, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the execution of the loan agreement, we issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&#160;F redeemable convertible preferred stock at an exercise price of $0.078&#160;per share, and in December 2018, in connection with the additional $5.0 million borrowed under the loan agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. In connection with the completion of our IPO in September 2019, the warrants were automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock at an exercise price of $14.32.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> testing products, promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We believe we have sufficient laboratory capacity to support increased test volume. Other than the addition of laboratory equipment, we expect that we will not need to make material capital expenditures in the near term related to our laboratory facilities. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed. Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to maintain and grow sales of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">fluctuations in working capital;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">the costs associated with our promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, including the expansion of our sales capabilities, and the extent and timing of generating revenue from such promotion;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payers and adequate market share and revenue for our testing products;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">the additional costs we may incur as a result of operating as a public company; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">&#9642;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as Janssen. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:71.099415%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(5,784)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,432)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(77)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,128)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,699&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">64,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(5,861)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash Flows from Operating Activities</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the nine months ended September&#160;30, 2019 was $5.8 million and primarily resulted from our net loss of $8.6 million adjusted for non-cash charges of $1.4 million related to depreciation, amortization, stock-based compensation, non-cash interest and the revaluation of our preferred stock liabilities, and changes in our net operating assets of $1.5&#160;million related to net increases in accounts payable and accrued liabilities. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities for the nine months ended September&#160;30, 2018 was $7.4&#160;million and primarily resulted from our net loss of $6.7&#160;million adjusted for non-cash charges of $1.4&#160;million for depreciation, amortization, stock-based compensation, non-cash interest and the revaluation of our preferred stock liabilities, and changes in our net operating assets of $2.2&#160;million related to net increases in accounts receivable and prepaid expenses. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash Flows from Investing Activities</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities for the nine months ended September&#160;30, 2019 was $0.1&#160;million and was due to net purchases of property and equipment. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities for the nine months ended September&#160;30, 2018 was $1.1&#160;million and was due to net purchases of short-term investments of $1.0&#160;million and purchases of property and equipment of $0.1&#160;million. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Cash Flows from Financing Activities</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for the nine months ended September&#160;30, 2019 was $70.5 million and primarily resulted from the net proceeds received from our IPO of $52.2 million as well as net proceeds received from the issuance of our redeemable convertible preferred stock of $18.4 million.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for the nine months ended September&#160;30, 2018 was $2.7&#160;million and primarily resulted from $2.7 million of net proceeds received from the issuance of our redeemable convertible preferred stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Management Estimates</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">For a description of our critical accounting policies, please see the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Significant Management Estimates" contained in the Prospectus. There have been no significant changes in our critical accounting policies and estimates during the three months ended September&#160;30, 2019 as compared to the critical accounting policies and estimates disclosed in Management&#8217;s Discussion and Analysis of Financial Condition and Operations included in the Prospectus, other than as set forth in Note 2 to the unaudited condensed financial statements included in this quarterly report.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There have been no new accounting pronouncements or changes to accounting pronouncements during the three and nine months ended September&#160;30, 2019, as compared to the recent accounting pronouncements described in the Prospectus that are of significance or potential significance to us. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During the periods presented we did not have, nor do we currently have any off-balance sheet arrangements, as defined under the rules and regulations of the SEC.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">JOBS Act Accounting Election</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="i_0_740"></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_749"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 4. Controls and Procedures</span></div><div style="text-align:center;"><span><br/></span></div><div></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this quarterly report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2019, our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting during the three months ended September&#160;30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_755"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Part II. Other Information</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_762"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item I. Legal Proceedings</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span><br/></span></div><div id="i_0_771"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Quarterly Report on Form 10-Q and in the Prospectus dated September 18, 2019 filed pursuant to Rule 424(b) under the Securities Act with the SEC on September 20, 2019, including our financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Business and Strategy </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We have incurred net losses since our inception. For the nine months ended September&#160;30, 2019 and 2018, we have incurred net losses of $8.6 and $6.7 million, respectively, and we expect to incur additional losses this year and in future years. As of September&#160;30, 2019, we had an accumulated deficit of $161.2 million. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products, to promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, to develop future testing products and to continue to execute our integrated testing and therapeutics strategy. We may not be able to generate sufficient revenue to achieve and maintain profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We only recently began transitioning toward an integrated testing and therapeutics strategy. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer history of utilizing an integrated testing and therapeutics strategy in addition to the sale of our testing products. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">A significant majority of our historical revenue has been derived from the sale of our AVISE&#174; CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE&#174; CTD. We are in various stages of research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to commercialize these testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we may not be able to sustain this growth or maintain existing revenue levels. Further, we cannot ensure the continued availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or successfully develop and commercialize additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing and future proprietary testing products with the promotion of therapeutics, and we may be unsuccessful in our promotion efforts for SIMPONI&#174;, which could adversely affect our ability to implement this strategy. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are in the process of integrating our historical testing products business with the promotion of therapeutics in an integrated testing and therapeutics strategy. Our integrated testing and therapeutics strategy leverages our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products to promote therapeutics. As a result, our future growth is dependent, in part, on our ability to leverage our unique commercial model of offering testing products combined with therapeutics, including with respect to the Janssen agreement, which we entered into in December 2018 to exclusively promote SIMPONI&#174; in the United States. Pursuant to the Janssen Agreement, we are entitled to receive a tiered promotion fee based on the total number of incremental prescriptions written above an established baseline. Our ability to effectively co-promote SIMPONI&#174; will require us to be successful in a range of activities, including hiring, training and deploying additional sales representatives and creating demand for SIMPONI&#174; through our commercial and sales activities as well as those of Janssen Biotech, Inc., or Janssen. If we encounter difficulties promoting SIMPONI&#174;, our ability to generate significant revenue under the Janssen Agreement will be harmed. Janssen also has the right to terminate the Janssen agreement with or without cause after 30-days&#8217; notice. If Janssen were to exercise this right, we may be unable to recoup substantial investments we have made and intend to make in order to support the promotion of SIMPONI&#174;. We have a limited history partnering with pharmaceutical companies for the promotion of therapeutics. Consequently, any predictions made about our future success or viability with respect to our promotion activities may not be as accurate as they could be if we had a history of successfully co-promoting therapeutics. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we fail to successfully promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, our ability to implement our integrated testing and therapeutics strategy and generate sufficient revenue to grow and sustain our business, and our business, financial condition and results of operations, will be materially adversely affected. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may be unable to manage our ongoing and future growth effectively, which could make it difficult to execute our business strategy. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition to the need to scale our testing capacity, our future growth plans will also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In particular, we expanded our salesforce from 31 representatives as of December 31, 2018 to 55 representatives as of September&#160;30, 2019 to help increase reach and frequency and support our integrated promotion of testing products and therapeutics. In addition, rapid and significant growth may strain our administrative and operational infrastructure and require us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our ability to manage our business and growth, as well as function as a public company, will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we lose or are unable to secure partners for our integrated testing and therapeutics strategy, or if our partners do not apply adequate resources to their relationships with us or are unable to provide, on a timely basis, an adequate and reliable supply of the therapeutics that we promote, our potential for profitability may be adversely affected. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition to the Janssen agreement, we plan to opportunistically evaluate, and may continue to enter into, additional agreements with pharmaceutical companies to integrate the promotion of our testing products with their therapeutics. We have also entered into, and may continue to enter into, other agreements that leverage our testing products and data generated from such tests. For example, we provide GSK our test result data to provide market insight into and help increase awareness of the benefits of an early and accurate diagnosis of SLE; and our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> MTX test data is used by Horizon Therapeutics to report on levels of MTXPG in patients undergoing methotrexate therapy in combination with its anti-gout product, KRYSTEXXA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, in an ongoing Phase 4 clinical trial. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The amount and timing of resources applied by our current or potential future partners are largely outside of our control. For example, we have limited control over, and rely on Janssen for, numerous activities that are critical to our ability to successfully promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, such as pricing decisions, manufacture and supply of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, reimbursement support, marketing materials, the prosecution and enforcement of patents and other intellectual property rights related to SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> and public communications and presentations regarding SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">. We likewise have limited control of how our other partners use the information provided by our testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If any of our current or future partners breaches or terminates our agreements, or fails to conduct the activities contemplated by our agreements in a timely manner, our success promoting the applicable therapeutics, testing products or information provided thereby could be diminished or blocked completely. It is possible that partners will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. For example, under the Janssen agreement, Janssen is not prohibited from developing or commercializing products that are competitive with SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">. If Janssen commercializes any competing products, it may provide lower levels of support to SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> or may terminate our agreement entirely. The effectiveness of our partners, if any, in marketing the applicable therapeutics will also affect our revenue and earnings. In addition, if our other partners encounter problems with our testing products or information provided by our testing products that they rely on as part of their efforts, our reputation and that of our testing products could be damaged, and it could impair our ability to enter into future agreements to promote therapeutics. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We rely on Janssen to provide, on a timely basis, an adequate and reliable supply of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">. Any delay or interruption of supply or Janssen&#8217;s failure to comply with regulatory or other requirements could limit its ability to make, or cause it to cease sales, of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">. Any manufacturing defect or error discovered after SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> has been produced and distributed could result in even more significant consequences, including costly recall procedures. In addition, the importation of pharmaceutical products into the United States is subject to regulation by the FDA, and the FDA can refuse to allow an imported product into the United States if it appears that the product fails to comply with applicable laws or regulations. Moreover, Janssen and its third-party manufacturers and suppliers may experience difficulties related to their overall business and financial stability. To the extent Janssen faces manufacturing difficulties or is unable to provide an adequate and reliable supply of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> on a timely basis, our reputation could be harmed and our business could suffer. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We do not have the capability and do not intend to discover or develop therapeutics on our own. Therefore, the success of our integrated testing and therapeutics strategy depends in part on our ability to acquire additional rights to promote therapeutics from new or existing partners. Other companies, many of which have substantially greater </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">financial, marketing and sales resources than we do, also compete with us for the acquisition of rights to therapeutics. In addition, under the Janssen agreement, we are prohibited from selling or promoting certain types of products that are used to treat the same indications that SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> is used to treat. We may not be able to successfully negotiate any additional agreements to promote therapeutics and, if established, these relationships may not be successful. For example, potential partners, particularly those that are actively marketing their own therapeutics, may be unwilling to license commercialization rights to us or otherwise enter into terms that allow us to meaningfully participate in sales growth for their products, which could limit the potential availability and value to us of additional agreements to promote therapeutics. The inability to enter into agreements for additional therapeutics could limit the overall growth of our business and adversely affect our business, financial condition and results of operations. Disputes could also arise between us and our existing or future partners, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes would be both expensive and time-consuming and may result in delays in the success of therapeutics or could damage our relationship with a partner. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may experience limits on our revenue if rheumatologists decide not to order our testing products or our promoted therapeutics or if we are otherwise unable to create or maintain demand for our testing products and promoted therapeutics. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we are unable to create or maintain demand for either our testing products or promoted therapeutics in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate rheumatologists about the benefits of our testing products through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. We will also need to generate demand for both our testing products and promoted therapeutics through one-on-one education by our salesforce. We also plan to focus on educating patients about the benefits of these testing products and therapeutics, which we believe will be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement from third-party payers may limit adoption by rheumatologists. With respect to SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> in particular, if we are unable to generate sales above certain thresholds agreed to with Janssen, we will not receive any payments under the Janssen agreement. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Rheumatologists may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our success depends on our ability to continue to develop and market testing products and promote therapeutics that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product or promoted therapeutic that we offer may not gain or maintain market acceptance among rheumatologists, third-party payers, patients and the medical community. Market acceptance of our testing products and promoted therapeutics depends on a number of factors, including: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the perceived accuracy of our test results by rheumatologists and patients;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the potential and perceived advantages of our testing products and promoted therapeutics over alternative products and therapeutics;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the demonstration in clinical studies of the performance and clinical validity of our testing products, the results of which studies may not replicate the positive results from earlier studies; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the demonstration of clinical efficacy and safety of our promoted therapeutics compared to other more-established products;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the introduction of new tests or therapeutics products that compete with our testing products or our promoted therapeutics or the introduction of generic versions of our promoted therapeutics;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the product cost in relation to alternative products;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the prevalence and severity of any adverse effects from our promoted therapeutics;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the willingness of the target patient population to try new therapies and of rheumatologists to prescribe these therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">any restrictions on the use of our promoted therapeutics, if approved, together with other medications;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">publicity concerning our testing products and promoted therapeutics or competing products and treatments;</span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the availability of coverage and adequate reimbursement by third-party payers, including government authorities;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">relative convenience and ease of administration; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, if we or our partners had to withdraw a product from the market, it could harm our business and could impact market acceptance of our other testing products or promoted therapeutics. If our testing products and promoted therapeutics do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payers or patients, we may not generate sufficient revenue from that testing product or therapeutic and may not become or remain profitable. Our efforts to educate the medical community and third-party payers regarding the benefits of our testing products and promoted therapeutics may require significant resources and may never be successful. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The sizes of the markets for our testing products and promoted therapeutics have not been established with precision, and may be smaller than we estimate. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our estimates of the annual total addressable markets for our current and potential future testing products and promoted therapeutics are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future testing products and promoted therapeutics may prove to be incorrect. If the actual number of patients who would benefit from our testing products and promoted therapeutics, the price at which we and our partners can sell future testing products, or the annual total addressable market for our testing products and promoted therapeutics is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may expend our limited resources to pursue a particular testing product or promoted therapeutic and fail to capitalize on other testing products or promoted therapeutics that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Because we have limited financial and managerial resources, we focus on specific testing products and promoted therapeutics. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing products. If we do not accurately evaluate the commercial potential or target market for a potential testing product or promoted therapeutic, we may forego other similar arrangements which would have been more advantageous for us to pursue.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our ability to successfully market and sell our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products and continue to promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement from third-party payers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our testing products, which may change from time to time, and our ability to successfully commercialize new testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the level of demand for our testing products and promoted therapeutics, which may vary significantly; </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the receipt, timing and mix of revenue for our testing products and promoted therapeutics; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">future accounting pronouncements or changes in our accounting policies; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the rate and extent to which payers make an overpayment determination and require us to return all or some portion of payments which we received in a prior period; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could have a material adverse effect on our business, financial condition and results or operations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to find replacements or transition to alternative suppliers. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing products. We also purchase components used in our testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If demand for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. We are also currently collaborating with third parties in an effort to implement multiplex technology in our laboratory. We may experience difficulties securing a partner for this technology and integrating such technology into our existing laboratory operations, which could affect our ability to meet demand for our testing products. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If third-party payers do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">products or promoted therapeutics, or if we or our partners are unable to successfully negotiate payer contracts, our commercial success could be compromised. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Successful commercialization of our testing products depends, in large part, on the availability of coverage and adequate reimbursement from third-party payers, including government payers, such as Medicare and Medicaid and private insurers. For the testing products that we develop and commercialize as well as the therapeutics we promote, each third-party payer decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Reimbursement by third-party payers may depend on a number of factors, including the payer&#8217;s determination that tests using our technologies are: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">not experimental or investigational; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">medically necessary; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">demonstrated lead to improved patient outcomes; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">appropriate for the specific patient; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">cost-saving or cost-effective; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">supported by peer-reviewed medical journals; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">included in clinical guidelines. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we are unable to provide third-party payers with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenue and our ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payers pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Third-party payers and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be used by third-party payers and health care providers as grounds to deny coverage for or refuse to use a test or procedure. In addition, third-party payers, have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Effective April 25, 2012, Palmetto GBA, the Medicare molecular diagnostic services program&#8217;s, or MolDx Program&#8217;s, contractor, assigned the AVISE&#174; MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients diagnosed with RA on methotrexate. Our current Medicare contractor, Noridian, has adopted this coverage policy. Other third-party payers make their own decisions as to whether to establish a policy to reimburse our testing products, however, and because approvals must be sought on a payer by payer basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payers who have not yet established a coverage policy applicable to our testing products. In addition, several Blue Cross Blue Shield plans and Aetna issued non-coverage policies with respect to AVISE&#174; Lupus, determining that AVISE&#174; Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">While our testing products are reimbursed by a number of third-party payers, we do not currently have contracts with significant private payers. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payers due to changes in their internal processes, documentation requirements and other issues, which could cause our revenue to fluctuate from period to period. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we are not successful in reversing existing non-coverage policies, or if other third-party payers issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payers currently reimburse for our testing products, such payers may withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our testing products altogether, any of which would reduce our revenue. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various third-party payers, including Medicare and private insurance companies, as well as patients, all of which have different billing requirements. We generally bill third-party payers for our testing products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">face increased risk in our collection efforts, including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Several factors contribute to the complexity of the billing process, including: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">differences between the list price for our testing products and the reimbursement rates of third-party payers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">compliance with complex federal and state regulations related to billing Medicare; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">disputes among third-party payers as to which party is responsible for payment; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">differences in coverage among third-party payers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the effect of patient deductibles, co-payments or co-insurance; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">differences in information and billing requirements among third-party payers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">changes to billing codes used for our testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">risk of government audits related to billing; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">incorrect or missing billing information; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the resources required to manage the billing and claims appeals process. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payers deny our claims, in order to obtain reimbursement for services that we provide, we may challenge coverage and payment denials. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, established a requirement for providers and suppliers to report and return any overpayments received from government payers under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Additionally, from time to time, third-party payers change processes that may affect timely payment. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payers. With respect to payments received from governmental programs, factors such as a prolonged government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal government healthcare programs. In addition, third-party payers may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In 2018, Noridian posted the final Medicare Physician Fee Schedule, or MPFS, and Clinical Laboratory Fee Schedule, or CLFS, which establishes the reimbursement rates to be paid by Medicare for our coverage area for tests performed after January 1, 2019. We have estimated that the implementation of these reimbursement rates will result in an approximate 10.1% reduction in anticipated reimbursements from Medicare from our AVISE&#174; CTD testing product from levels experienced in 2018. Revenue from Medicare comprised 26% and 31% of our revenue in the nine months ended September&#160;30, 2019 and 2018, respectively. Revenue from the sale of our AVISE&#174; CTD testing products comprised 83% and 86% of our revenue in the nine months ended September&#160;30, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We also rely on a third-party provider to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as well as not submitting claims to payers within the timeframe required. If claims for our testing products are not submitted to payers on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our business. </span></div><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">At times, we share our proprietary technology and confidential information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Significant safety or efficacy issues could arise for our promoted therapeutics, which could have an adverse effect on our revenue and financial condition. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety or efficacy issues are reported or if new scientific information becomes available (including results of post-marketing Phase 4 trials), or if governments change standards regarding safety, efficacy or labeling, our partners may be required to amend the conditions of use for a therapeutic. For example, a partner may voluntarily provide or be required to provide updated information on a therapeutic&#8217;s label or narrow its approved indication, either of which could reduce the therapeutic&#8217;s market acceptance. If safety or efficacy issues with a partner&#8217;s therapeutic arise, sales of the therapeutic could be halted by the partner or by regulatory authorities. Safety or efficacy issues affecting suppliers&#8217; or competitors&#8217; products also may reduce the market acceptance of one of our partner&#8217;s therapeutics. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">New data about a partner&#8217;s therapeutics, or products similar to a partner&#8217;s therapeutics, could negatively impact demand for such therapeutics due to real or perceived safety issues or uncertainty regarding efficacy and, in some cases, could result in product withdrawal. Furthermore, new data and information, including information about therapeutic misuse, may lead government agencies, professional societies, practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of such therapeutics or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of the applicable therapeutics and reduce our revenue or otherwise adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are unable to maintain or expand our sales and marketing force to adequately address our customers&#8217; and current or future partners&#8217; needs, our business may be adversely affected. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We sell our testing products through our own specialized salesforce and have recently increased our salesforce in order to achieve the optimal reach and frequency and support our strategy of integrating the promotion of testing products and therapeutics. Our testing products compete in a concentrated specialty market, that of autoimmune and autoimmune-related diseases, and utilizing a specialized salesforce is integral to our integrated testing and therapeutics strategy. As such, we believe it is necessary to maintain a salesforce that includes sales representatives with specific technical backgrounds and industry expertise. For example, to support the co-promotion of SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, we expanded our salesforce from 31 representatives as of December 31, 2018 to 55 representatives as of September&#160;30, 2019. Additional agreements for the promotion of therapeutics may require us to further expand our specialized salesforce. Training of additional sales representatives can be costly and time consuming, particularly given the level of experience and sophistication we seek in our salesforce. In addition, until recently, not all of our sales representatives have promoted therapeutics, including SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">, as part of our organization, and they will need to complete additional training in order to effectively promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> and any other therapeutics that we promote through additional agreements. If we are unable to effectively retain, train and integrate additional sales representatives, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our future sales will depend in large part on our ability to maintain an effective salesforce. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </span></div><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as anti-nuclear antibodies, or ANA, and anti-double-stranded DNA, or anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Progentec Diagnostics Inc., Kypha, LLC, Genalyte Inc., Protagen AG, DxTerity Diagnostics Inc., HealthTell, Inc. and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Direct competition for the promotion of SIMPONI&#174; includes all other companies with anti-TNF biologics and the marketing companies supporting their distribution and promotion. These products include HUMIRA&#174; from Abbvie Inc., ENBREL&#174; from Amgen Inc., CIMZIA&#174; from UCB, INFLECTRA&#174; from Pfizer, (biosimilar REMICADE&#174;) and RENFLEXIS&#174; from Merck &amp; Co. (biosimilar REMICADE&#174;). Additional competitors include companies with other biologic drugs indicated for RA that have significant sales or sales potential. Specifically, these include ORENCIA&#174; from Bristol-Myers Squibb Company, ACTEMRA&#174; from Roche, RITUXAN&#174; from Roche, XELJANZ&#174; from Pfizer, KEVZARA&#174; from Sanofi S.A., RINVOQ&#8482; from Abbvie Inc. and OLUMIANT&#174; from Eli Lilly and Company. There are also several late-stage RA drug and biosimilar development programs and several additional RA products that have minimal sales to date or that are indicated for other rheumatic indications competitive to SIMPONI&#174; such as psoriatic arthritis and ankylosing spondylitis. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; safety and efficacy with respect to promoted therapeutics; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payers as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective and that we are effective in promoting therapeutics. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We will continue to devote considerable resources to the research and development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">expend significant funds to conduct substantial research and development; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">conduct successful validation studies; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">achieve and maintain required regulatory certifications; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">failure of clinical validation studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as our testing products, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from any solution. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, we have not acquired other companies or therapeutics and, except with respect to certain collaboration agreements executed in connection with our integrated testing and therapeutics strategy, we have limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The diagnostics and therapeutics industries are subject to rapidly changing technology, which could make our testing products, promoted therapeutics and other testing products we develop obsolete. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could decline and our competitive position could be harmed. In addition, if our promoted therapeutics become obsolete and we are unable to expand such agreements or find new partners, our sales could decline and our competitive position could be harmed. For example, with respect to SIMPONI&#174; and the treatment of RA, active psoriatic arthritis, or active ankylosing spondylitis, there are many novel therapeutic approaches in development and we expect that the competition in this market will increase dramatically. If new therapeutics make SIMPONI&#174; obsolete or diminish the degree to which rheumatologists prescribe it, our ability to generate revenue under the Janssen agreement will be harmed. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to physicians and payers. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing and future customers and therefore materially adversely impact our business and prospects. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of claims related to testing products we may develop in the future. An errors and omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation or cause the applicable partner to suspend sales of its therapeutics. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as designed, which could lead increase costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </span></div><div style="margin-top:12pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our success depends largely on the skills, experience and performance of key members of our executive management team, including Fortunato Ron Rocca, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our testing products and the sale of promoted therapeutics. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time. We do not carry key man insurance for any of our employees.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If our sole laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including earthquake, fire, flood, power loss, communications failure or terrorism. In particular, we store all of our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our proprietary technology to a third-party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In order to rely on a third party to perform the tests contained in our testing products, we would need to engage another facility with established state licensure and Clinical Laboratory Improvement Amendments of 1988, or CLIA, accreditation under the scope of which tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In order to establish an additional clinical reference laboratory facility, we would have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. Beyond this time frame, we may need to further expand our laboratory space. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our testing products. Our ability to obtain clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As part of our process of determining CB-CAPs, which is part of our AVISE&#174; Lupus product, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the College of American Pathologists, or CAP, at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems because: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">patient specimens must be received, tracked and processed on a timely basis; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">test results must be reported on a timely basis; </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">billings and collections for all customers must be managed efficiently and accurately; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">third party ancillary billing services require proper tracking and reporting; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">pricing and other information related to our services is needed by our salesforce and other personnel in a timely manner to conduct business; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">patient-identifiable health information must be securely held and kept confidential; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">regulatory compliance requires proper tracking and reporting; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our business, results of operations and financial condition may be adversely affected if, among other things: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">services relating to our information technology, telephone or other systems are not kept current; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">data is lost or unable to be restored or processed; or </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">data is corrupted due to a breach of security. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as legally protected health information, including de-identified test reports, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events. In addition, we have limited control over the storage of sensitive data by our third-party therapeutics partners as well as risks related to the transfer and sale of de-identified data files to such partners. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we have not experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, and their implementing regulations and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. Complying with these </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Expedited, reliable shipping is essential to our operations. While we have recently begun working with United Parcel Service, we still rely extensively on a single carrier, Federal Express Corporation for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, or any other carrier we may use in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time could adversely affect our ability to receive and process patient specimens on a timely basis. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we or Federal Express were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express. If any new provider does not provide, or if Federal Express does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by &#8220;5-percent shareholders,&#8221; as defined in the Code, over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. Under recently enacted U.S. tax legislation, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our ability to use a portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. If we undergo an ownership change as a result of subsequent shifts in our stock ownership, our ability to utilize our NOL carryforwards and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code. Similar provisions of state tax law may also apply. As a result, if we earn net taxable income, our ability to use such pre-change NOL carryforwards and other pre-change tax attributes to offset taxable income and taxes, as applicable, may be limited. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Recently enacted U.S. tax legislation, known as the Tax Cuts and Jobs Act of 2017, has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes are effective immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and U.S. Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. Based on our current evaluation of this legislation, the reduction of the U.S. corporate income tax rate required a provisional write-down of our deferred income tax assets (including the value of our NOL carryforwards and our tax credit carryforwards). </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">There may be other material adverse effects resulting from the legislation that we have not yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In September 2017, we entered into a loan and security agreement, or the loan agreement, with Innovatus Life Sciences Lending Fund I, LP, or Innovatus. The loan agreement is collateralized by substantially all of our personal property, including our intellectual property. The loan agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million and achieve certain minimum amounts of annual revenue, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Innovatus, which we may not be able to obtain. On December 7, 2018, we borrowed an additional $5.0 million under the loan agreement, as a result of meeting the requisite trailing twelve-month revenue and gross margin milestones. As of September&#160;30, 2019, there was $25.0 million in principal outstanding under the term loan and an additional $1.2 million outstanding representing interest at 2.5% per annum payable in-kind by adding the amount to the outstanding principal balance of the term loans. Under the loan agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a two-year period commencing on October 1, 2020. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the loan agreement, the occurrence of a material adverse change in our business as defined in the loan agreement, our breach of any representation or warranty in the loan agreement, our breach of any covenant in the loan agreement (subject to a cure period in some cases), a change in control as defined in the loan agreement, our default on any debt payments to a third party in an amount exceeding $500,000 or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the loan agreement, Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Innovatus or any other debt we may incur in the future. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We expect capital expenditures and operating expenses to increase over the next several years as we expand our infrastructure, commercial operations and research and development activities. We believe, based on our current plan, that our current cash and cash equivalents and anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If our available cash balances and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or promoted therapeutics or lower-than-expected rates of reimbursement from commercial third-party payers and government payers, or other risks described in this &#8220;Risk Factors&#8221; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. In the case of the incurrence of further indebtedness, the loan agreement, subject to certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus. Under the loan agreement, we are required to make monthly interest payments at a rate equal to 11.0% (provided that 2.5% of the 11.0% is payable in-kind by adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. In addition, we may seek additional capital due to </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; our ability to successfully promote therapeutics; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our current loan agreement restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products, promoted therapeutics or market development programs, which could lower the economic value of those programs to our company. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The FDA may modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If the FDA ends its policy of enforcement discretion with respect to LDTs, and our testing products become subject to the FDA&#8217;s requirements for premarket review of medical devices, we may be required to cease commercial sales of our testing products and conduct additional clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical testing could significantly increase our test development costs and delay commercialization of any currently-marketed tests that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We and our third-party contractors are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA, Competent Authorities of the Member States of the EEA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our testing products. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our testing products, or to achieve sustained profitability. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices, known as the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling regulations, including the FDA&#8217;s general prohibition against promoting products for unapproved or &#8220;off-label&#8221; uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Even if we were able to obtain FDA clearance or approval for one or more of our testing products, if required, a testing product may be subject to limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the product. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The FDA has broad post-market enforcement powers, and if unanticipated problems with our testing products arise, or if we or our suppliers fail to comply with regulatory requirements following FDA clearance or approval, we may become subject to enforcement actions such as: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">operating restrictions, partial suspension or total shutdown of production; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">customer notifications or repair, replacement or refunds; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">refusing our requests for 510(k) clearance or PMA approvals or foreign regulatory approvals of new testing products, new intended uses or modifications to existing testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">withdrawals of current 510(k) clearances or PMAs or foreign regulatory approvals, resulting in prohibitions on sales of our testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">FDA refusal to issue certificates to foreign governments needed to export testing products for sale in other countries; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">criminal prosecution. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, results of operations and financial condition. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approvals. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing authorization that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Regulatory and Compliance Matters </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Healthcare policy and payment changes may have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Reimbursement to healthcare providers, such as specialized diagnostic service providers like us, is subject to continuing change in policies by third-party payers including governmental payers, such as Medicare and Medicaid, private insurers and other private payers, such as hospitals and private medical groups. Statutory and regulatory changes, retroactive rate adjustments and administrative rulings, and other policy changes may be implemented </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">with little or no prior notice, all of which could materially decrease the range of services for which we are reimbursed or the reimbursement rates paid for our testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">On April 1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things, implemented a new payment system for clinical laboratory tests reimbursed under the CLFS. Under the law, clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes. The reported data must include the payment rate and the volume of each test that was paid by each private third-party payer. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. We bill Medicare for our testing products, and therefore we are subject to reporting requirements under PAMA. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The final PAMA ruling was issued June 17, 2016. Data for reporting for the new PAMA process began in 2017, and in 2018, the Medicare payment rate for each clinical diagnostic lab test, with some exceptions, equaled the weighted median of the reported private third-party payer payment for the test, as calculated using data collected by applicable laboratories during the data collection period and reported to the Centers for Medicare and Medicaid Services, or CMS, during a specified data reporting period. These revisions to the CLFS have altered payment rates for clinical diagnostic lab tests under the CLFS, with estimated reductions in Medicare reimbursement rates for AVISE&#174; CTD of 10.1% and 3.2% in 2019 and 2018, respectively. We cannot be sure how revisions to the CLFS will affect reimbursement rates in the future. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Other laws make changes impacting clinical laboratories, many of which have already gone into effect. The ACA, enacted in March 2010, requires each medical device manufacturer to pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices that are listed with the FDA. This excise tax has been temporarily suspended until December 31, 2019, unless additional congressional action is taken. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the tax-based shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;. While the Texas District Court Judge, as well as the current presidential administration and CMS, have stated that this ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. There have been judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the current presidential administration to repeal and replace the ACA, and we expect that there will be additional challenges and amendments to the ACA in the future. We are monitoring the impact of the ACA in order to enable us to determine the trends and changes that may be necessitated by the legislation and that, in turn, may potentially impact our business over time. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Budget Control Act of 2011, among other things, resulted in aggregate reductions to Medicare payments to providers of 2% per fiscal year, beginning April 1, 2013, and due to additional legislative amendments to the statute, these reductions will remain in effect through 2027 unless additional congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Some of our flow cytometry tests are reimbursed by the Medicare program under the MPFS. On April 16, 2015, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which, among other actions, repealed the previous statutory formula by which CMS established annual updates to MPFS rates. MACRA created the Merit-Based Incentive Payment System which, beginning in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Medicare payments are significant to our business, not only because approximately 26% and 29% of the total payments we received from payers in the nine months ended September&#160;30, 2019 and 2018, respectively, were derived from the Medicare program, but also because other payers often use the MPFS and CLFS amounts as a </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">benchmark to develop their payment rates. We cannot predict whether Medicare and other third-party payer reimbursement rates that mirror Medicare&#8217;s will be sufficient to make our testing products commercially attractive. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, some third-party payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it could have a negative impact on our revenue in the short term. It is possible that third-party payers will resist reimbursement for testing products that we offer in favor of less expensive tests, may require pre-approval for our testing products or may impose additional pricing pressure on and substantial administrative burden for reimbursement for our testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Product pricing by companies is currently, and is expected to continue to be, under close scrutiny. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business in the future, or the effect any future legislation or regulation will have on us. Although we cannot predict the full effect of the recent legislative changes discussed above, including taxes imposed by the ACA, cost reduction measures, the expansion in government&#8217;s role in the U.S. healthcare industry and PAMA&#8217;s changes to the reimbursement methodology under the CLFS, such changes individually or in the aggregate may result in decreased profits to us and/or lower reimbursement by third-party payers for our testing products, which may adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform testing through our accreditation by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratory. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">an out of state laboratory and our testing products, as LDTs, must be approved by the New York Department of Health, or NYDOH, on a product-by-product basis before they are offered in New York. We are also be subject to periodic inspection by the NYDOH and required to demonstrate ongoing compliance with NYDOH regulations and standards. To the extent NYDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our testing products. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYDOH approval for our laboratory developed tests in New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states which would limit our revenue. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We and our partners, including those with whom we may enter into co-promotion or co-marketing arrangements, are also subject to healthcare fraud and abuse regulation by both the federal government and the states in which we or our partners conduct our business. These laws include, without limitation, state and federal anti-kickback, self-referral, fraud and abuse, false claims, and physician sunshine laws and regulations. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The Federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service, including laboratory services, reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Federal Anti-Kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not make the conduct per se illegal under the Federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Federal Anti-Kickback Statute has been violated. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. in order to have committed a violation In addition, the government may assert that a claim including items or services resulting from a violation of the Federal Anti-kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">On June 25, 2014, the Office of Inspector General of the Department of Health and Human Services, or the OIG, released a Special Fraud Alert, expressing concern regarding laboratory payments made to referring physicians and physician group practices for blood specimen collection, processing, and packaging. Specifically, the OIG expressed concern that such arrangements may implicate the Federal Anti-Kickback Statute when laboratories make payments to physicians for services that are already covered and reimbursed by Medicare, or are not commercially reasonable or exceed fair market value, all in order to induce physicians to order tests from such laboratory. Because the choice of laboratory and the decision to order laboratory tests is made or strongly influenced by the physician, with little or no input from patients, such payment may induce physicians to order more laboratory tests than are medically necessary, particularly when the payments are tied to, or take into account, the volume or value of business generated by the physician. We had entered into certain arrangements with physicians for services related to specimen collection, transporting and handling. Effective August 2015, we terminated all such agreements. To date, no regulatory authorities have contacted us regarding these arrangements. To the extent our prior arrangements are found to be inconsistent with applicable laws, we may be subject to significant penalties, including criminal penalties, and exclusion from participation in U.S. federal or state health care programs. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The Federal civil and criminal false claims law, including the False Claims Act, prohibit, among other things, any person from knowingly presenting or causing to be presented a false claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false or fraudulent claim paid by the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, private individuals have the ability to bring actions under these false claims laws in the name of the government alleging false and fraudulent claims presented to or paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are also subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring Medicare patients for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a prohibited referral. Many states have their own self-referral laws as well, which in some cases apply to all third-party payers, not just Medicare and Medicaid. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, under the federal civil monetary penalties statute, a person is prohibited from offering or transferring to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Federal Anti-Kickback Statute and civil False Claims Act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The ACA, among other things, also imposed new reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Manufacturers must submit reports by the 90th day of each calendar year. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">It is possible that some of our business activities could be subject to challenge under one or more of such laws, including our promotion of SIMPONI&#174;, which is subject to restriction of off-label use discussions Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state health care programs, such as Medicare and Medicaid in the U.S. and similar programs outside the U.S., a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Failure to comply with HIPAA, the HITECH Act, their implementing regulations, and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Numerous federal and state laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, security, use and confidentiality of individually identifiable health information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of individually identifiable health information within our company and with third parties. The Standards for Privacy of Individually Identifiable Health Information, or Privacy Standards, and the Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, made certain of the Security Standards directly applicable to business associates. Further, the HITECH Act and the Final HIPAA Omnibus Rule that was promulgated in 2013, made additional parts of HIPAA directly applicable to business associates. As a result, both covered entities and business associates are now subject to significant civil and criminal penalties for failure to comply with the Privacy Standards and/or the Security Standards. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as certain health care providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">HIPAA requires covered entities to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of individually identifiable health information, restricts certain disclosures and sales of individually identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The Final HIPAA Omnibus Rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we do not comply with the requirements of HIPAA, the HITECH Act or applicable state privacy and security laws, we could be subject to criminal or civil sanctions that could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our business. These laws are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our physician clients. In addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy and security of personal information, including individually identifiable health information, could also adversely affect our business operations. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our future growth may depend, in part, on our ability to develop and commercialize our testing products and promote therapeutics in foreign markets. We are not permitted to market or promote any of our testing products or promote therapeutics before we or our partners receive regulatory approval from applicable regulatory authorities in foreign markets, and we or they may never receive such regulatory approvals for any of our testing products or promoted therapeutics. To obtain separate regulatory approval in many other countries, parties must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we or our partners obtain regulatory approval of our testing products and promoted therapeutics, and ultimately commercialize our testing products or promoted therapeutics in foreign markets, we would be subject to additional risks and uncertainties, including: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">different regulatory requirements for approval of drugs in foreign countries; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">reduced protection for intellectual property rights; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the existence of additional third-party patent rights of potential relevance to our business; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">foreign reimbursement, pricing and insurance regimes; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">workforce uncertainty in countries where labor unrest is common; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to our Intellectual Property </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are unable to maintain intellectual property protection our competitive position could be harmed. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our ability to protect our technologies such as CB-CAPs and methotrexate polyglutamates, or MTXPGs, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products will be considered patentable or enforceable by the United States Patent and Trademark Office, or the USPTO, courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We apply for patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to 13 issued U.S. patents, and certain corresponding foreign counterpart patents, relevant to our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products. We also own one issued U.S. patent, two pending U.S. patent applications, and certain corresponding foreign </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">counterpart patents and patent applications relevant to our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further development of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products or prevent others from designing around our claims. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Certain of our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products, such as AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:7.8pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;"> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE&#174; testing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our CB-CAPs technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our testing products pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Filing, prosecuting and defending patents on our AVISE&#174; testing products in all countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our AVISE&#174; testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our AVISE&#174; testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The patent protection and patent prosecution for some of our testing products may be dependent on third parties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our testing products, which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our testing products. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, certain patent rights related to AVISE&#174; Lupus are licensed from the University of Pittsburgh, certain patent rights related to AVISE&#174; MTX are licensed from Prometheus. Our existing </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">license agreements as related to our AVISE&#174; testing products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE&#174; testing products. Additionally, we may not always have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be compromised by our licensors&#8217; acts or omissions. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from the University of Pittsburgh related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE&#174; testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our AVISE&#174; testing products, and our partner may be unable to acquire any necessary rights for our promoted therapeutics. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our AVISE&#174; testing products or our partners consider necessary or attractive in order to promote their therapeutic. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">terms that would allow us to make an appropriate return on our investment, or at all. If we or our partner are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE&#174; testing products and promote therapeutics, and our business, financial condition and prospects for growth could suffer. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures bring the possibility of third party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our AVISE&#174; testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE&#174; testing products may give rise to claims of infringement of the patent rights of others. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We cannot assure you that any of our current or future AVISE&#174; testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us from marketing our AVISE&#174; testing products, there may be third-party patents of which we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our AVISE&#174; testing products. If a third party that owns such a patent asserts it successfully against one of our current or future AVISE&#174; testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our AVISE&#174; testing products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE&#174; testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE&#174; testing products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE&#174; testing products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition to infringement claims against us, if third-parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE&#174; testing products and technology. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE&#174; testing products, the defendant could counterclaim that the patent covering such AVISE&#174; testing product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE&#174; testing products. Such a loss of patent protection could have a material adverse impact on our business. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. We are not aware of any third party infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#8217;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE&#174; testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Common Stock </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The public trading price for our common stock is affected by a number of factors, including: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">actual or anticipated variations in our and our competitors&#8217; financial condition and results of operations; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">changes in reimbursement by current or potential third-party payers; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">issuance of new securities analysts&#8217; reports or changed recommendations for our stock; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">actual or anticipated changes in regulatory oversight of our testing products; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">commencement of, or our involvement in, litigation; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">announced or completed acquisitions of businesses or technologies by us or our competitors; </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">any major change in our management; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">changes in accounting principles; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">announcement or expectation of additional financing efforts; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">future sales of our common stock by our executive officers, directors and other stockholders; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">general economic conditions and slow or negative growth of our markets. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our failure to meet the continued listing requirements of the Nasdaq Global Market, or Nasdaq, could result in a delisting of our common stock. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us and our business. Currently, we have limited analyst coverage and we do not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">If the stockholders who held shares of our common stock prior to our IPO sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and other legal restrictions on resale discussed in the prospectus for the IPO lapse, the trading price of our common stock could decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In connection with our IPO, each of our directors and officers and substantially all of our other stockholders entered into a lock-up agreement with the underwriters, which restricts their ability to sell or transfer their shares. The lock-up agreements pertaining to our IPO will expire 180 days from the date of the prospectus for the IPO. The underwriters, however, may, in their sole discretion, waive the contractual lock-up prior to the expiration of the lock-up agreements. After the lock-up agreements expire, these shares of common stock will become eligible for sale in the public market to the extent permitted by the provisions of various option agreements, the lock-up agreements and Rules 144 and 701 under the Securities Act.  In addition, our directors and executive officers may establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by these stockholders, or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:9pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In addition, the holders of 8,407,515 shares of common stock and holders of warrants to purchase 461,273 shares of common stock are entitled to rights with respect to registration of such shares under the Securities Act pursuant to an investors&#8217; rights agreement between such holders and us.  If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling additional shares to raise capital and are required to include shares held by these holders pursuant to the exercise of their registration rights, our ability to raise capital may be impaired.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim condensed financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">reduced disclosure obligations regarding executive compensation; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which will continue to require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the Securities and Exchange Commission, or the SEC, and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our testing products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Pursuant to Section 404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2020. When we lose our status as an &#8220;emerging growth company&#8221; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As of September&#160;30, 2019, our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 61% of our outstanding capital stock. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our loan agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">An active, liquid trading market for our common stock may not be maintained </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">Prior to our IPO, there had been no public market for our common stock. Our common stock only recently began trading on Nasdaq, but we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We could be subject to securities class action litigation. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div id="i_0_777"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Recent Sales of Unregistered Securities</span></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In July 2019 we entered into an agreement to issue shares of our Series H redeemable convertible preferred stock, pursuant to which we sold to H.I.G. Bio-Exagen, L.P. in a single closing in July 2019, in a private placement an aggregate of 233,446,519 shares of our Series H redeemable convertible preferred stock at a purchase price of $0.04712 per share, for an aggregate purchase price of approximately $11.0 million.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the issuance of the Series H redeemable convertible preferred stock, each share of issued and outstanding Series G redeemable convertible preferred stock was converted into 1.6553 shares of Series H redeemable convertible preferred stock, for a total of 246,521,076 shares of Series H redeemable convertible preferred stock.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon completion of our IPO, an aggregate of 2,613,699 shares of common stock, were issued to the holders of our Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of Series H redeemable convertible preferred stock remained outstanding at September 30, 2019.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:115%;">Use of Proceeds</span></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. The IPO closed on September 23, 2019 and we issued and sold 4,140,00 shares of our common stock at a price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. The joint book-running managers of the offering were Cowen and Company, LLC, Cantor Fitzgerald &amp; Co and William Blair &amp; Company, LLC. No offering expenses were paid or are payable, directly </span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:115%;">As of September 30, 2019, we have not used any of the proceeds from our IPO. There has been no material change in the planned use of such proceeds from that described in the Prospectus.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_783"></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i_0_789"></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i_0_795"></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 5. Other Information</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i_0_801"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Item 6. Exhibits</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.109290%;"><tr><td style="width:1.0%;"></td><td style="width:6.507223%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.386838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.791332%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.643660%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.149278%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.396469%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.125201%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Filing Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Form of Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">001-39049</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/23/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex32.htm">Form of Amended Restated Bylaws.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">001-39049</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/23/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated July  12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders&#8217; Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Registrant in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.1#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.2#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.3#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.4#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1034.htm">Offer Letter, dated October 12, 2010, by and between Thierry Dervieux, Ph.D. and the Registrant, as amended on September 9, 2011 and September 6, 2019.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.34</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.35</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.6#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1036.htm">Offer Letter, dated October 7, 2011, by and between Fortunato Ron Rocca and the Registrant, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.36</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.7#</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1037.htm">Offer Letter, dated May 16, 2017, by and between Kamal Adawi and the Registrant, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">333-233446</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10.37</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9/9/2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="xgn311-93019.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="xgn312-93019.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="xgn321-93019.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:76.5pt;"></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-36pt;padding-left:76.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">* &#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="text-indent:-36pt;padding-left:76.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">#&#160;Indicates management contract or compensatory plan.</span></div><div id="i_0_807"></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Signatures</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.760234%;"><tr><td style="width:1.0%;"></td><td style="width:55.862595%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.954198%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.183206%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">EXAGEN INC.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: November 12, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">by:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date: November 12, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">by:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Kamal Adawi</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Kamal Adawi</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>xgn311-93019.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:242%;">Exhibit 31.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:139%;">EXAGEN INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:242%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">I, Fortunato Ron Rocca, certify that&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:168%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:168%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;"> &#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:168%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:168%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:18pt;margin-top:9pt;"></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.648438%;"><tr><td style="width:1.0%;"></td><td style="width:48.326797%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.673203%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; November 12, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt;"><font><br></font></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>xgn312-93019.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:242%;">Exhibit 31.2</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:139%;">EXAGEN INC.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:242%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> &#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:18pt;margin-top:9pt;"></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:18pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.648438%;"><tr><td style="width:1.0%;"></td><td style="width:48.326797%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.673203%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; November 12, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Kamal Adawi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:3pt;"><font><br></font></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>xgn321-93019.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:43pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:201%;">Exhibit 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">18 U.S.C. SECTION 1350</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:167%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;"><font><br></font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">In connection with the Quarterly Report on Form 10-Q of Exagen Inc. (the &#8220;Company&#8221;) for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Fortunato Ron Rocca, the President and Chief Executive Officer, and Kamal Adawi, the Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:3pt;font-weight:400;line-height:167%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:139%;">Dated&#58; November 12, 2019</font></div><div style="margin-bottom:28pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.648438%;"><tr><td style="width:1.0%;"></td><td style="width:46.039216%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.758170%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.202614%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Fortunato Ron Rocca</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Fortunato Ron Rocca</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">President and Chief Executive Officer</font></div><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(Principal Executive Officer)</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:2pt;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:2pt;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Chief Financial Officer</font></div><div style="padding-left:3pt;padding-right:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:16pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:167%;">A signed original of this written statement required by Section&#160;906 has been provided to Exagen Inc. and will be retained by Exagen Inc. and furnished to the Securities and Exchange Commission or its staff upon request. These certifications will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor will these certifications be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:43pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>exdx-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:exdx="http://www.exagen.com/20190930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20190930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquitySharesRedeemedUponConversion" abstract="false" name="TemporaryEquitySharesRedeemedUponConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquitySharesRedeemedUponConversionAmount" abstract="false" name="TemporaryEquitySharesRedeemedUponConversionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividendSharesIssued" abstract="false" name="TemporaryEquityDeemedDividendSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_NumberOfOperatingLeaseExtensions" abstract="false" name="NumberOfOperatingLeaseExtensions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" abstract="false" name="ClassOfWarrantOrRightUnexercisedAndTerminated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_AccruedFinancingCostsCurrent" abstract="false" name="AccruedFinancingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OtherNoncashTransactionChangeInAccountingPrinciple" abstract="false" name="OtherNoncashTransactionChangeInAccountingPrinciple" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" abstract="false" name="TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuanceCosts" abstract="false" name="TemporaryEquityIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeemedDividend" abstract="false" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ConversionOfTemporaryEquityAmountConverted" abstract="false" name="ConversionOfTemporaryEquityAmountConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_MilestoneContingencyFairValueDisclosure" abstract="false" name="MilestoneContingencyFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" abstract="false" name="TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" abstract="false" name="SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_PreferredStockWarrantLiability" abstract="false" name="PreferredStockWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_WarrantsTemporaryEquityMember" abstract="true" name="WarrantsTemporaryEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquitySharesIssuedUponConversion" abstract="false" name="TemporaryEquitySharesIssuedUponConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" abstract="false" name="IncreaseDecreaseInFairValueOfFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" abstract="false" name="ProceedsFromIssuanceOrSaleOfTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_NoncashExerciseOfStockPurchaseWarrants" abstract="false" name="NoncashExerciseOfStockPurchaseWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_CapitalRoyaltyPartnersIILPMember" abstract="true" name="CapitalRoyaltyPartnersIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" abstract="false" name="DeferredOfferingCostsIncludedWithinCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" abstract="false" name="TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityProceedsReceivedPriorToIssuance" abstract="false" name="TemporaryEquityProceedsReceivedPriorToIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MilestoneObligation" abstract="false" name="MilestoneObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityTextBlock" abstract="false" name="TemporaryEquityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_StockOptionPlan2013Member" abstract="true" name="StockOptionPlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderCapitalLease" abstract="false" name="EquipmentPurchasedUnderCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" abstract="false" name="DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividend" abstract="false" name="TemporaryEquityDeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AssetsUnderCapitalLeaseMember" abstract="true" name="AssetsUnderCapitalLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" abstract="false" name="TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_TemporaryEquityRightsForMandatoryPurchase" abstract="false" name="TemporaryEquityRightsForMandatoryPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_ExpirationSep82024Member" abstract="true" name="ExpirationSep82024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_SaleOfTemporaryEquityPricePerShare" abstract="false" name="SaleOfTemporaryEquityPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_SeriesDAndSeriesEPreferredStockMember" abstract="true" name="SeriesDAndSeriesEPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" abstract="false" name="SaleOfTemporaryEquityConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" abstract="false" name="ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.exagen.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1402401 - Statement - Condensed Balance Sheets - (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofOperations" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations">
        <link:definition>1003003 - Statement - Unaudited Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity">
        <link:definition>1004004 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1105101 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedStatementsofCashFlows" roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows">
        <link:definition>1006005 - Statement - Unaudited Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNotes" roleURI="http://www.exagen.com/role/OrganizationNotes">
        <link:definition>2101102 - Disclosure - Organization - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>2402402 - Disclosure - Organization - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNotes" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes">
        <link:definition>2103103 - Disclosure - Summary Of Significant Accounting Policies - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary Of Significant Accounting Policies - Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary Of Significant Accounting Policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406403 - Disclosure - Summary Of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails">
        <link:definition>2407404 - Disclosure - Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>2408405 - Disclosure - Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails">
        <link:definition>2409406 - Disclosure - Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>2410407 - Disclosure - Summary Of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNotes" roleURI="http://www.exagen.com/role/OtherFinancialInformationNotes">
        <link:definition>2111104 - Disclosure - Other Financial Information - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>2312302 - Disclosure - Other Financial Information - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>2413408 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidexpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails">
        <link:definition>2414409 - Disclosure - Other Financial Information - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandequipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails">
        <link:definition>2415410 - Disclosure - Other Financial Information - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedliabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails">
        <link:definition>2416411 - Disclosure - Other Financial Information - Accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNotes" roleURI="http://www.exagen.com/role/BorrowingsNotes">
        <link:definition>2117105 - Disclosure - Borrowings - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>2318303 - Disclosure - Borrowings - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>2419412 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureminimumpaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails">
        <link:definition>2420413 - Disclosure - Borrowings - Future minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoPurchaseCommonorPreferredStockNotes" roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes">
        <link:definition>2121106 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoPurchaseCommonorPreferredStockTables" roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables">
        <link:definition>2322304 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails">
        <link:definition>2423414 - Disclosure - Warrants to Purchase Common or Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails">
        <link:definition>2424415 - Disclosure - Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNotes" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNotes">
        <link:definition>2125107 - Disclosure - Commitment and Contingencies - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2426416 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNotes" roleURI="http://www.exagen.com/role/FairValueMeasurementsNotes">
        <link:definition>2127108 - Disclosure - Fair Value Measurements - (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresandDisclosuresTables" roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables">
        <link:definition>2328305 - Disclosure - Fair Value Measures and Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairvaluemeasurementDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails">
        <link:definition>2429417 - Disclosure - Fair Value Measurements - Fair value measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairvaluelevel3Details" roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details">
        <link:definition>2430418 - Disclosure - Fair Value Measurements- Fair value level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2131109 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockDetails" roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails">
        <link:definition>2432419 - Disclosure - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.exagen.com/role/StockholdersEquityDeficit">
        <link:definition>2133110 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitDetails" roleURI="http://www.exagen.com/role/StockholdersEquityDeficitDetails">
        <link:definition>2434420 - Disclosure - Stockholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>2135111 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>2336306 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>2437421 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>2438422 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>2439423 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>2440424 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.exagen.com/role/RelatedParties">
        <link:definition>2141112 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesDetails" roleURI="http://www.exagen.com/role/RelatedPartiesDetails">
        <link:definition>2442425 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" roleURI="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018">
        <link:definition>2143113 - Disclosure - Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingChangesandErrorCorrectionsTables" roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables">
        <link:definition>2344307 - Disclosure - Accounting Changes and Error Corrections (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingChangesandErrorCorrectionsBalanceSheetDetails" roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails">
        <link:definition>2445426 - Disclosure - Accounting Changes and Error Corrections - Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingChangesandErrorCorrectionsOperationsDetails" roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails">
        <link:definition>2446427 - Disclosure - Accounting Changes and Error Corrections - Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails">
        <link:definition>2447428 - Disclosure - Accounting Changes and Error Corrections - Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>exdx-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20190930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d16bfc4d-acaa-495a-8a67-e2cd3131693f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e36e71b-9491-4527-a9e9-5b6a9efe67b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d16bfc4d-acaa-495a-8a67-e2cd3131693f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e36e71b-9491-4527-a9e9-5b6a9efe67b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b925f783-172b-4168-a154-452fb86a6744" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d16bfc4d-acaa-495a-8a67-e2cd3131693f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b925f783-172b-4168-a154-452fb86a6744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6f4dc776-88b5-4098-9c84-59218f107710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d16bfc4d-acaa-495a-8a67-e2cd3131693f" xlink:to="loc_us-gaap_AssetsCurrent_6f4dc776-88b5-4098-9c84-59218f107710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63b8125c-5c7e-438f-b309-ccb33394c2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d16bfc4d-acaa-495a-8a67-e2cd3131693f" xlink:to="loc_us-gaap_Goodwill_63b8125c-5c7e-438f-b309-ccb33394c2c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1cf06ce-09e5-4036-8033-d66fa1920b73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4d7f2e1c-665b-4b02-939f-639827594f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1cf06ce-09e5-4036-8033-d66fa1920b73" xlink:to="loc_us-gaap_AccountsPayableCurrent_4d7f2e1c-665b-4b02-939f-639827594f74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_851e35e9-d2e5-4598-9fd9-3f1891eee9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1cf06ce-09e5-4036-8033-d66fa1920b73" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_851e35e9-d2e5-4598-9fd9-3f1891eee9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_973a3391-7576-42c7-b54b-a644c0e26f7d" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityProceedsReceivedPriorToIssuance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d1cf06ce-09e5-4036-8033-d66fa1920b73" xlink:to="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_973a3391-7576-42c7-b54b-a644c0e26f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_56f576a3-2031-473c-b091-9dcf0ed31c91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_56f576a3-2031-473c-b091-9dcf0ed31c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_3dd3f3a6-210b-4c5f-ab0b-bafb24acb0d4" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:to="loc_exdx_PreferredStockWarrantLiability_3dd3f3a6-210b-4c5f-ab0b-bafb24acb0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_63ea7c28-fe9c-4250-88ab-b2acd99d532c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_63ea7c28-fe9c-4250-88ab-b2acd99d532c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ee5a9bf-f4da-48e7-a28f-5b56ba3928af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ee5a9bf-f4da-48e7-a28f-5b56ba3928af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_78c0ad72-fc3d-48fb-bd2f-bcf775a70e55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ddf5153-a66c-43d8-96cd-187fd4b258fb" xlink:to="loc_us-gaap_LiabilitiesCurrent_78c0ad72-fc3d-48fb-bd2f-bcf775a70e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fd3e01-de5f-4ef5-aea5-af9a4813b274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7508f588-8998-46a4-948b-b3680ed618dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fd3e01-de5f-4ef5-aea5-af9a4813b274" xlink:to="loc_us-gaap_StockholdersEquity_7508f588-8998-46a4-948b-b3680ed618dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f81a9a85-5cde-4f59-abda-dd16dc11302f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fd3e01-de5f-4ef5-aea5-af9a4813b274" xlink:to="loc_us-gaap_Liabilities_f81a9a85-5cde-4f59-abda-dd16dc11302f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4700d0db-027b-40ab-9c52-3b3868201129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c8fd3e01-de5f-4ef5-aea5-af9a4813b274" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4700d0db-027b-40ab-9c52-3b3868201129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_17cb3a3d-c2d7-46e1-86cf-73d0dd70ca3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71b613b1-520c-455d-85dd-35941b6fe943" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17cb3a3d-c2d7-46e1-86cf-73d0dd70ca3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71b613b1-520c-455d-85dd-35941b6fe943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ac83b0dc-25ae-453f-8232-41a3247f0c82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_17cb3a3d-c2d7-46e1-86cf-73d0dd70ca3b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ac83b0dc-25ae-453f-8232-41a3247f0c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ddf552a-be3b-4e77-b795-2ca788cf3a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7aa4d842-a876-427a-9e95-7509a3587ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ddf552a-be3b-4e77-b795-2ca788cf3a0a" xlink:to="loc_us-gaap_PreferredStockValue_7aa4d842-a876-427a-9e95-7509a3587ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_73da363e-c98d-45a1-960f-895e98e66617" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ddf552a-be3b-4e77-b795-2ca788cf3a0a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_73da363e-c98d-45a1-960f-895e98e66617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb788955-4793-4775-985d-3b4ca961ed74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ddf552a-be3b-4e77-b795-2ca788cf3a0a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cb788955-4793-4775-985d-3b4ca961ed74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f9de8788-2b70-4528-8087-38d99cb23674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ddf552a-be3b-4e77-b795-2ca788cf3a0a" xlink:to="loc_us-gaap_CommonStockValue_f9de8788-2b70-4528-8087-38d99cb23674" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_faef14fe-0df9-4751-a8fa-9492a1a18768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f6d76429-17a0-40fd-989d-1f26518a0969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_faef14fe-0df9-4751-a8fa-9492a1a18768" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f6d76429-17a0-40fd-989d-1f26518a0969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b062711e-756f-40eb-86f7-aa8bb65c299e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_faef14fe-0df9-4751-a8fa-9492a1a18768" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b062711e-756f-40eb-86f7-aa8bb65c299e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_103bd39a-cb0c-4087-b13a-99572296e573" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_faef14fe-0df9-4751-a8fa-9492a1a18768" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_103bd39a-cb0c-4087-b13a-99572296e573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9fa1c18d-b4f1-48f8-bfbe-e53fa9c79f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_faef14fe-0df9-4751-a8fa-9492a1a18768" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9fa1c18d-b4f1-48f8-bfbe-e53fa9c79f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb7c1e19-4741-4747-9aad-922e87815990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9f1b98d-bce6-4823-83a0-4c225d0b7dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb7c1e19-4741-4747-9aad-922e87815990" xlink:to="loc_us-gaap_CostsAndExpenses_a9f1b98d-bce6-4823-83a0-4c225d0b7dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99dd1b6d-9c92-4ca0-8625-da4f31e80c44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb7c1e19-4741-4747-9aad-922e87815990" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99dd1b6d-9c92-4ca0-8625-da4f31e80c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c23c5684-e69f-43d6-abab-ced45a2e56ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a5730b6-d4ef-4733-969a-55f8e8489eca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c23c5684-e69f-43d6-abab-ced45a2e56ed" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a5730b6-d4ef-4733-969a-55f8e8489eca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0caf382a-a9ac-48cc-a0f1-fd64b9694086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_ShareBasedCompensation_0caf382a-a9ac-48cc-a0f1-fd64b9694086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1c3e09e4-7d01-4d9c-a9d5-8ba7237002bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1c3e09e4-7d01-4d9c-a9d5-8ba7237002bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_83dba738-9b38-4d91-957d-eface70b3a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_83dba738-9b38-4d91-957d-eface70b3a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a56ad005-466f-494e-bed8-76e324c947bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_NetIncomeLoss_a56ad005-466f-494e-bed8-76e324c947bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8434ebde-cd23-4eb0-b212-24e6c64190ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8434ebde-cd23-4eb0-b212-24e6c64190ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_989282c9-92aa-4e42-99aa-f8427e5df069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_989282c9-92aa-4e42-99aa-f8427e5df069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_70c0ab69-f79b-45bb-a6bc-bf4a9a9b94b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_70c0ab69-f79b-45bb-a6bc-bf4a9a9b94b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80b2c274-a2b9-40c0-b1ce-7731d00fd169" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80b2c274-a2b9-40c0-b1ce-7731d00fd169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d7eea640-07ea-4013-84a0-1a4d5fbeb99e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_PaidInKindInterest_d7eea640-07ea-4013-84a0-1a4d5fbeb99e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c0e1fe9e-2972-48bc-9f08-9d2b27d30665" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c0e1fe9e-2972-48bc-9f08-9d2b27d30665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_15253f4e-0c2b-42e2-b764-7cee9228df32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_719efef4-f7f6-4d9e-8fef-5095fc2fd84c" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_15253f4e-0c2b-42e2-b764-7cee9228df32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b50123da-e772-4a80-a891-d8ccff828883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8a7f49-9ea1-4ec0-90f9-9959b53b0ace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b50123da-e772-4a80-a891-d8ccff828883" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8a7f49-9ea1-4ec0-90f9-9959b53b0ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee55713c-68e6-4388-b5ed-1abf4d95c79f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b50123da-e772-4a80-a891-d8ccff828883" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee55713c-68e6-4388-b5ed-1abf4d95c79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ba62d52e-8a55-45f1-b500-72c0ec3f15c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b50123da-e772-4a80-a891-d8ccff828883" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ba62d52e-8a55-45f1-b500-72c0ec3f15c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8da79ac-0568-4002-bab4-a7d8cce66a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_c0434f22-36ad-4f2e-9a98-cf16c13dad08" xlink:href="exdx-20190930.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8da79ac-0568-4002-bab4-a7d8cce66a5f" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_c0434f22-36ad-4f2e-9a98-cf16c13dad08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_8d0222f1-9722-406c-ba63-ec7f473e56db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8da79ac-0568-4002-bab4-a7d8cce66a5f" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_8d0222f1-9722-406c-ba63-ec7f473e56db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7111a18d-27b5-4a40-94cf-57aed7c93c99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b8da79ac-0568-4002-bab4-a7d8cce66a5f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_7111a18d-27b5-4a40-94cf-57aed7c93c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5cd8ac90-7d5f-4607-a346-7b02cc599bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_57857658-fabc-4c8d-9c50-25e67afe92a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5cd8ac90-7d5f-4607-a346-7b02cc599bc4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_57857658-fabc-4c8d-9c50-25e67afe92a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bf983b93-7019-4bb8-a784-1bb1d7d17741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5cd8ac90-7d5f-4607-a346-7b02cc599bc4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bf983b93-7019-4bb8-a784-1bb1d7d17741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b19d9340-987a-4c53-8621-197edc75c4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5cd8ac90-7d5f-4607-a346-7b02cc599bc4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b19d9340-987a-4c53-8621-197edc75c4e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6ea34e2e-283a-4f5c-bd19-c4d7084b14c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5cd8ac90-7d5f-4607-a346-7b02cc599bc4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6ea34e2e-283a-4f5c-bd19-c4d7084b14c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OrganizationNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45d3c070-1665-4725-b428-6c1e95ccc56d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_eeb90d4f-0b83-4f9c-8906-b9ec95afc68a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45d3c070-1665-4725-b428-6c1e95ccc56d" xlink:to="loc_us-gaap_RestrictedCash_eeb90d4f-0b83-4f9c-8906-b9ec95afc68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a2336704-c8c4-4476-89a0-f8e6d046f38d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45d3c070-1665-4725-b428-6c1e95ccc56d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a2336704-c8c4-4476-89a0-f8e6d046f38d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb4946c8-28c6-4045-add7-9a3fba0e5a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_05944098-31cf-4447-9a87-5be30cf95965" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb4946c8-28c6-4045-add7-9a3fba0e5a4b" xlink:to="loc_us-gaap_PrepaidRoyalties_05944098-31cf-4447-9a87-5be30cf95965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_6a947655-38da-4084-9d40-844d46ac44d7" xlink:href="exdx-20190930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb4946c8-28c6-4045-add7-9a3fba0e5a4b" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_6a947655-38da-4084-9d40-844d46ac44d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_3f04a133-d6c5-424d-963d-76b0661f7df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb4946c8-28c6-4045-add7-9a3fba0e5a4b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_3f04a133-d6c5-424d-963d-76b0661f7df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f4deda09-e841-41e0-bc09-649412f2a161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fb4946c8-28c6-4045-add7-9a3fba0e5a4b" xlink:to="loc_us-gaap_OtherAssetsCurrent_f4deda09-e841-41e0-bc09-649412f2a161" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_94dba27c-5876-4df4-a241-95a47fdada56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_48eecae0-3bad-481b-b509-54fb27151ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_94dba27c-5876-4df4-a241-95a47fdada56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_48eecae0-3bad-481b-b509-54fb27151ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3f902bd-3381-47d6-a5cd-17693c0dd93b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_94dba27c-5876-4df4-a241-95a47fdada56" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c3f902bd-3381-47d6-a5cd-17693c0dd93b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_b147aacb-c446-4605-9b7e-1abce2f42a78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_us-gaap_AccruedSalariesCurrent_b147aacb-c446-4605-9b7e-1abce2f42a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_655d24ed-6e84-4597-a786-df993ccb5772" xlink:href="exdx-20190930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_655d24ed-6e84-4597-a786-df993ccb5772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_31b20d5e-2810-49f0-a779-4578ed8cfa0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_31b20d5e-2810-49f0-a779-4578ed8cfa0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_7c7a36ea-55ff-47d4-b05b-0391b68642bd" xlink:href="exdx-20190930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_7c7a36ea-55ff-47d4-b05b-0391b68642bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_878405ad-fd48-445d-8020-883a29e06e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_us-gaap_InterestPayableCurrent_878405ad-fd48-445d-8020-883a29e06e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_dd5db1eb-9a46-4371-bcaa-7171f3ae1534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_dd5db1eb-9a46-4371-bcaa-7171f3ae1534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e7e95429-9aec-4989-803d-8ca41e4c6c80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e7e95429-9aec-4989-803d-8ca41e4c6c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedFinancingCostsCurrent_e392694a-75fc-421f-b2c7-83a4c941b75a" xlink:href="exdx-20190930.xsd#exdx_AccruedFinancingCostsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f542ab6b-7c44-4713-af0d-3af48832adcc" xlink:to="loc_exdx_AccruedFinancingCostsCurrent_e392694a-75fc-421f-b2c7-83a4c941b75a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_5dea67b1-f28b-4c6c-a26c-977dbcd93706" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_42aebc59-fe0c-4ac6-bac6-75238135a535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_5dea67b1-f28b-4c6c-a26c-977dbcd93706" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_42aebc59-fe0c-4ac6-bac6-75238135a535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_10183e0f-d68e-483a-8cf5-4caf51894b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_5dea67b1-f28b-4c6c-a26c-977dbcd93706" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_10183e0f-d68e-483a-8cf5-4caf51894b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_70970bda-b541-424e-87fd-62a9692edb86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_5dea67b1-f28b-4c6c-a26c-977dbcd93706" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_70970bda-b541-424e-87fd-62a9692edb86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aaa1d62f-adf4-46e3-93ae-c1865c2b710a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_5dea67b1-f28b-4c6c-a26c-977dbcd93706" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_aaa1d62f-adf4-46e3-93ae-c1865c2b710a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_517de63c-dfe8-4820-b3b3-724fbe80d307" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_87c041ed-2e6e-433e-bf8b-aeb6d16527e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_517de63c-dfe8-4820-b3b3-724fbe80d307" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_87c041ed-2e6e-433e-bf8b-aeb6d16527e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_08612845-f97e-4274-b1eb-cf0ffbde948a" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_517de63c-dfe8-4820-b3b3-724fbe80d307" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_08612845-f97e-4274-b1eb-cf0ffbde948a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_8b5dff59-93a1-46ac-b90c-4f84b1d93979" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_517de63c-dfe8-4820-b3b3-724fbe80d307" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_8b5dff59-93a1-46ac-b90c-4f84b1d93979" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsNotes"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluemeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluelevel3Details"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStock"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficit"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficitDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlan"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedParties"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedPartiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="simple" xlink:href="exdx-20190930.xsd#CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsTables"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>exdx-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20190930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended" id="i9f478eccc6ac42bf85159432a8a08ff2_73c5a7a7-4b9d-462b-b420-d80d1bd2b2a6"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended" id="ic02a6e95c1be4f5184cf4425cf5467b6_aa7baf07-4210-4c43-8154-743aa8bab2ca"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" id="ic53825308ae74f8fa1d31c15d40ced54_c5d9871d-c942-4016-9bd8-b4b493664c89">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_aac914f4-0d47-447f-beea-4515f83dede5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_aac914f4-0d47-447f-beea-4515f83dede5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_91d6d503-cdd9-4d4d-82c1-e323b318f6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_91d6d503-cdd9-4d4d-82c1-e323b318f6ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d61a0b68-8e50-44fb-b8eb-b289a5d6b570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d61a0b68-8e50-44fb-b8eb-b289a5d6b570" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_9ba72180-495f-46e6-bd03-4704e88cefe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_9ba72180-495f-46e6-bd03-4704e88cefe7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_c8836eb8-5203-4186-9f14-af429cc85922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_c8836eb8-5203-4186-9f14-af429cc85922" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0e762fd-d482-4624-aa02-98d456663ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0e762fd-d482-4624-aa02-98d456663ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ca99c5a3-bb23-40b6-82e9-59d579fac660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ca99c5a3-bb23-40b6-82e9-59d579fac660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_641a771c-12b0-4f4a-b849-042cfba554d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_641a771c-12b0-4f4a-b849-042cfba554d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_162489c2-6326-4111-966e-43b57cda0e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_162489c2-6326-4111-966e-43b57cda0e5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd6c1a5a-e640-416f-bd01-2596f8d64c22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd6c1a5a-e640-416f-bd01-2596f8d64c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a0d27ffd-e630-4aa4-97ee-f820c12c7f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a0d27ffd-e630-4aa4-97ee-f820c12c7f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c18ce8b1-536e-4b1f-ad4e-a53136e53cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesIssued_c18ce8b1-536e-4b1f-ad4e-a53136e53cf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0692efbd-1c3c-4398-8fa8-4adc2964c8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0692efbd-1c3c-4398-8fa8-4adc2964c8cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_601832e1-d52e-4f2c-9ed2-b29256046211_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:to="loc_us-gaap_ClassOfStockDomain_601832e1-d52e-4f2c-9ed2-b29256046211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:to="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c243e96d-33fe-404c-929e-9ecf5e0b384b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c243e96d-33fe-404c-929e-9ecf5e0b384b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended" id="i8fbd04cfec104b03a0fa0866653b0462_5ab38eeb-1a81-4c13-a343-52d97fb21666"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended" id="ie8310308f17d46b18ae3a26b300d7fdb_a42476eb-1796-4f98-95cd-98440c1f1238">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31382515-c944-408b-993e-0a43c4abb66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_31382515-c944-408b-993e-0a43c4abb66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0a4d34a1-7144-4b5e-a06f-bbfcd4e0a6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0a4d34a1-7144-4b5e-a06f-bbfcd4e0a6a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_e0fb615c-c84c-424f-bc4c-7fa0b99f32fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_e0fb615c-c84c-424f-bc4c-7fa0b99f32fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_a8db9db5-fe8c-46a2-8db0-b2d1f82c008a" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_a8db9db5-fe8c-46a2-8db0-b2d1f82c008a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_6cdd2e9b-6795-4e5f-b66c-a7da5e8395b0" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_6cdd2e9b-6795-4e5f-b66c-a7da5e8395b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ff0622e2-20d8-498e-b8fd-4577127d971a" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ff0622e2-20d8-498e-b8fd-4577127d971a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_4253aa0f-8f0f-418e-bff8-05834452b08d" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_4253aa0f-8f0f-418e-bff8-05834452b08d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_04b55471-44a7-4986-ba8d-6a29def76c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_04b55471-44a7-4986-ba8d-6a29def76c9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_58d52a35-4125-415f-8057-4b938ea8e4d8" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_58d52a35-4125-415f-8057-4b938ea8e4d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_d1cb5bc0-1a5d-408f-b7d3-af99ee5e7a30" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_d1cb5bc0-1a5d-408f-b7d3-af99ee5e7a30" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_db23637c-075e-4bf8-83f1-6144814107c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0ed8ce48-9699-4fbb-ae6e-766ad0b55ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38b297ff-271d-4a79-ba60-69621951d5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_38b297ff-271d-4a79-ba60-69621951d5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_669a34ec-58d3-411f-844e-d61a4660db91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockholdersEquity_669a34ec-58d3-411f-844e-d61a4660db91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_c9799e0d-2f5e-4698-a8b2-06a4a758ea97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_c9799e0d-2f5e-4698-a8b2-06a4a758ea97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_fc90f335-11c8-4627-810c-9b71a18dc5c5" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_fc90f335-11c8-4627-810c-9b71a18dc5c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a83e27f-9c48-4532-a947-c402571f9e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a83e27f-9c48-4532-a947-c402571f9e0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ddf1937b-44d5-403a-9865-32cfbbeaf840" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ddf1937b-44d5-403a-9865-32cfbbeaf840" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ccbf470-baa7-4caa-a16c-89e3e4e0ba1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ccbf470-baa7-4caa-a16c-89e3e4e0ba1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_d4e289a1-ecba-4fa7-ba52-2550f971cfa3" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_d4e289a1-ecba-4fa7-ba52-2550f971cfa3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_4a043002-2f40-4e66-b859-31475cf5f4fc" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_4a043002-2f40-4e66-b859-31475cf5f4fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_1e50d180-ae2a-416a-97d3-300841be5109" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_1e50d180-ae2a-416a-97d3-300841be5109" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_ddc2622d-b42a-4b56-8b7e-0f41d6cef4d2" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_ddc2622d-b42a-4b56-8b7e-0f41d6cef4d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_aa9b6452-7a70-4c81-b0f1-29f5d9941510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_aa9b6452-7a70-4c81-b0f1-29f5d9941510" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_74b03ffd-55e3-420a-a939-7e63f6ed497d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_74b03ffd-55e3-420a-a939-7e63f6ed497d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ea957d99-9924-4ebd-a42c-476176bfb384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ea957d99-9924-4ebd-a42c-476176bfb384" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d9e6a41a-4265-4f54-8fd1-08c77cbfa86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d9e6a41a-4265-4f54-8fd1-08c77cbfa86d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_ce0f6ecf-82ff-4cd0-a670-281e48a02bd9" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_ce0f6ecf-82ff-4cd0-a670-281e48a02bd9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_3ca80ce2-29f5-4c11-8de9-6f33a945c4ae" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_3ca80ce2-29f5-4c11-8de9-6f33a945c4ae" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_01de96de-2778-402c-89a9-1106ae264930" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_01de96de-2778-402c-89a9-1106ae264930" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_452aef2a-9949-4cc3-be9b-13b7db57a05c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_NetIncomeLoss_452aef2a-9949-4cc3-be9b-13b7db57a05c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_49cbd2a8-67d0-4cb3-9a98-5aa4adc5b073" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3813ae24-fd92-42fd-b707-4f17670e4ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:to="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f15eb7b8-c44d-46e4-9106-270e18d427a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:to="loc_us-gaap_EquityComponentDomain_f15eb7b8-c44d-46e4-9106-270e18d427a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:to="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dc2a7026-82e4-4672-ad25-4194e09a6c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_CommonStockMember_dc2a7026-82e4-4672-ad25-4194e09a6c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c9627b0-21bf-4e86-86dc-bcbaf6d73625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c9627b0-21bf-4e86-86dc-bcbaf6d73625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8b956eab-589c-4dae-b34d-fff7187d098a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_RetainedEarningsMember_8b956eab-589c-4dae-b34d-fff7187d098a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended" id="ie43b96105fbf4d43bd938f4060e1182d_87b67842-b379-424f-aadb-02ec7d024d60">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_a296bf3c-ee4f-4567-9b41-0d877a5b93c6" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_a296bf3c-ee4f-4567-9b41-0d877a5b93c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts_f013721f-9e26-4730-9a9f-51feed230e86" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:to="loc_exdx_TemporaryEquityIssuanceCosts_f013721f-9e26-4730-9a9f-51feed230e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:to="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73629aa4-9d3e-465a-9dc9-bfc502e6f66d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:to="loc_us-gaap_ClassOfStockDomain_73629aa4-9d3e-465a-9dc9-bfc502e6f66d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:to="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_dd3f46df-56f3-4b87-a917-67fc7ec538b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_dd3f46df-56f3-4b87-a917-67fc7ec538b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_0056e53c-f338-48fb-aa3e-ce4e73ce57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_0056e53c-f338-48fb-aa3e-ce4e73ce57e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_8578c0e1-f3c8-4fe8-84ff-2799f477a767" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_8578c0e1-f3c8-4fe8-84ff-2799f477a767" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended" id="i9fec909cfa984cb5ab1eb862a1cb351e_593e55a3-3e46-4bef-89c6-1ca79b8f4588">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2742873e-0360-4001-bf79-533b158af4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_NetIncomeLoss_2742873e-0360-4001-bf79-533b158af4a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_903c8ed6-4225-44cf-95bb-3ce7fd272ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_903c8ed6-4225-44cf-95bb-3ce7fd272ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8794c10c-c969-4cd9-9446-901c1238c377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8794c10c-c969-4cd9-9446-901c1238c377" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_49721e22-6477-4bdc-905c-906c853f0293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_PaidInKindInterest_49721e22-6477-4bdc-905c-906c853f0293" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_32a3f781-edba-40cc-80f5-212161fe9e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_32a3f781-edba-40cc-80f5-212161fe9e0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2c8169d5-4bd3-434c-b4a3-a095f16838d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2c8169d5-4bd3-434c-b4a3-a095f16838d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e9ed5c25-8caf-4ed2-9ae3-2c73424efe94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_ShareBasedCompensation_e9ed5c25-8caf-4ed2-9ae3-2c73424efe94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61422170-0911-4b12-9de6-75c7e29c67b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61422170-0911-4b12-9de6-75c7e29c67b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cf7ee7bb-86d7-4918-98e6-101d6dcc7dc5" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cf7ee7bb-86d7-4918-98e6-101d6dcc7dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1f4f037c-9668-4162-8e04-c7c6d068e265" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1f4f037c-9668-4162-8e04-c7c6d068e265" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e480be1-771b-4fe7-97fa-b3475488a52e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e480be1-771b-4fe7-97fa-b3475488a52e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2ef1779-3321-4057-ab78-5c88cbb70e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2ef1779-3321-4057-ab78-5c88cbb70e0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3906b30f-2505-4b77-9790-f2838c44fcef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3906b30f-2505-4b77-9790-f2838c44fcef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcc73ca3-1f93-414b-9df2-afd79d264edf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcc73ca3-1f93-414b-9df2-afd79d264edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_701c9efb-7333-47a3-9a75-ce9f69524342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_701c9efb-7333-47a3-9a75-ce9f69524342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8d73d81d-93a0-4cdb-96ca-6c782910feb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8d73d81d-93a0-4cdb-96ca-6c782910feb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ba4997e8-ffc5-46a5-8896-a5be1c58c24b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ba4997e8-ffc5-46a5-8896-a5be1c58c24b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69cdf71c-d397-41e1-bdf9-73bf0dd0df0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69cdf71c-d397-41e1-bdf9-73bf0dd0df0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d693be0-4798-4719-b3b3-860a2c3c8177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d693be0-4798-4719-b3b3-860a2c3c8177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_e860ccc3-a871-4974-8e0a-fb5f825a1be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_e860ccc3-a871-4974-8e0a-fb5f825a1be8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_7c950cac-b251-49aa-9651-86485491d7d7" xlink:href="exdx-20190930.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_7c950cac-b251-49aa-9651-86485491d7d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92863174-813a-4276-a8a6-dcf84b0fd40d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92863174-813a-4276-a8a6-dcf84b0fd40d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d39a6815-45bd-4fa8-92b3-a82a98c5351f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d39a6815-45bd-4fa8-92b3-a82a98c5351f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44af0a76-ba50-482a-913b-32a268b7d1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44af0a76-ba50-482a-913b-32a268b7d1d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63ef4460-06c7-4cb5-8ebd-a8fa7fa69de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3a725a56-db43-4018-9afb-774b4a92dbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:to="loc_us-gaap_InterestPaidNet_3a725a56-db43-4018-9afb-774b4a92dbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_5693d4a2-28d6-4160-8a1c-186a46810c89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_5693d4a2-28d6-4160-8a1c-186a46810c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_df496195-a336-47c3-a5c3-c15dbd06abe8" xlink:href="exdx-20190930.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_df496195-a336-47c3-a5c3-c15dbd06abe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c6dbc1f-e9ed-495a-90cf-86caaabb037c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c6dbc1f-e9ed-495a-90cf-86caaabb037c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_95749915-9e64-4726-88e4-31d15c48e0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_95749915-9e64-4726-88e4-31d15c48e0ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_64d20ed6-b64a-4edd-b350-cfaebe561eb8" xlink:href="exdx-20190930.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_64d20ed6-b64a-4edd-b350-cfaebe561eb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_8cf632d2-c228-4de4-8349-ed2b2e475052" xlink:href="exdx-20190930.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_8cf632d2-c228-4de4-8349-ed2b2e475052" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_29fa9898-4dbd-4493-b6ce-b841bfd159e9" xlink:href="exdx-20190930.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_29fa9898-4dbd-4493-b6ce-b841bfd159e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b2470da4-0d77-4253-9c95-ed125bb8fd31" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b2470da4-0d77-4253-9c95-ed125bb8fd31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_c93ced0e-2876-4340-a8de-78a0b5badf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_c93ced0e-2876-4340-a8de-78a0b5badf5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted_46a1406b-4825-4af4-b156-a87bcaa1eba4" xlink:href="exdx-20190930.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_ConversionOfTemporaryEquityAmountConverted_46a1406b-4825-4af4-b156-a87bcaa1eba4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeemedDividend_2c92e822-831f-4a04-8cd3-1408e3099971" xlink:href="exdx-20190930.xsd#exdx_DeemedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_DeemedDividend_2c92e822-831f-4a04-8cd3-1408e3099971" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_a16ab571-f3ea-44ea-9fda-2a823afa35ee" xlink:href="exdx-20190930.xsd#exdx_OtherNoncashTransactionChangeInAccountingPrinciple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_a16ab571-f3ea-44ea-9fda-2a823afa35ee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_74456b72-1fdb-490d-991c-39be3b13d102_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:to="loc_us-gaap_ClassOfStockDomain_74456b72-1fdb-490d-991c-39be3b13d102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:to="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_093f56f9-b1a1-4c43-8b6b-c0b018f5dcb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_093f56f9-b1a1-4c43-8b6b-c0b018f5dcb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_1cb924b8-cdbe-4d45-ba9b-2426e7813a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_1cb924b8-cdbe-4d45-ba9b-2426e7813a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_176fbc34-2749-43fb-8eea-58ef1948f551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_176fbc34-2749-43fb-8eea-58ef1948f551" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OrganizationNotes" xlink:type="extended" id="ibd242a8b47a348138f6dc50c963226f4_79ed7eaa-143a-4417-8b8d-38d3fb08b8fd"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended" id="i99e7ab34820a4d358d29064f790cec1c_671f9d18-ced5-48f3-a9b0-724ac503131a">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3c52f8ad-9efe-4ce9-a291-89ee28520d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3c52f8ad-9efe-4ce9-a291-89ee28520d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bf6bfad5-bb99-4c76-8a03-8a416e07d900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bf6bfad5-bb99-4c76-8a03-8a416e07d900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_071cba22-805b-4c1f-8b79-2d27718a4f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_071cba22-805b-4c1f-8b79-2d27718a4f88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_34119cd9-1cfa-4835-852c-e5b86f1869b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_34119cd9-1cfa-4835-852c-e5b86f1869b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b2e44a9-9f83-4cee-a086-b8c0141783d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b2e44a9-9f83-4cee-a086-b8c0141783d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_787a0388-520d-490e-8152-f0ab8f0bf3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_787a0388-520d-490e-8152-f0ab8f0bf3a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e94a192-29b1-4dcf-a63a-73b370c2285b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:to="loc_us-gaap_EquityComponentDomain_5e94a192-29b1-4dcf-a63a-73b370c2285b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:to="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5d959cd7-2f2a-40f8-ada5-bbd2a62abc82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:to="loc_us-gaap_CommonStockMember_5d959cd7-2f2a-40f8-ada5-bbd2a62abc82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38fa02fe-2588-4aa3-8c77-476c0f4c0f11_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38fa02fe-2588-4aa3-8c77-476c0f4c0f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4b59f9bd-42c7-4459-acd2-26df0d764112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:to="loc_us-gaap_IPOMember_4b59f9bd-42c7-4459-acd2-26df0d764112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_34939efc-6852-4786-a1fa-3adcf9c3d675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:to="loc_us-gaap_OverAllotmentOptionMember_34939efc-6852-4786-a1fa-3adcf9c3d675" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="extended" id="i4298f62c9fc047958f2c7d4d9e5657e6_3fc31345-d8ba-418e-86ad-5f96f3f6cfe3"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" id="if44514900bdd422786f23b1cb80b9c2d_ef8f9826-e32a-457c-ba34-eb5d49f5f50f"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" id="i9662ab5987d041d292e466d29c814a92_e5be544d-41a7-4c12-a920-74ed5439eb6e"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i6d3bd69bba794a579d5bf8c8629e9b1e_edcadbe4-7d52-4d63-8e7c-e3aa73c35a36">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f36b23fb-dd5e-4a9d-9229-0decf7c9debc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_RestrictedCash_f36b23fb-dd5e-4a9d-9229-0decf7c9debc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_d2990150-f4a4-4925-a1f9-6aa6dc8e6235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_DeferredOfferingCosts_d2990150-f4a4-4925-a1f9-6aa6dc8e6235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ea5acba4-a9d5-4202-9f7a-eba083ebc5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ea5acba4-a9d5-4202-9f7a-eba083ebc5ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_91412b21-38ca-4baa-9bcc-be8a6816d85f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_AdvertisingExpense_91412b21-38ca-4baa-9bcc-be8a6816d85f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a1706f8-3b35-42d9-b1db-5be7a00ae4c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a1706f8-3b35-42d9-b1db-5be7a00ae4c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2b4c868f-b1d5-433c-b549-eb4ad4ab9af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_CostOfRevenue_2b4c868f-b1d5-433c-b549-eb4ad4ab9af2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_dd40f489-359f-4e28-897e-0d978269818c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_dd40f489-359f-4e28-897e-0d978269818c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29dc8e85-db73-4a8c-9109-990539aed313_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_29dc8e85-db73-4a8c-9109-990539aed313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_64a368df-8a25-4559-a8b3-54dd633c9ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:to="loc_us-gaap_IPOMember_64a368df-8a25-4559-a8b3-54dd633c9ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf843fda-6ed3-4bfa-bc4e-51c29377c8de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf843fda-6ed3-4bfa-bc4e-51c29377c8de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_5c38ab1c-dba1-4ed9-b358-d5578247d87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:to="loc_us-gaap_OtherAssetsMember_5c38ab1c-dba1-4ed9-b358-d5578247d87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:to="loc_srt_ProductsAndServicesDomain_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:to="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_51d4d4ae-766b-4cff-b6a8-0c7a343ead61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:to="loc_us-gaap_ShippingAndHandlingMember_51d4d4ae-766b-4cff-b6a8-0c7a343ead61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:to="loc_us-gaap_SegmentDomain_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:to="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_6125018b-8320-4d74-b9ca-dec3538cc318" xlink:href="exdx-20190930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:to="loc_exdx_JanssenSIMPONIMember_6125018b-8320-4d74-b9ca-dec3538cc318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:to="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:to="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_188884fa-3411-4428-9713-75a0418f8733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_188884fa-3411-4428-9713-75a0418f8733" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="extended" id="ice957d8db9ef4457bbbaf4b255abb01c_dfa7776c-bf07-4a3a-8186-5c7b03f3a669">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_226861bd-30ba-47c9-9971-cd123f6df89c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_226861bd-30ba-47c9-9971-cd123f6df89c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64063f70-4408-440a-bf00-109ff8bf335b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:to="loc_srt_ProductsAndServicesDomain_64063f70-4408-440a-bf00-109ff8bf335b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:to="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_cef2dbe3-1f0f-4ffe-ad6d-dbc26e297e86" xlink:href="exdx-20190930.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:to="loc_exdx_AVISECTDTestMember_cef2dbe3-1f0f-4ffe-ad6d-dbc26e297e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c46d3423-193d-4fb7-9ae9-e79dec0ecf55_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:to="loc_srt_NameOfMajorCustomerDomain_c46d3423-193d-4fb7-9ae9-e79dec0ecf55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:to="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d9ce81fa-8cf9-4cb4-a7ba-1bc6cfd15bc4" xlink:href="exdx-20190930.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_MedicareMember_d9ce81fa-8cf9-4cb4-a7ba-1bc6cfd15bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_b35dbed2-e54f-4422-b827-fa3269efeac6" xlink:href="exdx-20190930.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_BlueShieldMember_b35dbed2-e54f-4422-b827-fa3269efeac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_e4c90235-cdc4-46f3-8265-2b1aa1515d1f" xlink:href="exdx-20190930.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_UnitedHealthcareMember_e4c90235-cdc4-46f3-8265-2b1aa1515d1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_1185de77-9281-473c-8680-09410b60a470" xlink:href="exdx-20190930.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_MedicareAdvantageMember_1185de77-9281-473c-8680-09410b60a470" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_61399467-3d51-45f6-8de6-f7d86fc0785b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_61399467-3d51-45f6-8de6-f7d86fc0785b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_61930c82-044c-4942-8882-6d0f8edd958a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:to="loc_us-gaap_SalesRevenueNetMember_61930c82-044c-4942-8882-6d0f8edd958a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_e164c71c-c5dd-4988-b0b6-cb0d2eb96a40" xlink:href="exdx-20190930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:to="loc_exdx_ReceivableBenchmarkMember_e164c71c-c5dd-4988-b0b6-cb0d2eb96a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2b4392c-ccdc-4167-96e4-4ec270898623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2b4392c-ccdc-4167-96e4-4ec270898623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e7959796-51c8-4ee3-ae87-9efbdd421408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e7959796-51c8-4ee3-ae87-9efbdd421408" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="i84a13027ed43461faa8bb18a587c2b0f_b6c4ef26-850d-44e9-8411-f81f5e64fdbf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93e8612-ba8f-4e31-a93a-e9cdf0f40e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93e8612-ba8f-4e31-a93a-e9cdf0f40e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a01d56e7-7693-42be-87f5-8c0be6b5cf93_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:to="loc_us-gaap_SegmentDomain_a01d56e7-7693-42be-87f5-8c0be6b5cf93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:to="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_7e41afb4-2b67-42dc-adc1-1018508ab61a" xlink:href="exdx-20190930.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_HealthcareInsurersMember_7e41afb4-2b67-42dc-adc1-1018508ab61a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentMember_82138573-f516-42d3-9645-6837b0c87c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_us-gaap_GovernmentMember_82138573-f516-42d3-9645-6837b0c87c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_1fdc8291-ce12-434d-b601-ffda9a055e24" xlink:href="exdx-20190930.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_ClientMember_1fdc8291-ce12-434d-b601-ffda9a055e24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_02f53ffe-fc2b-45de-a0a1-4f47e37f1605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_us-gaap_AllOtherSegmentsMember_02f53ffe-fc2b-45de-a0a1-4f47e37f1605" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_914c4c32-9f06-4d88-8c83-98b8be4b8ef0" xlink:href="exdx-20190930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_JanssenSIMPONIMember_914c4c32-9f06-4d88-8c83-98b8be4b8ef0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended" id="i87e6a05d02494baaa32120bced4a8cc2_c7fe8a5a-705a-4685-a1d6-e02d63502bff"/>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="ic28b309c606e4ca1bf6f7ccd061c4943_7c361c64-d26f-4073-825e-ae36178e5684">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f8ecba0c-ad61-4fa1-8f6a-cb5cec2ce007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f8ecba0c-ad61-4fa1-8f6a-cb5cec2ce007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ef361c6d-2b77-4195-9708-39d194ff3172_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ef361c6d-2b77-4195-9708-39d194ff3172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_18ac1279-de7d-4667-918f-9642e81ead9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_18ac1279-de7d-4667-918f-9642e81ead9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WarrantsTemporaryEquityMember_82dd7814-5838-4aa1-8f95-5de30be4455f" xlink:href="exdx-20190930.xsd#exdx_WarrantsTemporaryEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_exdx_WarrantsTemporaryEquityMember_82dd7814-5838-4aa1-8f95-5de30be4455f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4cf5c4ac-23b2-4ba8-9eb3-06535cbe1f54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_WarrantMember_4cf5c4ac-23b2-4ba8-9eb3-06535cbe1f54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c50bc574-15cf-4afd-95f1-c0b5b9d530a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_StockOptionMember_c50bc574-15cf-4afd-95f1-c0b5b9d530a7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="extended" id="idb11fa6b1f6f4735bd6e2899620acc22_118ed128-20c4-4183-b358-9bc0fef883d0"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended" id="i58358f4e359a458e92b057917fd232bb_420c003c-1f36-4467-9325-559d1d500ee2"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="i0dff01b062d84ff0beb342d55364b6d5_1997292e-e6da-401c-8be4-9ffcf10f20ae">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a47c5eb7-4bf6-4f8a-98c0-325dc1f18322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a47c5eb7-4bf6-4f8a-98c0-325dc1f18322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cb5111df-e082-4a7e-88ed-1c58a8f131dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cb5111df-e082-4a7e-88ed-1c58a8f131dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b522c38-b907-4a5b-9f55-a9085023973f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8b522c38-b907-4a5b-9f55-a9085023973f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_b0e68324-e5f2-4a9c-8191-e52e3d4adf34" xlink:href="exdx-20190930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_b0e68324-e5f2-4a9c-8191-e52e3d4adf34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended" id="i56c19f4f74064e60bcbe981c6bf4e052_efacf470-4696-478a-b3d6-59a62d86a885"/>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended" id="i2649cf829e394f359f2c04affee9c8f0_7f479e12-d4a0-4b40-9268-e2fc73d8dc83">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_520a49af-3d68-417e-8312-4abebcebc475" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_520a49af-3d68-417e-8312-4abebcebc475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45ccf000-0e37-4e3c-9c23-0e0d6540d574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45ccf000-0e37-4e3c-9c23-0e0d6540d574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_412d6be8-823d-4f2e-bf54-dfbbbf98312f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_412d6be8-823d-4f2e-bf54-dfbbbf98312f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9dadaa49-3ae0-4656-8f05-5c10b93be3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9dadaa49-3ae0-4656-8f05-5c10b93be3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_6ccbf79e-868c-40cd-98cd-bef883d45118" xlink:href="exdx-20190930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_exdx_LaboratoryEquipmentMember_6ccbf79e-868c-40cd-98cd-bef883d45118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_92e6c643-5281-4c6b-8e98-8dd1e5900b81" xlink:href="exdx-20190930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_92e6c643-5281-4c6b-8e98-8dd1e5900b81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ee70f0b0-f92e-4521-bd84-d3f6962b00e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ee70f0b0-f92e-4521-bd84-d3f6962b00e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5a53b2c5-f26f-4051-8595-694fc7310680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_ConstructionInProgressMember_5a53b2c5-f26f-4051-8595-694fc7310680" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended" id="i7ca9aa86b6c84403b0b5d1e59803231f_75789c29-17a2-40b4-a8b6-8ee50710e935"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNotes" xlink:type="extended" id="i0e3fa6c7d8414c8dac73f6b8c86682d3_2367494c-cb83-438a-b94b-734009009c6b"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended" id="i3f3bddbeefe149f89e51514de94c15b3_8ba6de60-dcef-4e40-bbd8-b042abe57841"/>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="icdbb47f3f47d46af80dc67f5e153ebfd_7507d86b-f3d0-40db-a6e2-7fd94454d0d5">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31906e50-99f2-4268-89a6-dc7a7898c29f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31906e50-99f2-4268-89a6-dc7a7898c29f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e1af8cad-3dc0-4e82-a703-defa5450ad84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e1af8cad-3dc0-4e82-a703-defa5450ad84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4abe7725-42a7-4cdd-a064-65624a726d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4abe7725-42a7-4cdd-a064-65624a726d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_1f76bcc2-dd82-4741-85fd-aedc2b15d2ce" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_1f76bcc2-dd82-4741-85fd-aedc2b15d2ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dc6f8976-af1b-4e98-a770-e644cd3a9802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dc6f8976-af1b-4e98-a770-e644cd3a9802" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_06a3355b-c46a-4874-8a42-acae9c3ebd52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_06a3355b-c46a-4874-8a42-acae9c3ebd52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_656039cb-9274-4175-b638-2ce2e04e3a72" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_656039cb-9274-4175-b638-2ce2e04e3a72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_71f9b499-59c3-4ff2-9636-1310de560645" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_71f9b499-59c3-4ff2-9636-1310de560645" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_e3a0a900-9cd7-474b-8f8f-29e65b8946a4" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_e3a0a900-9cd7-474b-8f8f-29e65b8946a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_c62c94e8-4f68-47c8-9813-6066e5214bbd" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_c62c94e8-4f68-47c8-9813-6066e5214bbd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_635e8688-6efc-4fb2-89ab-c6795e542d73" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_635e8688-6efc-4fb2-89ab-c6795e542d73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_3a500a1e-775e-434e-9473-d2fe63351f6b" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_3a500a1e-775e-434e-9473-d2fe63351f6b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_70d9dc2e-8116-43e6-8bc7-02cadad42737" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_70d9dc2e-8116-43e6-8bc7-02cadad42737" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_77d3511b-1974-4507-bde1-ca921dd7cb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_77d3511b-1974-4507-bde1-ca921dd7cb1e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_163481b7-fe08-48f6-b0d8-d2d09bd380d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_163481b7-fe08-48f6-b0d8-d2d09bd380d6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72de139c-5b52-427d-ae26-51b4bc202361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72de139c-5b52-427d-ae26-51b4bc202361" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8e71684c-e56d-474e-956f-60ac5b45d291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8e71684c-e56d-474e-956f-60ac5b45d291" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_40d9d0ed-2ca7-49aa-8028-d35818a590fe" xlink:href="exdx-20190930.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:to="loc_exdx_Term2017Member_40d9d0ed-2ca7-49aa-8028-d35818a590fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c198ec55-946f-4762-bf73-b1f5251e3e58_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c198ec55-946f-4762-bf73-b1f5251e3e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_29b63f37-6b67-4b75-873f-81a141909339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:to="loc_us-gaap_LoansPayableMember_29b63f37-6b67-4b75-873f-81a141909339" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_cdcdf2c5-0c86-4bd8-afa6-adf9ed9f6d07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_cdcdf2c5-0c86-4bd8-afa6-adf9ed9f6d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d76905a-0693-489b-97eb-406ba5fee685_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d76905a-0693-489b-97eb-406ba5fee685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_c13fd4d2-dcdb-4587-afbe-dafabda936c4" xlink:href="exdx-20190930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_c13fd4d2-dcdb-4587-afbe-dafabda936c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_b40e3d6b-5036-49da-82fe-2bc2fa139e32" xlink:href="exdx-20190930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_b40e3d6b-5036-49da-82fe-2bc2fa139e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f809eac4-15e8-46c0-8241-3a39d2df7d48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:to="loc_us-gaap_ClassOfStockDomain_f809eac4-15e8-46c0-8241-3a39d2df7d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:to="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_c538f407-1dfa-47da-8939-e1b2a0118f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_c538f407-1dfa-47da-8939-e1b2a0118f9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended" id="i76f8f0dbf70c44828fafb10717bd15d7_7e13d9f5-6299-4ff1-a546-6a3aec7e60b5"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="extended" id="id64eb9c21ecb4a7c98ed0f76c3270375_f6701171-188d-4f42-b117-9fbaa42e3873"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="extended" id="if152dc8ea2ba448ca8e79ad76d80278a_9ae187e4-bff9-4e1f-b923-199624bc8b77"/>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="extended" id="if2ed4c916e65414fa4080c7e06812c07_caf7789a-b77f-4b09-a289-df91eb9ccbf8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb0abe7-1668-4841-ad70-fe2b5542ff23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb0abe7-1668-4841-ad70-fe2b5542ff23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightExercised_70ccfef2-844d-4394-bf2c-c5b458d0dcfe" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_ClassOfWarrantOrRightExercised_70ccfef2-844d-4394-bf2c-c5b458d0dcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_bcca404e-d5cd-49bd-98ea-36e119c9d802" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightUnexercisedAndTerminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_bcca404e-d5cd-49bd-98ea-36e119c9d802" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cf60d0e4-3c13-4d96-a0de-0bcfab7a2a0d" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cf60d0e4-3c13-4d96-a0de-0bcfab7a2a0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:to="loc_us-gaap_ClassOfStockDomain_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:to="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_23195521-61f1-45db-a8e3-d2ba0312c13d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_23195521-61f1-45db-a8e3-d2ba0312c13d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SeriesDAndSeriesEPreferredStockMember_f5cb7f12-bc6d-49c6-b5f0-70a74ccf7b9a" xlink:href="exdx-20190930.xsd#exdx_SeriesDAndSeriesEPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:to="loc_exdx_SeriesDAndSeriesEPreferredStockMember_f5cb7f12-bc6d-49c6-b5f0-70a74ccf7b9a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="extended" id="i8a3cc29e4f3345d59ae7bb6f5ea50440_c3ff12b7-73cc-4dd5-bb26-9a010b890f48">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dcbc1ac0-a3d8-4509-a0d1-3ca262991741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dcbc1ac0-a3d8-4509-a0d1-3ca262991741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fb92d0e-7a1a-4f26-a19c-031d620ca60c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fb92d0e-7a1a-4f26-a19c-031d620ca60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a398db63-53d5-47b2-8734-0b3073a69d9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a398db63-53d5-47b2-8734-0b3073a69d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_2d6ed2fc-e336-4471-952a-b9df6fe080e8" xlink:href="exdx-20190930.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationJan192026Member_2d6ed2fc-e336-4471-952a-b9df6fe080e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_98abe634-1872-4e59-b7c4-805af2f3bd9e" xlink:href="exdx-20190930.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationMar312026Member_98abe634-1872-4e59-b7c4-805af2f3bd9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_308d8e9a-17d3-4ca6-ab79-184239580a6f" xlink:href="exdx-20190930.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationApr12026Member_308d8e9a-17d3-4ca6-ab79-184239580a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep82024Member_4761f7e8-d48a-4dbf-a194-5ab031b72789" xlink:href="exdx-20190930.xsd#exdx_ExpirationSep82024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationSep82024Member_4761f7e8-d48a-4dbf-a194-5ab031b72789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_084f5b4b-0772-4281-a2f9-94a850a2e4cd" xlink:href="exdx-20190930.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationDec72025Member_084f5b4b-0772-4281-a2f9-94a850a2e4cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="extended" id="ifcaed2eb1faa4b7f9869a0c5614b8335_eb62afb1-5976-4e38-b292-ccec139b78ce"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="i2d252abdb64b45eab9527e2aafdc5ca2_754450d1-9bab-49dd-b893-f5474468e1af">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_520606df-aee7-4419-9227-f9c9c64092b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_NetRentableArea_520606df-aee7-4419-9227-f9c9c64092b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NumberOfOperatingLeaseExtensions_69a52b9b-8c6a-446d-aeb3-ca52ed0f0f9f" xlink:href="exdx-20190930.xsd#exdx_NumberOfOperatingLeaseExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_NumberOfOperatingLeaseExtensions_69a52b9b-8c6a-446d-aeb3-ca52ed0f0f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8ce8a27f-2d35-4f40-bc30-371e4e135bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8ce8a27f-2d35-4f40-bc30-371e4e135bef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_83452d59-523d-4d27-8bb9-3746d6764ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_OperatingLeaseExpense_83452d59-523d-4d27-8bb9-3746d6764ac8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_0f490cea-4635-4727-92d2-48d45af7d777" xlink:href="exdx-20190930.xsd#exdx_MilestoneObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_MilestoneObligation_0f490cea-4635-4727-92d2-48d45af7d777" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_802340c9-adff-420f-ab9e-9d9e5e3ae77a" xlink:href="exdx-20190930.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_802340c9-adff-420f-ab9e-9d9e5e3ae77a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_8d8bc336-f659-45b8-ba52-a4991dcfaeb0" xlink:href="exdx-20190930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_8d8bc336-f659-45b8-ba52-a4991dcfaeb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9f34c0e2-a74b-4d84-a0d8-90c01c9333cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9f34c0e2-a74b-4d84-a0d8-90c01c9333cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_945dd876-6f1a-4e55-81fa-0dd78c2e2eee" xlink:href="exdx-20190930.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_AdvancePayment_945dd876-6f1a-4e55-81fa-0dd78c2e2eee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_5e9ea9d3-d04a-4d73-ae0d-f2105c75f501" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_5e9ea9d3-d04a-4d73-ae0d-f2105c75f501" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_30c8e386-2db3-4f4e-8bb8-9e6f1b69b8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_30c8e386-2db3-4f4e-8bb8-9e6f1b69b8e7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_fdf29614-0e8b-4419-ac17-4c4505433e2c_default" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:to="loc_exdx_RentalPropertyByTypeDomain_fdf29614-0e8b-4419-ac17-4c4505433e2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:to="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_285c2e8c-d77a-40d5-9a26-2237bf0a63a5" xlink:href="exdx-20190930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:to="loc_exdx_OfficeAndLaboratoryMember_285c2e8c-d77a-40d5-9a26-2237bf0a63a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a797a38c-ce74-4c5c-993c-d7d3625dc213" xlink:href="exdx-20190930.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:to="loc_exdx_OfficeMember_a797a38c-ce74-4c5c-993c-d7d3625dc213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e764da2f-4102-4d49-b4fa-13c6fe73caee_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e764da2f-4102-4d49-b4fa-13c6fe73caee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_7fc84724-fe84-45c0-9293-9b3907e3324b" xlink:href="exdx-20190930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_7fc84724-fe84-45c0-9293-9b3907e3324b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f09f71a5-0c51-418d-b033-26f429c5595e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:to="loc_srt_RangeMember_f09f71a5-0c51-418d-b033-26f429c5595e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:to="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5495cad6-f124-442b-9b88-12d5110274f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:to="loc_srt_MinimumMember_5495cad6-f124-442b-9b88-12d5110274f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2af5b7dd-b22a-4bd3-b4c3-d6daf1a8c770" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:to="loc_srt_MaximumMember_2af5b7dd-b22a-4bd3-b4c3-d6daf1a8c770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0dac7e14-9497-4d3f-b72d-be5cea35f6c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0dac7e14-9497-4d3f-b72d-be5cea35f6c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_b3e1e40f-af68-4b00-a05e-734d2cae3e15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_b3e1e40f-af68-4b00-a05e-734d2cae3e15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsNotes"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="extended" id="ibe485ec718da4b6ab4dabda4b8b514aa_da8d50d2-1a86-49c0-908e-e6da6cf4ad78"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended" id="id558b002dbbc4baba51d9e0ecf8db80b_624815bf-033f-494e-941d-b700c6ef05e3"/>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluemeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="extended" id="ie97e10a7f07846778107ffa966c54fb0_8a0ea517-e055-4a59-b2f7-ddeae75118ac">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f71831dc-1d94-4ede-a3a7-ed7463f33ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f71831dc-1d94-4ede-a3a7-ed7463f33ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_fe7d61a2-94d0-483f-96ec-c209ba0f002d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:to="loc_us-gaap_DerivativeLiabilities_fe7d61a2-94d0-483f-96ec-c209ba0f002d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1defa0f-41f3-4601-b079-7d706621e177_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e1defa0f-41f3-4601-b079-7d706621e177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8c3227e0-fc36-4329-b9dd-f607353faa9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8c3227e0-fc36-4329-b9dd-f607353faa9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14702fd3-91af-4c84-80a4-45aaa2968235_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14702fd3-91af-4c84-80a4-45aaa2968235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_afff71c2-82d7-4a11-bab6-827ae2e3b66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_afff71c2-82d7-4a11-bab6-827ae2e3b66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2b6c608d-4ae1-4aae-a8df-dc92012b0987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2b6c608d-4ae1-4aae-a8df-dc92012b0987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aaff36de-ce97-4f8a-9c6c-67793077a4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aaff36de-ce97-4f8a-9c6c-67793077a4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfab17b2-43bb-43d7-bd6a-3b9eac487832" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfab17b2-43bb-43d7-bd6a-3b9eac487832" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4df3368-3fd0-4051-ac3a-bfba334f1763_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4df3368-3fd0-4051-ac3a-bfba334f1763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_73a7d43e-b29e-4344-8ccb-cc2b12ab2c88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:to="loc_us-gaap_WarrantMember_73a7d43e-b29e-4344-8ccb-cc2b12ab2c88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluelevel3Details"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="extended" id="i5492f7a4154940a79739667f565626ef_6f76bf0b-7d75-414e-a1d3-8e491b45c7f6">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_64c51e52-3b56-4eea-8fdf-050e62211b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_64c51e52-3b56-4eea-8fdf-050e62211b7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_f5151058-5186-450f-8005-12c025bb2394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_f5151058-5186-450f-8005-12c025bb2394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_fee9922f-e0c1-4a33-b9ab-f9aaf5dc6843" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_fee9922f-e0c1-4a33-b9ab-f9aaf5dc6843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_e2ea7cf4-089c-4e4b-aa35-c02722f115eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_e2ea7cf4-089c-4e4b-aa35-c02722f115eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_58552081-aa91-4ba9-b445-27e0c0af8306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_58552081-aa91-4ba9-b445-27e0c0af8306" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_37b6737c-7a2d-49b3-adf0-a5bc0e1489bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e58c089a-7663-417a-a905-019e3b4b042d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e58c089a-7663-417a-a905-019e3b4b042d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStock"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" id="ifec6755ca94b4efe992b11209217895f_769414ae-d608-45de-b061-4b5e7c20b111"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended" id="id7bf1c3670224f8c804d818f341c93fe_b500b1c7-9c3d-4621-af58-ccb8b5307e62">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_79d2f2ec-dfe3-4f9f-ba81-a084fab9e0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_79d2f2ec-dfe3-4f9f-ba81-a084fab9e0a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_299ce75b-5a35-44d7-9650-a5b3394273ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_299ce75b-5a35-44d7-9650-a5b3394273ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_34132afb-754f-4254-8377-e4a5349f52b4" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_34132afb-754f-4254-8377-e4a5349f52b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_3ae0ef04-6d2d-47e8-be17-17a45b918f59" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_3ae0ef04-6d2d-47e8-be17-17a45b918f59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_4a0e4b41-b0ae-4d26-8103-f01d8f859234" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_4a0e4b41-b0ae-4d26-8103-f01d8f859234" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_0503d6e0-5a8c-44f3-9a28-5a4bef28cf70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_0503d6e0-5a8c-44f3-9a28-5a4bef28cf70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityRightsForMandatoryPurchase_5c601e65-c388-4d39-9e5c-f9186e99699c" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityRightsForMandatoryPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityRightsForMandatoryPurchase_5c601e65-c388-4d39-9e5c-f9186e99699c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_64b7bfde-e0f5-448f-bc1c-9bf9100df5e7" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_64b7bfde-e0f5-448f-bc1c-9bf9100df5e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_a1602391-8efc-4634-a29f-bc889406da29" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_a1602391-8efc-4634-a29f-bc889406da29" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_06e3e096-4c5a-4cd3-9278-b448d88bf882" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_06e3e096-4c5a-4cd3-9278-b448d88bf882" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesIssuedUponConversion_45efac37-1cfe-49b1-aff9-7e3c6f680968" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquitySharesIssuedUponConversion_45efac37-1cfe-49b1-aff9-7e3c6f680968" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b4fa4ab8-1ab0-4d67-8297-a5c38d912e52" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b4fa4ab8-1ab0-4d67-8297-a5c38d912e52" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_db909888-4fde-4715-9177-fe140f254059_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:to="loc_us-gaap_ClassOfStockDomain_db909888-4fde-4715-9177-fe140f254059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:to="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_94cfb80b-9c0a-427a-93e0-c6536ca6919e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_94cfb80b-9c0a-427a-93e0-c6536ca6919e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_293b1b14-3e28-42f8-b9ba-c9cc3b903775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_293b1b14-3e28-42f8-b9ba-c9cc3b903775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_fb4aaf44-2e5a-4194-b329-fcffa107f0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_fb4aaf44-2e5a-4194-b329-fcffa107f0ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_434b7738-d08a-41b3-b486-2fe9cc0af345_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:to="loc_us-gaap_EquityComponentDomain_434b7738-d08a-41b3-b486-2fe9cc0af345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:to="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c147ad7-53a0-4b8b-8a0a-da04dacda365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:to="loc_us-gaap_CommonStockMember_7c147ad7-53a0-4b8b-8a0a-da04dacda365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bd193fa-7a69-4735-8a67-a259482765c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bd193fa-7a69-4735-8a67-a259482765c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6f91aff7-ba15-4c5b-8755-9c4cb0940443" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:to="loc_us-gaap_IPOMember_6f91aff7-ba15-4c5b-8755-9c4cb0940443" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="extended" id="i098c0a873ef44717b5a4950bdf050e3c_d26b2a57-b323-44bd-bead-e74fc120c2e2"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficitDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="extended" id="i1cf56dd1833845fdbe4fd4ca6adea0ee_96f7a236-135c-4728-8441-a0ea55a5707c">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ac09f1f6-94a0-4b11-8f5f-8906be3877f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ac09f1f6-94a0-4b11-8f5f-8906be3877f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a7fa5338-ba92-47cc-991f-3d24c98719a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a7fa5338-ba92-47cc-991f-3d24c98719a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_20332134-a455-47ce-9183-227fc966adda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_20332134-a455-47ce-9183-227fc966adda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf61c5fb-d377-4df1-9507-74848ea21543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf61c5fb-d377-4df1-9507-74848ea21543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c20cdef4-7fb2-462d-a87e-c716c6ec386e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c20cdef4-7fb2-462d-a87e-c716c6ec386e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_741d68e2-5ce6-4756-9cce-73b83c0b91a6" xlink:href="exdx-20190930.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_exdx_StockIssuanceCosts_741d68e2-5ce6-4756-9cce-73b83c0b91a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa26c397-0675-4131-8fbb-27d758ce3e83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa26c397-0675-4131-8fbb-27d758ce3e83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_973c14ec-b880-4713-baa5-ab2ca1612354_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_973c14ec-b880-4713-baa5-ab2ca1612354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_795b71f9-8f8f-4220-8e62-2cfae30b5cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:to="loc_us-gaap_IPOMember_795b71f9-8f8f-4220-8e62-2cfae30b5cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f0193298-796a-48b2-8130-e4f550c6f009" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f0193298-796a-48b2-8130-e4f550c6f009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0c42e9c6-4d3d-4059-a9f9-170ebce04c83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:to="loc_us-gaap_EquityComponentDomain_0c42e9c6-4d3d-4059-a9f9-170ebce04c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:to="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ea344422-7883-47eb-a5c3-608ff87370c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:to="loc_us-gaap_CommonStockMember_ea344422-7883-47eb-a5c3-608ff87370c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlan"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended" id="i352e354337cb4523b1135a80f08c7c6e_c21f61e8-7fc4-4e1a-a5b0-7dc1051e7cbf"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended" id="if671cf4fea0f4fd98c849aa1b7c24749_a497e882-dc82-4d85-8be4-ed447f1316e6"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="i6602c74a4c7f49d29aeae674c2724a4a_13f55684-ceb5-4645-ac47-e0bbc5786e2b">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4c6b486a-35bb-40b6-b7fd-52bdbbe43088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4c6b486a-35bb-40b6-b7fd-52bdbbe43088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_9ec68872-f2c4-4662-8755-5858bca89987" xlink:href="exdx-20190930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_9ec68872-f2c4-4662-8755-5858bca89987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_554e990f-a0bc-46d3-a083-bad144e90f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_554e990f-a0bc-46d3-a083-bad144e90f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e8bd46b-84c5-43ff-9b9e-512e05833754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e8bd46b-84c5-43ff-9b9e-512e05833754" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c7764bf-762c-4777-9b47-4e72cb14b141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c7764bf-762c-4777-9b47-4e72cb14b141" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_abadc6af-a459-4700-80e6-658e30150858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_abadc6af-a459-4700-80e6-658e30150858" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fc2671f6-6d70-411c-bf54-94672d20a86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fc2671f6-6d70-411c-bf54-94672d20a86d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b1b0d30b-487d-4ac3-bc30-f472e66074ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b1b0d30b-487d-4ac3-bc30-f472e66074ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de81c86e-f0ef-405e-9110-1ef4769a3d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de81c86e-f0ef-405e-9110-1ef4769a3d70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:to="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:to="loc_us-gaap_PlanNameDomain_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:to="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockOptionPlan2013Member_5ac623b1-c446-4322-81fe-92fcee7e0fb1" xlink:href="exdx-20190930.xsd#exdx_StockOptionPlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:to="loc_exdx_StockOptionPlan2013Member_5ac623b1-c446-4322-81fe-92fcee7e0fb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_140d28a0-6848-4cf2-8ebd-ab44d865b466" xlink:href="exdx-20190930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_140d28a0-6848-4cf2-8ebd-ab44d865b466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:to="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d280459-43a0-4943-a60a-e3c6c31be7ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d280459-43a0-4943-a60a-e3c6c31be7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7e845a26-5218-4cc3-b328-ce925501ac71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:to="loc_us-gaap_EmployeeStockMember_7e845a26-5218-4cc3-b328-ce925501ac71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98720094-b843-48c4-99ae-76306eae436f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98720094-b843-48c4-99ae-76306eae436f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="i78e0aab673ac48de954ba588d59b920c_73a928b0-e668-4682-beeb-0294869f8f6a"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="i8cc0e2a8b1354164a5db09bb8f781634_f02c61bb-1e8a-4e51-a13e-4c67746bdd20">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdf23d7f-b3ae-464a-851b-f8b2df8fd570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdf23d7f-b3ae-464a-851b-f8b2df8fd570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ff23db6-aef0-4239-85ab-cfe664bffe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ff23db6-aef0-4239-85ab-cfe664bffe6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_392aa647-efdb-4452-b090-b3b82fda306c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_392aa647-efdb-4452-b090-b3b82fda306c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7e9fd7ce-c1ca-4347-839a-4d9666327035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7e9fd7ce-c1ca-4347-839a-4d9666327035" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6003946a-dd1c-46ad-a087-704a2a2447c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6003946a-dd1c-46ad-a087-704a2a2447c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1287d432-a543-4971-bcf9-d85fa5e8c24d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1287d432-a543-4971-bcf9-d85fa5e8c24d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:to="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebb3d4e8-84be-4471-a812-239568f1e718_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:to="loc_srt_RangeMember_ebb3d4e8-84be-4471-a812-239568f1e718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:to="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cb9e38ae-69d3-4e03-b3b3-94be5948fb0d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:to="loc_srt_MinimumMember_cb9e38ae-69d3-4e03-b3b3-94be5948fb0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89f742e4-de8c-4383-b494-2de7c4281874" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:to="loc_srt_MaximumMember_89f742e4-de8c-4383-b494-2de7c4281874" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="ic21c1c7844394fffa015ffe58660a5ae_4ce8c548-1fea-40fa-b079-2e751cd492de">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bdf0a3d5-954d-4b30-9476-da1cf60d47ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bdf0a3d5-954d-4b30-9476-da1cf60d47ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9810d270-b4f9-4b8e-bd73-daa40a0b06d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_CostOfSalesMember_9810d270-b4f9-4b8e-bd73-daa40a0b06d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_24f552f8-e4a9-4cb5-8e2d-f2b65a641c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_24f552f8-e4a9-4cb5-8e2d-f2b65a641c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0a9da63-cf65-4e6c-9fc3-90155c29c7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0a9da63-cf65-4e6c-9fc3-90155c29c7ef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedParties"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended" id="idef537c2383044869fc77081ead5d57b_f9a44960-0565-43da-b9fd-f3d6cc411ddf"/>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="extended" id="i8359308b31fe4f67b745ba03a54ef57f_ccefe7c3-3fc1-4580-8c35-d75b240e08c8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca3f4260-46bd-44c1-89b0-8e23f9fae9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca3f4260-46bd-44c1-89b0-8e23f9fae9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dbb1072f-72d7-47cc-8179-4cb377670fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dbb1072f-72d7-47cc-8179-4cb377670fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a17b30f4-5eb6-45d0-a624-e51598b8d6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a17b30f4-5eb6-45d0-a624-e51598b8d6a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a4aae07b-55a2-42e1-aa61-f9bb04af5574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a4aae07b-55a2-42e1-aa61-f9bb04af5574" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_b052ed28-c32d-44ad-878a-8c0fb59cd09f" xlink:href="exdx-20190930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_b052ed28-c32d-44ad-878a-8c0fb59cd09f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_d2d5aae9-aee1-48a5-9274-26443079dd0e" xlink:href="exdx-20190930.xsd#exdx_MilestoneObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_exdx_MilestoneObligation_d2d5aae9-aee1-48a5-9274-26443079dd0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_526e96a7-3fab-407d-bc92-d70fb087e3c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:to="loc_us-gaap_RelatedPartyDomain_526e96a7-3fab-407d-bc92-d70fb087e3c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:to="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3a5cb946-1b57-4485-a131-6c4e9eb97f61" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:to="loc_srt_DirectorMember_3a5cb946-1b57-4485-a131-6c4e9eb97f61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_baa72c96-bd0d-494c-b54e-a5a24c820f67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:to="loc_srt_ExecutiveOfficerMember_baa72c96-bd0d-494c-b54e-a5a24c820f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0366e35f-3d0b-488e-8996-0393e6b7e078_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0366e35f-3d0b-488e-8996-0393e6b7e078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConsultingServicesMember_67cc555e-b019-4e4e-b9bc-8b76cfe6df47" xlink:href="exdx-20190930.xsd#exdx_ConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:to="loc_exdx_ConsultingServicesMember_67cc555e-b019-4e4e-b9bc-8b76cfe6df47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e8111647-0e1e-43d1-b335-a1b8f3d7ab06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:to="loc_us-gaap_LicensingAgreementsMember_e8111647-0e1e-43d1-b335-a1b8f3d7ab06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="simple" xlink:href="exdx-20190930.xsd#CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="extended" id="i374f021953c346afb1acc8c5832be5a8_9c310704-3dc4-491e-886d-8fae6d29f70d"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsTables"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="extended" id="i3066ae7b10f345b3b2119e72121dd091_1997aac6-f4d2-4e9d-9ac7-28bf1e3f64e9"/>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="extended" id="ide75bfa5244e41249edec475d2341c98_0a347e7e-8415-493a-9046-2cc583ccc1d8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_80f04fa2-527b-4883-b022-c3610a7c455c" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_exdx_PreferredStockWarrantLiability_80f04fa2-527b-4883-b022-c3610a7c455c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e88a5aa6-0ee9-482f-99a2-312090cabd25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_Liabilities_e88a5aa6-0ee9-482f-99a2-312090cabd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c653351-1819-4114-9df9-fb1c6997da3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c653351-1819-4114-9df9-fb1c6997da3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f36589fd-819e-4d1c-897c-2786f307d83a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_StockholdersEquity_f36589fd-819e-4d1c-897c-2786f307d83a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:to="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d8bff514-b01a-489d-a8a9-9589f28566cb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:to="loc_srt_RestatementDomain_d8bff514-b01a-489d-a8a9-9589f28566cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:to="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_9ebd5e2f-947c-4683-b66f-9f48395d687c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_9ebd5e2f-947c-4683-b66f-9f48395d687c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_4f3cff44-ca2a-4ada-987a-bf4cdcf7a153" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:to="loc_srt_RestatementAdjustmentMember_4f3cff44-ca2a-4ada-987a-bf4cdcf7a153" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="extended" id="iee2d532f519d44298ceefe54eda07fb8_7ef61f14-26d8-4534-877f-208271d1b3ca">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_927ce25e-052f-4b62-920c-64b91aba912b" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_927ce25e-052f-4b62-920c-64b91aba912b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1071ba50-106c-4f95-bcf4-3303c40fe878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLoss_1071ba50-106c-4f95-bcf4-3303c40fe878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18e93703-30ca-4df5-9e98-1e6b8bb4221b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18e93703-30ca-4df5-9e98-1e6b8bb4221b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6818fb78-1aad-45d7-88b9-222d437056fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6818fb78-1aad-45d7-88b9-222d437056fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_12519eb4-3ba4-45fe-8cce-2b44577eb85a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_12519eb4-3ba4-45fe-8cce-2b44577eb85a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:to="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f167e08f-b497-4672-aee3-fe2387dcde4e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:to="loc_srt_RestatementDomain_f167e08f-b497-4672-aee3-fe2387dcde4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:to="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_eaf26aac-ed70-49ac-b262-2dc6a566f771" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_eaf26aac-ed70-49ac-b262-2dc6a566f771" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_f55b3925-bcf0-45dc-89f1-8d4cd381366a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:to="loc_srt_RestatementAdjustmentMember_f55b3925-bcf0-45dc-89f1-8d4cd381366a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="extended" id="ib2c76b652d5448e0b63fcda3cf4deaf8_06176c80-ea9c-45b5-9625-d1adde519ebf">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_9fb67d2e-aec6-441b-97b5-dc69349c79cf" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_exdx_PreferredStockWarrantLiability_9fb67d2e-aec6-441b-97b5-dc69349c79cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_707dde23-fe61-4ec9-b759-2fe4b9f75e80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_707dde23-fe61-4ec9-b759-2fe4b9f75e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_ba5efd42-ba2e-456d-bcdb-bcf256d38203" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_ba5efd42-ba2e-456d-bcdb-bcf256d38203" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_15aed5d3-a30d-4008-8521-590935aeb012" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:to="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:to="loc_srt_RestatementDomain_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:to="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_78d72b8e-c8d1-4716-9e49-01d687c32843" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_78d72b8e-c8d1-4716-9e49-01d687c32843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_8966a5da-dab2-4c02-aa25-78e0aefa3a35" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:to="loc_srt_RestatementAdjustmentMember_8966a5da-dab2-4c02-aa25-78e0aefa3a35" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>exdx-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_886a18c6-02a7-4b40-a54c-176829d134f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ConsultingServicesMember_2832342e-9653-4d19-bc2c-fff192bd2575_terseLabel_en-US" xlink:label="lab_exdx_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_exdx_ConsultingServicesMember_label_en-US" xlink:label="lab_exdx_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_exdx_ConsultingServicesMember_documentation_en-US" xlink:label="lab_exdx_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConsultingServicesMember" xlink:href="exdx-20190930.xsd#exdx_ConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ConsultingServicesMember" xlink:to="lab_exdx_ConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a30524b1-abde-4d8b-97d3-2c9dd5072fa2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_854dcf93-61e7-4a7b-aff0-845d615cd999_terseLabel_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series G to Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_label_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Temporary Equity, Amount Converted</link:label>
    <link:label id="lab_exdx_ConversionOfTemporaryEquityAmountConverted_documentation_en-US" xlink:label="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Temporary Equity, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:href="exdx-20190930.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:to="lab_exdx_ConversionOfTemporaryEquityAmountConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_234a3a56-1e9b-4ae9-b968-416d096b93e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_c6170aca-c2a1-452a-b290-72dbe7cfa1f9_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_297e3bbb-1dbf-431f-8f0d-3a6aaa2eb330_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_20f6e56a-5c0a-461c-bc29-dff82787169d_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Note 8)</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_label_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion, Amount</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_documentation_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:to="lab_exdx_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_35e06920-07c2-4984-88ff-26561790953c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_08be6acb-ee29-4ffb-85e4-fa81103bb694_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_30b70736-b879-4aab-9f62-adba1fe47115_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a36f4050-a36e-440d-9f32-1451fca390a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6f2c9db4-929d-4c50-96d8-a5d08ce98a8c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_55910f00-e009-4882-8c02-03a818024bf4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2d5260f2-4c6f-4172-902c-faaca692164d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_9aed1548-c989-43a5-87ca-66688dc0025d_terseLabel_en-US" xlink:label="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment upon adoption of ASC 606</link:label>
    <link:label id="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_label_en-US" xlink:label="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Transaction, Change in Accounting Principle</link:label>
    <link:label id="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_documentation_en-US" xlink:label="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Transaction, Change in Accounting Principle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:href="exdx-20190930.xsd#exdx_OtherNoncashTransactionChangeInAccountingPrinciple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:to="lab_exdx_OtherNoncashTransactionChangeInAccountingPrinciple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_e255f411-baa1-43a9-aaca-14a71dca2f7d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5d3785f4-05cf-4e53-b3fc-65b11f22aa9a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_64b8c06a-6277-4d29-8628-f33b23cfceda_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_39c86a60-fd9b-4378-83ec-08979db3de38_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20190930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WarrantsTemporaryEquityMember_1858718d-4558-407d-8b03-1244fb41ac90_terseLabel_en-US" xlink:label="lab_exdx_WarrantsTemporaryEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_WarrantsTemporaryEquityMember_label_en-US" xlink:label="lab_exdx_WarrantsTemporaryEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Temporary Equity [Member]</link:label>
    <link:label id="lab_exdx_WarrantsTemporaryEquityMember_documentation_en-US" xlink:label="lab_exdx_WarrantsTemporaryEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WarrantsTemporaryEquityMember" xlink:href="exdx-20190930.xsd#exdx_WarrantsTemporaryEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WarrantsTemporaryEquityMember" xlink:to="lab_exdx_WarrantsTemporaryEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_ec6df67f-6b44-4ecc-8d29-db6de2c5e193_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember" xlink:to="lab_us-gaap_SeriesGPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3027df7c-7d7e-4e89-9ee0-2d4f556eeb8f_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7f4e1177-6759-4d80-99fc-0a5bdb91231a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_48cfb8c8-109f-4ec0-ab59-b7877ddead9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_302c0d56-12b9-4ab9-8c5f-7843c4bb978d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares to be called upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8773e58f-ec5e-4af1-8637-723dee48440c_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares called upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d950f952-5c3c-43cb-8480-b5f0e4023b42_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2977da72-d885-461d-9547-28cbe3768847_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_6e0bcbf4-4624-445f-8777-400de81b58eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_ab62f228-3c15-486f-be78-e60410619d70_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20190930.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ea145db5-c4ff-4bea-9ae5-8a2c9f6362a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_feb3f082-c283-4be7-a07f-607ac755eb56_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember" xlink:to="lab_us-gaap_RedeemablePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_31ecea20-b068-4a21-b55d-66d1cdcd2d37_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20190930.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_94fa577b-6367-42ee-9bf8-c0d7f5a83ab5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_90ee5ac3-ab14-4c32-8cb8-d6c7d9e03a51_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1b79f683-1dc6-4363-b5cc-7eb164b5d47d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f74f7f72-99c7-4be1-a882-7c4055215872_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_172ba93e-4793-49f7-bb55-b75cd0b28ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_f4db6354-b3a2-4bad-8d63-2a7fff6d733e_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13d16550-d597-47d0-8266-4a795d5d13e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClassOfWarrantOrRightExercised_e6b8a007-2ac6-4174-ab6d-9e703b2abb99_terseLabel_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightExercised" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClassOfWarrantOrRightExercised" xlink:to="lab_exdx_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_81e2d56c-b90e-4b72-a402-3555b83f1b70_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_58a17e24-fe2b-421e-b9df-f1505553d852_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_8d4c0ebe-c78b-457d-95e5-7e1fdd451db1_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_28ab62db-1c68-43d4-a212-ce0ee1046bd7_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_f00c0dc5-753a-40e0-b259-b7d613b1d817_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of liability classified warrants to stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c08f47e1-5fab-45d4-a3f0-7a2e8ef93c18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_db67df2b-7243-415f-ab56-5f9e2dfc03f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_38c622a9-dd4d-4150-8ac1-1f5b827374a2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_39bdba56-01b9-4797-8d71-2526264e5d16_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_00b09170-ca40-4b6d-b0c0-dcb2e0083941_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ad3ad4b1-a1bc-4797-b143-54c3917aacc4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0c18a8cd-821e-4e87-bf2c-44d3ac5cb6ee_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6a31c400-9221-49fe-b3fa-02df0ef04025_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_52a35b37-8e56-4249-bc9f-497978a7e185_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6a1030ed-b6de-490e-804f-73a5b1ea2088_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7c9f301f-52fe-401b-88af-5801b4187d5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d23020e4-9e37-4908-b4dc-e379b79fd073_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3eab5e60-32b9-4ea5-8e7c-6dfc0a0bfe13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0dd98a74-e86d-43ec-afe9-ae60505b0d0c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8b905f21-33b5-4768-b83c-52bd6e819777_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, September 30, 2019 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_a5035410-77cc-4bad-9507-c9c9296c89d3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6a1ba531-e93e-4e8b-97bb-7dc89a504672_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64d390cf-a232-45d2-ad06-643cb757b34d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_62868870-3082-4eb0-81a3-e90704becd61_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_18a62f8c-218e-4546-aa2b-0ad649c0cb54_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_505447b9-0a6e-4b25-bb48-e5b220d4d523_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_ad6d7182-c3a3-417a-b8dd-ab7940c8e68f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b607fc16-8da4-4583-8e06-2fa25253f0cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8f709ce1-7136-4fac-91a8-947578b3d64a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fe2b9c66-2859-4c55-9264-9528f02abc5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_a1c6b9dc-df9f-4eaf-95a5-38a161007454_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20190930.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e5559ce5-d63f-4ea5-b5ac-12c06e322c4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2bfb44d4-3c68-41cf-b9b6-1d998f139678_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_57f25d0a-8d15-4602-abbf-391bb08c1faa_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c5c4d60c-9d4e-4740-b2fb-a695f89e304a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0c8fbe6d-52ac-440c-b161-f07f932521f0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_793df98f-aec3-45d4-996c-01cab4c7c1ba_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Scientific Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e9c55b14-5353-47d0-9208-e86aec0d4523_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_66244030-354f-4176-a5ec-392e3bf2071b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_414b71e1-00b9-4c3a-a4d8-b0b99392a892_terseLabel_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants unexercised and terminated</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_label_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unexercised and Terminated</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_documentation_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unexercised and Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightUnexercisedAndTerminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:to="lab_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_98f59ac4-673e-43c1-8b65-54f84fc4905a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_af10d5b4-5616-4a83-8bc6-ff507816b443_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_19cd0781-b898-4635-ba22-7dfba48317ef_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20190930.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9a8cc1bf-c5dc-4274-baaf-25f16273338d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0c537fed-24d0-41ad-bc46-5db65093c3bf_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_a148e7b0-0b63-4d88-916c-7f62bfe46a4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_00382bba-2b07-4d50-8f35-f9bc1646b977_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_50c7e15c-af91-4ff9-8b29-afe66bf09938_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20190930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_9c305dca-fa4f-4900-94ee-264f7c689ca9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_d7a067e5-3bac-4fd8-8e82-cc8a1fda5c8d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_95bf77ae-3a22-4da9-86f2-3360a02eeb08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7830ec09-4499-40a7-9f4b-f9331c355325_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_72b774cc-7cfd-4b81-86aa-b122f72f1755_terseLabel_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_label_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP [Member]</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_documentation_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:href="exdx-20190930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:to="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ef68e676-2c81-4d17-bd70-0ea8969b76fe_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b72c93a8-0261-4813-827d-56765e95e2c8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_5c7d5dc7-9f07-4af3-89c5-11cbd33b566d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_1805c012-929d-4613-ac58-20204c338607_terseLabel_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation, fair value</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_label_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_documentation_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:href="exdx-20190930.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:to="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d462750a-be53-45d5-8c20-51ea832d31e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_308ddba0-a3e5-477d-b0f7-022b88c0ec91_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_8309b2aa-f5e8-497d-ac46-a9f891f695a7_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0945f712-cb64-4015-b64f-ca6189ec1cfa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NumberOfOperatingLeaseExtensions_e664ae58-c515-44b2-9647-6b2bdb927f88_terseLabel_en-US" xlink:label="lab_exdx_NumberOfOperatingLeaseExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating lease extensions</link:label>
    <link:label id="lab_exdx_NumberOfOperatingLeaseExtensions_label_en-US" xlink:label="lab_exdx_NumberOfOperatingLeaseExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Lease Extensions</link:label>
    <link:label id="lab_exdx_NumberOfOperatingLeaseExtensions_documentation_en-US" xlink:label="lab_exdx_NumberOfOperatingLeaseExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Lease Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NumberOfOperatingLeaseExtensions" xlink:href="exdx-20190930.xsd#exdx_NumberOfOperatingLeaseExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NumberOfOperatingLeaseExtensions" xlink:to="lab_exdx_NumberOfOperatingLeaseExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_18397538-d0ec-4740-a3fa-69a49dfee2a7_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series F redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series F Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember" xlink:to="lab_us-gaap_SeriesFPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_01babd96-4471-4e57-87f2-38fd6f700ebc_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20190930.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7912cd77-45ae-456c-b825-b265e03e8476_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e557c024-e816-41ce-95f8-85cc60533b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_90ccb79f-1b54-4656-a8f7-bdbe45f955a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f9f76a2f-bbad-4232-9659-88b5716002c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_da2b5734-1ce2-4a97-a811-12458e136778_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d003b29f-8fc7-495d-ab88-7a1b3634ae21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_0d753ff9-fdf5-480b-b2d4-6776f495a557_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_7fa5408a-5cf8-48f6-94a0-f08684a7a9fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ecd0777c-5092-46f1-b3f0-d863c994a9e5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 (remaining)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SeriesDAndSeriesEPreferredStockMember_84bc6792-9674-41b7-b404-1b73f1d5af76_terseLabel_en-US" xlink:label="lab_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D and Series E redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_SeriesDAndSeriesEPreferredStockMember_label_en-US" xlink:label="lab_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D and Series E Preferred Stock [Member]</link:label>
    <link:label id="lab_exdx_SeriesDAndSeriesEPreferredStockMember_documentation_en-US" xlink:label="lab_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D and Series E Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:href="exdx-20190930.xsd#exdx_SeriesDAndSeriesEPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:to="lab_exdx_SeriesDAndSeriesEPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_7e1a5bd1-9d4a-4eb8-8379-d1f350ea2406_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_319d8ba5-e2fe-4b9e-9b8c-f170f1734d06_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Included within Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:href="exdx-20190930.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:to="lab_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_80757983-2cd7-4496-b203-ee964119f19c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a5b1dc97-980e-472e-9a07-7c7da77267ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_f0fade05-2e2c-4293-a41d-51a91e44f826_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f3449246-4701-41ca-9229-089359cf709a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_57d9135a-7762-4f26-9480-c0d984b49589_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_038898b9-0dd3-4026-88a8-09265c9e4ca1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fd4b344d-481c-4363-a4e6-af8088bda02c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_d47e63d8-2a4f-410a-9bb3-e6e0c7433e11_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received prior to issuance of Series&#160;G redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_label_en-US" xlink:label="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Proceeds received prior to issuance</link:label>
    <link:label id="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Proceeds received prior to issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityProceedsReceivedPriorToIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:to="lab_exdx_TemporaryEquityProceedsReceivedPriorToIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7a29e781-28f1-43bd-9ef5-1bb9ac3de6c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_03aed10f-7c24-46ee-98f4-f1bf6b5c5344_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b554219b-ac82-4b70-b07c-49d551fb6f37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a8098582-be64-400e-b56d-2d6786cd047f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_48995681-f662-42c2-bd94-124ca32e098f_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Note 8) (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_a7d804c6-d657-4567-95f9-158317356043_verboseLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_label_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesRedeemedUponConversion_documentation_en-US" xlink:label="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Redeemed upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:to="lab_exdx_TemporaryEquitySharesRedeemedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_084724e2-d75e-4be4-9558-4d22fd091eec_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2214f2cd-871c-42dc-95dd-e85c65a01834_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1c266738-9643-43f9-bad2-23353fea2437_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f1c51f69-8961-4e30-ae79-6e295e5842f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instruments Measured on Recurring Basis, Level 3 Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a8c77964-2bb5-4f22-90bc-8be14a76d34d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d575634d-121c-4e9d-856c-df9f2a020eed_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305a4870-bf72-4e19-befa-e505a0b184e6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d42f1eb3-5726-400b-a706-7cea8bee96da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_d91ca00c-726b-460e-8484-5404bf850519_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f660a5c9-2ebb-4148-967f-37b6edc9979b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_38c9e859-fed7-4032-ab9f-5d86dc292b7e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3e7f207e-1a37-4858-891d-bb89dc988495_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_fa3a4e9e-1bf9-4acf-9f07-a8f4702d9b76_verboseLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of financial instruments</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Financial Instruments</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:to="lab_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9e36d58-cbc3-4975-86df-ea69f5d01f40_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1d842dfe-8bd5-4030-81eb-01199ebb15be_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_449bf534-7190-457a-b9a4-68452e2b8b16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_7fab685d-f3df-450c-afeb-a1736dfb59a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_93e1b5fc-3a23-4fb1-a2ac-33d034c6dbe3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_99efb54f-d22e-4858-8782-5b8e93f6f145_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">As Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityRightsForMandatoryPurchase_3913b1e3-e778-49cd-a6ba-2a6521b8c083_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to require mandatory purchase, temporary equity</link:label>
    <link:label id="lab_exdx_TemporaryEquityRightsForMandatoryPurchase_label_en-US" xlink:label="lab_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Rights for Mandatory Purchase</link:label>
    <link:label id="lab_exdx_TemporaryEquityRightsForMandatoryPurchase_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Rights for Mandatory Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityRightsForMandatoryPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:to="lab_exdx_TemporaryEquityRightsForMandatoryPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0695d219-d140-4bca-9284-f9c56c2d55dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4ee361b6-6801-4436-8f2a-363d95b5c97f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in public offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_df735e31-ae38-48fa-9667-d874b43bfb43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d4c8c4f-f412-4aa9-b30a-d17f7ea697b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f52257db-8c18-41b2-9690-3ca0de1e75e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_621ae271-157e-424b-a4f4-ecb8589bc51d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_53dda6ab-d712-4202-bb88-13d8260ba7c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e3ef75e6-fcd8-413b-9cb3-790a285d9efa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ee939895-2969-4b9b-bdb8-9ad48c2200d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_56bfc624-ce67-4b69-a31c-75099afef540_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20190930.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5fd7ce89-15d3-44fa-93a3-4ebf63c6615a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_dcc1c43f-4c7c-4326-9a10-beac8de62843_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bdad61a7-dd03-43cb-8900-4e71c16e6613_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f1e614e6-86d0-4f1f-a62a-c12bba02253e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_72b0e7ab-d7a8-497a-8c90-eccaadae8c54_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_94722df7-f3d5-4913-89bf-d20decbfd537_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5cf9877b-28b4-455c-8669-03890bb50f1c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_ddf07df2-3526-4e11-b177-63d12e5a2d6f_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_9838cfbc-f02e-485e-9c06-3bb544b6e898_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7c3b1b83-3e7d-470d-b98a-359752b9a9f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_db5fef79-86ff-4405-838c-f09d7dfc5dc0_terseLabel_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold, temporary equity</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Number of Shares Issued in Transaction</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:to="lab_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_256802f7-8339-4f02-b445-04e36fdde686_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquitySharesIssuedUponConversion_c0d0225e-7327-4a68-bb3c-cd5343752c9a_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion, temporary equity (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesIssuedUponConversion_label_en-US" xlink:label="lab_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued upon Conversion</link:label>
    <link:label id="lab_exdx_TemporaryEquitySharesIssuedUponConversion_documentation_en-US" xlink:label="lab_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:to="lab_exdx_TemporaryEquitySharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_15d7f9da-6aaf-4cec-bc50-3c1fbe5441ed_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recorded in connection with financing transactions</link:label>
    <link:label id="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="lab_us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_5228b66a-5595-45bc-92ff-86f2fdc9ab18_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_655a31bc-09c8-42a1-9058-bb1b3d249a6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f7b1fe5-46bb-4321-8ff7-d6d62ef2793d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d2bb2d69-c2fa-4509-ab11-8d1b9984b693_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d77f5f6d-fda8-49b4-b890-c25ba7211d9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_161e5bfb-314e-4133-bfdf-3c766ba0f303_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_112644a0-702b-498f-ab40-41ad027247bf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b25f95bb-540f-424c-9a88-ee357844f828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_f0715073-7096-48c6-86a4-ac8159db34ac_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ac7cbd70-3502-4054-ba58-601852ddd725_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_befd9ef4-f41d-4fef-880c-2968de41d267_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuanceCosts" xlink:to="lab_exdx_TemporaryEquityIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_cd7fedb1-e083-4770-84fd-08f517c431ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1be360f8-3bf0-43d8-ac30-46547cfc7ab6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d0c1cb71-c441-4148-a5d6-defeed48787b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_07b1729f-caf4-42a9-9e4f-af3f65abe4ef_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_f3c271a4-f13c-4eb6-a299-8a757b4af31b_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_54f9c22f-c090-46bd-a501-f81c7c162bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a2aec5ad-acad-4bc6-a280-3b6ae4f45568_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_6397af71-acae-4b67-82b0-49598c50cb3c_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_df360861-d09c-47e8-8ba8-2f1d24e857c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_7d64faae-d5eb-469f-b546-186e26ce3adb_terseLabel_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under capital lease</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_label_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease [Member]</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_documentation_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:href="exdx-20190930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:to="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ec39ee0f-d83f-442e-b2b5-3aa83e5bc1d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_d6e21d09-0ac4-47dc-a5a7-cd649e334e6c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a2af14af-e006-485a-b18e-fcef68084db0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f1a4d781-4015-4bce-b73f-6c47d04006d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, September 30, 2019 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bf4a783e-2c78-4d62-8426-652abc8b3960_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f969ed7d-4d54-46db-8f86-51175728b423_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_0336b0c2-3d8e-44ac-970d-0ac6f1078366_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f2ae9711-0619-4d84-84d3-b451f680e5a9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4e859edf-21e9-4ee2-b29d-98a0003a3f55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentMember_67e6b62d-5a3d-4865-adb9-7a424db8e489_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_us-gaap_GovernmentMember_label_en-US" xlink:label="lab_us-gaap_GovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember" xlink:to="lab_us-gaap_GovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f94f7a26-5007-4829-b5ae-4a6d8c6acef1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_c6fd5b6c-3b26-4fa8-8982-f219d78ea49f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1e4715e5-5545-4b9b-baf6-1362eb8b35c7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ab94a3ea-92db-4266-9632-c82679683457_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_ffe98781-7673-433f-95d5-74ea372463bf_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_b49d0313-18b0-4d1b-9d19-0d99404727fc_terseLabel_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of temporary equity, price per share (in dollars per share)</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_label_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Price Per Share</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityPricePerShare_documentation_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfTemporaryEquityPricePerShare" xlink:to="lab_exdx_SaleOfTemporaryEquityPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_a2fb29d8-5087-49a1-a60e-5f734ec638b0_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_193f06ca-77ef-4aab-808b-57e6108d01c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_1239fe03-540c-4dbc-8e96-652703f759ae_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_b17200ff-cd54-4b98-bc41-2960fb5876dd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_502829fc-cb45-4e75-a161-4d16c3442d4e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9acdbabf-13e6-4842-a460-c1fefd21520b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6d45cbd0-ad5c-4655-87c9-8eb198552df3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_0b3a10b7-9e05-41d1-88bf-5d8020aa724f_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_513c4708-07b2-4e97-a2f0-dc6447865981_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fb0019e5-6a90-4c10-9303-e19aafe677bb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_3eac93ca-987b-4025-8492-9818a54bc94c_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20190930.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1d7cc500-99e2-446b-aa2d-442550b14594_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_442a9c9d-096a-4592-bdd8-9552f5599f4c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_480b1934-6140-41ff-9dad-f4d6edcb4134_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_3e187d6b-3cb3-4472-a4c1-1e68a8ff7ffc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockOptionPlan2013Member_288e60a2-7c16-4a30-9244-53ef09270d65_terseLabel_en-US" xlink:label="lab_exdx_StockOptionPlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Option Plan</link:label>
    <link:label id="lab_exdx_StockOptionPlan2013Member_label_en-US" xlink:label="lab_exdx_StockOptionPlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan, 2013 [Member]</link:label>
    <link:label id="lab_exdx_StockOptionPlan2013Member_documentation_en-US" xlink:label="lab_exdx_StockOptionPlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan, 2013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockOptionPlan2013Member" xlink:href="exdx-20190930.xsd#exdx_StockOptionPlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockOptionPlan2013Member" xlink:to="lab_exdx_StockOptionPlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_6eee8216-7660-4e22-b7e5-b1ac081ed4dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_48bc23e4-abe4-47fe-bf8e-33f4ab2ccc31_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3b0c4761-ff59-47d9-80d1-d6707b967b9e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_dd7af195-7d12-4fb1-89ce-8f4f83de6f5c_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:href="exdx-20190930.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:to="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_1d660fbc-1b5d-4041-82af-0c64495f16ce_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20190930.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d40ea09b-52c0-450a-b809-e2548950634a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_dccf9c51-d676-480f-a59e-bdd7069ef5ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Correction of Immaterial Misstatements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c7dafff7-6853-4686-aebd-2edd032f645a_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8459d11f-caa2-4bcd-aea6-18bfce553ef0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c44fc0f1-05c6-451b-bbb5-c55d4b7ef8b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1986d80f-ee15-4b33-9336-513f2c009db8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneObligation_a86e250e-7d96-4239-8e40-c0fda18ab862_terseLabel_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_0159b291-1774-451b-b1f0-6a4fc7eee195_verboseLabel_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_label_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_documentation_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation" xlink:href="exdx-20190930.xsd#exdx_MilestoneObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneObligation" xlink:to="lab_exdx_MilestoneObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c893ab56-8595-4cd7-8767-8256648cb070_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_b861170c-4648-4227-84d9-4461ced7d339_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_2b0e016b-50c9-4373-a854-f0ae16879889_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_bd4eb87a-00fc-4266-a20b-485159c90a28_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_97809864-66ba-448f-a040-da5d71733139_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_b94cb047-c169-4830-b1ff-f7a40cf9cb8f_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8) (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend, Shares Issued</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendSharesIssued_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:to="lab_exdx_TemporaryEquityDeemedDividendSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98551ecf-8eae-4a13-80bf-22d47dcf01c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_06577101-1ba2-4400-a540-8b1ab340c233_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_5b55012d-1339-4048-a85b-9d1c71765dd8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0b009217-f435-45fe-8b97-cd896ab625fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_fabb3851-206f-48d2-93f6-2f432cf83088_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_ef51bc1e-7ed9-46dd-9dc7-d1540edd1243_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to Purchase Common or Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock" xlink:to="lab_us-gaap_PreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_f968fe0f-ae3d-4f8a-b47c-cf35361418cd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_dd7f6f29-3f3a-4380-bf1a-8c16812be801_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20190930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_34daae27-c3e9-4e5a-96f3-bc9195b2eda2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_55105776-02b2-4c7d-a76e-b5978c6aff95_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_97b5c83a-9a7b-4cd3-af55-8b29a0c4fc66_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:to="lab_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_93b35191-4100-498b-8d7a-621a837cbc25_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_87cc7cb9-9335-4ecb-a17e-40724e5f26c6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bd66e28a-0a35-40b3-a43e-eaa77da4ae4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dfd627eb-4d91-4a1f-b164-0404bbf5c5b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5d6271ce-d680-40a1-b6cd-8848fc15ada1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_24e9a982-f5a2-4c8e-8cb9-e8d6c36e5b0a_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_65d22611-323e-49db-8b29-6391b7433ccd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_a275973a-949f-466b-9839-d649379f3cad_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20190930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_f33e5723-43d0-4137-92ac-3359f5cfda62_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_b7e65572-de43-45af-b538-6233809cef0c_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e7289a9b-a282-4130-8528-34091b662dfe_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd8cc115-4f05-4400-88cf-4bc17423552e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6249388e-ee89-4c01-ab60-58440ec30db8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_230d3589-0f0a-4290-a947-bc0588061f00_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d0a25dc0-0e63-4562-b591-c3f68daa3824_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dd950b70-8a1f-4ead-93b8-a1ac14e4313b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_68c91b06-5800-405d-a560-5624ab380587_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_16894dd0-7e9c-40ec-bc71-1249954f41b1_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_d02dfa38-ec16-43b6-9981-46ef8285100c_terseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20190930.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_b0f8c61d-1053-4732-a649-ee87dca722de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_94efc7e6-be82-4125-8db4-a215e4dd20ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_62dfbbc9-fe55-4419-a721-fe867daee30a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4aa954b3-0bfe-47d5-892e-31efa520867c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_bb506832-92a3-4a33-a69d-a0b2809f0c6a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_128e966a-d180-4034-a632-73e9b50d7796_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8e70e1cd-0244-46cd-b746-09bc81079fdd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2aec589d-208e-4ae9-ae79-78bd9d84fa87_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_48607fcf-7f95-44c0-b50b-6b20124cbe20_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_f53453b1-12ad-4db1-9f01-c22a8ef4237a_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:to="lab_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_8cbc6d8b-b80f-42a9-ade2-3ae295529494_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_0d8dc374-4750-41c7-a0d4-ef6a872d261b_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion to redemption value of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_9410d899-bcc0-4635-967c-43514d6bd27e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_457cd046-1284-43db-9203-3e749fe5548e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fbda940b-375c-4f42-867d-2afe71811fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8870b39a-814b-4643-ac2b-d128342252e2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_ee724217-2425-4325-a59b-61df165c43f7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_03b9903f-557a-48f6-9901-ad0fbe98700b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_098636d5-da13-49f2-a895-35d749d5b8fc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses table</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6bd170fa-08cc-4ce7-b45f-6fd6650abcf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_61bd82c3-e0a1-4fcd-8bac-6450e6b79753_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued during period (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_cc95a185-c2e4-4c17-bed0-972c1338f1ec_terseLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_44de772b-6533-4183-b2a3-5d9e5d46182b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_15d610a1-767c-4c65-acc8-f0c3421fbd3f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_966b8da5-db11-4ffc-adfc-23aa5931643b_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 8)</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9d17c7c8-6f0c-4d16-abd2-2f6cb14d8dca_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cff22e6d-7e55-4fd6-a82b-a6cc9db7e279_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_bc69c1a0-8731-4778-990e-33a19a4327a1_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20190930.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_0f20e80d-9e08-4541-9796-8238914f691a_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, interest only milestones, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Interest Only Milestones, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Interest Only Milestones, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_34c9c382-f93c-45de-9449-3c7f4e1758aa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8d6db24-54e0-4510-a609-53d444e2aa6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d8f10b5e-97c6-48e4-95a9-d7d3ddeeda4f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2018 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f410da6-7c13-4658-9bd5-c08eec0f78da_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, September 30, 2019 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1c09e10f-b033-4e58-a6ce-052ff850dbc0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_d52892f3-6253-4d37-a7ef-b11a2776871b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b1b09771-9e7c-47c2-bf31-407871de12be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_c39d0c08-4391-4719-8e76-9e04f778e309_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_0cdae17a-3db9-45db-a71b-e14f5d800466_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from conversion/issuance of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4ae5fbbc-e789-495d-8c05-773b125a8203_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_557153bc-8169-4a45-8568-4d4d6c20fa6a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e023f9a4-3c5c-48f8-b676-f5490086ef2a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_dbd09a9d-83ad-489c-85b4-f7b88163a287_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_75c45066-3225-47c0-a5e4-50f697bd85e8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_9f7442b0-b0e5-4429-a2be-9f07025442dd_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a68e090e-82f4-4ae8-9366-09c90701f730_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_e50f84be-ea12-4947-8724-6e1f2e796499_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, term</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_c016f877-61d1-41f0-8a2b-803cfefe9ddf_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20190930.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_579eb81e-ac6d-4903-8f4d-b020609b3211_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3f1a4142-b297-4b43-ae26-ea367b09ede4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_bd8d4c08-86b9-43f4-b07e-2a680753bb01_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders (diluted)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_7ea99772-e68d-4278-9883-d1442e0c27e5_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20190930.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2efbc18c-de81-42f6-a16d-0ef7ebe33b1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2423c651-2700-4f51-bc49-19ee800f5f16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_e24a7ff5-fc89-4b76-9cc5-e4401a3f3097_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20190930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f14bb468-5d25-4f6e-8755-e9afccdff94d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_38dcced1-1781-455e-8ad4-1318a291f304_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividend_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividend" xlink:to="lab_exdx_TemporaryEquityDeemedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_2e62c873-4a78-4880-a5f3-4e3fd808a86f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_86e05d07-33d7-4c0f-901d-9e9947ca1ec2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_35d6d738-cb41-457c-94e4-29777354fbb0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_0f04dc2c-5eab-492c-aad2-15eddf932564_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_71fd8203-3c3f-453f-af81-be8fad396986_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_77e7db81-1d15-4cb8-b2e3-1491f1e1462a_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20190930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_f69a2d90-5cd4-4b78-8e16-96be1efb85ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f8d43afd-055e-45d9-a5e3-ae4044985e2a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6691e06b-1c5b-409f-aea2-621f2ef60828_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_2b2c02ba-eabb-4051-845a-bdd9dccb9bdd_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_41f0b333-06cd-4794-9ea3-e25e5325c2f8_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of changes in accounting principle related to revenue recognition</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_34621595-6826-4ad4-ad92-3e83eb110f96_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7626e355-66a3-43d1-ba79-3803610918c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_289e39d0-daa3-4faa-9441-554a82e77f86_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d2280caf-b448-4edc-8153-53c72a85eb27_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_f480bc21-005e-4374-b820-b55d8467e233_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_93baf6a7-7dbb-46ee-be21-d4c87908fcdd_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_905da570-d1b2-4742-ba5e-562807280a51_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_68ebcac2-e35f-4388-85d5-7ab69b976dd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2b6b36eb-e1d1-470e-938b-122247259f0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ed87d0a2-7cc6-46fa-ab61-89f9b77b092d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_d2b9bf11-e659-43a3-ae51-19aed63d8ec0_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_62d1e56f-0c07-4184-a1c0-29a2617c3347_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_3664fa1f-6fb5-4e46-9a31-0e05825300fc_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_02ef6f30-b681-44e1-8065-e1b0c3aa8a14_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20190930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9d65badc-014a-409a-b91c-d200c90ee5dc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue (excluding amortization of purchased technology)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d8e714c0-3e45-4d00-a422-5ddfe4a84c9f_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Member</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d3507f1f-9c8e-41b5-ba8b-ce793996f7d1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_89b3dd5c-2848-467a-aa7a-9187c56603e8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_fc6177fe-ba29-4f73-98c7-db67a34e63aa_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_89a04550-a4a1-40f6-823c-faa8535ae92b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_6c041193-b60f-4da3-9d9c-572923d70156_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_bb1dfa89-64b6-4380-90dc-8119a0ad604c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3d02c0be-fb65-4b22-bd5a-8edbb7449694_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_750e063c-c05a-4688-ae7d-8c02fab769a0_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20190930.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31f78551-eed5-4d93-8ff6-9536b90f7d0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94ecdfe9-bf20-47a1-9325-e17ce663d044_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c43108a2-3301-4122-8d91-1564d1198c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e834104f-18c9-42e3-9e6d-ae64f94b93fb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a28cf5a5-8ff5-407c-b0ea-d3d1bc6a7fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a05af562-362f-4bf4-8c2a-fd36c1b83eb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_494f5458-54c8-41a6-8b7e-8d5ed480d647_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_b3740f9a-854d-449a-9e62-18d2eb580796_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20190930.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_dba04937-6e25-41cd-a74d-fb58e5537e2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3b03577b-177c-4e40-ac47-1e788a8956d3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5e3e27f6-08cc-42f3-8b41-7e14b9d3e7b5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_eb614777-b822-46b2-aeb1-3816406f112f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_421798f0-bb9f-4859-954b-a98ef8c7c3e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_52939e16-7bf2-4884-897f-2059656a5205_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_67ab3e74-83df-4ea8-a6a8-03fa2f701776_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c709b1a0-fccf-4beb-9cfc-40d1f7187467_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_60669899-1ff3-4235-8d1e-0305ec036096_terseLabel_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common and preferred stock warrants</link:label>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_label_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Exercise of Stock Purchase Warrants</link:label>
    <link:label id="lab_exdx_NoncashExerciseOfStockPurchaseWarrants_documentation_en-US" xlink:label="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Exercise of Stock Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:href="exdx-20190930.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:to="lab_exdx_NoncashExerciseOfStockPurchaseWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b9ac378b-543e-4bce-bb5d-9e323173fffa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_11271801-165d-4782-a299-ce8a47463502_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedFinancingCostsCurrent_e46cfc16-5b9d-4773-a61d-7964a332bc01_terseLabel_en-US" xlink:label="lab_exdx_AccruedFinancingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued deferred offering costs</link:label>
    <link:label id="lab_exdx_AccruedFinancingCostsCurrent_label_en-US" xlink:label="lab_exdx_AccruedFinancingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Costs, Current</link:label>
    <link:label id="lab_exdx_AccruedFinancingCostsCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedFinancingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedFinancingCostsCurrent" xlink:href="exdx-20190930.xsd#exdx_AccruedFinancingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedFinancingCostsCurrent" xlink:to="lab_exdx_AccruedFinancingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_84d34766-158e-4e67-bb20-e919ef961cc5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6ee770af-fd3c-433c-b2ee-af4d378ff8de_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2590ea5a-1da9-4f6c-8696-7b830e51e22d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7a687232-8ed9-4f51-bc77-9d3cb003205a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_ced59475-7f03-484c-b3bd-5fc179693fd1_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_29f767b2-6675-42ed-ae22-43be70a77524_terseLabel_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</link:label>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_label_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Temporary Equity and Liabilities to Permanent Equity</link:label>
    <link:label id="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_documentation_en-US" xlink:label="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Temporary Equity and Liabilities to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:href="exdx-20190930.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:to="lab_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_e4c1a2ef-ffcd-4841-acd0-a40a06725d30_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase in shares available for issuance under the Plan</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20190930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeemedDividend_b563cd05-256d-444f-a9f7-378c49e7959e_terseLabel_en-US" xlink:label="lab_exdx_DeemedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from issuance of Series F redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_DeemedDividend_label_en-US" xlink:label="lab_exdx_DeemedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_exdx_DeemedDividend_documentation_en-US" xlink:label="lab_exdx_DeemedDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend from issuance of redeemable convertible preferred stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeemedDividend" xlink:href="exdx-20190930.xsd#exdx_DeemedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeemedDividend" xlink:to="lab_exdx_DeemedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f8ec38f7-1b85-412e-88d5-6ad20394c6b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5d70ffea-00ab-487f-9ff4-5868482ab57a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_831e5a66-0de5-4a68-b694-a90a254ed4f7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_024c8a34-51ba-4da2-825c-d9f5b1d6db3f_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20190930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ad72be5c-3974-436c-9832-3ce5afb4075b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_6a57270b-4fe1-4661-a644-56fc95fdbe7f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:to="lab_us-gaap_NewAccountingPronouncementEarlyAdoptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_9ef07762-08fa-4312-aab1-4cbc8c369d91_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20190930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdbaf786-c352-4ac6-9087-8bdb5571124a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_30049722-ae7c-4bbf-9ec2-21e83294338d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_35c18f8c-1a8b-4d3c-8088-16cbb0379aa9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_2f5b8ab7-9729-48ec-b0f6-ed516c4e4b71_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5458960b-e42d-4813-92c3-5c185acdf9a2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_76fdca48-0669-4b7d-812e-c47748f6faba_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20190930.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5c3efc1a-926f-4f9b-b435-6b2c106fc944_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_513c26df-5b52-4128-8444-6fd78e84d1a8_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20190930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_c9067647-57e0-48a1-8c10-e7d206424047_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20190930.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_7b646c88-306c-4d0b-8d4f-b9a7a40136c9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Principles, Early Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_label_en-US" xlink:label="lab_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Principles, Early Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="lab_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_65b611a9-dc33-41ae-8f42-6c924eb202fb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockAbstract_58a953fc-96ca-4a7e-8d92-1984dfb6ec16_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract" xlink:to="lab_us-gaap_DividendsPreferredStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5a1637cf-f4c4-42d5-aa18-d16d768c52d6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock warrant liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_b95e05bb-045a-4b02-a847-a8af8acdeef4_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration to be received under mandatory purchase, temporary equity</link:label>
    <link:label id="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_label_en-US" xlink:label="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Consideration to be Received Under Mandatory Purchase</link:label>
    <link:label id="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Consideration to be Received Under Mandatory Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:to="lab_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4fb722f5-7224-49e6-9bbe-71a24507a1a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_208091c3-18d9-414d-85f2-01a96ec876bd_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6de4d9b6-c0ba-4d17-8595-e01ae78f4e46_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_685102f4-5373-4846-8112-869f39383b9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4ffa0f9d-fa1e-4d33-8580-e127cddd6f29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_ecd46d0d-3af1-49a4-afde-616a9ed00f08_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_d7037d86-3920-4ebe-be57-97307a81b4e8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e78ce07d-3d57-4c86-a7a6-391ac7db3c4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2018, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8b966e9-5959-4158-b3b7-297d04fbef43_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_ca699950-eb0f-43de-938b-4755cadd921c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9cf4a7d7-f849-4585-8882-5f269c787106_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_4c341ea8-af86-4282-8498-b123ee970077_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred&#160;Stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_0b73d1a4-e57a-4d5a-9570-5e0bbd0bef16_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_label_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Text Block]</link:label>
    <link:label id="lab_exdx_TemporaryEquityTextBlock_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityTextBlock" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityTextBlock" xlink:to="lab_exdx_TemporaryEquityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d657001f-93b5-4fe7-bb10-c8061117ab7a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0c92cc57-d73c-4877-ad11-c7819c3b469f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_69ceb6c9-d25e-483c-a55e-776f72f22b63_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20190930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_0fe1994d-9ce4-472d-86c6-332e47f28736_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_83e15c1d-ab37-408d-91e7-ffb840876f70_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4adc73e7-adbf-4ea3-aae3-94679fb2672e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b22c97b4-b26a-4f12-bf36-d3d046a5637a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4b74df9d-b007-4f65-a306-b39011a04c34_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_52cf2152-4886-4402-b863-48dd02d755a4_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_53b78bac-693c-4886-bd9c-6427433b27af_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_57db65de-45c9-4772-bf9b-2eff3b0ef003_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesHPreferredStockMember" xlink:to="lab_us-gaap_SeriesHPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_f7f89d3e-b29d-4cec-bb8e-4794cd38f8c6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_169f1ade-bade-4d67-af24-c1542f5be7c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_913ca5f8-282c-4b56-b131-627a80b96441_terseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b62ef3de-8f00-44a8-b385-1b942dade550_netLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_a89252ff-807e-4d18-9755-e8039c3bef52_verboseLabel_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature, temporary equity</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_label_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</link:label>
    <link:label id="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_documentation_en-US" xlink:label="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:to="lab_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_ace38cba-1dc7-462e-a557-edae3e4c17bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0c575c58-3892-4510-966e-e0a34a9939f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42a5b400-ce36-4c79-b8bd-06a6269d5fa7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0209fafd-451b-44a8-b43a-113334fdd275_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fba811b8-1e28-4e46-ae10-5f1e9a9a4ab2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b6743d91-ca1d-4498-a6c1-3025b501e2a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d9086722-3871-423b-aaed-22ad5e9f4eb1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ba0244a7-2bce-4946-aebb-d150f17c046b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_5b22a194-21fe-4aa6-aad6-0c17737344de_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rentable area (square feet)</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7fcf2bb0-f6d2-494d-8c24-6274df8db67e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8faf80d7-a394-4618-9b7f-0feef787522c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c3e7eb34-947a-4ff3-b30a-b57015742ae2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f19d0f98-95bd-4428-b203-8ba297a877f2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_f44b8404-4818-4e5f-b848-49d893270398_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual purchase commitment</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f58c0d2b-f883-4b88-9a09-1e16e7adf5ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_596df59d-dbaf-4bcf-9b03-94cc2803c976_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_02d1ffdf-121a-49d4-a910-f699223e0ff9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cff58011-f350-46e6-8498-342dd79fc453_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d46d4a9d-c353-44f3-9223-cec3393ec6df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a4ed4d2a-5f84-4a63-ba9d-dbc2a1219aeb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0df933e0-bb75-47d2-b956-0258d18b672b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5d8d6c1e-d269-46c2-b353-444c01ac28ca_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b768835-b241-446c-aac6-540af4eb3b70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in Shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_573b88d6-8001-4718-b6a5-564bc05ca399_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in Shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_e761b4ca-fb21-4d9e-85da-0bcf98c7f525_terseLabel_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_label_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Temporary Equity</link:label>
    <link:label id="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_documentation_en-US" xlink:label="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:href="exdx-20190930.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:to="lab_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c1fdfe-9979-4d4f-ad9a-cf3c628e8fd5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_7e44ee64-6fe4-452d-9804-d9709ab93e88_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum issuance of equity securities and subordinated debt</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Issuance of Equity Securities or Subordinated Debt</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Issuance of Equity Securities or Subordinated Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a597b639-c2d3-4bb3-9207-650aeca4ad77_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b1839187-4f95-472d-a91e-cc74535aec05_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8e43875d-0ab3-4517-b6e0-e2a12b1925e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_9e7b9942-0468-4995-8204-8de57c9126be_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred with related party (bi-weekly rate)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_968fa9c4-bada-451c-bb6c-7e0c01dbca5f_terseLabel_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_label_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_documentation_en-US" xlink:label="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:to="lab_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ff7d6db4-6291-4d7d-aa58-5cc5f0a72941_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a71d67f7-743e-46ea-b876-908750496821_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2b255d9e-ba0f-4497-8ffa-534b8368c5d0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6ad35d17-376e-49ee-805a-7940bb1faa6b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_014bacc5-9e1b-4a1e-979c-8473f8ee0d3f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c333fa1e-bb64-4538-b43d-8bd311610bed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_91c73add-c0b0-4a62-8c01-d5933cac3432_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Cost</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_276e6936-bb79-4094-b35b-48b6040c8020_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep82024Member_84cd0228-2573-4c1e-aedf-f23f0f22db20_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep82024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 8, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep82024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep82024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 8, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep82024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep82024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 8, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep82024Member" xlink:href="exdx-20190930.xsd#exdx_ExpirationSep82024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep82024Member" xlink:to="lab_exdx_ExpirationSep82024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e85c9f90-f534-4ee3-9115-707dce2f393e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_063eafe2-40f5-47ad-b982-55acc32438ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance under Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7eb55e5b-b906-41e7-9ec3-9dd292b28b3b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_526e72a1-20be-4ca3-a011-91337f7a0c47_terseLabel_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of temporary equity</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Consideration Received on Transaction</link:label>
    <link:label id="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Temporary Equity, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:to="lab_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0f73ed92-be9f-4eb0-9cd7-5b2c59e3b02a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_716ce5d5-7fd0-47a8-bd47-7d4e8161a36f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_5b6074c4-7a26-4fff-9af5-9b2c82312e5d_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20190930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_63683ab6-97f8-47c7-811e-023c7dae9da3_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0c734779-e5c0-4a33-9395-b43a44845d06_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7ed17c29-8517-4473-82ba-45bd342db204_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_645fc073-6d8f-4844-b460-a3ea23dacc26_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_739a22d1-215b-459c-aa4f-b3484901bb98_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_15e0f41e-d1dd-4018-a9a0-997746bdf875_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_66e7ce38-2d6d-44a0-b243-989c67a1ac2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PreferredStockWarrantLiability_51e5b7e5-b1d3-4a5d-a6fd-ef3f8808aa91_terseLabel_en-US" xlink:label="lab_exdx_PreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock warrant liabilities</link:label>
    <link:label id="lab_exdx_PreferredStockWarrantLiability_d98c0b5f-3855-4471-9b7d-90fa9d93cfde_periodStartLabel_en-US" xlink:label="lab_exdx_PreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_exdx_PreferredStockWarrantLiability_9a6a2790-4f0a-4ec7-a6af-60887cf558b3_periodEndLabel_en-US" xlink:label="lab_exdx_PreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_exdx_PreferredStockWarrantLiability_label_en-US" xlink:label="lab_exdx_PreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock warrant liability</link:label>
    <link:label id="lab_exdx_PreferredStockWarrantLiability_documentation_en-US" xlink:label="lab_exdx_PreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PreferredStockWarrantLiability" xlink:to="lab_exdx_PreferredStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2be6c458-ef84-4bfb-b3d5-6a71e55f3d12_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6d1c483e-db3a-43af-af46-b9dd65b82eff_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0f4d0f24-8207-4fab-ab20-8e2e755ca8ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock in connection with initial public offering (Note 8)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_bf2673d2-662a-48fd-9bff-c6f84a868358_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b9a8abcf-4d23-4fff-a3a9-2cfc2b699242_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6bc1630d-1804-49e7-b51c-520b2928bfcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f5a45803-43aa-43ba-af67-d6e75e3b568f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_5706a3f5-a4c6-482b-83d0-4ba4f5cc19e6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_15b85e4f-3841-4f61-bc6d-6c124496a9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_1a9b4dc5-56f0-4a54-8f44-ee473b978141_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_cf242bb6-b126-44fe-9dc4-49a9197c2583_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_b25ace58-c8a6-4384-9338-0c649db75a83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_be410df4-d0da-4998-9af5-3a718b227899_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants, shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d650f3ed-e601-4155-9106-f047086a7d62_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_51b44916-4b9e-451f-9691-6ea4ffa6b460_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>exdx-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:9b45ba3f-dbd4-40ba-8f08-ee2aad5f7857,g:cadabc5b-7aa4-43e6-ba6a-126e58c9b074-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20190930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_40930c64-28f8-4d4e-b251-10a1107ad8a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentType_40930c64-28f8-4d4e-b251-10a1107ad8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fe872f5d-e301-483c-aad1-b19ecf73ef45" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentQuarterlyReport_fe872f5d-e301-483c-aad1-b19ecf73ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_58c27ec7-98a9-4d86-ad86-7adccaeb5250" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentPeriodEndDate_58c27ec7-98a9-4d86-ad86-7adccaeb5250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_13c761c5-74e0-4f18-9577-8f197156c845" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentTransitionReport_13c761c5-74e0-4f18-9577-8f197156c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6073963b-683a-42eb-8561-14f105a36d78" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityFileNumber_6073963b-683a-42eb-8561-14f105a36d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6abb4c67-5854-4338-8e22-e9f74aee6882" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityRegistrantName_6abb4c67-5854-4338-8e22-e9f74aee6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_419700f8-9aa8-4682-b8c6-edf1c6f27cf2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityIncorporationStateCountryCode_419700f8-9aa8-4682-b8c6-edf1c6f27cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40aaad61-6aa1-41a8-b481-47021ca21281" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityTaxIdentificationNumber_40aaad61-6aa1-41a8-b481-47021ca21281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c9c5294d-5811-4f0f-b86a-ddaed00baaf1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityCentralIndexKey_c9c5294d-5811-4f0f-b86a-ddaed00baaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ed8e3097-e407-44af-9627-9b382f3c842a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_CurrentFiscalYearEndDate_ed8e3097-e407-44af-9627-9b382f3c842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4bdbc70a-0633-4c22-ace5-2c566a210f08" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentFiscalYearFocus_4bdbc70a-0633-4c22-ace5-2c566a210f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_450f1bd0-b900-49a5-8e9d-a64b95dfbe3e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_DocumentFiscalPeriodFocus_450f1bd0-b900-49a5-8e9d-a64b95dfbe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dcc74ad5-afcb-416a-859c-5e048a205160" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_AmendmentFlag_dcc74ad5-afcb-416a-859c-5e048a205160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_594bc24a-4e98-429e-95ec-0f335d18b96d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityAddressAddressLine1_594bc24a-4e98-429e-95ec-0f335d18b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_60d4eebf-3113-4b9e-b415-e72e317a9cfa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityAddressAddressLine2_60d4eebf-3113-4b9e-b415-e72e317a9cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_83ebc616-d907-4ea0-a9e3-115b5a54f883" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityAddressCityOrTown_83ebc616-d907-4ea0-a9e3-115b5a54f883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_05a0d08c-f8c6-4cff-b3ad-8fe3be94fa57" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityAddressStateOrProvince_05a0d08c-f8c6-4cff-b3ad-8fe3be94fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_63fc126c-1b75-415a-a8fb-7222d6310206" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityAddressPostalZipCode_63fc126c-1b75-415a-a8fb-7222d6310206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f9ad46f8-7bff-45f1-9d36-1b44bf8b0e03" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_CityAreaCode_f9ad46f8-7bff-45f1-9d36-1b44bf8b0e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1c22e69c-2865-49ee-a66e-3032eb5b0d94" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_LocalPhoneNumber_1c22e69c-2865-49ee-a66e-3032eb5b0d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ffce17aa-4b1f-4f84-9fd5-f3af20e9ec87" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_Security12bTitle_ffce17aa-4b1f-4f84-9fd5-f3af20e9ec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_935bcc5d-fc1e-41dc-83a4-7958ffe10826" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_TradingSymbol_935bcc5d-fc1e-41dc-83a4-7958ffe10826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cda9c56a-73a0-4ef9-b240-0eee62ba6f9c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_SecurityExchangeName_cda9c56a-73a0-4ef9-b240-0eee62ba6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_39602bf8-a4c7-4819-b003-06884c9415cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityCurrentReportingStatus_39602bf8-a4c7-4819-b003-06884c9415cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0bacca6-91ab-43e0-901e-390d96472b15" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityFilerCategory_c0bacca6-91ab-43e0-901e-390d96472b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7ddcf070-9c1c-4c23-a857-9c9c9eb5df0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntitySmallBusiness_7ddcf070-9c1c-4c23-a857-9c9c9eb5df0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c343557e-ffac-482c-96f4-3687c19ea1f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityEmergingGrowthCompany_c343557e-ffac-482c-96f4-3687c19ea1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_a53d2208-684d-4f41-b7eb-6298b1cb61b1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityExTransitionPeriod_a53d2208-684d-4f41-b7eb-6298b1cb61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b6bc4101-262f-4078-b8d9-86d2687aad87" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityInteractiveDataCurrent_b6bc4101-262f-4078-b8d9-86d2687aad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f0157573-d16d-4bb6-86dd-84bb89f69e1d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityShellCompany_f0157573-d16d-4bb6-86dd-84bb89f69e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b0192b1a-1a56-49f5-a895-7d6e9869697e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1b6caf4e-3513-40ce-88e9-c90e59313728" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b0192b1a-1a56-49f5-a895-7d6e9869697e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5e0ffc77-e3ed-4a4a-972b-e68be8bd576b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e0ffc77-e3ed-4a4a-972b-e68be8bd576b" xlink:to="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930fd155-3b68-4fa3-886a-47333837f8fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930fd155-3b68-4fa3-886a-47333837f8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9d6edba3-ff0f-46c1-aa88-756d3fca0940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9d6edba3-ff0f-46c1-aa88-756d3fca0940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_8d2de78c-e674-4164-b641-866b460bc70f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_8d2de78c-e674-4164-b641-866b460bc70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_707266a3-8327-4bf7-98cf-149396c2d6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0a9ee858-2982-49e3-85cd-1f3d1df78a50" xlink:to="loc_us-gaap_AssetsCurrent_707266a3-8327-4bf7-98cf-149396c2d6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d828d4e-13a4-4cce-887d-499bb8541f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5d828d4e-13a4-4cce-887d-499bb8541f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c3c3b0c9-ea7a-406e-984c-dc6f408f497a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:to="loc_us-gaap_Goodwill_c3c3b0c9-ea7a-406e-984c-dc6f408f497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_286254bc-137e-44ef-a71c-d3844dd96179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_286254bc-137e-44ef-a71c-d3844dd96179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a2384485-954e-4fd3-9121-824d8fa175a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_140bb360-a9d6-4035-a111-39674ee1e579" xlink:to="loc_us-gaap_Assets_a2384485-954e-4fd3-9121-824d8fa175a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5e0ffc77-e3ed-4a4a-972b-e68be8bd576b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00e0facb-5813-4d5d-a571-7ea0eb468441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:to="loc_us-gaap_AccountsPayableCurrent_00e0facb-5813-4d5d-a571-7ea0eb468441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_631a9c34-bcd3-4451-8ffb-494ac77a08b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_631a9c34-bcd3-4451-8ffb-494ac77a08b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_bed8797d-9e8c-4a7f-9209-c1eb32eaed77" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityProceedsReceivedPriorToIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:to="loc_exdx_TemporaryEquityProceedsReceivedPriorToIssuance_bed8797d-9e8c-4a7f-9209-c1eb32eaed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f7d0cc8-e26e-41ed-a2b8-9658ac00b4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7f75cc54-bfa8-4f08-ac31-dcd29f55b474" xlink:to="loc_us-gaap_LiabilitiesCurrent_9f7d0cc8-e26e-41ed-a2b8-9658ac00b4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0c988897-9532-4cdd-969e-384c62d17ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0c988897-9532-4cdd-969e-384c62d17ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_2f7de2c4-9f8e-4e2c-bf6d-d2618c05acd7" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_exdx_PreferredStockWarrantLiability_2f7de2c4-9f8e-4e2c-bf6d-d2618c05acd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_aefb54b9-4628-4cd7-b329-c593a2e26b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_aefb54b9-4628-4cd7-b329-c593a2e26b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d861fb79-bacd-4d59-8d33-63299b703b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d861fb79-bacd-4d59-8d33-63299b703b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b1e49315-fd2e-4900-ab08-4a9975585515" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_Liabilities_b1e49315-fd2e-4900-ab08-4a9975585515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8bda22d2-0c97-4a2a-bc7c-f44c98a6a3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8bda22d2-0c97-4a2a-bc7c-f44c98a6a3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cbec9947-d6fd-4b2c-ac5b-6b609da91486" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:to="loc_us-gaap_PreferredStockValue_cbec9947-d6fd-4b2c-ac5b-6b609da91486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_32dfa445-a6da-458e-a9ef-fb4a4bf7029f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:to="loc_us-gaap_CommonStockValue_32dfa445-a6da-458e-a9ef-fb4a4bf7029f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_18bd5dbc-aba8-40cb-bd83-e2b4526ce5cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_18bd5dbc-aba8-40cb-bd83-e2b4526ce5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_867b6b22-a0af-487b-b795-16b6817c55f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_867b6b22-a0af-487b-b795-16b6817c55f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a9017de-b8b8-4f03-a033-2491f1de6c5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_970a2f85-df8b-4158-a8b8-ee325c37f5e1" xlink:to="loc_us-gaap_StockholdersEquity_4a9017de-b8b8-4f03-a033-2491f1de6c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32315cd2-7b5f-4c92-b3d6-8e521b3cfbee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32315cd2-7b5f-4c92-b3d6-8e521b3cfbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d0fd0109-aa61-451b-8a66-b7e5ede2af1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b82548f8-2081-436d-98cd-e81935d54b5c" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d0fd0109-aa61-451b-8a66-b7e5ede2af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0c329e06-a3d7-4c03-a81e-8f130960b796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0c329e06-a3d7-4c03-a81e-8f130960b796" xlink:to="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_601832e1-d52e-4f2c-9ed2-b29256046211" xlink:to="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c243e96d-33fe-404c-929e-9ecf5e0b384b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_da12cb62-65c7-4383-8915-657285dc7e1d" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c243e96d-33fe-404c-929e-9ecf5e0b384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_55c12eee-9ccd-4be0-9a04-87725716f1b6" xlink:to="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_aac914f4-0d47-447f-beea-4515f83dede5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_aac914f4-0d47-447f-beea-4515f83dede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_91d6d503-cdd9-4d4d-82c1-e323b318f6ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_91d6d503-cdd9-4d4d-82c1-e323b318f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d61a0b68-8e50-44fb-b8eb-b289a5d6b570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d61a0b68-8e50-44fb-b8eb-b289a5d6b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_9ba72180-495f-46e6-bd03-4704e88cefe7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_9ba72180-495f-46e6-bd03-4704e88cefe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_c8836eb8-5203-4186-9f14-af429cc85922" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsPreferredStockAbstract_a583d61e-6c9b-4487-94e1-a597c4984c2f" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_c8836eb8-5203-4186-9f14-af429cc85922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0e762fd-d482-4624-aa02-98d456663ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0e762fd-d482-4624-aa02-98d456663ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ca99c5a3-bb23-40b6-82e9-59d579fac660" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ca99c5a3-bb23-40b6-82e9-59d579fac660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_641a771c-12b0-4f4a-b849-042cfba554d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_641a771c-12b0-4f4a-b849-042cfba554d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_162489c2-6326-4111-966e-43b57cda0e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_23d896ac-3bec-48a2-937c-0d63b1d6d70e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_162489c2-6326-4111-966e-43b57cda0e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a4f6bb6b-3ddd-4c2e-9485-fcaff3dd5069" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd6c1a5a-e640-416f-bd01-2596f8d64c22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd6c1a5a-e640-416f-bd01-2596f8d64c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a0d27ffd-e630-4aa4-97ee-f820c12c7f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a0d27ffd-e630-4aa4-97ee-f820c12c7f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c18ce8b1-536e-4b1f-ad4e-a53136e53cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesIssued_c18ce8b1-536e-4b1f-ad4e-a53136e53cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0692efbd-1c3c-4398-8fa8-4adc2964c8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e017dc4a-c508-4607-aadb-f6e9e7018c4a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0692efbd-1c3c-4398-8fa8-4adc2964c8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63cebb34-daa3-4503-9237-f31f59ea9112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63cebb34-daa3-4503-9237-f31f59ea9112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_142d3226-2b3a-4b49-83fc-3fcffbac3e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_142d3226-2b3a-4b49-83fc-3fcffbac3e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23e397fd-7a8a-435e-8ff9-a582837fe2c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23e397fd-7a8a-435e-8ff9-a582837fe2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bc3699bd-e1d3-4ea6-b02c-7cdbbc8f4d63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bc3699bd-e1d3-4ea6-b02c-7cdbbc8f4d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_70a61aa2-4751-4099-a603-8a1f0773f13c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_70a61aa2-4751-4099-a603-8a1f0773f13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c7c11830-6557-4114-90a5-c76f08458d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ee79f0ed-e99d-4a5d-8435-562ec752f51e" xlink:to="loc_us-gaap_CostsAndExpenses_c7c11830-6557-4114-90a5-c76f08458d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87b57482-910c-46a2-8284-b73465d906bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_OperatingIncomeLoss_87b57482-910c-46a2-8284-b73465d906bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5bd9a2c0-b6a4-4537-ac10-ec363fcbc215" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_InterestExpense_5bd9a2c0-b6a4-4537-ac10-ec363fcbc215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_3c75a683-c943-4e0e-a3e4-c9ae62754a58" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_3c75a683-c943-4e0e-a3e4-c9ae62754a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_583794c1-1ced-4e19-b0dc-d6bb47b9cb54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_583794c1-1ced-4e19-b0dc-d6bb47b9cb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da79732a-d5c3-4749-8647-83f115333561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_NetIncomeLoss_da79732a-d5c3-4749-8647-83f115333561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_0597d902-c55c-49f6-a98c-04ddf4e383c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_0597d902-c55c-49f6-a98c-04ddf4e383c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_aae26080-3790-4777-aa14-9c5067f41c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_OtherPreferredStockDividendsAndAdjustments_aae26080-3790-4777-aa14-9c5067f41c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a51c9086-dff0-48de-b70d-52a3e8702e51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a51c9086-dff0-48de-b70d-52a3e8702e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1d5b2a61-37df-45eb-a5f5-197dd36d6425" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1d5b2a61-37df-45eb-a5f5-197dd36d6425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a8928538-a6f6-4e23-bc4f-d55cbe4fd589" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a8928538-a6f6-4e23-bc4f-d55cbe4fd589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f82b8eb2-6300-42d3-bc3f-c30fb1884dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a8928538-a6f6-4e23-bc4f-d55cbe4fd589" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f82b8eb2-6300-42d3-bc3f-c30fb1884dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0ed18c86-9fba-4fae-9773-72339fb64cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cdf9de4f-bb36-4188-b737-cd46e0a42d83" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0ed18c86-9fba-4fae-9773-72339fb64cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_79059f60-b8db-4f11-8181-9f09f184ebff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0ed18c86-9fba-4fae-9773-72339fb64cfe" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_79059f60-b8db-4f11-8181-9f09f184ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dda84c51-819c-4947-830c-59215941f30b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dda84c51-819c-4947-830c-59215941f30b" xlink:to="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f15eb7b8-c44d-46e4-9106-270e18d427a9" xlink:to="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_dc2a7026-82e4-4672-ad25-4194e09a6c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_CommonStockMember_dc2a7026-82e4-4672-ad25-4194e09a6c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c9627b0-21bf-4e86-86dc-bcbaf6d73625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c9627b0-21bf-4e86-86dc-bcbaf6d73625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8b956eab-589c-4dae-b34d-fff7187d098a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a7e0198-fedf-4e5b-b9c5-7f6cc1a2f266" xlink:to="loc_us-gaap_RetainedEarningsMember_8b956eab-589c-4dae-b34d-fff7187d098a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_be7d48ac-3700-404d-a0fe-b32580246608" xlink:to="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_31382515-c944-408b-993e-0a43c4abb66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_31382515-c944-408b-993e-0a43c4abb66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0a4d34a1-7144-4b5e-a06f-bbfcd4e0a6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0a4d34a1-7144-4b5e-a06f-bbfcd4e0a6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_e0fb615c-c84c-424f-bc4c-7fa0b99f32fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_e0fb615c-c84c-424f-bc4c-7fa0b99f32fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_a8db9db5-fe8c-46a2-8db0-b2d1f82c008a" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock_a8db9db5-fe8c-46a2-8db0-b2d1f82c008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_6cdd2e9b-6795-4e5f-b66c-a7da5e8395b0" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock_6cdd2e9b-6795-4e5f-b66c-a7da5e8395b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ff0622e2-20d8-498e-b8fd-4577127d971a" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_ff0622e2-20d8-498e-b8fd-4577127d971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_4253aa0f-8f0f-418e-bff8-05834452b08d" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquityDeemedDividendSharesIssued_4253aa0f-8f0f-418e-bff8-05834452b08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_04b55471-44a7-4986-ba8d-6a29def76c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_04b55471-44a7-4986-ba8d-6a29def76c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_58d52a35-4125-415f-8057-4b938ea8e4d8" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_58d52a35-4125-415f-8057-4b938ea8e4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_d1cb5bc0-1a5d-408f-b7d3-af99ee5e7a30" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversionAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversionAmount_d1cb5bc0-1a5d-408f-b7d3-af99ee5e7a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_db23637c-075e-4bf8-83f1-6144814107c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_db23637c-075e-4bf8-83f1-6144814107c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0ed8ce48-9699-4fbb-ae6e-766ad0b55ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_58ec875a-cf7b-413d-828d-2d25834e67cf" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0ed8ce48-9699-4fbb-ae6e-766ad0b55ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_055b915b-e628-4264-a84c-4f42b5c51354" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38b297ff-271d-4a79-ba60-69621951d5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_38b297ff-271d-4a79-ba60-69621951d5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_669a34ec-58d3-411f-844e-d61a4660db91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockholdersEquity_669a34ec-58d3-411f-844e-d61a4660db91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_c9799e0d-2f5e-4698-a8b2-06a4a758ea97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_c9799e0d-2f5e-4698-a8b2-06a4a758ea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_fc90f335-11c8-4627-810c-9b71a18dc5c5" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue_fc90f335-11c8-4627-810c-9b71a18dc5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a83e27f-9c48-4532-a947-c402571f9e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a83e27f-9c48-4532-a947-c402571f9e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ddf1937b-44d5-403a-9865-32cfbbeaf840" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ddf1937b-44d5-403a-9865-32cfbbeaf840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ccbf470-baa7-4caa-a16c-89e3e4e0ba1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2ccbf470-baa7-4caa-a16c-89e3e4e0ba1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_d4e289a1-ecba-4fa7-ba52-2550f971cfa3" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity_d4e289a1-ecba-4fa7-ba52-2550f971cfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_4a043002-2f40-4e66-b859-31475cf5f4fc" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature_4a043002-2f40-4e66-b859-31475cf5f4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_1e50d180-ae2a-416a-97d3-300841be5109" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_1e50d180-ae2a-416a-97d3-300841be5109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_ddc2622d-b42a-4b56-8b7e-0f41d6cef4d2" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends_ddc2622d-b42a-4b56-8b7e-0f41d6cef4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_aa9b6452-7a70-4c81-b0f1-29f5d9941510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_aa9b6452-7a70-4c81-b0f1-29f5d9941510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_74b03ffd-55e3-420a-a939-7e63f6ed497d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_74b03ffd-55e3-420a-a939-7e63f6ed497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ea957d99-9924-4ebd-a42c-476176bfb384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ea957d99-9924-4ebd-a42c-476176bfb384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d9e6a41a-4265-4f54-8fd1-08c77cbfa86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d9e6a41a-4265-4f54-8fd1-08c77cbfa86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_ce0f6ecf-82ff-4cd0-a670-281e48a02bd9" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_ce0f6ecf-82ff-4cd0-a670-281e48a02bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_3ca80ce2-29f5-4c11-8de9-6f33a945c4ae" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_3ca80ce2-29f5-4c11-8de9-6f33a945c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_01de96de-2778-402c-89a9-1106ae264930" xlink:href="exdx-20190930.xsd#exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability_01de96de-2778-402c-89a9-1106ae264930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_452aef2a-9949-4cc3-be9b-13b7db57a05c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_NetIncomeLoss_452aef2a-9949-4cc3-be9b-13b7db57a05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_49cbd2a8-67d0-4cb3-9a98-5aa4adc5b073" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_49cbd2a8-67d0-4cb3-9a98-5aa4adc5b073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3813ae24-fd92-42fd-b707-4f17670e4ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9154e68-8dab-4a61-986e-528b9e8d10eb" xlink:to="loc_us-gaap_StockholdersEquity_3813ae24-fd92-42fd-b707-4f17670e4ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b3feb51d-9cb6-43ff-874a-70a69cd4495d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b3feb51d-9cb6-43ff-874a-70a69cd4495d" xlink:to="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73629aa4-9d3e-465a-9dc9-bfc502e6f66d" xlink:to="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_dd3f46df-56f3-4b87-a917-67fc7ec538b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_dd3f46df-56f3-4b87-a917-67fc7ec538b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_0056e53c-f338-48fb-aa3e-ce4e73ce57e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_0056e53c-f338-48fb-aa3e-ce4e73ce57e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_8578c0e1-f3c8-4fe8-84ff-2799f477a767" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ccf3d0e8-0df4-4f08-92f6-aeb63514aee2" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_8578c0e1-f3c8-4fe8-84ff-2799f477a767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac05ff28-424d-4d55-9fd2-f8a63b821235" xlink:to="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_a296bf3c-ee4f-4567-9b41-0d877a5b93c6" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_a296bf3c-ee4f-4567-9b41-0d877a5b93c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityIssuanceCosts_f013721f-9e26-4730-9a9f-51feed230e86" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f72b9028-a468-4ef0-9a21-ea96573d2034" xlink:to="loc_exdx_TemporaryEquityIssuanceCosts_f013721f-9e26-4730-9a9f-51feed230e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20190930.xsd#UnauditedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f2c8cead-9e69-4b3d-8d73-648015f7da20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f2c8cead-9e69-4b3d-8d73-648015f7da20" xlink:to="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_74456b72-1fdb-490d-991c-39be3b13d102" xlink:to="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_093f56f9-b1a1-4c43-8b6b-c0b018f5dcb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_093f56f9-b1a1-4c43-8b6b-c0b018f5dcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_1cb924b8-cdbe-4d45-ba9b-2426e7813a61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_1cb924b8-cdbe-4d45-ba9b-2426e7813a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_176fbc34-2749-43fb-8eea-58ef1948f551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_00cd39ff-05cb-4015-97a6-47087f955390" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_176fbc34-2749-43fb-8eea-58ef1948f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_066185e8-156a-4d91-8119-3882f6eba69d" xlink:to="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2742873e-0360-4001-bf79-533b158af4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_NetIncomeLoss_2742873e-0360-4001-bf79-533b158af4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_903c8ed6-4225-44cf-95bb-3ce7fd272ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_903c8ed6-4225-44cf-95bb-3ce7fd272ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8794c10c-c969-4cd9-9446-901c1238c377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8794c10c-c969-4cd9-9446-901c1238c377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_49721e22-6477-4bdc-905c-906c853f0293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_PaidInKindInterest_49721e22-6477-4bdc-905c-906c853f0293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_32a3f781-edba-40cc-80f5-212161fe9e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_32a3f781-edba-40cc-80f5-212161fe9e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2c8169d5-4bd3-434c-b4a3-a095f16838d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2c8169d5-4bd3-434c-b4a3-a095f16838d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e9ed5c25-8caf-4ed2-9ae3-2c73424efe94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_ShareBasedCompensation_e9ed5c25-8caf-4ed2-9ae3-2c73424efe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bc2a2df-09c5-4f8e-b478-9f1e85ee7713" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61422170-0911-4b12-9de6-75c7e29c67b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61422170-0911-4b12-9de6-75c7e29c67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cf7ee7bb-86d7-4918-98e6-101d6dcc7dc5" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_cf7ee7bb-86d7-4918-98e6-101d6dcc7dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1f4f037c-9668-4162-8e04-c7c6d068e265" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1f4f037c-9668-4162-8e04-c7c6d068e265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e480be1-771b-4fe7-97fa-b3475488a52e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e480be1-771b-4fe7-97fa-b3475488a52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2ef1779-3321-4057-ab78-5c88cbb70e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a93071e7-e9a9-4b4d-9aea-ebfce74a02bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e2ef1779-3321-4057-ab78-5c88cbb70e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3906b30f-2505-4b77-9790-f2838c44fcef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d8877e9-1f6f-43e5-b0f8-bedccafafcd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3906b30f-2505-4b77-9790-f2838c44fcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcc73ca3-1f93-414b-9df2-afd79d264edf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcc73ca3-1f93-414b-9df2-afd79d264edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_701c9efb-7333-47a3-9a75-ce9f69524342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_701c9efb-7333-47a3-9a75-ce9f69524342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8d73d81d-93a0-4cdb-96ca-6c782910feb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8d73d81d-93a0-4cdb-96ca-6c782910feb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ba4997e8-ffc5-46a5-8896-a5be1c58c24b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ba4997e8-ffc5-46a5-8896-a5be1c58c24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69cdf71c-d397-41e1-bdf9-73bf0dd0df0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2a41c950-c58c-4b45-8b3a-619e0317bc0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69cdf71c-d397-41e1-bdf9-73bf0dd0df0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d693be0-4798-4719-b3b3-860a2c3c8177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_6d693be0-4798-4719-b3b3-860a2c3c8177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_e860ccc3-a871-4974-8e0a-fb5f825a1be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_e860ccc3-a871-4974-8e0a-fb5f825a1be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_7c950cac-b251-49aa-9651-86485491d7d7" xlink:href="exdx-20190930.xsd#exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity_7c950cac-b251-49aa-9651-86485491d7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92863174-813a-4276-a8a6-dcf84b0fd40d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9420ac37-2b46-4486-b9f3-44302bdf017d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92863174-813a-4276-a8a6-dcf84b0fd40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d39a6815-45bd-4fa8-92b3-a82a98c5351f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d39a6815-45bd-4fa8-92b3-a82a98c5351f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44af0a76-ba50-482a-913b-32a268b7d1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44af0a76-ba50-482a-913b-32a268b7d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63ef4460-06c7-4cb5-8ebd-a8fa7fa69de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63ef4460-06c7-4cb5-8ebd-a8fa7fa69de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3a725a56-db43-4018-9afb-774b4a92dbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_09eafa07-a390-43d2-bc40-867d933d71b1" xlink:to="loc_us-gaap_InterestPaidNet_3a725a56-db43-4018-9afb-774b4a92dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8684de8-67c0-4a2d-8041-f10cdb3952be" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_5693d4a2-28d6-4160-8a1c-186a46810c89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_5693d4a2-28d6-4160-8a1c-186a46810c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_df496195-a336-47c3-a5c3-c15dbd06abe8" xlink:href="exdx-20190930.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_df496195-a336-47c3-a5c3-c15dbd06abe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c6dbc1f-e9ed-495a-90cf-86caaabb037c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c6dbc1f-e9ed-495a-90cf-86caaabb037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_95749915-9e64-4726-88e4-31d15c48e0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_95749915-9e64-4726-88e4-31d15c48e0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_64d20ed6-b64a-4edd-b350-cfaebe561eb8" xlink:href="exdx-20190930.xsd#exdx_NoncashExerciseOfStockPurchaseWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_NoncashExerciseOfStockPurchaseWarrants_64d20ed6-b64a-4edd-b350-cfaebe561eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_8cf632d2-c228-4de4-8349-ed2b2e475052" xlink:href="exdx-20190930.xsd#exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities_8cf632d2-c228-4de4-8349-ed2b2e475052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_29fa9898-4dbd-4493-b6ce-b841bfd159e9" xlink:href="exdx-20190930.xsd#exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity_29fa9898-4dbd-4493-b6ce-b841bfd159e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b2470da4-0d77-4253-9c95-ed125bb8fd31" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b2470da4-0d77-4253-9c95-ed125bb8fd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_c93ced0e-2876-4340-a8de-78a0b5badf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_c93ced0e-2876-4340-a8de-78a0b5badf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConversionOfTemporaryEquityAmountConverted_46a1406b-4825-4af4-b156-a87bcaa1eba4" xlink:href="exdx-20190930.xsd#exdx_ConversionOfTemporaryEquityAmountConverted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_ConversionOfTemporaryEquityAmountConverted_46a1406b-4825-4af4-b156-a87bcaa1eba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeemedDividend_2c92e822-831f-4a04-8cd3-1408e3099971" xlink:href="exdx-20190930.xsd#exdx_DeemedDividend"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_DeemedDividend_2c92e822-831f-4a04-8cd3-1408e3099971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_a16ab571-f3ea-44ea-9fda-2a823afa35ee" xlink:href="exdx-20190930.xsd#exdx_OtherNoncashTransactionChangeInAccountingPrinciple"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a991510c-02aa-48dc-aa33-7a15eca48170" xlink:to="loc_exdx_OtherNoncashTransactionChangeInAccountingPrinciple_a16ab571-f3ea-44ea-9fda-2a823afa35ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a629d934-df0d-4f25-a375-91a0817e48b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_b77e76cd-cb39-45fd-973c-e8e85d9b3cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a629d934-df0d-4f25-a375-91a0817e48b9" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_b77e76cd-cb39-45fd-973c-e8e85d9b3cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_920ee9f4-6755-4e3f-ae9f-7e9d06003245" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_920ee9f4-6755-4e3f-ae9f-7e9d06003245" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5e94a192-29b1-4dcf-a63a-73b370c2285b" xlink:to="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5d959cd7-2f2a-40f8-ada5-bbd2a62abc82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3888569b-c3d0-42bd-a0ac-0d3b6c7e1701" xlink:to="loc_us-gaap_CommonStockMember_5d959cd7-2f2a-40f8-ada5-bbd2a62abc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38fa02fe-2588-4aa3-8c77-476c0f4c0f11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4b59f9bd-42c7-4459-acd2-26df0d764112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:to="loc_us-gaap_IPOMember_4b59f9bd-42c7-4459-acd2-26df0d764112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_34939efc-6852-4786-a1fa-3adcf9c3d675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81672550-4c1c-4dc6-8bec-52e377af9f72" xlink:to="loc_us-gaap_OverAllotmentOptionMember_34939efc-6852-4786-a1fa-3adcf9c3d675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_edaddb78-e486-4512-b77e-b5814ed7e90a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3c52f8ad-9efe-4ce9-a291-89ee28520d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3c52f8ad-9efe-4ce9-a291-89ee28520d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bf6bfad5-bb99-4c76-8a03-8a416e07d900" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bf6bfad5-bb99-4c76-8a03-8a416e07d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_071cba22-805b-4c1f-8b79-2d27718a4f88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_071cba22-805b-4c1f-8b79-2d27718a4f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_34119cd9-1cfa-4835-852c-e5b86f1869b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_34119cd9-1cfa-4835-852c-e5b86f1869b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b2e44a9-9f83-4cee-a086-b8c0141783d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b2e44a9-9f83-4cee-a086-b8c0141783d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_787a0388-520d-490e-8152-f0ab8f0bf3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_b403a0bd-739a-4db6-852d-d6245bc08a5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_787a0388-520d-490e-8152-f0ab8f0bf3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1f199581-a166-41f1-a229-dfd0c731a81c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_af228ca9-7cb5-4b9a-a6d0-bc2faa90bfc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1f199581-a166-41f1-a229-dfd0c731a81c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_af228ca9-7cb5-4b9a-a6d0-bc2faa90bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_86da135d-340d-45cd-bff0-19c06f20ab26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_86da135d-340d-45cd-bff0-19c06f20ab26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d5d073b6-ff09-41c0-9429-76decf59fb89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d5d073b6-ff09-41c0-9429-76decf59fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d899f6e-75df-4b71-ac97-4e830b5c2ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8d899f6e-75df-4b71-ac97-4e830b5c2ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2affa2bd-e0a8-4da9-9867-3740a6e42b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2affa2bd-e0a8-4da9-9867-3740a6e42b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8433707b-4840-405c-87c2-e1e413decb98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8433707b-4840-405c-87c2-e1e413decb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52234246-dfc7-43f2-aa1d-944e32c83b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52234246-dfc7-43f2-aa1d-944e32c83b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_189a9e2b-170a-484e-9938-c6cd7c3aab74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_189a9e2b-170a-484e-9938-c6cd7c3aab74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_a94a3ca6-a253-4e9a-91fd-37b220c9b002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_a94a3ca6-a253-4e9a-91fd-37b220c9b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_479be5b4-eedd-4ffa-bda7-249f01839396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_479be5b4-eedd-4ffa-bda7-249f01839396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bfd0fe08-35d9-4a37-8bde-3b0eb207e38f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bfd0fe08-35d9-4a37-8bde-3b0eb207e38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d67922ec-cd6e-4915-9a25-fef97ea39a51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d67922ec-cd6e-4915-9a25-fef97ea39a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_35e105e1-75c0-4835-8356-b7d0a3ab7966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55d8026e-a75e-46f5-b804-2957f19ed6d7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_35e105e1-75c0-4835-8356-b7d0a3ab7966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4246640b-52be-406a-a7c6-1651f0b2804f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4246640b-52be-406a-a7c6-1651f0b2804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8f9f265a-54f5-4f0f-b73f-c5cfabb2ee92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8f9f265a-54f5-4f0f-b73f-c5cfabb2ee92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a5d242ee-6c78-465c-9509-454eacee2abf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a5d242ee-6c78-465c-9509-454eacee2abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b9e27f3e-c3c2-4718-abe3-914b3cdbce64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b9e27f3e-c3c2-4718-abe3-914b3cdbce64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_94158985-9584-454f-b39c-9bdc8e13a244" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35e733af-eaeb-4870-832b-904db519b89c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_94158985-9584-454f-b39c-9bdc8e13a244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49d8dc55-01f7-4ae4-b0cc-fd6f1d9ad332" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49d8dc55-01f7-4ae4-b0cc-fd6f1d9ad332" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_29dc8e85-db73-4a8c-9109-990539aed313" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_64a368df-8a25-4559-a8b3-54dd633c9ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d7e4985-b328-46dc-ac14-1cb2b02400b6" xlink:to="loc_us-gaap_IPOMember_64a368df-8a25-4559-a8b3-54dd633c9ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf843fda-6ed3-4bfa-bc4e-51c29377c8de" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_5c38ab1c-dba1-4ed9-b358-d5578247d87d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24472ee5-6c28-45ba-a39b-bcc98c3887b3" xlink:to="loc_us-gaap_OtherAssetsMember_5c38ab1c-dba1-4ed9-b358-d5578247d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0eaac0cf-2b9b-4e1f-88c1-c528f1d8c840" xlink:to="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_51d4d4ae-766b-4cff-b6a8-0c7a343ead61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b37a263c-53a5-4e14-93e0-0f0e0aac9b1b" xlink:to="loc_us-gaap_ShippingAndHandlingMember_51d4d4ae-766b-4cff-b6a8-0c7a343ead61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ad91f4f-66a2-424f-b2fe-fc2c15dbf6d7" xlink:to="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_6125018b-8320-4d74-b9ca-dec3538cc318" xlink:href="exdx-20190930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8e831311-cfbe-4c92-9eab-8ed87a46e4d1" xlink:to="loc_exdx_JanssenSIMPONIMember_6125018b-8320-4d74-b9ca-dec3538cc318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_791bbb07-4a6d-4c43-8190-0dfb42a7ff0f" xlink:to="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_188884fa-3411-4428-9713-75a0418f8733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_4e1e7b8a-c188-4024-80bc-cd0dc415b771" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_188884fa-3411-4428-9713-75a0418f8733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionTable_70acba41-1127-499b-8d53-c40435937d90" xlink:to="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f36b23fb-dd5e-4a9d-9229-0decf7c9debc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_RestrictedCash_f36b23fb-dd5e-4a9d-9229-0decf7c9debc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_d2990150-f4a4-4925-a1f9-6aa6dc8e6235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_DeferredOfferingCosts_d2990150-f4a4-4925-a1f9-6aa6dc8e6235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ea5acba4-a9d5-4202-9f7a-eba083ebc5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ea5acba4-a9d5-4202-9f7a-eba083ebc5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_91412b21-38ca-4baa-9bcc-be8a6816d85f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_AdvertisingExpense_91412b21-38ca-4baa-9bcc-be8a6816d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a1706f8-3b35-42d9-b1db-5be7a00ae4c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a1706f8-3b35-42d9-b1db-5be7a00ae4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2b4c868f-b1d5-433c-b549-eb4ad4ab9af2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_CostOfRevenue_2b4c868f-b1d5-433c-b549-eb4ad4ab9af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_dd40f489-359f-4e28-897e-0d978269818c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems_ce5780aa-7496-4b50-ac8c-10fa6bfd038d" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_dd40f489-359f-4e28-897e-0d978269818c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce2332b9-7c1b-4b83-814b-0bda9e8cb013" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce2332b9-7c1b-4b83-814b-0bda9e8cb013" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_64063f70-4408-440a-bf00-109ff8bf335b" xlink:to="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_cef2dbe3-1f0f-4ffe-ad6d-dbc26e297e86" xlink:href="exdx-20190930.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_181c96f8-fc25-4750-adfe-d8abb7212914" xlink:to="loc_exdx_AVISECTDTestMember_cef2dbe3-1f0f-4ffe-ad6d-dbc26e297e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c46d3423-193d-4fb7-9ae9-e79dec0ecf55" xlink:to="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_d9ce81fa-8cf9-4cb4-a7ba-1bc6cfd15bc4" xlink:href="exdx-20190930.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_MedicareMember_d9ce81fa-8cf9-4cb4-a7ba-1bc6cfd15bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_b35dbed2-e54f-4422-b827-fa3269efeac6" xlink:href="exdx-20190930.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_BlueShieldMember_b35dbed2-e54f-4422-b827-fa3269efeac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_e4c90235-cdc4-46f3-8265-2b1aa1515d1f" xlink:href="exdx-20190930.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_UnitedHealthcareMember_e4c90235-cdc4-46f3-8265-2b1aa1515d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_1185de77-9281-473c-8680-09410b60a470" xlink:href="exdx-20190930.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_84ce0a70-f343-4b81-9aed-fb881e757d78" xlink:to="loc_exdx_MedicareAdvantageMember_1185de77-9281-473c-8680-09410b60a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_61399467-3d51-45f6-8de6-f7d86fc0785b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_61930c82-044c-4942-8882-6d0f8edd958a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:to="loc_us-gaap_SalesRevenueNetMember_61930c82-044c-4942-8882-6d0f8edd958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_e164c71c-c5dd-4988-b0b6-cb0d2eb96a40" xlink:href="exdx-20190930.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2beec465-17a9-42d0-a0b1-1cc1cea4b80a" xlink:to="loc_exdx_ReceivableBenchmarkMember_e164c71c-c5dd-4988-b0b6-cb0d2eb96a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6bfcd91b-74c8-451b-a9d2-b5cd828e4ddf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a2b4392c-ccdc-4167-96e4-4ec270898623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a2b4392c-ccdc-4167-96e4-4ec270898623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e7959796-51c8-4ee3-ae87-9efbdd421408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_90ecacc2-0cc1-4041-bc15-4247bc482c90" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e7959796-51c8-4ee3-ae87-9efbdd421408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b70ddcd5-fa99-4bb5-8b79-8cf4c42d7fb4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_226861bd-30ba-47c9-9971-cd123f6df89c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_63a349ee-9e83-418f-95c3-696367728bfa" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_226861bd-30ba-47c9-9971-cd123f6df89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e2025647-39d5-4776-aaba-19f2ca8dcde6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e2025647-39d5-4776-aaba-19f2ca8dcde6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a01d56e7-7693-42be-87f5-8c0be6b5cf93" xlink:to="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_7e41afb4-2b67-42dc-adc1-1018508ab61a" xlink:href="exdx-20190930.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_HealthcareInsurersMember_7e41afb4-2b67-42dc-adc1-1018508ab61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentMember_82138573-f516-42d3-9645-6837b0c87c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_us-gaap_GovernmentMember_82138573-f516-42d3-9645-6837b0c87c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_1fdc8291-ce12-434d-b601-ffda9a055e24" xlink:href="exdx-20190930.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_ClientMember_1fdc8291-ce12-434d-b601-ffda9a055e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_02f53ffe-fc2b-45de-a0a1-4f47e37f1605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_us-gaap_AllOtherSegmentsMember_02f53ffe-fc2b-45de-a0a1-4f47e37f1605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_914c4c32-9f06-4d88-8c83-98b8be4b8ef0" xlink:href="exdx-20190930.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0e6eb36f-ed58-49dc-8b74-3a825655ff67" xlink:to="loc_exdx_JanssenSIMPONIMember_914c4c32-9f06-4d88-8c83-98b8be4b8ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22b1a532-4936-4d0a-b4f2-ca8ed7c9e493" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93e8612-ba8f-4e31-a93a-e9cdf0f40e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20df1859-87fc-4c43-b50c-e376b9b8c80f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c93e8612-ba8f-4e31-a93a-e9cdf0f40e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9287f810-bcc3-4d38-8a90-3cd5d5b86580" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_183c1196-bc69-4e3c-8364-ff9e8f0c7d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9287f810-bcc3-4d38-8a90-3cd5d5b86580" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_183c1196-bc69-4e3c-8364-ff9e8f0c7d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_05a8d79e-a751-45de-b598-499ba82af0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9287f810-bcc3-4d38-8a90-3cd5d5b86580" xlink:to="loc_us-gaap_RestrictedCash_05a8d79e-a751-45de-b598-499ba82af0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8a9b87a-cff0-4eac-a5bf-1f24cf23e963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9287f810-bcc3-4d38-8a90-3cd5d5b86580" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8a9b87a-cff0-4eac-a5bf-1f24cf23e963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#SummaryOfSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b79c5cb0-803d-4810-9443-e6a4c215c44a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b79c5cb0-803d-4810-9443-e6a4c215c44a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ef361c6d-2b77-4195-9708-39d194ff3172" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_18ac1279-de7d-4667-918f-9642e81ead9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemablePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_18ac1279-de7d-4667-918f-9642e81ead9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WarrantsTemporaryEquityMember_82dd7814-5838-4aa1-8f95-5de30be4455f" xlink:href="exdx-20190930.xsd#exdx_WarrantsTemporaryEquityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_exdx_WarrantsTemporaryEquityMember_82dd7814-5838-4aa1-8f95-5de30be4455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4cf5c4ac-23b2-4ba8-9eb3-06535cbe1f54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_WarrantMember_4cf5c4ac-23b2-4ba8-9eb3-06535cbe1f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c50bc574-15cf-4afd-95f1-c0b5b9d530a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e909432c-5412-4acf-b4ec-9353cd2aa70c" xlink:to="loc_us-gaap_StockOptionMember_c50bc574-15cf-4afd-95f1-c0b5b9d530a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6891e7ff-f886-498d-9cb9-c3e1747ab8ee" xlink:to="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f8ecba0c-ad61-4fa1-8f6a-cb5cec2ce007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dafe50f5-43ad-453d-b786-bcb2372ba76d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f8ecba0c-ad61-4fa1-8f6a-cb5cec2ce007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_ca659361-9083-479a-b133-537bec9604dd" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_049251a0-e822-479e-ad08-e0f3de3d7f17" xlink:href="exdx-20190930.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ca659361-9083-479a-b133-537bec9604dd" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_049251a0-e822-479e-ad08-e0f3de3d7f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_940a9750-765a-4ab3-9a3f-54251131a826" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0f043191-991c-42a0-9dfd-18f046a22a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_940a9750-765a-4ab3-9a3f-54251131a826" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0f043191-991c-42a0-9dfd-18f046a22a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_af20de88-09c2-468e-97dc-6186067e0826" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_940a9750-765a-4ab3-9a3f-54251131a826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_af20de88-09c2-468e-97dc-6186067e0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c9223e78-cc41-404c-9954-ce05ef170699" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_940a9750-765a-4ab3-9a3f-54251131a826" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c9223e78-cc41-404c-9954-ce05ef170699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_3c306d6d-9251-48a5-9025-c5b234e22238" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_3c306d6d-9251-48a5-9025-c5b234e22238" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8b522c38-b907-4a5b-9f55-a9085023973f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_b0e68324-e5f2-4a9c-8191-e52e3d4adf34" xlink:href="exdx-20190930.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_32ba535f-6191-4d8d-a07f-686f0b7d9af1" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_b0e68324-e5f2-4a9c-8191-e52e3d4adf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad7b084e-8fe4-48dc-8b3c-a60676241985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a47c5eb7-4bf6-4f8a-98c0-325dc1f18322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a47c5eb7-4bf6-4f8a-98c0-325dc1f18322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cb5111df-e082-4a7e-88ed-1c58a8f131dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd60a5b0-d63c-44c6-9308-566834a13512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cb5111df-e082-4a7e-88ed-1c58a8f131dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a62bc984-d805-490f-a263-1e60254bedb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:to="loc_us-gaap_OtherAssetsCurrent_a62bc984-d805-490f-a263-1e60254bedb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_fb34ba60-122c-4fee-b5b7-7198219146d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:to="loc_us-gaap_PrepaidRoyalties_fb34ba60-122c-4fee-b5b7-7198219146d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_13f3c53a-1f92-47cc-aac9-a32683d3e028" xlink:href="exdx-20190930.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_13f3c53a-1f92-47cc-aac9-a32683d3e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_cbc8e4fa-1141-4e67-8328-9503225311a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_cbc8e4fa-1141-4e67-8328-9503225311a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b27e4d98-29c6-4e5f-b1fa-6725f6924dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_203f7eeb-1a38-4b34-a50b-c3b3468b8920" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b27e4d98-29c6-4e5f-b1fa-6725f6924dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c07049d5-a889-468a-b74e-c1db6a366c3f" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c07049d5-a889-468a-b74e-c1db6a366c3f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d756bb7-b7c4-49a7-aee8-98c4e6f3a781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9dadaa49-3ae0-4656-8f05-5c10b93be3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9dadaa49-3ae0-4656-8f05-5c10b93be3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_6ccbf79e-868c-40cd-98cd-bef883d45118" xlink:href="exdx-20190930.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_exdx_LaboratoryEquipmentMember_6ccbf79e-868c-40cd-98cd-bef883d45118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_92e6c643-5281-4c6b-8e98-8dd1e5900b81" xlink:href="exdx-20190930.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_92e6c643-5281-4c6b-8e98-8dd1e5900b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ee70f0b0-f92e-4521-bd84-d3f6962b00e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ee70f0b0-f92e-4521-bd84-d3f6962b00e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5a53b2c5-f26f-4051-8595-694fc7310680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a903bc4-39fc-4203-8d78-a65ecebae2c0" xlink:to="loc_us-gaap_ConstructionInProgressMember_5a53b2c5-f26f-4051-8595-694fc7310680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_35d741d0-f753-4149-8b5c-05acbce44077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_520a49af-3d68-417e-8312-4abebcebc475" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_520a49af-3d68-417e-8312-4abebcebc475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45ccf000-0e37-4e3c-9c23-0e0d6540d574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45ccf000-0e37-4e3c-9c23-0e0d6540d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_412d6be8-823d-4f2e-bf54-dfbbbf98312f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f99e3d59-abb3-4100-9e54-030027ff7662" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_412d6be8-823d-4f2e-bf54-dfbbbf98312f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#OtherFinancialInformationAccruedliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:href="exdx-20190930.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_4e0449e7-ebb2-43bb-a65c-ba9f7827148d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_AccruedSalariesCurrent_4e0449e7-ebb2-43bb-a65c-ba9f7827148d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedFinancingCostsCurrent_0ed45ebb-fb59-470f-8862-23ed996279af" xlink:href="exdx-20190930.xsd#exdx_AccruedFinancingCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_exdx_AccruedFinancingCostsCurrent_0ed45ebb-fb59-470f-8862-23ed996279af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_7dea1c94-77ec-477d-80b0-88ff27cdc4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_InterestPayableCurrent_7dea1c94-77ec-477d-80b0-88ff27cdc4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_397935dd-b1c1-4bb6-ac70-2b5dd1cec5d6" xlink:href="exdx-20190930.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_397935dd-b1c1-4bb6-ac70-2b5dd1cec5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_269b0770-c97c-429f-a50b-f7a4c7cca8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_269b0770-c97c-429f-a50b-f7a4c7cca8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a57e215f-1311-4fa0-a992-662914b19c1d" xlink:href="exdx-20190930.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a57e215f-1311-4fa0-a992-662914b19c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c6cc2329-a209-435e-91a1-7d879125a043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c6cc2329-a209-435e-91a1-7d879125a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9865da74-a310-43bf-95f3-1ba5138c7cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9865da74-a310-43bf-95f3-1ba5138c7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2b51a585-ccf0-480e-9c09-0d4f39c7451a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_ddacc268-5575-4390-8da0-22a7e0587bef" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2b51a585-ccf0-480e-9c09-0d4f39c7451a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aff7fc41-d153-420c-a598-5af79583ab33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5019a08d-9bf0-4e52-bf78-6bf85eb64718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aff7fc41-d153-420c-a598-5af79583ab33" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5019a08d-9bf0-4e52-bf78-6bf85eb64718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_86878af0-2b82-47e5-bb42-ca801a2f4846" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_59a5e569-7bbd-4402-8019-ef2b7819aa47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_86878af0-2b82-47e5-bb42-ca801a2f4846" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_59a5e569-7bbd-4402-8019-ef2b7819aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2dc8243c-56b2-4bea-a63f-846bd7d3ab5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2dc8243c-56b2-4bea-a63f-846bd7d3ab5b" xlink:to="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d9eb05c-cefc-4d25-ae5b-5b74003e7ff8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_40d9d0ed-2ca7-49aa-8028-d35818a590fe" xlink:href="exdx-20190930.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b759669-f812-4ff6-b63d-8ef254c1a485" xlink:to="loc_exdx_Term2017Member_40d9d0ed-2ca7-49aa-8028-d35818a590fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c198ec55-946f-4762-bf73-b1f5251e3e58" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_29b63f37-6b67-4b75-873f-81a141909339" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:to="loc_us-gaap_LoansPayableMember_29b63f37-6b67-4b75-873f-81a141909339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_cdcdf2c5-0c86-4bd8-afa6-adf9ed9f6d07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4daf6b90-df93-4ccf-93a6-31893f77107d" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_cdcdf2c5-0c86-4bd8-afa6-adf9ed9f6d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_4d76905a-0693-489b-97eb-406ba5fee685" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_c13fd4d2-dcdb-4587-afbe-dafabda936c4" xlink:href="exdx-20190930.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_c13fd4d2-dcdb-4587-afbe-dafabda936c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_b40e3d6b-5036-49da-82fe-2bc2fa139e32" xlink:href="exdx-20190930.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8a9a7e0f-7f3a-4316-9c78-056e88965f95" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_b40e3d6b-5036-49da-82fe-2bc2fa139e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f809eac4-15e8-46c0-8241-3a39d2df7d48" xlink:to="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_c538f407-1dfa-47da-8939-e1b2a0118f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7e450288-c58e-4a21-8931-6b9566fe8e32" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_c538f407-1dfa-47da-8939-e1b2a0118f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1453a538-e83e-48f7-abfc-2df9e73ab8ef" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31906e50-99f2-4268-89a6-dc7a7898c29f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31906e50-99f2-4268-89a6-dc7a7898c29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e1af8cad-3dc0-4e82-a703-defa5450ad84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e1af8cad-3dc0-4e82-a703-defa5450ad84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4abe7725-42a7-4cdd-a064-65624a726d80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4abe7725-42a7-4cdd-a064-65624a726d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_1f76bcc2-dd82-4741-85fd-aedc2b15d2ce" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_1f76bcc2-dd82-4741-85fd-aedc2b15d2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dc6f8976-af1b-4e98-a770-e644cd3a9802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dc6f8976-af1b-4e98-a770-e644cd3a9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_06a3355b-c46a-4874-8a42-acae9c3ebd52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_06a3355b-c46a-4874-8a42-acae9c3ebd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_656039cb-9274-4175-b638-2ce2e04e3a72" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_656039cb-9274-4175-b638-2ce2e04e3a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_71f9b499-59c3-4ff2-9636-1310de560645" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_71f9b499-59c3-4ff2-9636-1310de560645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_e3a0a900-9cd7-474b-8f8f-29e65b8946a4" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_e3a0a900-9cd7-474b-8f8f-29e65b8946a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_c62c94e8-4f68-47c8-9813-6066e5214bbd" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease_c62c94e8-4f68-47c8-9813-6066e5214bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_635e8688-6efc-4fb2-89ab-c6795e542d73" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt_635e8688-6efc-4fb2-89ab-c6795e542d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_3a500a1e-775e-434e-9473-d2fe63351f6b" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_3a500a1e-775e-434e-9473-d2fe63351f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_70d9dc2e-8116-43e6-8bc7-02cadad42737" xlink:href="exdx-20190930.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_70d9dc2e-8116-43e6-8bc7-02cadad42737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_77d3511b-1974-4507-bde1-ca921dd7cb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_77d3511b-1974-4507-bde1-ca921dd7cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_163481b7-fe08-48f6-b0d8-d2d09bd380d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_163481b7-fe08-48f6-b0d8-d2d09bd380d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72de139c-5b52-427d-ae26-51b4bc202361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72de139c-5b52-427d-ae26-51b4bc202361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8e71684c-e56d-474e-956f-60ac5b45d291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e301fe93-7090-4792-b218-6a5c3f506590" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8e71684c-e56d-474e-956f-60ac5b45d291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b5d1e52b-935b-4692-9e66-5ab212b96bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b5d1e52b-935b-4692-9e66-5ab212b96bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5194a350-ae2c-4192-b017-e684fd83dd53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5194a350-ae2c-4192-b017-e684fd83dd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3ec0f175-13b6-4146-9205-eea7f6d57662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3ec0f175-13b6-4146-9205-eea7f6d57662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_204dbc8a-9434-454f-a81d-bd59f2460a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_204dbc8a-9434-454f-a81d-bd59f2460a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_86131146-af50-4180-9b6d-de86808433ba" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_86131146-af50-4180-9b6d-de86808433ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_525c98dd-ca9c-4f87-9b3a-92f0a7f4ffde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_525c98dd-ca9c-4f87-9b3a-92f0a7f4ffde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_4cb7947e-a7dc-45ac-aa18-c31536462602" xlink:href="exdx-20190930.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_4cb7947e-a7dc-45ac-aa18-c31536462602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8ce43e43-e0c6-42f5-a282-565b104a2f19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1f3e3af-4229-4033-9b95-84cc850b5a30" xlink:to="loc_us-gaap_LongTermDebt_8ce43e43-e0c6-42f5-a282-565b104a2f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e024c358-da72-4109-9bc4-867c00d4534b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockTextBlock_28e4d305-1ca8-41cd-870a-0e7f338efdd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e024c358-da72-4109-9bc4-867c00d4534b" xlink:to="loc_us-gaap_PreferredStockTextBlock_28e4d305-1ca8-41cd-870a-0e7f338efdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d036c8a6-fe4c-4c85-8a56-7b0b6e5cc457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bf924663-d9c1-4f7c-a679-8bc7c5f749ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d036c8a6-fe4c-4c85-8a56-7b0b6e5cc457" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bf924663-d9c1-4f7c-a679-8bc7c5f749ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_caf56e43-c900-403a-b94a-7a7a11f77f62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_caf56e43-c900-403a-b94a-7a7a11f77f62" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72c90c7b-4f6a-4343-b0ba-4d4ad7fd98d7" xlink:to="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_23195521-61f1-45db-a8e3-d2ba0312c13d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_23195521-61f1-45db-a8e3-d2ba0312c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SeriesDAndSeriesEPreferredStockMember_f5cb7f12-bc6d-49c6-b5f0-70a74ccf7b9a" xlink:href="exdx-20190930.xsd#exdx_SeriesDAndSeriesEPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ac070ec2-414a-4e04-93a7-69672acb3722" xlink:to="loc_exdx_SeriesDAndSeriesEPreferredStockMember_f5cb7f12-bc6d-49c6-b5f0-70a74ccf7b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_7850b3e5-48ad-4db2-9d65-7b5cf5b63d4f" xlink:to="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb0abe7-1668-4841-ad70-fe2b5542ff23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7fb0abe7-1668-4841-ad70-fe2b5542ff23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightExercised_70ccfef2-844d-4394-bf2c-c5b458d0dcfe" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_ClassOfWarrantOrRightExercised_70ccfef2-844d-4394-bf2c-c5b458d0dcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_bcca404e-d5cd-49bd-98ea-36e119c9d802" xlink:href="exdx-20190930.xsd#exdx_ClassOfWarrantOrRightUnexercisedAndTerminated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated_bcca404e-d5cd-49bd-98ea-36e119c9d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cf60d0e4-3c13-4d96-a0de-0bcfab7a2a0d" xlink:href="exdx-20190930.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_fba31602-ba1b-4fa4-9f31-c4b5873d4c40" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_cf60d0e4-3c13-4d96-a0de-0bcfab7a2a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a8a8a450-5092-42a5-9259-f9234953ed16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a8a8a450-5092-42a5-9259-f9234953ed16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a398db63-53d5-47b2-8734-0b3073a69d9c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_2d6ed2fc-e336-4471-952a-b9df6fe080e8" xlink:href="exdx-20190930.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationJan192026Member_2d6ed2fc-e336-4471-952a-b9df6fe080e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_98abe634-1872-4e59-b7c4-805af2f3bd9e" xlink:href="exdx-20190930.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationMar312026Member_98abe634-1872-4e59-b7c4-805af2f3bd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_308d8e9a-17d3-4ca6-ab79-184239580a6f" xlink:href="exdx-20190930.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationApr12026Member_308d8e9a-17d3-4ca6-ab79-184239580a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep82024Member_4761f7e8-d48a-4dbf-a194-5ab031b72789" xlink:href="exdx-20190930.xsd#exdx_ExpirationSep82024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationSep82024Member_4761f7e8-d48a-4dbf-a194-5ab031b72789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_084f5b4b-0772-4281-a2f9-94a850a2e4cd" xlink:href="exdx-20190930.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d3153c87-3fc2-4c7d-8824-615d8a338c6a" xlink:to="loc_exdx_ExpirationDec72025Member_084f5b4b-0772-4281-a2f9-94a850a2e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3bdec366-8005-4f64-9de5-bac3c4920b9f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dcbc1ac0-a3d8-4509-a0d1-3ca262991741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dcbc1ac0-a3d8-4509-a0d1-3ca262991741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fb92d0e-7a1a-4f26-a19c-031d620ca60c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_acfe4a64-49e0-41f2-b48f-ba9d442422f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4fb92d0e-7a1a-4f26-a19c-031d620ca60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d596aad3-b36e-4b3b-8139-201a85d6a240" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0da15ddc-1de9-4f2d-b1e9-543f33724a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d596aad3-b36e-4b3b-8139-201a85d6a240" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0da15ddc-1de9-4f2d-b1e9-543f33724a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85094a39-22dc-4fec-a51b-9ddcb7e50db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85094a39-22dc-4fec-a51b-9ddcb7e50db5" xlink:to="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:href="exdx-20190930.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_fdf29614-0e8b-4419-ac17-4c4505433e2c" xlink:to="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_285c2e8c-d77a-40d5-9a26-2237bf0a63a5" xlink:href="exdx-20190930.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:to="loc_exdx_OfficeAndLaboratoryMember_285c2e8c-d77a-40d5-9a26-2237bf0a63a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a797a38c-ce74-4c5c-993c-d7d3625dc213" xlink:href="exdx-20190930.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_99c8e2f6-fc92-4676-8d7a-72fb5b1cdbdf" xlink:to="loc_exdx_OfficeMember_a797a38c-ce74-4c5c-993c-d7d3625dc213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e764da2f-4102-4d49-b4fa-13c6fe73caee" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_7fc84724-fe84-45c0-9293-9b3907e3324b" xlink:href="exdx-20190930.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_503c9ae1-c23d-487c-874d-27f622d271bb" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_7fc84724-fe84-45c0-9293-9b3907e3324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f09f71a5-0c51-418d-b033-26f429c5595e" xlink:to="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5495cad6-f124-442b-9b88-12d5110274f5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:to="loc_srt_MinimumMember_5495cad6-f124-442b-9b88-12d5110274f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2af5b7dd-b22a-4bd3-b4c3-d6daf1a8c770" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d5c26ce-fcef-4882-8b4f-acd60c4d05e5" xlink:to="loc_srt_MaximumMember_2af5b7dd-b22a-4bd3-b4c3-d6daf1a8c770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0dac7e14-9497-4d3f-b72d-be5cea35f6c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_b3e1e40f-af68-4b00-a05e-734d2cae3e15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5729a184-9e22-4d91-b489-9d3cf988010b" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_b3e1e40f-af68-4b00-a05e-734d2cae3e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4d84f729-637a-4205-9471-9da4e0571789" xlink:to="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_520606df-aee7-4419-9227-f9c9c64092b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_NetRentableArea_520606df-aee7-4419-9227-f9c9c64092b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NumberOfOperatingLeaseExtensions_69a52b9b-8c6a-446d-aeb3-ca52ed0f0f9f" xlink:href="exdx-20190930.xsd#exdx_NumberOfOperatingLeaseExtensions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_NumberOfOperatingLeaseExtensions_69a52b9b-8c6a-446d-aeb3-ca52ed0f0f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8ce8a27f-2d35-4f40-bc30-371e4e135bef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8ce8a27f-2d35-4f40-bc30-371e4e135bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_83452d59-523d-4d27-8bb9-3746d6764ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_OperatingLeaseExpense_83452d59-523d-4d27-8bb9-3746d6764ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_0f490cea-4635-4727-92d2-48d45af7d777" xlink:href="exdx-20190930.xsd#exdx_MilestoneObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_MilestoneObligation_0f490cea-4635-4727-92d2-48d45af7d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_802340c9-adff-420f-ab9e-9d9e5e3ae77a" xlink:href="exdx-20190930.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_802340c9-adff-420f-ab9e-9d9e5e3ae77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_8d8bc336-f659-45b8-ba52-a4991dcfaeb0" xlink:href="exdx-20190930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_8d8bc336-f659-45b8-ba52-a4991dcfaeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9f34c0e2-a74b-4d84-a0d8-90c01c9333cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9f34c0e2-a74b-4d84-a0d8-90c01c9333cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_945dd876-6f1a-4e55-81fa-0dd78c2e2eee" xlink:href="exdx-20190930.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_exdx_AdvancePayment_945dd876-6f1a-4e55-81fa-0dd78c2e2eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_5e9ea9d3-d04a-4d73-ae0d-f2105c75f501" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_5e9ea9d3-d04a-4d73-ae0d-f2105c75f501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_30c8e386-2db3-4f4e-8bb8-9e6f1b69b8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6268d981-8497-4c5a-b8a1-c045e0c6571a" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_30c8e386-2db3-4f4e-8bb8-9e6f1b69b8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsNotes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fb404490-cbe8-45eb-9700-3cd2a83e2070" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a7764773-4dda-424a-9910-cd78979baf54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fb404490-cbe8-45eb-9700-3cd2a83e2070" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a7764773-4dda-424a-9910-cd78979baf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasuresandDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e5b6954-c515-4165-936b-806f936dd204" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_21717c86-f563-4a09-90e0-6abcd31cce82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e5b6954-c515-4165-936b-806f936dd204" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_21717c86-f563-4a09-90e0-6abcd31cce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f2c5ec7c-6505-4d3b-9ca0-7d267d6b9b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e5b6954-c515-4165-936b-806f936dd204" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_f2c5ec7c-6505-4d3b-9ca0-7d267d6b9b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluemeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_742fcc27-a767-4ab5-bbaa-0c91845fc76a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_742fcc27-a767-4ab5-bbaa-0c91845fc76a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e1defa0f-41f3-4601-b079-7d706621e177" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8c3227e0-fc36-4329-b9dd-f607353faa9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_11e0995c-aa0a-45e2-a443-e0c0211cc9ef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8c3227e0-fc36-4329-b9dd-f607353faa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_14702fd3-91af-4c84-80a4-45aaa2968235" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_afff71c2-82d7-4a11-bab6-827ae2e3b66d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ad153dc0-4745-4821-87a4-33f286c972a8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_afff71c2-82d7-4a11-bab6-827ae2e3b66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7164072c-d7f6-41e7-9bb4-ab04fc6f6d70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2b6c608d-4ae1-4aae-a8df-dc92012b0987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2b6c608d-4ae1-4aae-a8df-dc92012b0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aaff36de-ce97-4f8a-9c6c-67793077a4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aaff36de-ce97-4f8a-9c6c-67793077a4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bfab17b2-43bb-43d7-bd6a-3b9eac487832" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_854e5214-973d-4736-98a6-cd1d59917ec2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bfab17b2-43bb-43d7-bd6a-3b9eac487832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a4df3368-3fd0-4051-ac3a-bfba334f1763" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_73a7d43e-b29e-4344-8ccb-cc2b12ab2c88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f82740e3-1176-46c7-90f3-5452e978569b" xlink:to="loc_us-gaap_WarrantMember_73a7d43e-b29e-4344-8ccb-cc2b12ab2c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_17df0d9b-5866-4842-aca2-58e00b6fc9b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f71831dc-1d94-4ede-a3a7-ed7463f33ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_18b2f2a5-0d8b-49d7-938a-b03887b448a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f71831dc-1d94-4ede-a3a7-ed7463f33ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_6047dd43-e55f-4f69-ab1c-baaa365fd627" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_fe7d61a2-94d0-483f-96ec-c209ba0f002d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8fbce7ed-5078-4170-b5f7-0e2e1fc62c25" xlink:to="loc_us-gaap_DerivativeLiabilities_fe7d61a2-94d0-483f-96ec-c209ba0f002d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="simple" xlink:href="exdx-20190930.xsd#FairValueMeasurementsFairvaluelevel3Details"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d10a76b6-725a-40dd-b039-bc1828616623" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d10a76b6-725a-40dd-b039-bc1828616623" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca0d50be-9be4-4ea4-b29f-3dafc4d7a96f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e58c089a-7663-417a-a905-019e3b4b042d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54d49643-0adc-4ccf-abf7-36b2af0a21d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e58c089a-7663-417a-a905-019e3b4b042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b201fb8d-9512-4f98-92c6-c790603f8fae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ae8c9b57-2377-4504-bf9b-899ae0235a2d" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_64c51e52-3b56-4eea-8fdf-050e62211b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_64c51e52-3b56-4eea-8fdf-050e62211b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_f5151058-5186-450f-8005-12c025bb2394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_f5151058-5186-450f-8005-12c025bb2394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_fee9922f-e0c1-4a33-b9ab-f9aaf5dc6843" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_fee9922f-e0c1-4a33-b9ab-f9aaf5dc6843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_e2ea7cf4-089c-4e4b-aa35-c02722f115eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_e2ea7cf4-089c-4e4b-aa35-c02722f115eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_58552081-aa91-4ba9-b445-27e0c0af8306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_58552081-aa91-4ba9-b445-27e0c0af8306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_37b6737c-7a2d-49b3-adf0-a5bc0e1489bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_62f1fed5-2b85-408e-b711-8097f17705e6" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_37b6737c-7a2d-49b3-adf0-a5bc0e1489bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_9c871b1e-c048-4615-89bf-1e7611d62b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityTextBlock_e64d4f71-5ab2-429f-8294-bbd03cb74bb6" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_9c871b1e-c048-4615-89bf-1e7611d62b9f" xlink:to="loc_exdx_TemporaryEquityTextBlock_e64d4f71-5ab2-429f-8294-bbd03cb74bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RedeemableConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_0a156882-75b1-4225-af20-891a4bfe5592" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_0a156882-75b1-4225-af20-891a4bfe5592" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db909888-4fde-4715-9177-fe140f254059" xlink:to="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_94cfb80b-9c0a-427a-93e0-c6536ca6919e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesGPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_94cfb80b-9c0a-427a-93e0-c6536ca6919e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_293b1b14-3e28-42f8-b9ba-c9cc3b903775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_293b1b14-3e28-42f8-b9ba-c9cc3b903775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_fb4aaf44-2e5a-4194-b329-fcffa107f0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ed5bec3-d237-413e-87b8-9c07f9fdb5bc" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_fb4aaf44-2e5a-4194-b329-fcffa107f0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434b7738-d08a-41b3-b486-2fe9cc0af345" xlink:to="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7c147ad7-53a0-4b8b-8a0a-da04dacda365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_721f0f36-fb39-4c3c-a9c4-6bd009f0a0ea" xlink:to="loc_us-gaap_CommonStockMember_7c147ad7-53a0-4b8b-8a0a-da04dacda365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7bd193fa-7a69-4735-8a67-a259482765c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6f91aff7-ba15-4c5b-8755-9c4cb0940443" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f3c4c92c-5a47-460b-a8cc-285084e534eb" xlink:to="loc_us-gaap_IPOMember_6f91aff7-ba15-4c5b-8755-9c4cb0940443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_54c61354-0f64-44b4-a8e9-8be683cfe03d" xlink:to="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_79d2f2ec-dfe3-4f9f-ba81-a084fab9e0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_79d2f2ec-dfe3-4f9f-ba81-a084fab9e0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_299ce75b-5a35-44d7-9650-a5b3394273ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_299ce75b-5a35-44d7-9650-a5b3394273ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_34132afb-754f-4254-8377-e4a5349f52b4" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction_34132afb-754f-4254-8377-e4a5349f52b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityPricePerShare_3ae0ef04-6d2d-47e8-be17-17a45b918f59" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityPricePerShare_3ae0ef04-6d2d-47e8-be17-17a45b918f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_4a0e4b41-b0ae-4d26-8103-f01d8f859234" xlink:href="exdx-20190930.xsd#exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction_4a0e4b41-b0ae-4d26-8103-f01d8f859234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_0503d6e0-5a8c-44f3-9a28-5a4bef28cf70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_0503d6e0-5a8c-44f3-9a28-5a4bef28cf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityRightsForMandatoryPurchase_5c601e65-c388-4d39-9e5c-f9186e99699c" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityRightsForMandatoryPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityRightsForMandatoryPurchase_5c601e65-c388-4d39-9e5c-f9186e99699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_64b7bfde-e0f5-448f-bc1c-9bf9100df5e7" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase_64b7bfde-e0f5-448f-bc1c-9bf9100df5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_a1602391-8efc-4634-a29f-bc889406da29" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesRedeemedUponConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquitySharesRedeemedUponConversion_a1602391-8efc-4634-a29f-bc889406da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividend_06e3e096-4c5a-4cd3-9278-b448d88bf882" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividend"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityDeemedDividend_06e3e096-4c5a-4cd3-9278-b448d88bf882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquitySharesIssuedUponConversion_45efac37-1cfe-49b1-aff9-7e3c6f680968" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquitySharesIssuedUponConversion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquitySharesIssuedUponConversion_45efac37-1cfe-49b1-aff9-7e3c6f680968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b4fa4ab8-1ab0-4d67-8297-a5c38d912e52" xlink:href="exdx-20190930.xsd#exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_46fb87e9-dfe4-43b9-85d8-f33c18c534c9" xlink:to="loc_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature_b4fa4ab8-1ab0-4d67-8297-a5c38d912e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f03ec9e7-233d-40f8-a8c7-ab084047980c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_88dc0926-9e8f-48db-a332-e68a39fd41e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f03ec9e7-233d-40f8-a8c7-ab084047980c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_88dc0926-9e8f-48db-a332-e68a39fd41e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockholdersEquityDeficitDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_19e99b90-0d77-4341-bb47-52cc9eb9cebc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_19e99b90-0d77-4341-bb47-52cc9eb9cebc" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_973c14ec-b880-4713-baa5-ab2ca1612354" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_795b71f9-8f8f-4220-8e62-2cfae30b5cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:to="loc_us-gaap_IPOMember_795b71f9-8f8f-4220-8e62-2cfae30b5cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_f0193298-796a-48b2-8130-e4f550c6f009" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8c02737-10e8-44fa-b26c-af0461d73739" xlink:to="loc_us-gaap_OverAllotmentOptionMember_f0193298-796a-48b2-8130-e4f550c6f009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0c42e9c6-4d3d-4059-a9f9-170ebce04c83" xlink:to="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ea344422-7883-47eb-a5c3-608ff87370c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fdb0b06d-91b7-453d-877b-f3ffc8d834b1" xlink:to="loc_us-gaap_CommonStockMember_ea344422-7883-47eb-a5c3-608ff87370c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_31b36f0c-5e86-4c22-b8c8-247e70ae561f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ac09f1f6-94a0-4b11-8f5f-8906be3877f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ac09f1f6-94a0-4b11-8f5f-8906be3877f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a7fa5338-ba92-47cc-991f-3d24c98719a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a7fa5338-ba92-47cc-991f-3d24c98719a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_20332134-a455-47ce-9183-227fc966adda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_20332134-a455-47ce-9183-227fc966adda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cf61c5fb-d377-4df1-9507-74848ea21543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cf61c5fb-d377-4df1-9507-74848ea21543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c20cdef4-7fb2-462d-a87e-c716c6ec386e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c20cdef4-7fb2-462d-a87e-c716c6ec386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_741d68e2-5ce6-4756-9cce-73b83c0b91a6" xlink:href="exdx-20190930.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_exdx_StockIssuanceCosts_741d68e2-5ce6-4756-9cce-73b83c0b91a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa26c397-0675-4131-8fbb-27d758ce3e83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_39182e29-b88e-4046-9bd7-583d3fbb026d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_fa26c397-0675-4131-8fbb-27d758ce3e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a009e25-2cac-4773-9805-377ac5c35de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b570729e-a1e8-484d-849c-04e6a99f304d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a009e25-2cac-4773-9805-377ac5c35de2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b570729e-a1e8-484d-849c-04e6a99f304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3b3809a-bc3b-4db9-9688-9d96240a0bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_18a04af6-cdc1-42f2-85b9-6bd5f48b0359" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3b3809a-bc3b-4db9-9688-9d96240a0bed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_18a04af6-cdc1-42f2-85b9-6bd5f48b0359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7be33e72-dd68-4b74-bbad-65a187fe5e12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3b3809a-bc3b-4db9-9688-9d96240a0bed" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7be33e72-dd68-4b74-bbad-65a187fe5e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c83d08df-b1be-49e9-8967-4571a9303ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3b3809a-bc3b-4db9-9688-9d96240a0bed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c83d08df-b1be-49e9-8967-4571a9303ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23b7f521-2b25-47a2-a8dd-64a5c27a20e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23b7f521-2b25-47a2-a8dd-64a5c27a20e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:to="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4c370e36-da98-4bd5-ab73-5f7dd3c3ee9b" xlink:to="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockOptionPlan2013Member_5ac623b1-c446-4322-81fe-92fcee7e0fb1" xlink:href="exdx-20190930.xsd#exdx_StockOptionPlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:to="loc_exdx_StockOptionPlan2013Member_5ac623b1-c446-4322-81fe-92fcee7e0fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_140d28a0-6848-4cf2-8ebd-ab44d865b466" xlink:href="exdx-20190930.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_45a80fb0-12e3-4dd6-b5bf-d41c4cb2f15c" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_140d28a0-6848-4cf2-8ebd-ab44d865b466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:to="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1d280459-43a0-4943-a60a-e3c6c31be7ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7e845a26-5218-4cc3-b328-ce925501ac71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:to="loc_us-gaap_EmployeeStockMember_7e845a26-5218-4cc3-b328-ce925501ac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98720094-b843-48c4-99ae-76306eae436f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5fef9f6-961f-4715-a8b2-d830282615e5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98720094-b843-48c4-99ae-76306eae436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc20eb66-6361-40b2-a1ea-0bc325c0a974" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4c6b486a-35bb-40b6-b7fd-52bdbbe43088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4c6b486a-35bb-40b6-b7fd-52bdbbe43088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_9ec68872-f2c4-4662-8755-5858bca89987" xlink:href="exdx-20190930.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_9ec68872-f2c4-4662-8755-5858bca89987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_554e990f-a0bc-46d3-a083-bad144e90f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_554e990f-a0bc-46d3-a083-bad144e90f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e8bd46b-84c5-43ff-9b9e-512e05833754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5e8bd46b-84c5-43ff-9b9e-512e05833754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c7764bf-762c-4777-9b47-4e72cb14b141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8c7764bf-762c-4777-9b47-4e72cb14b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_abadc6af-a459-4700-80e6-658e30150858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_abadc6af-a459-4700-80e6-658e30150858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fc2671f6-6d70-411c-bf54-94672d20a86d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fc2671f6-6d70-411c-bf54-94672d20a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b1b0d30b-487d-4ac3-bc30-f472e66074ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b1b0d30b-487d-4ac3-bc30-f472e66074ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de81c86e-f0ef-405e-9110-1ef4769a3d70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ba6249b-5ed2-4265-a6a7-6f22727d779a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de81c86e-f0ef-405e-9110-1ef4769a3d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84d34024-e994-47df-b71f-6936d48a976f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84d34024-e994-47df-b71f-6936d48a976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9fbf0d3-9505-45d0-95e7-4f10e9388e67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c9fbf0d3-9505-45d0-95e7-4f10e9388e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192e8355-3326-445a-9067-4f7d0333fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_192e8355-3326-445a-9067-4f7d0333fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cd7222b2-0edf-4c11-9652-b28f209a16a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cd7222b2-0edf-4c11-9652-b28f209a16a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b8288ba-1760-4504-a1d7-267bd631602f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b8288ba-1760-4504-a1d7-267bd631602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67288816-7c1f-464b-b0f0-14f154ec3b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3082729-05de-4142-900c-3172060d1b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67288816-7c1f-464b-b0f0-14f154ec3b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b241ab1-420b-4198-981f-c77440b821b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b241ab1-420b-4198-981f-c77440b821b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bd6cec6-6a60-4deb-9204-b5ffb25d276e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bd6cec6-6a60-4deb-9204-b5ffb25d276e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dfb758f6-736a-43f5-9ca8-97dea56f2b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dfb758f6-736a-43f5-9ca8-97dea56f2b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_778f3b36-9a9f-4fdb-af11-153a934682e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_778f3b36-9a9f-4fdb-af11-153a934682e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f9895424-01a3-4ee9-a91d-0af7efe472b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f9895424-01a3-4ee9-a91d-0af7efe472b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f81b1b87-3b2d-4280-aef3-0688d9d2aa6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fff9a31-df61-457b-81fe-7e5531e383b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f81b1b87-3b2d-4280-aef3-0688d9d2aa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4ff5cd5f-10c6-4282-a324-9718e98831af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4ff5cd5f-10c6-4282-a324-9718e98831af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b7506741-a08e-4ba3-80be-7ce2c277e441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b7506741-a08e-4ba3-80be-7ce2c277e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4bebf007-0ecd-4930-bc20-6fcc2c169053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_4bebf007-0ecd-4930-bc20-6fcc2c169053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a014a5a-0f4e-46a9-996d-ad95163ae26f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a014a5a-0f4e-46a9-996d-ad95163ae26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b995713c-7f9c-4a3c-a060-e7428a21409d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b995713c-7f9c-4a3c-a060-e7428a21409d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d9d98e93-443b-4371-89dd-f95ff1860da2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_61250b07-41ea-4e2c-8f4c-159fd3763341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d9d98e93-443b-4371-89dd-f95ff1860da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_33e04703-3372-4b60-8984-7d202421069d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_33e04703-3372-4b60-8984-7d202421069d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ac7ea11-7302-4f20-9019-6047c5ab5200" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ac7ea11-7302-4f20-9019-6047c5ab5200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9e29d949-c487-4e46-99ee-8b3da4d7d1df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9e29d949-c487-4e46-99ee-8b3da4d7d1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d4c5f7a0-ff74-4381-809a-1900a96ae2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c209f4f-d709-4511-ae02-a5ac623542d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d4c5f7a0-ff74-4381-809a-1900a96ae2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b061cf-6a08-4b74-bf53-e63a5bc2108e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1b061cf-6a08-4b74-bf53-e63a5bc2108e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:to="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ebb3d4e8-84be-4471-a812-239568f1e718" xlink:to="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cb9e38ae-69d3-4e03-b3b3-94be5948fb0d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:to="loc_srt_MinimumMember_cb9e38ae-69d3-4e03-b3b3-94be5948fb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89f742e4-de8c-4383-b494-2de7c4281874" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_278342df-de22-4dc9-b1f3-64bfe1a6806b" xlink:to="loc_srt_MaximumMember_89f742e4-de8c-4383-b494-2de7c4281874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3af0e2e-5698-411f-8938-ea9801121529" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdf23d7f-b3ae-464a-851b-f8b2df8fd570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdf23d7f-b3ae-464a-851b-f8b2df8fd570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ff23db6-aef0-4239-85ab-cfe664bffe6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ff23db6-aef0-4239-85ab-cfe664bffe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_392aa647-efdb-4452-b090-b3b82fda306c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_392aa647-efdb-4452-b090-b3b82fda306c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7e9fd7ce-c1ca-4347-839a-4d9666327035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7e9fd7ce-c1ca-4347-839a-4d9666327035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6003946a-dd1c-46ad-a087-704a2a2447c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6003946a-dd1c-46ad-a087-704a2a2447c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1287d432-a543-4971-bcf9-d85fa5e8c24d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d18d14b9-1736-450f-b3c1-40016af1c630" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1287d432-a543-4971-bcf9-d85fa5e8c24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56045b46-9b4e-4dd2-a438-a1cb28c4649e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_56045b46-9b4e-4dd2-a438-a1cb28c4649e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7fc66e96-ff2e-44af-be08-2ad1fee1ccdb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9810d270-b4f9-4b8e-bd73-daa40a0b06d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_CostOfSalesMember_9810d270-b4f9-4b8e-bd73-daa40a0b06d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_24f552f8-e4a9-4cb5-8e2d-f2b65a641c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_24f552f8-e4a9-4cb5-8e2d-f2b65a641c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0a9da63-cf65-4e6c-9fc3-90155c29c7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_937b8d2f-8280-41c4-9a97-a08e0ae212d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f0a9da63-cf65-4e6c-9fc3-90155c29c7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_adc27dd8-a6ce-4619-9a13-f898c6b3fafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bdf0a3d5-954d-4b30-9476-da1cf60d47ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c7d32a3-19f2-4a72-975b-1e3fda6dde9b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bdf0a3d5-954d-4b30-9476-da1cf60d47ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedParties" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_773ff2b2-0cef-4903-8aac-5b6120583a37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_68ca3c70-dc4d-4d60-8454-ce49274ac3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_773ff2b2-0cef-4903-8aac-5b6120583a37" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_68ca3c70-dc4d-4d60-8454-ce49274ac3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#RelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b3253a78-a13b-45de-a711-0c966c9f4b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b3253a78-a13b-45de-a711-0c966c9f4b1a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526e96a7-3fab-407d-bc92-d70fb087e3c4" xlink:to="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3a5cb946-1b57-4485-a131-6c4e9eb97f61" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:to="loc_srt_DirectorMember_3a5cb946-1b57-4485-a131-6c4e9eb97f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_baa72c96-bd0d-494c-b54e-a5a24c820f67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63eee045-240b-4242-8c1c-b93b99631afc" xlink:to="loc_srt_ExecutiveOfficerMember_baa72c96-bd0d-494c-b54e-a5a24c820f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0366e35f-3d0b-488e-8996-0393e6b7e078" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ConsultingServicesMember_67cc555e-b019-4e4e-b9bc-8b76cfe6df47" xlink:href="exdx-20190930.xsd#exdx_ConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:to="loc_exdx_ConsultingServicesMember_67cc555e-b019-4e4e-b9bc-8b76cfe6df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e8111647-0e1e-43d1-b335-a1b8f3d7ab06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91422a03-bba8-4b92-9137-69dc687dda6f" xlink:to="loc_us-gaap_LicensingAgreementsMember_e8111647-0e1e-43d1-b335-a1b8f3d7ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc7d78ca-2d2d-4afa-9b2a-ef9bde659740" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca3f4260-46bd-44c1-89b0-8e23f9fae9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca3f4260-46bd-44c1-89b0-8e23f9fae9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dbb1072f-72d7-47cc-8179-4cb377670fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dbb1072f-72d7-47cc-8179-4cb377670fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a17b30f4-5eb6-45d0-a624-e51598b8d6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a17b30f4-5eb6-45d0-a624-e51598b8d6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a4aae07b-55a2-42e1-aa61-f9bb04af5574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a4aae07b-55a2-42e1-aa61-f9bb04af5574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_b052ed28-c32d-44ad-878a-8c0fb59cd09f" xlink:href="exdx-20190930.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_b052ed28-c32d-44ad-878a-8c0fb59cd09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_d2d5aae9-aee1-48a5-9274-26443079dd0e" xlink:href="exdx-20190930.xsd#exdx_MilestoneObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6571c988-43e9-4e99-89e9-2519f25ece45" xlink:to="loc_exdx_MilestoneObligation_d2d5aae9-aee1-48a5-9274-26443079dd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="simple" xlink:href="exdx-20190930.xsd#CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_672766c5-cec2-4650-9f25-60c91835eed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_64cf567b-97d8-4915-8efe-6b9f23f3d0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_672766c5-cec2-4650-9f25-60c91835eed3" xlink:to="loc_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_64cf567b-97d8-4915-8efe-6b9f23f3d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ea243424-ddf6-4075-a9a4-1ec40d0cdaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_07f1e6ae-b4d4-41c5-b806-7ef8b3540546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ea243424-ddf6-4075-a9a4-1ec40d0cdaf0" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_07f1e6ae-b4d4-41c5-b806-7ef8b3540546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_4d63085f-c54e-49e2-b35a-f49856636096" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_4d63085f-c54e-49e2-b35a-f49856636096" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:to="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_d8bff514-b01a-489d-a8a9-9589f28566cb" xlink:to="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_9ebd5e2f-947c-4683-b66f-9f48395d687c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_9ebd5e2f-947c-4683-b66f-9f48395d687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_4f3cff44-ca2a-4ada-987a-bf4cdcf7a153" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5e1b7331-6ae2-436b-8ec5-339e7d0880d4" xlink:to="loc_srt_RestatementAdjustmentMember_4f3cff44-ca2a-4ada-987a-bf4cdcf7a153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_ee06257a-8a30-438a-9daa-e57491d3e2b5" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_80f04fa2-527b-4883-b022-c3610a7c455c" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_exdx_PreferredStockWarrantLiability_80f04fa2-527b-4883-b022-c3610a7c455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e88a5aa6-0ee9-482f-99a2-312090cabd25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_Liabilities_e88a5aa6-0ee9-482f-99a2-312090cabd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c653351-1819-4114-9df9-fb1c6997da3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c653351-1819-4114-9df9-fb1c6997da3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f36589fd-819e-4d1c-897c-2786f307d83a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d1d9480f-9dda-49cd-b80e-c8895db6325d" xlink:to="loc_us-gaap_StockholdersEquity_f36589fd-819e-4d1c-897c-2786f307d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f85bcb4d-753d-409b-9767-e4fc28593e50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f85bcb4d-753d-409b-9767-e4fc28593e50" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:to="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f167e08f-b497-4672-aee3-fe2387dcde4e" xlink:to="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_eaf26aac-ed70-49ac-b262-2dc6a566f771" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_eaf26aac-ed70-49ac-b262-2dc6a566f771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_f55b3925-bcf0-45dc-89f1-8d4cd381366a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5f3498b9-0f18-4fc8-a045-795108d8e23e" xlink:to="loc_srt_RestatementAdjustmentMember_f55b3925-bcf0-45dc-89f1-8d4cd381366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_c14fec2c-2ac2-4084-8471-ef2daa6a24ac" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_927ce25e-052f-4b62-920c-64b91aba912b" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_927ce25e-052f-4b62-920c-64b91aba912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1071ba50-106c-4f95-bcf4-3303c40fe878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLoss_1071ba50-106c-4f95-bcf4-3303c40fe878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18e93703-30ca-4df5-9e98-1e6b8bb4221b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_18e93703-30ca-4df5-9e98-1e6b8bb4221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6818fb78-1aad-45d7-88b9-222d437056fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6818fb78-1aad-45d7-88b9-222d437056fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_12519eb4-3ba4-45fe-8cce-2b44577eb85a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_56f65498-3d5b-4222-aea8-102fc683a700" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_12519eb4-3ba4-45fe-8cce-2b44577eb85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20190930.xsd#AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ea2473a7-fdd7-43d8-a3fb-2f692e0c4037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ea2473a7-fdd7-43d8-a3fb-2f692e0c4037" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:to="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_eddcc76a-97c9-4ce9-a9d3-79c4d5b17db9" xlink:to="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_78d72b8e-c8d1-4716-9e49-01d687c32843" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_78d72b8e-c8d1-4716-9e49-01d687c32843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_8966a5da-dab2-4c02-aa25-78e0aefa3a35" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_f236c3c9-d1cf-43c8-a532-28bfb36f80e8" xlink:to="loc_srt_RestatementAdjustmentMember_8966a5da-dab2-4c02-aa25-78e0aefa3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_031734fc-36b0-4db2-b4dc-4e61f383c042" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_9fb67d2e-aec6-441b-97b5-dc69349c79cf" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_exdx_PreferredStockWarrantLiability_9fb67d2e-aec6-441b-97b5-dc69349c79cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_707dde23-fe61-4ec9-b759-2fe4b9f75e80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_707dde23-fe61-4ec9-b759-2fe4b9f75e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_ba5efd42-ba2e-456d-bcdb-bcf256d38203" xlink:href="exdx-20190930.xsd#exdx_IncreaseDecreaseInFairValueOfFinancialInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments_ba5efd42-ba2e-456d-bcdb-bcf256d38203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PreferredStockWarrantLiability_15aed5d3-a30d-4008-8521-590935aeb012" xlink:href="exdx-20190930.xsd#exdx_PreferredStockWarrantLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_4d11a0a4-c797-4279-8991-9672144cc254" xlink:to="loc_exdx_PreferredStockWarrantLiability_15aed5d3-a30d-4008-8521-590935aeb012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6604640800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2012, the Company's Board of Directors adopted the 2013 Stock Option Plan (the Plan). Pursuant to the Plan, employees, consultants, and directors may be granted either incentive stock options or non-qualified stock options to purchase shares of the Company's common stock. In July 2019, the number of shares reserved for issuance under the Plan was increased from 669,806 to 1,663,681 shares. </span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total of (i) 2,011,832 shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and will initially be reserved for issuance under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be increased annually on the first day of each fiscal year during the term of the 2019 Plan, beginning with the 2020 fiscal year, by an amount equal to 4% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year or such smaller amount as the Board of Directors may determine. As of September&#160;30, 2019, 1,199,631 shares remained available for future awards.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The options generally expire <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzU_c6825e11-0fc3-4e9f-9041-6ef37ef4651d">ten</span> years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODA_bc7e3512-1d71-474f-a1f3-d50463190609">four</span> years from the date of grant.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:45.953216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.011696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">661,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">814,339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(153)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">37.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Outstanding, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.89</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Vested and expected to vest, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.89</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercisable, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30.74&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.56</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:45.953216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">59%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">59%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">2.0%-2.6%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">5.75-6.08</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6.08</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">5.75-6.08</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6.08</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock-based compensation expense recorded related to options granted in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:38.497076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035088%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, total unrecognized compensation cost was $6.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5&#160;years.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 120,000 shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 fiscal year, by an amount equal to 1% of the total number capital stock outstanding on December 31 of the preceding calendar year or such smaller other amount as the Board of Directors may determine. There has been no stock-based compensation expense incurred related to the ESPP for the three and nine months ended September&#160;30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790557968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company leases approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in January 2021, with options to extend the lease for two additional 36-month periods. In addition, the Company also leases approximately 19,500 square feet of office space in Vista, California, under a lease that expires in January 2021 with an option to extend the lease for an additional 24-month period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019 and 2018, rent expense was $0.1 million. For the nine months ended September&#160;30, 2019 and 2018, rent expense was $0.3 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition-related liabilities</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at September&#160;30, 2019 and December 31, 2018.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies ranging from 2.5% to 7.5%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $4.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Licensing Agreements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 3.0% to 20.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Supply Agreement</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2018, the Company entered into a supply agreement with one supplier for reagents which includes a minimum annual purchase commitment of $3.25 million for each of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjEwMDA_c43a2b30-47ae-46c0-8186-19be08bba125">three</span> years covered by the agreement, which terminates in 2021.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation</span></div>The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793369840">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 3,086,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6785933600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember', window );">AVISE CTD Test | Revenue Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6808239904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember', window );">Assets under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804628688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares to be called upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares to be called upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan payable | Capital Royalty Partners II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Term loan, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease', window );">Term loan covenant, interest only milestones, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt', window );">Term loan covenant, minimum issuance of equity securities and subordinated debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Term loan, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund | Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock</a></td>
<td class="nump">3,846,154<span></span>
</td>
<td class="nump">15,384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued to purchase redeemable convertible preferred stock, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares to be called upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Interest Only Milestones, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Issuance of Equity Securities or Subordinated Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736913312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued during period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Common stock options, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board Member | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred with related party (bi-weekly rate)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued during period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Common stock options, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Chief Scientific Officer | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneObligation', window );">Milestone obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=exdx_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=exdx_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736081712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">532,606,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">1,470,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">12,559,492<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">12,559,492<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">750,300,000<span></span>
</td>
<td class="nump">750,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,606,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 163,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795109360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 10,439<span></span>
</td>
<td class="nump">$ 8,223<span></span>
</td>
<td class="nump">$ 30,173<span></span>
</td>
<td class="nump">$ 22,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue (excluding amortization of purchased technology)</a></td>
<td class="nump">4,783<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="nump">14,217<span></span>
</td>
<td class="nump">11,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">7,306<span></span>
</td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">20,787<span></span>
</td>
<td class="nump">14,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,596<span></span>
</td>
<td class="nump">9,356<span></span>
</td>
<td class="nump">36,614<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,157)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
<td class="num">(6,441)<span></span>
</td>
<td class="num">(4,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,141)<span></span>
</td>
<td class="num">(1,756)<span></span>
</td>
<td class="num">(8,630)<span></span>
</td>
<td class="num">(6,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(2,768)<span></span>
</td>
<td class="num">(4,640)<span></span>
</td>
<td class="num">(6,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Deemed dividend recorded in connection with financing transactions</a></td>
<td class="num">(13,601)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,601)<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income (Loss) Available to Common Stockholders, Basic</a></td>
<td class="num">(17,080)<span></span>
</td>
<td class="num">(4,524)<span></span>
</td>
<td class="num">(26,871)<span></span>
</td>
<td class="num">(14,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders (diluted)</a></td>
<td class="num">$ (17,080)<span></span>
</td>
<td class="num">$ (4,524)<span></span>
</td>
<td class="num">$ (26,871)<span></span>
</td>
<td class="num">$ (14,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (USD per share)</a></td>
<td class="num">$ (11.29)<span></span>
</td>
<td class="num">$ (71.80)<span></span>
</td>
<td class="num">$ (48.70)<span></span>
</td>
<td class="num">$ (227.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</a></td>
<td class="nump">1,513,189<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="nump">551,730<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187283-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6783233552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Common or Preferred Stock - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called upon exercise of warrants</a></td>
<td class="nump">512,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">569,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated', window );">Number of warrants unexercised and terminated</a></td>
<td class="nump">9,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=exdx_SeriesDAndSeriesEPreferredStockMember', window );">Series D and Series E redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called upon exercise of warrants</a></td>
<td class="nump">119,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="nump">27,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClassOfWarrantOrRightUnexercisedAndTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Unexercised and Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClassOfWarrantOrRightUnexercisedAndTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=exdx_SeriesDAndSeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=exdx_SeriesDAndSeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001628280-19-014001-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-19-014001-xbrl.zip
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M<\2X\/E0,"]%H/<#XS;\6K_]@&4@CAE.75(\&8&1DD>KR< G2K5GUG\VWK6
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M.<$4K!.2@,Q5E(7DR2GO@J(@C&8!O%L;F!;MSLX)'^H596 ,^JY$:(.P>)F
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M'*-G'X6.6B!: 5:@.L,=<.SV0[[O>RB$8XJ(G1?^<Y.X'Y:!>967 1\\0P>
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MC?%%1#??ISG+Y\T?B&X6P9(5GY70[Z_X;'Y\QJ[QF9"1)%Z/AB&?N<3J!@.
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M0/8]G'V79X3,:)3$.[ A)A#1*;#*)G ^DFQUI-H6]C':YA39AR>(1@40&G6
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M&237#P<CQV9,7])A[[C.2WB<5Q,#8$W4%3/P:EZO?AH+3U$%KRY%!_7  _3
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MT=7@>#UPZ7) MW6NB4HA$A)E$IZMK6OZXI94-M0"J 50"Z 6F&EH$+7 W+3
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MJE22@K.[C.)9>FN1E\C+1O 2#0(4\)46\&D,@GGXP- @:(!!<!G -=YS3K6
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MFP4I%HI@SJI(<X@B<\YE)FP6IN7+WM%1KSNJ64.S\M&\O#0KG= I$:J >4-
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MHRDGZA;4+:A;GH=NF2I[+ L?O4[&QRAHMB932A+-U9]"$D]W*Y?ID\90R\Q
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MIE^_ALXP?^2Z)YUJ2^<SR5Q>\IZ]GVB#ND9U-/92+]P=L9#A6O]J>5;;[HJ
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MV\@Y31%$+%"NLX"$40!8>^X=+[J[!I&/C=QZ57I^/G_M4E))2BI)$? BX$7
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MU'M3'$2KI=X_ETJ95\2_I\M@I^,K?]+A>>B901K-F>^*GIM+S[V9)>TB,)
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M( %Q(PCA/#)'^=:VKE5MN_I@<S'S-PW'%K[7O>#8\G!LQDP/D7(-AB-IE45
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M &!#88Y9T!:4L]1AB(8:[9ESWF(%:;4P^Y,!@()P2T:X&>IOE;!&<XVB X<
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MH3<N+'W4,YW^Z+%>GYK.2=CK[(SJSZ:1>]MK=5SKO%TV,CRY5,G.L9?)2 Y
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MA]:,.]&Z&(D0!%DB+(*<+:\" Z2HUT)IH('0U=CDFQE/*B"WR2"G(UB=J&T
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M:P-;V[1^B=K/LWIMG:"T@-[B02\&B)I8%H-+OT?ME:8X_?01$^ W [J$,E)
M;U6@-Y.UDE23$M$BI8 FT',"*<,5DD:+8((GFH72IZ!L75GQJ#V_DMUU9.,E
MM2AK(FJM-BPR'CR 4MHR&UQB=M(8+[GRA7ZO2Q-=JY%KO4TD(3-O2P("Z@C2
M/D3D@1J2N ,'+[>VR0HTT6:F%M47.@O(+2!)W!'%E;"4"PE":<.YX,Q9)ZS!
M)/I"M]<(<E.ZK;'R5DN&O :%<O\V9+DQ*!"C@HQ$8AT+R-6*7V^(._OYE(^L
M(Y-^J35&P"C0@5#LE0&/@\JM<Y+NX#&!E6>EV^3ZU,IL9;<H5&2,<D1Y- C
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M"T2=O9:4;KEY]5$PO<F12\%\>'X,V7""QUZ<' V;2E5GAN_",4E<[B@%A)J
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MLQ<-!ZL0UU8]2]J=O,TVLW%JWVQ=<9'!_@A&%Z90J@$&FI5R3#>KE//6I2&
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M7X=Q3K_<@=0J2'WZJ$5)HA$,>>4!I#RVR$1GD0(:&:SDVN$GLZTXY4)*T%2
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M\&EA%=-@FL%@FL(#-S%R>N9;I.A#?W[O294, HQ@&L?VR^;*8,: X'/K#XV
MG_O5!#I[&\0':%N!M5L!__D([8UCME<O'S?!NX_X(R\WSJTJ7W3/_2PSA"_^
MR[/70&=,Y5^!.8?QJ5\,_'Y2F)?-6+_(+MWK<0H&34Y?@^\V@2M>P>P8I9&#
MSR^<&X-1^7/AZJW+<L1>U2Y''.^R/?HA+1GT]OI_P3/>B+WM-V+_ #Y__>W3
MA^,W9!^^>W_P[T]GER-VOSKVH;]#]_[XBWXX@/9N?\+P/[%WL,-V_WC;A[;
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M&W!']>+7QP \S''$S@!\MP%8;,?$4AN."4%2IJ6\P!E2S@A$L8K88Z>5U\D
M$+)^:5+OI(K\SX?^ZQ),>QP.'P!5#  ROAA&^)!6#=RP[BKJW.L1^_4Q:??H
MTX0O_LO,GOU>#<S P>"\3+K56;5;6+7E9(,R1LZ8+%%9>HXX(PY9J2F2)BI>
M<D/!L<F'#-8^V>#ZX.&C6EGH8.]',?D.V^X%VQ:,G9>BC-$S1##\PXESR"@+
M_Y2 <S(HI[S9>,Z>4J7XGQW9ND69;W#T*BT,AOI624&ZW%9K:8%N3[Q7 T8[
MK6J\-J=I-U)G?FYN?E9*PEMJ@C>*(AQ] &KM2J14-,@)20U71LI(@5JK\R>3
M?G2X:'U@:PV#0AU8_4BZW('578+54G1;!V>Q]X@2G.KM*H6L9AQI%1FW@0NN
M4E(<^0!1@ ZLUIH//^4(]F@Z=D>F#G7: '\X'/HZ'\6IP_ASY6ZW0ZD+Z3PZ
M&_6]A'HYI/.ZU:@_DC*]&/AWK2IU!NL6!FLEBYN0/.JT%4?IB#AW:3\.%@AC
MXB)W6M*\'T<_ +ON@CL=QCTVC+O+L'6'<7>*<0M2KJ5DOG04F:!I.CT>D2HE
M0V!] N%6>EQBP#C..HQ[*AC7!;"_0=''PU/36SE#O0Y^5A<46H<(=JLC;V<J
MTAF@6QB@E;KPSKN2:HQ8 &K-->=(NY3H0D2P/EY:B=W&<XF[J-"CB@IU:+4.
M(>P.K>X$K99BV,QC(,H<E2+M]U#>(XTQ![KL"+:<&$, K4K<+;@]*K3J8M@W
M(LBN5PU2JZ$!4W]:) W_7$U.U]CGZ>(ZZT.EE^,Z2XFB7K9*]2[I5&>H;F&H
M5BJ\<U9&3C B*;B3-B,B'9E A KNF"I3CL:-YUU8Y^F$=3J(6Q_^W4'<O4'<
M@HL';",Q6"*,4T9=)C!2U OD+2'>4TR5X!O/"5_WTA4=QG6AZ^^5W,N5I,U#
M"VW.&;CKS<(U.%.,4E[NKM+Z$[)2=Q73;LX$A3^3[LRL56>>;F&>5BJD"VR#
MP8X@:R1#W%F*C) N)?DOO=28QT#2=L?S=8*[4-$:AXHZR%J'P'8'67<'64NG
M&1EGSKJ(B% EXHH[9&QI44D%]]H[ ?]L/%?KEWRD0ZPNN/V]DMN?'(5Q8<YG
M+%]C?ZB+^:P?F\YZ=$'LIS-.-S=.R[NQ,2>Z%*Y$0:F ."82&:,I<LQ38JV-
M.IUU%%IVX9ZG$N[IX&W]F'<';W<);PON38UW@6B%<$S[X!3&R"CJ$<%*V:"(
M$C%N/*>X@[<G V]=-/L;^TR^DX0_[92]^":%S;NTOG=3&OYQV/J'R_W>,8#O
MRR5V\&*R6^$OF06\^.BB=ES$@ CE)>*!4J28-XA1QZ(-C&.3=I=N<KY^BP9W
M.<L>)VOHS$UG;GY*<_-PF>8[<_/=YF;OY=S<:*PH5EPA%0E%/'J'@!XP!**T
M@7@:;#IZQ38U?8!MHIVY61=SD]W2?^9RH;.:IO]<J1_<_)T@H!I,\S:CI?JL
MEY1Y;B;G1_Q1T(W+*Z5F<=+SXKCF<*[*X"(I+>1ZKH3M):65]X:34/"MXIY+
M*&\'.]FN:M<;UM/QNM1+)KLS4.N_(1^.?^L#J/ /?^^>O#]^\^7#MN.[7W?8
M^Z\ = ?_.4Y M'OLOIRME_QA^S_]W3_>L[VO1_#^WZJ];6C;U\.ON\?^>.^/
MO\C>W[OBPQ\[ (Z_+]=+%GL'[G3_Q4<%-%@3@5$H%4-<"HJ,I@*5%%R:M/U3
M4][8(U#&X%\D:X(U5U01B26QG)6EU6DC3C"":&*EM6?K*_\V'(]S#>+ZO*8O
MZ_$9K6]D\^V7K39.,R>C5,YJ$GG4RAH+1-]365(3.3E3[OE'3HS\CHNJD%]2
M#1ET6Q8'8=PO_AR:P7D(:-O\J"I8[PR*1070U,'-7+7ZY; /[3LMPI?@II/@
M"U-,4L=[T/'"'(Y#Z*<]E[^D:U>'Y=?BI)H<%3N#P?"SF4SKXL\JAN*=J\+
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MT6VVMGH1\QP>W4B7%OXLT&6E1\;R>58S+L @XWO1U"JGWZ[=X].2 /AO!$J
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MLK,'.;&:&Z] TTF/. \42>\U,GEF@B0BLQ)OO!F=#Y8I,IH:\2?=NQ:^W.7
M%T_8G0T!<HZ.EH99^Q(H;/Z 0>SX<]V+TX)^L7-=D#79[M9!'A2E.<@:1P5(
M&*)SI 7S*,^8\,YFF9!AXPW+%W$&2MO=.DTS+LK-UDY_<LSMV?D?+>#*P2,H
M)*Z"IU0JF@=N%5/2!4)5IBV6#&-[A4*BC4)Z,)%TMPZ,4C90HA .%'@?$X:
M0QTR00?CE*6"Q^F6JIW=7B$]C@:J%!  L$H'7:F"=/_64N@.E-9(H8<2V.[V
MUGGG\(!FN0)R((@1"5((?D2:^("HSZE@6F1: X%1?JT4VFSMS<T=JD[_5%]4
MIE-%5%[;HWI$4>DG<@G(LSPSQ]Z.$@5%SJ\,)MO39W#%[::9K;\CYWWMXQH=
M#;UOI<TK6\ M<?KW:G=, HXQ;-IN#>$=(Q\".O*M<UVV_O=UB1(+ MPPZG*
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M,^6O.J7*I[Q>,]Y6E*)J;S)*=:8EYI9H0W# W(@\M[FC+'N$V0-O=7D4QYO
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MU XCKH- *HB <J9RJ:B5RLD;F6XMA\(V!' C >#=K0/M.9PRSY'-112]% A
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MPOLI7K301BB2V$Z=VO5V4([*AIH2-7VZW 5JDJED)D=*&HTX"1PI)S4*%K/
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MA:9F6Z\*WV&!RYF=A@0+B8;4CFG@V2%U/=>E$0_#8.OU8O6SYSZMM;E=6XP
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M.$DU[138R,L\<_P?5;D"_4S_5=?E)$O1F+G)FGET<I/"QJ/FNLS;!?UGWW3
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MMS"_0H 6OS^K0Z;L9[AH])HGX,6MDH???6HFQ(T4\2)\0N<*POVD;5.J.#+
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M2/QOW&CLKF!<D_( OG91$NO3^U>OW[[Y^=5>\.\G^"!@+JU 9OR16KE)>57
M0Z9=&7UR>#$2,]$>W-.6=.:=]L!Z^32R>'0LH8+N-<NR)IGXKG(Y=0WZ_B:;
M-G/X:O@H^<#38Y9M\\LWPP])Q^!_M8W[7CRN)^OO,>[=Q&'IX9??*Q^RA:M'
M/[N;T;MRD1;W6=3C9_'LVO\[KX*;>^4.QJ!!/AZD,_B4[]+\)EW5W_PY^N)/
MS>9ZO^XV*[NU;I]O'_KN<]N'[K3^[751-9[C\>%%WW,\/CM\\OMZCFA>9\$X
M&]VD P9V&/8T _W6P.OPP^H6G9-ZA H.IZ@F!0CZ>9EG#KR7JER!L4;_K.?9
M<DFK#U?,X?_D^A]Y.H:O3>NZG&0I^C@W63./3'HZQ?%<OP8]LZ#_['TS?<I=
ME.+6;AW?Z>TOW.F-)NDR;O+VHDO5N-.[I-O;;K2AK9W=0>=#L9?3T\/CK=Y!
M;K',RY5#%R0G>?>?!GKB#[#_O8T STG1-V_SAGG0Z1%J*^ 4D],%7DV=YG _
M?//$L75\#+9(,WI-'6M.CGB<.(RS,_S[.J."/.W*+5*8>7B+_R(>J?VJZ(M2
MT.L-+1J8.S-7US!X6,7:5=?9Q-6/8UM&#8!^- V 'M=>_&2?(Y$/-QVI\0CB
M,"F+&O8J7O=[;KQ'(5C==@>O0KN#R[C=P4X+UAM04\'2Z_5T .^T MW5YB!-
M8B"B9FE@JTUHZ;T:2U!(*@=RYOA?&!(LRMBL%&DE9ZR:2N#TZWE86RM<GM_E
M18??9:=EJ<M:8XV")X?G V;UL\/S+30*YO!1(-GP]V*2+='P66"<'RR!MJEA
M@["[M/:\'L'<8^ 5=E9>8L+558L1&--5>4,W5A66HU.Q^;WC6:=AX7<O^1CJ
M\5]B/?[?M![_I:_'?S50C[_36P,MN,E=: CBO7,\D,R\.#L\>]C-PS8P:G&T
M;?GS?- ?/\\?GK@7X(T.;!0\6\ NH5 B_GL)9X:K<#AU4TX^PH[$_=&,\BP=
M9WF&;NKCT/E<$_E*:B)_-C61.RW9O5+/I".ZHTCCGQX?/OOC0VM\DY\473])
MZ_EHG.:P$6F'HL#"T]UJ!!/_T8']#'-;:\;W7K'AWB? ^0+3L *[7O-B6RGG
MFZ7ZI^P?;09^YHH\D^?I$C?$"-P5F,')_;VOTZV2\5] 3M)KLF=:4E6%5$>
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M3H_WLV[_191-%<VL03"+&.YNF2TM-[JK%?JJD),@K8B5*#H T*.)W6IU$RE
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M:L!#WOZ%$QY-1H)(D5D^(1>NF9=-!?+D\RDK27*/,>2*FX8V!U.X-MG!%08
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M9\3+/]:.65$37@CH Y JU!4>-(.(65I_4D@Q8YZP'?6Y-CR"4BO#!9#KZ?1
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M%Z"UIYEJHSPM4,>+IAN$ [EBCJHL=$\UO1?[:;5?!A=2#[W^\@CE2;\Y<@3
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M88R\<"G0N>DCL4IGQUXK!_&S:SQBI2A4C#F]C@XNV,2I.;8B;@!^ESV\_9F
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MCJ[EC=.!INR8%^6U1O)-Y*B')O"1) XU$L5/E)*3SAIRA@]1(=@/[@VZK(9
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M(A!X)NG>A'$!5D5N^(!K2R, &.J-(4)[N)1CXKHB",YARZW&P2+0VPE+V)T
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M?456'PR49Y67_87M941JQ*I%:UH.9/CQ(6(FCSC;%:IW*#N(]D_^E?Q2E/4
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M;=O>RDR>6&HVPPCO9./G]'>Z)+46)74Y2B*?\E[H# B7Z9A!%\[@!ISQ^Q
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M3-$TM*-= 2G!:E#"-'0,=S68TH2LVFY@CQWKA,Z^+D@R6?05?XI%@/SB:0Q
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M,#+JDG]Z$^9J#<X-\X$YSB,:G1!J5=$IB2W/'@'M'H'YDED,FQD2</52Q),
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M,UR=46#:I_<X[<-$2-3/=L&L%LQ'A;862V%*"I*5*\!XAB^PNI @'* Z+UP
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MTT?*Y#CA!'0\/UT<0!4+YKY&JG^E./35?0$RGWPLEU(MZ8I0J/RT$.#"^+S
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M#AU$!<T-C/CANSTW,.G>E::8 5_+_HL=DFM4]DL#)9=2'"K'05%TU3EEM=-
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M5<M8P]G+WJC<O*O!.6>?H-23K'UO67M3G,M]8"@')X[1=V%:T1$"$65# A=
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M\JJ8$)N7]O-*K3@/@<?$B<"SBP#5@4MECKYY:OJ\=<=V) +AU"G1I%XNB'0
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MF7!&;,69P%FX:&)*$-ITU34&9IK:^PQ-3<7 T(;+D58LL^S0/0P/@Q]E?K9
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MAF<.G3ETMG>3YM#9'EJG?9TRA\Y>%#H;.G3FT-GCH[-A.:/KE,*-B,N\+XJ
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M[7E)A]-DOI'_L\Q7T7__/U!+ P04    " "CB6Q/,Q486?@1  !KP0  $0
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MZ]GYCO(0J)MJ=[<-WIB".*]@9,!KR _Q-37#W$RD+=>NBR4A145LC=60H(8
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M,)K/KMY9"(Y0MH+CWVY/OQ39[DR<=M,+Z.:?3U%:\^-)>O6_E\.+8I=^@_G
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MPFAXMCS./;")<L[QB<:H'$T(U;'<ORD(1/2<C "E4Y--RBUHW-()^2H)EEH
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ME$JC7)&#IZ"\;%*$MP%M%:XF+%.\G7[VH\4&$55.2NHLTA(S+NV+?L#6$!5
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MS,M)6B*E2L123@GRZ;D#JL$U\9W6DW-(+?;;F(D*:J@9<A<.K[>YKHA)2:7
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MD.&;LE]5=Y0O 1VRG[[[?U!+ P04    " "CB6Q/JV%Z_!%P  !&FP0 %0
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M08"/(UR1:.(D$0PFB8BZ&.%U*EI+DXK1UD4[ ' 1"B>)2L&93EHQ+XQF3BL
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MIO-!^=5,2T\FMWGC3;8,U3?UAN7H%-- $@N"!T:^K%$!,"O1IMCLJ>4>M>-
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M17 RP3P_&&[Z*4,2T@5ZW1U9.+:FI,X;4UHMT0N$')ID>#T,Z_#>0K]JO)?
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M1O%L!'5Z[.A-!8?H5;;QBO!92I,KS.=#B,/S?7M4[?"4=I>?'5>V<O7I$@0
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MUV2"RR&9\,@A?B@B;"/J)@2 T?0M?*G[W?*$DH$.MJ(<L]'6"4/.,.]485Z
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M,T:3#/]5C"I)J414;5:6K2/OHI$&6?]R(K!V7PB2<,UZM^2S$OS;<M>6_QN
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M\@I0$H+@K:)L%AA]'T_(4"LX6!73D4_)HW#\5,J<5F'H<UIU>LW:"](."L8
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M3'XLYK<CASJ4[-^!=*=L/ :OA&BS\P+O+!.R@1B1P#LM'"$9[;I$UAY%]$.
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M<7%^L53>?V$>Y/%B9+*SK$=+D*'965(:7G.-P%I3=GPS%]1=FBH\#^TUR<S
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M1)K9 <_FJW:A1).^@G;0VW\U+=UUR%FX$)(%KNO&47FA'IV7U@GE)S0.<>A
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M9N&1G=HB'1Z@!01TB( :$IW<EKD\=9HFY:R?I;%MT1D_1I/7K!D^DW,J5C-
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M E)[L%&_*4<%WJP1^ ET&*A=X1H%4,-P!;:!  T28!>**[ &0V5MUF5:%![
MMT?NKS65-A>1R768=+%ZK1G:7Q1?38Z)XQ[7>DK55D]-[(<ZO/M8<-5WB$LV
MJ>YQQ3_C'^G3ZFE!G5B@B+LP$%B=G2F#VA<.C+#'8RX2G[KQ)-&.AH+/;K&5
MHD(A996[ZT984&"5&O'4R#M1 *+I].NMF'.<U)%72@O!AEO)@5OJ7S7>#84
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MX=W7]U^ER=YFSF.7AB1A%#*A:J-S+.12@0/HQ]@-7<>)D$&$P>']YT;SM81
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MD8<A$4Z2^%II]&='FIL)H"0#:X&;0^HZA,[@0*,768VC'UMXC<Q.QU"Z C6
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M(8J0.B87&(8)1@D3G'MF9S,]8\V-<1M1P4<@Q>3\J2[W**?X&R^J5'U^[G0
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MKXJ'9D/_UR_T2O?[*6K'Q*]93DI>?%/.B-J/)O\L5957M>Z*+GA,N#1P19C
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M/A=RJQI"09G:QOH$)I3X,$H<[,4!2[@PZB4R1(BYD:]<CQS#?,8AT.LQZMB
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MR;0 ENFT:9ZHC3@98Q^';<W#1GCUTVXB^*A1<D/Q&R<M0%.&5\H(,$/H=#*
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M85! 2.P<SA@0A<M4P[&B$MOA-ZG/'.[I8V[3N!8S:>1\2)RD%L?$R>HWL?L
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M\]85_WN&P&-S/ JP(U/060J%@]A)([=/\H1[D!V<>SL2PB^597L8TO?DT?8
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M%<VGG&LN62XY8)0(@.P_ (I89O^:4EX@(1GRO^9SK9>Y$4436^G20;25[*W
M=1DSXJJ8946 L7\56X^=40S$QC8+CD!J\;G-$ % !>R)8@ VT8[H,G"1]D.W
M<.C=#5U]>;J]T"WYCW9"-Q\>9D2]_ZXWC\OENDI#55?Z:C[(5!$I"V@M)Z;M
MA@AA 3C/E/TI*PHH4E0P%&)#7>UI;LSH! 5[29MB?F%VTW54_<RF*%B-S(D7
M81K!:+J)14R;Z7IGDYI,-W4^M9ANOQ#N)GFT;2G7WB]+_F5AISUGDBD &>;
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MYO*2IE(KHO*<W5T'O=/AW-BCJ=V]/D@8N1)Z%^Q,0 U3+$ !I84X)SG@M$#
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MB.UEC[<8A.,5D[@#>I^49,-1.27$ 2V$U]YS259M8Q69[J-4FHUUBBE#2D%
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M$Q\$].I[[O7O?WR@)?!MO=F5_ZSLB_>F;MN:(U7KCROE\K17#+1 G+,"B1Q
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M1@ZNP3*]2+*N>Q&\EM7K[G9?YBSL+_;!W?;MJHX0;LI,"Y42:#B 5$J I"9
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M$F C<\H!JZZ8(Y"*!QQ1LS;W=#=MZN;;>I_E;_9X91AA[%TB=:B>2Q2]$*F
MC) 4,.VN$!.9 6%<1!TDEB.43C.A0[RN%_J8FWNU2E!>E9UH_*K6# RCATM
M^M'"G?",3 <'!V@38?N3$S#".;B'^C&G_Z5N)IWV/7J>3O>^1^/69W]O7I?.
M1;I2VX7,F8+2Q8;ES(7/6ABI)MC%BR%#"-4Y# JY]^AS;G;":VVI526JD:]F
MA/H.Z[:L*[4WMUS_XB*]0F^\AMU3#1D[*!77*>$@5X*Y@W]A;;M4 )TB4R@*
M(<(X3@7W@:,W31K'&^/W[V7GVN.49=R[0^6W*$2&?^1%HJ]TNX5Z+_+X-=LO
MX#-%M?9NM[.HTWX!!]\*[9=>';;JO%I_^U;6UU0?5^JH ,DA%T1@+<:@-F<T
M13IR5QG%CZOA=%.*CU A<1!H,>=-F "3SJ!!V)S.I6&-#)M5;[X]+=<_M+;6
MQ_=2ZLO>[G=N2=ON=%V1=_O9[:&Z_^Z2K5AKY+_T[J.6ZR^K*GUY=83WRWK3
M_,H]ERX0UX410@)-J#4M6*$ E;  A.0BS0I.,QA4&W=:\>=F8=;YI];MH9;+
M8Y*LUKODA]Y9BZ15Y<'^[(HFNVW7/W3YY:N[G<.MC<*_Z,0!<\A2'6:@3/SM
M^%'Z?+^("8]'+V3'>DCV2K>GH4Y+^]OZ>_G8^5YJ5:N<.AUEXZT@+S-&,9>@
MB368= U[F=$Y701?2(J!JRC?.'K=MKD,K*"EM&OWZW+Y;*5;% 5)B]PN>S3%
M=MGCJ "TP!0@A126&30<!V4SN='?W-8I%Q:Y=$[13A(NX42NC%=5"YW\]-=/
MKP=G,+DU IZ+1SQ<1V;[5M)##I.'Y.<]I(V\$1G;#YBH%'NCRVDYT4__,Q+S
M?"U2[=Q?RY5^N]/?M@L-L]PPCD N"^FJ8%(@,,' %(A!2+$V61#A7.]J;EQS
MJ3JL$S:II+VWD.X!8<]3VBBXC7U(.Q"R^ZOJGJ$Q:F7=0V\O6UWW3.N;%7;/
MWQA:>K%['?'P,2NA(./,;L9SKBQ=,&NI% (!0P2U)DO.,QI4;OM*/W/CBI,;
MOG<0Q35@_5@B EPC4\0@I 84*>S%(6[MP<M=35Q2L%??\TJ!_8\/XX2_<^<D
MV#7!1Z20J( 8@SS+"A>N 0$O- (%-)@1H6BA:0@3'+4^M_G?"%<E.'VRC7YU
MU_/E^MNW]6K(@=TQDLP0A#(!@8#:(HDR!G@F-& &$I@5]A=*A9VB#L9RFO/2
M%LU[0//CR\% C,R2C5PCA+==U#@F'QYW,"D+7M3ME/LN/W3'/3MQ.Z1?7 GI
M_UOM<EJI-W\\:6E__+QVO^I$^O^]<;,_UE[VCZW_W1EU[M#FF2]=2J!TP3'5
MT*65HYE! '%- <LM^T(FF:6)U) \*%!_/JK-C>MKS2KOB&YT<[3OW(</2:M4
MTFB5[-5*.GHE3K$!]\!F,1XA%\AF(?",>#WFS;/.=_BF\QW^K?H.CZZEQ?@H
MA]U=F]7X1[_T-@_MIK\M-P^]KZSO,Y1PJ%-V]<458_S0["<.P1SUP=-"VZT4
M178CH'F: <00 91D"&"=FDP3AA$+BHR]U>'<%N(/W8U6+>A#L@M>66_B[.N@
MC8?>Z&[:ML[G'L)7'0@_]$=P#'#6^B$3UV5[H\^)';=^")R[;SW?&U1[ZKN+
M.6X8<"%AB@TE!.!4I0"E!@+*,P$HS*711C.EO KT76A[;KS12)=LUC_XTF5;
M29YJ08.J 1VAUT\1=V(R,ANT<'RX%X2@&D=#P9BL:)$?**'%ARZI?:.:T-$K
M4Y8'NB3K2;V?BX],G+-H?W_Y<;M]_E8;<:WM]K?UTC:S+'<_7 ;,14&8%C35
M@$NLK,4$<T -4D# #&+(1)ZE7JGX)Y1Y;N2YWVI^WXLY44*;@'$.\%#,9_3F
M[WHXY'5(.IH_'-P/!^6K5,4S2(03/E2S2(T3(/:_1K*<\'&(ECYG0-<#5S!W
MT/>VJK?V^MGESJB-]*KO=_H?U;]L%[E).4I1!D3&"$ "Y8#K#-M-?(Z)@$PK
MC8+6()]>Y[:*= L]=H])70K1TD72\N5YO;JFVNKSR@[)/S9E==M E5NY?G:[
MULH)L'7W*>N;3"=%6>M+KBPT^YK7D'HN-[$':NP%HQJ06N"DEKAQ#3RTR7VL
MV/4#$:]0!L$4E:R].IZ6;D.P."/,H)<')TT^) -X_,[+I;NY_'G]JIK3E00N
M/XAEE#9\6BBJD+O.3[&[$IX;9*UOHD'&,86DR(6 029XL 1SH\)]2#O?[3:E
M>-Y5=[]WZR->;%1(?FI"W -I+'R8_"AM5/!'IC>'^U'ND&2O@$._5B'IZO 0
M/QI^,("1$RX'"C%UWN5A&%U(OSRPH0'N56MAEG7&GO_-5RG+8(;;P#C-&2,D
M QI3!5#FZ@%2F@.5(I1I*#.B"V]/Z]5NYD9S;423W@N<6(F?77*&E+DDN1D.
M\#Q>1]?#$QL%LY'9Z<T13'N(AA0,O(Y5@,,V"F83^6ZO8!?)AWL3B5YW[O6W
MI_/LWM3@R,E[^^GH63@6F39"IE0"I6EJ*=)@P%.L -2&:*'S7*0RQ$CLZ6MN
M/'F:D$,>W::I=[$XT/SK@]K/T(L$X,BDV9O,9)*T)6.89WW=S24ER363R^>5
MH<ZVIGIS4P&^L=R:I$%M\IX,9;G$10HR B% QOXD)&(@95I3"$UA4ASF;//H
M=6Z4<B@^[A+%=<3^MR8OED]RGSL&P=<]%AG:T=UC$5 =X!T+0"FN=\RGXXF]
M8P%8G'O'0EZ^XT#@J&&W? ?/B[Y&9C4A+LR!REX99R+XP!+=/WR]Q^D=PS>U
MO^@1OOW6 &^'W1ILMWKUZ>UO']Z_>]ML+W6&.#&F $:Z%%W")6V5L@ :(9CR
MW.20>=T%OMK#W!;:1L;DIT;*D#+,%Q'T<&;<B\O(I' &R1 /QD5L IP7]V(T
MD=_"__,)\UCTJ=_KK+CXXG1^BCZYCUP4O0^&L9G2Y<(55]YXKM)GS\]H[E5R
M)4_\B_[S_5_2544/2^RV76.W6O[YR_K[O]MWZN75_G"ZJIZW-\F'=56-]H.Z
M_L P&_"CWFK[TE>7JT=_U\OUDV,2%W^RVNJ%29$0"%-0*'=)WF -*"GL$LFX
MD5(9PY *V9_V]C:WY;(5ML[==1"WNE9IY0V\_]V/M)^Q'0V_D:?V$70=29-&
MU'AVMA<B,<WL_@XGM;*]=#\ULOU>&F!CGR3&KI/*MSFQ%SE54FJ5@I0XEWE1
M6";A"H$T3RG/6&JM;:^PLMM=S8U&FNSZK7@!=F4_HA[&=S2<1J:+\T3X8X$6
M8)5' V\B\WPXB&'FNA<NO79[?PO3&?!>FAQ9\GYOW%GO\IW>O=:;\KO]7KZ[
MH&"]^[7DHHH";DK@J?>K?0$\EVEQ^]?56FSUYKL+&'F[>GJN"N19!.Q+U5?W
M%UZN7%3)VY5</BM7U+M-V+C(-,XD)3E G%" *'5YD(RKI9D;12'E%'M=K'M9
M->9&^A_MA[&O5N@\\*9<<:L(M^.^3VP5:$"^T ?B9YG.?]A'7L.Z145=[-X!
MA*1"(?EIC\.?DA:)9+WJ5""MP'A(NG D-1[),2 /B8.DC0ML87'!Z2TP(Q0Q
M?9&!':4LZK2:O$RAU1<9K:NE6U]&FJ$>D27?N2LZF]V/SQN^VG+I^GN]=FDT
M%A1K6"A(0)XK I"$!C"8*L T8XA(GFJ9A7E$>GJ;WZI6"9M4TB8=<9/?:X$#
MS^?[H?9UB40"<'27R&#L!CA%/#")ZQ3IZW!BIXB'[N=.$9^7!N;):9C.1;/E
MA<**Y!1(@9P7A$C D$8@8X20O$!&"!A2([;3=A!73% ;MBI1D2P/ @9FO>F@
M!@U$2F82%)H+@)C]B7.5@;302AF69P4.NI(X%+4)&#8B:G[T.1"+D<GR5P\
MPO/\G*L:-:5/I_EIL_><ZW66J.?"(^$'CY8977ZQ3S^^B?5R05*C7!4SD,O<
M6"ZS?W!#4R T-5SE##/J%;MXUO+LYF0M7%)+YS<AS^&Z?4X[&(2QO;-^^@<=
MU5[4]8ZCVN/V)CNJO:A&]ZCV\@-#TF%)N7G6JC.17]E'2\F7GW;/ZL<KNW-R
M.8X(T40).PM3E19V>R(H$)G.08I8:E*=(NQ7#B6@S[E-UT;J1#:R)ELG;.(L
MNN_>V6!",/<XB(F/Y,ASO@6Q(_%#TLJ<5$+;O]=BQT<T)%-7=&2GRN 5 ^'
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M)S>]4(QTCG.YSY<ZU>E%H.>,I_^]H:PD]6I;KKX\?MGHNA!/D_-2:E4P1 I
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MJC"S(-@HR1$%KI(XL.NH M1=0I2($$0--EQX^=2OM#^W&5L;ROL;LJ'ELBX
MZ'&>>1\L8^\P*D1:Z>JJ3O<A$I(+Y"YDIDK@$8)08*:-J_KWI\<X?VW"G!97
M93Y.1'']L3#FVFYVBX_ZJ:G&O4\H^<I%CNC-D\N$_<Z.7E/WI9"Y-C+EUNK
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M?Q>]D;SZ#$=9<A?IV8;OHM:BJ#'I>$/:A_,[VNN#&2D*24!.<G-REV/ ,H9
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MQP.K8V#M*.0&N (SA@G\:E6+C&Y>6S&=,]IS,Z8#$6.W8SIGWYF&3&<O"W3
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MC-HKU<::X_ZH5O?<W#BP2KT3;3+N9_V7NCK;?\Z78E9D!<XH*P!!"NLE#T<
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M1X#E"0=Y&K.4I)@ISEU(Q4+FU!BFHVFT4W5@QS,;R.U(Q#.0@1EE((;.'.*
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MEYA_W>KF7N8VG*W)I.+FG4/H_?\]#TOZQ-FW=_AYL5Q/"CHKBLZ DI2FG$Q
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MFW1POII(;Y@@/P:"2A0C.U)IK%<\F'%.)4^.;BK#'9'?2<-^ .D^=SF @+L
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M5/&.^XXMO*5Q@_Q&UNA$B?<0Z2WF'S_@\NP5QO65G 5+WCGG+<6K4H!*F=:
M\0@4Q28C,K>E-#DBO9N<;G:RAA[VZ7H8>U-[>_'0C8C^%I:U2_N%\+Y-!"T,
M%*G>%'>T,.A;6G$DHBP,=XGID/)^F]C#S^EFTQH>*T-+N8,MZ]7NL;51^QE^
M"%^O"+ >NP0LD63A01GA*OXMT,Y+.[#V,@@RL5$TB<L>H:N;S:R=01I2,QT
M;9.:O\K"=QN;G>$E6@^1%D>-0#VX+"488L='RV3432HX[B=IW.SWD\!K('UT
M@*PK3$PB1^4EUU"R(.M;._B&2 ZE"MY;K9W6=UT1']3='F?,RUC9R(,DWH&[
M76^43-=GFPK+>7ZYF-?V"#A/E147<Q B"R"GSQ(#(D!,-D%1BKS 8(*\Z^[P
M %6O]],TSA28)P734!KIP!(]("%O61#%:<C%U<[2FH)<%^O87RETDK9H;.)'
MG7@R-_@UY">%UD#ZZ !9UX..;45XBIB\5Q:R*?7J)$4:H4Z,-M$PGX/GRC5)
M+=U!R]AWA(91\^VBUY-DW@%LKMR?W-(O12Y!*0W!Y !*4X@:/!8H485:F<F$
M;^)JWR1D[+* )H Y2=H=H.5%SIO*B#![&Z84=[X,GZ?D=TUX+8+(D: >:X*6
MI0@Q.PDHHM+")+RS+]< !VMWTS-N@JD1=H:0?0<0>H?K,)UC_CDLY^3&K5ZD
M='YV/@MKS*^P3--T/7'&1A/KU!T6"BAGB2/K-7"RH8[;I'5I$J(]3MJX2:5&
MP!I8(QU@[+:@)A1L,FXS0JQB485)XD5*$,KSPC,:VJ.?QKL>-W/4"$,G2KR#
ML/^Q<(.V:LEUHDC31DUK('D!468##K7@4:82\8[.'>WK*,<9W3A6-NETW72
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MA]U!]MYP*#*T1I0,6=5.M$;0&@R,6'-9:6.,#,FU1V:?X>J3(N9!M ZBONY
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MC;39;W+@LDIZ3^'Z.FLW20LB*@-*.0/1UP:^2M:486&\S5CE8<@?UX-XFN1
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MX.:B4T=$)+=; [?!UZ-YBMM9Y,!3X@D#K4C6I.+L,<+&38@."X-',7:"3CK
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M6))O7\.R];?+2I6<K>,*M*-@4(7 P15:B3JC9!&5TC?G -USJOO@8T9.R[1
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M[EZ1_66Y6*TF*6K.>2Y0\WADL2TM5(<9>-(NN,(EOWG,V]B^;<@:U[8U1MF
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M00R^6"<L5Z[)%8J[R>GZB/L07=^Q(9XJ_;$SKSL6=B*:?]SV?MHQPC K34Q
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M)KICD<R61&(7UJ)J> -VP8+S#I+T>Y)' NE/</5NX=S&EJ\=_G;FG(H8"R,
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M5XK=[H/%!K';?63<T8MYC3EASBE9$\#;5)MMUI9(/DNP/BFZIKC-T?]/['8
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MF.AGD7%Q*JN@TQ!P*ZM@']8?:17\-LV[A-PV/ZA_1#H*__M__7]02P,$%
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M]A7@.8#SQ=XMX^/+N+_7@*AB/Y=?,KRWA,] \J47:OVC_-HB4\]OXE-Q;5O
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M[#G@=L?<=VJR_X,06[-Y4XB97.":<^/VDIA?_]&)> ]\L+BJ0A+03F+$8<[
M":DMF%")9H(J11CHB)4I/!9%R!B%\_7Z^01+%!*@SP2_I?JZ C9>J_<=>@V?
MT30%*I"T* 2!I(<T22X8E1,K8-<+#8&HDEK5)$%Y!BU:5R*5HXM0DA0W!]&B
M*&3T8%QI76("UL7%W8>Y3%E<?9AB49:+C$NRH>K:^(G*:EFKRG6I:49!+9F'
M7T!F86E*<4A3JN96,@: V!'+H*RP6JM-]GPS R2%NNH6<5!;F*\0P,>")$00
M%ND>H#"%,!B(C1%@CHB'5GQ3OKJF_*,-)G<1R98FPJ*KH62O4DQA>TRE$OI6
M1M?XC$VZ!+YB@=2$TWMF_%R1#N;15 M;@J18Y]/5SR.V?C6Q)@&'L+7-%6DO
M%C;OT5]:+)[VFP[S=<GI/U!+ 0(4 Q0    ( *.);$_+;!1T#OT" "KF'P 1
M              "  0    !E>&1X+3(P,3DP.3,P+FAT;5!+ 0(4 Q0    (
M *.);$\S%1A9^!$  &O!   1              "  3W] @!E>&1X+3(P,3DP
M.3,P+GAS9%!+ 0(4 Q0    ( *.);$\-#338Y!@  ''W   5
M  "  60/ P!E>&1X+3(P,3DP.3,P7V-A;"YX;6Q02P$"% ,4    " "CB6Q/
MJV%Z_!%P  !&FP0 %0              @ %[* , 97AD>"TR,#$Y,#DS,%]D
M968N>&UL4$L! A0#%     @ HXEL3U=IF6J&YP  9<<) !4
M ( !OY@# &5X9'@M,C Q.3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( *.);$^P
MR@&N.)   !"6!@ 5              "  7B ! !E>&1X+3(P,3DP.3,P7W!R
M92YX;6Q02P$"% ,4    " "CB6Q/@AY40WH(  "<-0  $
M@ 'C$ 4 >&=N,S$Q+3DS,#$Y+FAT;5!+ 0(4 Q0    ( *.);$]Z5W3Q8 @
M %\U   0              "  8L9!0!X9VXS,3(M.3,P,3DN:'1M4$L! A0#
M%     @ HXEL3TK&-)^;!@  N"(  !               ( !&2(% 'AG;C,R
A,2TY,S Q.2YH=&U02P4&      D "0!$ @  XB@%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786121808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements- Fair value level 3 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Remeasurement of financial instruments</a></td>
<td class="num">(267)<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Net exercise of preferred stock warrants</a></td>
<td class="num">(510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3', window );">Reclassification of liability classified warrants to stockholders' equity (deficit)</a></td>
<td class="num">(726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset) out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736916624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2018 (in Shares)</a></td>
<td class="nump">661,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in Shares)</a></td>
<td class="nump">814,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in Shares)</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in Shares)</a></td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in Shares)</a></td>
<td class="num">(153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, September 30, 2019 (in Shares)</a></td>
<td class="nump">1,475,006<span></span>
</td>
<td class="nump">661,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2018, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">13.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 8.26<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
<td class="text">9 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 10,993<span></span>
</td>
<td class="nump">$ 6,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">10,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, September 30, 2019 (in Shares)</a></td>
<td class="nump">1,475,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 8.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, September 30, 2019 (in Shares)</a></td>
<td class="nump">20,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercised, September 30, 2019, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 30.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>258</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003003 - Statement - Unaudited Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofOperations</Role>
      <ShortName>Unaudited Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004004 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1006005 - Statement - Unaudited Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedStatementsofCashFlows</Role>
      <ShortName>Unaudited Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1105101 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1402401 - Statement - Condensed Balance Sheets - (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets - (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101102 - Disclosure - Organization - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/OrganizationNotes</Role>
      <ShortName>Organization - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103103 - Disclosure - Summary Of Significant Accounting Policies - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary Of Significant Accounting Policies - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Other Financial Information - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNotes</Role>
      <ShortName>Other Financial Information - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Borrowings - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNotes</Role>
      <ShortName>Borrowings - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes</Role>
      <ShortName>Warrants to Purchase Common or Preferred Stock - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Commitment and Contingencies - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNotes</Role>
      <ShortName>Commitment and Contingencies - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Fair Value Measurements - (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsNotes</Role>
      <ShortName>Fair Value Measurements - (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141112 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143113 - Disclosure - Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018</Role>
      <ShortName>Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary Of Significant Accounting Policies - Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies - Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary Of Significant Accounting Policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary Of Significant Accounting Policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Other Financial Information - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformationNotes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Borrowings - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/BorrowingsNotes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables</Role>
      <ShortName>Warrants to Purchase Common or Preferred Stock - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Fair Value Measures and Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables</Role>
      <ShortName>Fair Value Measures and Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Accounting Changes and Error Corrections (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables</Role>
      <ShortName>Accounting Changes and Error Corrections (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Organization - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OrganizationNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary Of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Summary Of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414409 - Disclosure - Other Financial Information - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415410 - Disclosure - Other Financial Information - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails</Role>
      <ShortName>Other Financial Information - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416411 - Disclosure - Other Financial Information - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Borrowings - Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails</Role>
      <ShortName>Borrowings - Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Warrants to Purchase Common or Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails</Role>
      <ShortName>Warrants to Purchase Common or Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails</Role>
      <ShortName>Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Fair Value Measurements - Fair value measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails</Role>
      <ShortName>Fair Value Measurements - Fair value measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - Fair Value Measurements- Fair value level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details</Role>
      <ShortName>Fair Value Measurements- Fair value level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/RedeemableConvertiblePreferredStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Stockholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDeficitDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/RelatedParties</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Accounting Changes and Error Corrections - Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails</Role>
      <ShortName>Accounting Changes and Error Corrections - Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Accounting Changes and Error Corrections - Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails</Role>
      <ShortName>Accounting Changes and Error Corrections - Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Accounting Changes and Error Corrections - Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails</Role>
      <ShortName>Accounting Changes and Error Corrections - Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exdx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - exdx-20190930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - exdx-20190930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exdx-20190930.htm">exdx-20190930.htm</File>
    <File>exdx-20190930.xsd</File>
    <File>exdx-20190930_cal.xml</File>
    <File>exdx-20190930_def.xml</File>
    <File>exdx-20190930_lab.xml</File>
    <File>exdx-20190930_pre.xml</File>
    <File>xgn311-93019.htm</File>
    <File>xgn312-93019.htm</File>
    <File>xgn321-93019.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786123488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">10,439<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
<td class="nump">30,173<span></span>
</td>
<td class="nump">22,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of changes in accounting principle related to revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of changes in accounting principle related to revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790595824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures and Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.970760%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.385965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Financial Instruments Measured on Recurring Basis, Level 3 Hierarchy</a></td>
<td class="text"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes a roll-forward of the financial instruments measured on a recurring basis and classified within Level&#160;3 of the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:82.941520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liability<br/>Classified<br/>Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(267)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(510)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of liability classified warrants to stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(726)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6785154480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:51.147877%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:69.491228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes the Company's revenues as disaggregated by payer category (in&#160;thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:43.374449%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">17,716&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">15,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Government</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Client</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Janssen (SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,799&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt;">Includes patient self-pay that is immaterial</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:71.099415%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:71.099415%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:35.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,202,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,202,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">203,549&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">203,549&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">934,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">934,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">69,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">69,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,936,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,411,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,936,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,411,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803950880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803751520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">461,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">282,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">74,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep82024Member', window );">Warrant expiration September 8, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, shares</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep82024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep82024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6806862672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,667,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,500,000<span></span>
</td>
<td class="nump">750,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversion', window );">Temporary Equity, Shares Redeemed upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,573,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividend', window );">Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Beneficial conversion feature, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction', window );">Number of shares sold, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,282,048<span></span>
</td>
<td class="nump">9,615,384<span></span>
</td>
<td class="nump">88,030,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction', window );">Proceeds from sale of temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityRightsForMandatoryPurchase', window );">Right to require mandatory purchase, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,051,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase', window );">Consideration to be received under mandatory purchase, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversion', window );">Temporary Equity, Shares Redeemed upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,928,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction', window );">Number of shares sold, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,914,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,246,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction', window );">Proceeds from sale of temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividend', window );">Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,967,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction', window );">Number of shares sold, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,446,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction', window );">Proceeds from sale of temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesIssuedUponConversion', window );">Shares issued upon conversion, temporary equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,521,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Beneficial conversion feature, temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Number of Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Consideration to be Received Under Mandatory Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityRightsForMandatoryPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Rights for Mandatory Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityRightsForMandatoryPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Issued upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesRedeemedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Redeemed upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesRedeemedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790625280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Common or Preferred Stock - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following warrants to purchase common stock were outstanding as of September&#160;30, 2019:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.532164%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888889%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">282,402</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">74,018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">131</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">83,778</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.32</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2024</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,944</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.32</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1) Prior to the conversion upon IPO, the remaining warrants were for the purchase of Series F redeemable convertible preferred stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790758864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The carrying value of the Company's cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 1 -&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 2 -&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 3 -&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying condensed balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Payers are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payer (i.e. each individual third-party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Collection of the Company's net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Codification (ASC) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span> (Topic 606) as of January&#160;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Cost</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Advertising and Marketing Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million for the three months ended September&#160;30, 2019 and 2018, and $1.1 million for the nine months ended September&#160;30, 2019 and 2018, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting </span></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">period) on a straight-line basis. The fair value of stock options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div>Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and options outstanding under the Company's stock option plans. For the three and nine months ended September&#160;30, 2019 and 2018, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Reporting</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Leases&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases: Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement: Disclosure Framework--Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&#160;2018-13 on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786509968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,828<span></span>
</td>
<td class="nump">$ 13,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,194<span></span>
</td>
<td class="nump">$ 152,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering</a></td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering</a></td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>exdx-20190930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exdx="http://www.exagen.com/20190930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20190930.xsd" xlink:type="simple"/>
    <context id="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i698b14fde74d48c986bc7722d2a47d8e_I20191108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-11-08</instant>
        </period>
    </context>
    <context id="i9e798451cd564d85a050ce8581db466a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib1618f264237473e8438081b30871740_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8d776fef836147e8aa9fca48608805fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i51e871fb34404f9181118c3f2d995264_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia29630b56e3742939a0bdba1189a6cbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4a482197c34d44c3ae90623f48d4b912_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9b5aac5ad5ae438abb53532ed876958a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i64c8f49f4ea54bc58629c4cf906e85ac_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i594311f90cd64628a3d0aa29e07f0898_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i20a1c50a126f4905ba75a973e1a3e682_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8e681c5c446e4f03a7abffd537dd5352_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3229df7dacf74fca997f4b0f45d5bb9b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia414d6d243b647818871ad407f657257_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i23ae889f40dd442a96d1fcd4f3335f02_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i822fcb2995c1470cb62140417fcb6f90_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iececa9bd8c374f448e2c8c12d96a1d37_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i25e5197af80646e69a15779b9738a368_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i21b9dac09b37446fb247a953a02f8cfd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1a5c654aa4fe4cd2af17f3785df2fe7b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4f4bdb7e8bdd41f98f110e1f34540e3e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i15c321aea67a4b76bb1d06797b32516f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i355fab1a4851405d964d3ce01c25e0cb_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i40961c268efa4e669f1ab85e0e151e85_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5e60ced97b104c0abfde5ea44bf688d1_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i7b4c6d0140a2430f9e5cc852e998ada7_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ice03cdba22334e48a533d94a025d010e_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ibdf8495c14984c22b8ce5f6c41ee86e8_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2ad03575f3844523a836225bd6a1ff75_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="id0f39641f06e425987e31b75e8435957_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i5dd86c6fc3a247958775687c6c9081f7_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i15803c46e4214e129bb899b341202df8_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i0ce8694d9ba647108d4ea5ab8b905c1b_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i337919a6832e4104bc0864899a13424e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i8f88d3ad0c564ab193266b222933588d_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ic9a450e5a552453fa6bac61e4872ceba_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ifee63a714e044b14bee48842ecfb743b_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iae2f6600a9cd41b7908364073cd2f4b1_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="idcd81548cfe74374b9b0ab13f94caa0a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i5d80c008209c426a814d7dd70f19e32f_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i30025f8cbc5f45baa8876d50bde62fe7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-23</startDate>
            <endDate>2019-09-23</endDate>
        </period>
    </context>
    <context id="i2cdf719c7a7e4723b6692faeb9eec292_I20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-23</instant>
        </period>
    </context>
    <context id="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-23</startDate>
            <endDate>2019-09-23</endDate>
        </period>
    </context>
    <context id="i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9cfb3b43b3d643db9c0aa9a4cf494dc2_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i1f0a93f41a20455ebdd1ecf05f3d71f1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5f42ba8fdddf43508fe432039d3bea83_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i3a5a1b65ea2e4772af6730adb19a219b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id6c397043b0a4757a1ab205b9203c35c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie6bf1ae302d841fc97de1f33e7991b73_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i84325f36965b4db489f07aff6f65377b_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i48533d3983e8456cbeabafad30dbeb68_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie9910315e8ba4f9ebdbc616cfe66741f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8d86bef637f5439da150d6607648998b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iec2569645c6b438594320c445bd2f7df_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i42b6a2a4f7464d0c962375e478a9a57f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9f4b9180e4b54309b12c8bde22fbd406_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idbf3daa4d6ce48df96adce7481138367_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife08467e105c4ca290a3a0fa3636d3ea_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i412a4bc0981e429bb2c3c5e64c8588b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4fe4f91b3fec4fef9d89209d8df0145a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2bb9a3f35ed44889b3becb647aad758d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc18586b25674689a55653cbc6ba01fd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4a849e120d8a4d0e8a2192315f7f1d31_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icab7fdcf6ea44e4196147db770e82818_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6bfbb7c25a64494dbfebb530261307a8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5ead417360294b46b273d3316cc3ac11_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0e2db87ab7524a10b5714856382436dc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i82e71d7bdf8b4e58ab63f9e4492e3a24_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if7491bc1715c402c87c11f837d462f25_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d50576626ca4bb09058ce09556f99f6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iac7d07ac43134c56bd65c32a20842780_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b3c7dcf56ca41a4b105284483e7e373_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i117917342465407baf079c005b0dfcb3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0986e73045a14160ba73146b0023d069_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5a60fb4a5d5d4f5289b1f4c0113fe3e8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i21d1f81cc6e84b5494d096638cfd9d83_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i24e975d35170436cab761c1a79d6a68f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i92d1b13bd06f4289b57c9968d5a5034f_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia9d710d634904421a501a1631a9070fa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie7e26ceee4414fc2ab3a53e749e41b4a_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i35ae2ebb8e184bd395a0b6b0997eb389_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iebc7396f4e6249ecafc16cddc8b813e2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i05cd8526aa4f4a2897a2f2d8cdd90fa4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9774db8f05cb4b99b9d4806cbefe7bbe_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i0717d7c677d6448da99afc8400886103_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2036583b6802432094a2445756a97d97_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3c0d3ee1297444fc9aa08f456ef2c9c7_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50eedc9033db402abed9620d44e35700_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6c30c3ce04a84e4d874b74595bca6d56_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9c143e96ac9b4806bef7c462dd041d9e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i199eae29222f49ccbbc2f5f8369952de_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ic77e882cd1974313a78b7279282ccfd2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i717f3fbc203143a2b2caad2a58d2a79d_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i4c29ece949cf4a19a46b6de69ea06eb8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i67896f9ab6ed4543aecbdd23e5c897fc_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ica3ed9cee3e94243840bca963f193791_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1c087d67dc248d6a8b02fc4a43f742c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia6060eadd8f24bc1be3eb453cc22ca19_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8542a7dabeb54160bf0ca8be742e9212_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i349270c037f94e44af2351837279531e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1efe7f934c0047d1bd2ce2d9c861261e_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5fbce37a02d245539b9bcdbbdeea57b7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0f1132f9c16d4dc1af50508da38762d4_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exdx:WarrantsTemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i260086f6c68e4de8b8f8f51fc380212a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iec80ab26441a4e79a659a24f2e383d48_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i621ecaf0fe824109be7c5edd830fcf40_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85a81e346b614153977eb22e41d41635_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i25ef04b2fcfa49d582c1daa128336b09_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i705ad45db6ea4e2195c730551dac08dc_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ife9c9599bc1a428cac54f6b6233b42a7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib99b30654d864c038634ae1e2765c0e4_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i40e030b64dea4330b9962390e9b32038_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i167c8bf3e14242d4b6b0b5533837f6e1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice1fa1729eb34b299178d8caf2161699_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i321e9cae976c4953b8b700e620bfb3ce_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i69188b3f953943e8857feda39af6a513_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i879c70b4b5494742ae2de43311dee3aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib83471b6a9094305b6ad8430295ff5cc_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7547ba12aab74508ae6730cee6b11777_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3f8b0aeca3d46d185477b020a4cad1f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6c9982c73979435b8b18653fef66b69e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie67a92bb4ee44f42b31178b35355abc0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i52ca50f81cf04570bc17e8f427844a2e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia55d1a24be2548af9b0dd677741eb14f_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ie724734be96b41eb9f3acb00203b7563_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i784c198f85794d068e262abe227f7399_D20181207-20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-07</startDate>
            <endDate>2018-12-07</endDate>
        </period>
    </context>
    <context id="ida1326b9e5734d61880de0e289e849bb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id19b52fc68724d4c9866d0bbfa02eb24_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i593387046d9c4d19baf524fd531f341c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic84146f62f914258a7de7f505ec8dae3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9f42b4e0da004e11a3d759fb51a524c2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="if57cc12cbbd74a1ca2bdcab1be975050_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="id95d3234e4504a759f6d486b2d115f8d_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i4f9edfc62e2b4d1bad85e451eacf5407_I20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-07</instant>
        </period>
    </context>
    <context id="iece3f21b80234006a7c103426a2665ce_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia15176551c5942c6996c700737062eb7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">exdx:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7d71efa9a85b42ea9b589b656b2491e8_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">exdx:SeriesDAndSeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id6b232544b0e4c3982a50c01fa3beedd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia072d734c1074dffafc2727ff7d43637_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icbbd59a27b684af7ad1433a642355d7b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if49e177a5bc240e58f5c1feec55322b0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep82024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2dbe833388254c769b6515006ac2d21a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0b712c3e3658431f99e266dbcbea25a3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i049fe228926f4c9398df1295ac08300c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib88479b12a8647d596f63546f0bbdd6e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icba0cb4c451d417dbe3f4f8dfab39b44_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7ec9d6e18a8246b99def6548100abbca_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i97157708442344caa00fafca0fbb5704_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9cdbf37439b04f6980d34a5eb0f08877_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4d2cf5de0966423685b89de08ef5d10f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9aeb522a5a804c1ab10f04b766c6d235_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if8cdfd7d55d447c6a6ba587c0fb72778_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia8396f778183403a8b3d18137e1d7154_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia5b7d6be4807402181770f969bd3b3c8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9cc77115ea38400ebaa8de4fdf3c7cd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib1c4da20970f49bab695c3ca35f9f79a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i202d9a2d99d343aeb330da6b95303d98_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i578d8c5006254318b4ecbd98581f9308_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib206ca9a730640ff880db0ca2948c48f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i48be9f8c11ab46a0a2b04915df9f4383_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ife24fcb5063e4bf2a8ca790bfd29a229_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i08cb01ea319e4dcf9a9ae2d18095b29c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib871a4638845441c862fde06e4cc74f2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab6de603a8d9482782ee114aee3bf819_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i18c74d0be6304b29b0107390ce9abeec_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i51991cbb9983403c883bb01e0ecacfe4_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="if76ec7383c01495aa62e382bd4f709f7_I20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="i6ac11f467d4a414d8b4dc99e134c6b38_I20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="i9f3012c64b3841629d97963b5c65859a_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ibd111bb967164dd1b749064f44fe4ace_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6821094327564f7ba91627dc90eeb669_D20180131-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-31</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="id07edc4e5b92475b8e47bad4f0b1c23f_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i8b4fe828275f44fdbff0acdc8da1a56f_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3ecfcc3c27f94cccbdb02d3266aed9c6_D20180101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i34cec7509c0b444690051ce059a40fc2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i3a943c5b22a147a0a01ed7c2ddc3799b_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i74d7a070fb6e417cbecca982fcd80243_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i1936657650f8443fb7d623789b65864b_I20190923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-09-23</instant>
        </period>
    </context>
    <context id="i6966cf5374bc41b5875121d7c8d99c81_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:StockOptionPlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ief83568c465c465ab430cf56fab8b518_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:StockOptionPlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="ie73e694807f84cd394cbd47d74001ce4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iae39458ccf0d427992cbe4b9527b3bf2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iebae713e20d543688dfbdbe7e08cf864_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c5dcfbeb31e4eb58cbd0c160cec9a94_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if0c70eba81b941949fd1d670216abba6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2ecd63e9c5f4460db504293975df2da0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icda4e23b775541d98dd6601b0687861c_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8317e42cca1547e9993f03b3818b96f3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i23dea42dd5f74d579f2d9bf2d1dd0899_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie58c1033dd94444781da3f845ffefc22_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icefda7fbf4b24e1c95147ec5fc5fbd6a_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6c606ae405a1436dae303d8eb1512adc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99104c1c22ba4f62b010859df135eb14_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i39b3ab090ddd4194a42e7530e862e17f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i156a4580a77d4e07840641d780bf4cf0_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6c0fd8531c4e483bb241496bd66cde52_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib98b0d24446a4951aa7a1010ab0bfe0a_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i029c39ddb96e43e7add282e21e47eeb1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i88c8b9c0ae1445a795a53d86906d1dc1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide5daf739bda4ce99c2faed14eefff7e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5649d541959437c953f9b7daa0a171d_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i23243689232c443f8220af8eb34ad150_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i61985dc8dff1424b8c09ade62daae302_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i92647d4518404696ab919e985542dc23_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2c33b5d4543e4472a07114c686f5e1ba_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">exdx:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if36ac713957946c8b6ec9a842cee9f1b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idcaca6cf8313483db51df9c1afdb0e41_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0bb1b252737849b5896adb5e69e39207_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i050d48ebbcd24210b1475a4d33bb14c6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6525292a42e544c98b6b7fe58ef7a0b2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i84f237a8b0314f22ba9545b209899f19_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="leaseextention">
        <measure>exdx:leaseExtention</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzMtMS0xLTEtMTAzODc_6c71be27-2680-4eb5-8a0a-c175a9ee488c">0001274737</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzQtMS0xLTEtMTA0MDM_bba7ce84-9a5c-4074-a7a2-3110169862a7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzUtMS0xLTEtMTA0MDU_01c9fe00-d15f-437f-b71c-b3bd1f5b7197">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzYtMS0xLTEtMTA0MDc_85206b4e-e8eb-41e9-a62a-db846ae997a3">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84NzUvZnJhZzozMGY1OGE3MTNiMzQ0ZTBlOTI5YjNhYzdmYWMzNTBmYy90YWJsZTo4NWM3Y2E4YmVhMWE0YTE2YmY5OTlmYTk0YmQ3NWI4ZS90YWJsZXJhbmdlOjg1YzdjYThiZWExYTRhMTZiZjk5OWZhOTRiZDc1YjhlXzctMS0xLTEtMTA0MDk_770a3f70-a30e-4a23-8428-811181de1fbc">false</dei:AmendmentFlag>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjEwMDA_c43a2b30-47ae-46c0-8186-19be08bba125">P3Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzU_c6825e11-0fc3-4e9f-9041-6ef37ef4651d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifebcb2cbe0d04f2e9d24608c4f64a7c8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODA_bc7e3512-1d71-474f-a1f3-d50463190609">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i92647d4518404696ab919e985542dc23_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NDg_b98a8d34-8542-45c3-b460-7428b1e5f9cc">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8xMzc0Mzg5NTM2MzU3Mw_a62eb45b-a768-45cb-808f-7969cadef007">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8xLTAtMS0xLTEwNDI4_bb7f4575-6214-424b-be6b-76fedfe28d92">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8yLTAtMS0xLTEyODA2L3RleHRyZWdpb246YmFkNTVmYjk2YjM3NDJmNDhkZTRmYzM2ZjgwZWVhMzlfNjA0NzMxMzk1MjgwMw_ca5f8fee-1a39-4b6d-929e-bf2ab84140f3">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6N2FhZWFiNjYxOTVjNDQ5YzliZWM0MTc5NTA1YmE4MmEvdGFibGVyYW5nZTo3YWFlYWI2NjE5NWM0NDljOWJlYzQxNzk1MDViYTgyYV8zLTAtMS0xLTEyODE1_9c0a2a14-fcf2-4d45-ae2d-fc308bbba25a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzM2_55ca7dbd-0042-4b09-be0e-4fd0eb700bfb">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzI1_d915f38d-b123-4eb7-97ab-ecc87a8027da">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8wLTAtMS0xLTEyOTEz_64febce5-29be-413d-8aa0-81156c67853a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8wLTYtMS0xLTEyOTE1_58ebcf91-110c-40ba-9b5c-2f5b1cdac513">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8zLTEtMS0xLTEyOTE5_23862ce3-e889-4c21-912f-cdc267de4a76">1261 Liberty Way,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF8zLTItMS0xLTEyOTIx_4c9b52b8-974c-44c4-8ba9-bad22e727a3b">Suite C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTEtMS0xLTEyOTIz_d7fe719b-db04-418b-91db-77a3333557cf">Vista</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTItMS0xLTEyOTI1_5c7d9cd7-c36f-4ca6-9f5b-30a1dd2d7605">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6OGQwMzZkOTEzZjBkNDZlYzljYTc1M2U0MWM3MWUzNzQvdGFibGVyYW5nZTo4ZDAzNmQ5MTNmMGQ0NmVjOWNhNzUzZTQxYzcxZTM3NF80LTYtMS0xLTEyOTE3_d818aa6a-7b47-48c5-98f8-082620d004f1">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6YzUyMDUxMWRjZTJlNDVlYjgyMTgxZjNkYzUyNDE5NWIvdGFibGVyYW5nZTpjNTIwNTExZGNlMmU0NWViODIxODFmM2RjNTI0MTk1Yl8wLTAtMS0xLTEyODk2_5d121edd-c9a7-4c28-8258-41c1bcd0c0c2">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6YzUyMDUxMWRjZTJlNDVlYjgyMTgxZjNkYzUyNDE5NWIvdGFibGVyYW5nZTpjNTIwNTExZGNlMmU0NWViODIxODFmM2RjNTI0MTk1Yl8wLTEtMS0xLTEyODk4_9675ac26-2219-4d6d-a8ce-6aa6dcfe495f">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTAtMS0xLTExMjM5_608ad7a5-6913-4335-8cdf-054f4837e12c">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTItMS0xLTExMjQy_22438200-b287-41eb-9f15-78e5843bf9e8">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6MTM1ZmVmYWY3ZTYzNDRjN2EyYzJhN2VkNDljNDFmMDYvdGFibGVyYW5nZToxMzVmZWZhZjdlNjM0NGM3YTJjMmE3ZWQ0OWM0MWYwNl8xLTQtMS0xLTExMjQ0_0e265523-cb3e-417d-bc9d-e82bc6c55825">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODgy_271fdced-9585-44c3-9d37-932628115452">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODg3_6f788aee-053b-4799-bdb1-99fdcfd43cce">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF8yLTAtMS0xLTExMjQ2_ff25061b-d9ee-42e1-806e-06ae402479c4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF8yLTQtMS0xLTExMjQ5_00bbb45d-5c68-4efc-922c-45e36f9dd6f7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGFibGU6NjkwZmMzMDZlMjczNGE5OThjNTUxZGJjNzQyNmM4YzAvdGFibGVyYW5nZTo2OTBmYzMwNmUyNzM0YTk5OGM1NTFkYmM3NDI2YzhjMF80LTQtMS0xLTExMjUx_d074640a-508e-46aa-90e9-ad63399a9034">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5NzYx_4bc867c1-4b96-4a5e-9ab0-c5140a432cfd">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5ODc5_9301bfcb-2bf1-4fb7-9cbf-6b1d93320443">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i698b14fde74d48c986bc7722d2a47d8e_I20191108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8xL2ZyYWc6YzBlNDUzMWZkNWExNDExOWE5ZWZjMzRmNjlhODM0MjUvdGV4dHJlZ2lvbjpjMGU0NTMxZmQ1YTE0MTE5YTllZmMzNGY2OWE4MzQyNV8zMjk4NTM0ODk5Nzgz_0d85ba27-4895-4ac5-b502-4640cda3c9db"
      unitRef="shares">12560990</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNS00LTEtMS0w_59fd1148-cd35-407c-a76f-fcc72eb91147"
      unitRef="usd">77828000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNS02LTEtMS0w_73ab613d-1a06-4723-afe4-fd7debb1fd64"
      unitRef="usd">13164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNi00LTEtMS0w_0639af98-dc0e-48b1-b784-21e63e61d178"
      unitRef="usd">6238000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNi02LTEtMS0w_0645d0f3-d82e-4af2-8ab6-28e7bd41be04"
      unitRef="usd">5952000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNy00LTEtMS0w_cccb441d-e6d8-470a-923d-2c60a665c0ff"
      unitRef="usd">1686000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfNy02LTEtMS0w_ac302b74-5c18-4321-9ad2-939e165b0e27"
      unitRef="usd">2196000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOC00LTEtMS0w_5b03f385-e290-4937-b6a9-1101b0947539"
      unitRef="usd">85752000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOC02LTEtMS0w_f21d50ba-9cde-4da6-969e-abd0f97d1799"
      unitRef="usd">21312000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOS00LTEtMS0w_e74bcdca-124e-402d-9e0c-653a892da247"
      unitRef="usd">1314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfOS02LTEtMS0w_bf9eeaf1-5a82-4aed-972a-475e6a6f289e"
      unitRef="usd">1566000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTEtNC0xLTEtMA_8f115615-7552-4eaf-903f-7d1dc41abb8a"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTEtNi0xLTEtMA_af452212-f1fc-4460-9b9e-acdac7e20e90"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTItNC0xLTEtMA_6a648440-14fd-44f0-8a75-6eccadcbbe2e"
      unitRef="usd">172000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTItNi0xLTEtMA_3454effe-7f86-4378-979f-acb2f50b7ab1"
      unitRef="usd">503000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTMtNC0xLTEtMA_565b14bf-50c5-42a7-886c-a4fa236e54ec"
      unitRef="usd">92744000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTMtNi0xLTEtMA_917b66fe-35d2-4c2e-ac07-c9e835b50f92"
      unitRef="usd">28887000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTYtNC0xLTEtMA_81f519ab-8c81-4ea0-b01a-5d9fd4d06ba9"
      unitRef="usd">1213000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTYtNi0xLTEtMA_4a4bc050-0169-47e8-b2f0-5ca0707b1b01"
      unitRef="usd">1279000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTctNC0xLTEtMA_4895def9-945e-412e-97e7-c54caab42039"
      unitRef="usd">6449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTctNi0xLTEtMA_60815fec-41f0-4b2f-833b-0f94871a590a"
      unitRef="usd">3923000</us-gaap:AccruedLiabilitiesCurrent>
    <exdx:TemporaryEquityProceedsReceivedPriorToIssuance
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTgtNC0xLTEtMA_997c99e3-8c0e-4122-aa7d-e24895d65aa5"
      unitRef="usd">0</exdx:TemporaryEquityProceedsReceivedPriorToIssuance>
    <exdx:TemporaryEquityProceedsReceivedPriorToIssuance
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTgtNi0xLTEtMA_20fde7d5-79ba-49b4-9fcd-881fd65e049e"
      unitRef="usd">3750000</exdx:TemporaryEquityProceedsReceivedPriorToIssuance>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTktNC0xLTEtMA_875f2ea1-eddc-4634-a144-9570fcf266fe"
      unitRef="usd">7662000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMTktNi0xLTEtMA_be2ce0ff-6379-447f-9415-f2abdad4c432"
      unitRef="usd">8952000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjAtNC0xLTEtMA_56c0c002-d9e7-40da-8159-e97c45de03e9"
      unitRef="usd">25677000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjAtNi0xLTEtMA_1065f92c-de9a-4103-851e-a68b9785755d"
      unitRef="usd">24617000</us-gaap:LongTermDebtNoncurrent>
    <exdx:PreferredStockWarrantLiability
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjEtNC0xLTEtMA_8d19661d-c58d-45c9-a9c0-9b8d03bc5f5a"
      unitRef="usd">0</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjEtNi0xLTEtMA_4028dbe6-ee8d-4567-9be6-ebd3047ecfff"
      unitRef="usd">1503000</exdx:PreferredStockWarrantLiability>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjItNC0xLTEtMA_63eccde2-fda2-4be9-8d29-90d9e533470d"
      unitRef="usd">245000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjItNi0xLTEtMA_123732da-7756-462a-a82a-7da8102ddea0"
      unitRef="usd">245000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNC0xLTEtMA_aab6eea5-b571-45d1-bf20-d42ca896652d"
      unitRef="usd">510000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNi0xLTEtMA_360ad91e-506a-41f5-adfb-42cf80387312"
      unitRef="usd">304000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtNC0xLTEtMA_9a81ef19-7428-4759-908d-2d9b6ecbdb25"
      unitRef="usd">34094000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtNi0xLTEtMA_0952e222-0973-4184-a791-950a3025b98f"
      unitRef="usd">35621000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNC0xLTEtMTEzMDQ_e9d9644b-e274-4eb4-88d7-76b87b59f0a9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjMtNi0xLTEtMTEzMDU_177c1d25-e6b4-447d-9ec9-88c056b3bb08"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg2Mw_b186f830-ba20-4179-84cf-a409963b7efb"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg2Mw_d099f148-dac4-4529-a534-7e43ee59a55f"
      unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc1MA_435243fb-83fc-4c01-8b40-125e5ba41ef9"
      unitRef="shares">750300000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc1MA_8698a61f-5096-44ca-ba21-9407addea36f"
      unitRef="shares">750300000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTg1Mw_45143215-4def-479d-a573-d5c89d92e86b"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc3NQ_3336f3b8-c4c2-4740-a427-c5ba4c26b03f"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ib21a0e21952a4a7aadfc69c9540e19a3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTc5MQ_a533e801-b631-4a9e-a1ab-b7ad0a9229bb"
      unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i8d776fef836147e8aa9fca48608805fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjQtMC0xLTEtMTEyOTMvdGV4dHJlZ2lvbjoyNzk3OGFhZGVmZWU0NjBlYjM4NDhkNzYwN2M2YmNlN18xNDI5MzY1MTE2MTgwNA_f842bea5-a276-46a1-8404-822876a5ecdf"
      unitRef="usd">163316000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNC0xLTEtMA_d76cabf8-6006-41fb-971b-9b36493c0b12"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNi0xLTEtMA_689c2bf6-ee36-4425-a301-98bceca84859"
      unitRef="usd">105232000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI4Mg_07d8efb4-d2b8-400e-a541-82c533697fbb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI4Mg_a1e6580d-fe7e-46a1-bed2-68e0368b3c45"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTI5NA_7d746f79-da97-40c6-ae12-90ef2d1944fc"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4Mg_2a0eb5cc-2662-42e5-a650-7c3568edca9e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4Mg_990a6f3c-3388-4102-baf6-ebd0c0896061"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_17e08aa1-01ef-410a-8128-1e679834b892"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_7711eac3-3786-4118-b378-8d303fa945fe"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtMC0xLTEtMTEzNDgvdGV4dHJlZ2lvbjozMmM5MGE3MDc3YTA0ZDliOWE2MjIzZjgyNzgzNTFjYV8xNDI5MzY1MTE2MTQ4NA_cc9ac07d-9bba-490a-ae94-9a464ae65b15"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNC0xLTEtMTEzMTQ_a8c5ffa1-b444-456d-86b9-68157eb83030"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjYtNi0xLTEtMTEzMTY_d4cb6bd2-4b8b-426d-85d6-20b2bac337a6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzcw_6faec5c5-28f2-4150-a071-a36ca7ec1bbd"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzcw_fc964da7-d1c7-4657-bfd7-5e56b6c3e6ca"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzgz_b8435cd8-3603-459d-971a-62c49b46cc72"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxMzk4_504c8c78-fc46-4197-a098-acebb64e80d7"
      unitRef="shares">1470000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDEw_2362ef11-c285-45f7-9ca2-5eb9a377a29b"
      unitRef="shares">12559492</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDEw_46241b5e-15b0-4cad-803f-8f8f7035ec9e"
      unitRef="shares">12559492</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDE4_1296ac2a-25b3-4ef8-8e43-264d5d5412e6"
      unitRef="shares">63005</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjctMC0xLTEtNTg4NC90ZXh0cmVnaW9uOmUwYjY2NmMxYWIyYTQ5ZDg5ZTJmZjYxY2I5YTkzNjcxXzE0MjkzNjUxMTYxNDE4_c0c3c104-f742-42d1-8917-b5ab710ba78e"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjgtNC0xLTEtMA_6dfc4131-3a69-4895-9912-982533109201"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjgtNi0xLTEtMA_0932ef0d-b71f-4c40-a1eb-39af62abd954"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjktNC0xLTEtMA_487852d1-3afe-4f45-a017-5f16e3bdad46"
      unitRef="usd">219831000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMjktNi0xLTEtMA_ba8ed7de-af8e-4ee3-8a75-0e3e2e605f82"
      unitRef="usd">40598000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzAtNC0xLTEtMA_ff3575f1-06ef-4da8-afa6-7f03aeb97c5c"
      unitRef="usd">-161194000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzAtNi0xLTEtMA_3f4b2fb8-a508-4ce2-9192-442f013b1bfa"
      unitRef="usd">-152564000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzEtNC0xLTEtMA_5891ef5f-6407-4e4b-b4d7-b5f0d4881124"
      unitRef="usd">58650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzEtNi0xLTEtMA_417208a8-b207-459a-b18b-1ed60d243a15"
      unitRef="usd">-111966000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzItNC0xLTEtMA_dde0924c-61e1-4233-a5d5-3b5829fa9a3c"
      unitRef="usd">92744000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yNS9mcmFnOjc4Y2E4MzBlN2JkZDQzY2Y5NGQ1N2M1Mzk3ODA2NWUzL3RhYmxlOjc0NjQ4MTkxMjkyMTQ0Y2Y4ODA4ODE2OWNmYTA3YzZjL3RhYmxlcmFuZ2U6NzQ2NDgxOTEyOTIxNDRjZjg4MDg4MTY5Y2ZhMDdjNmNfMzItNi0xLTEtMA_34aabcc0-8e95-443e-a7da-89a849d45c2a"
      unitRef="usd">28887000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy0yLTEtMS0w_a8a2284f-6350-4c5a-8440-f3595b9a6e0e"
      unitRef="usd">10439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy00LTEtMS0w_8872cb29-5274-40da-9a77-c1d82d379183"
      unitRef="usd">8223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy02LTEtMS0w_d0df24b3-f5d9-4840-974d-b0c9cabdbb12"
      unitRef="usd">30173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMy04LTEtMS0w_03602f4e-6c7d-4e95-ab3b-d9e93d9132b4"
      unitRef="usd">22799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS0yLTEtMS0w_463104be-bfcc-4f81-9689-570200faf362"
      unitRef="usd">4783000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS00LTEtMS0w_22ea699d-5a99-49a2-8d73-cc2be9125b88"
      unitRef="usd">3852000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS02LTEtMS0w_30b1f38e-585c-443c-b17b-12e068fdca90"
      unitRef="usd">14217000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNS04LTEtMS0w_91ab12fe-9ea0-4241-a3aa-f6ff9c324c89"
      unitRef="usd">11376000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi0yLTEtMS0w_0ac21535-f4fd-4bfc-82d5-932bf065ae64"
      unitRef="usd">7306000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi00LTEtMS0w_004741e8-7191-4186-9ba7-9dbcbc977dda"
      unitRef="usd">4932000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi02LTEtMS0w_4093c0f9-446c-467b-a137-07c713e13d12"
      unitRef="usd">20787000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNi04LTEtMS0w_209a613f-28af-4bf8-a27e-289ef5103967"
      unitRef="usd">14419000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy0yLTEtMS0w_a8fc2934-5fb3-45c4-b773-9b6cc26bd23b"
      unitRef="usd">507000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy00LTEtMS0w_e4454e44-fcf5-4086-a83a-c9ef80b681d3"
      unitRef="usd">525000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy02LTEtMS0w_f2c67ecd-4a01-424c-bcf1-7840e2592cd5"
      unitRef="usd">1610000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfNy04LTEtMS0w_c753d07c-6907-4a8f-abfa-3e14f4cf940c"
      unitRef="usd">1592000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC0yLTEtMS0w_be54e756-a8bf-4030-87c4-1335c758cfbf"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC00LTEtMS0w_2328de9a-1b77-49fa-80b2-95fcda623fdc"
      unitRef="usd">47000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC02LTEtMS0w_7e80b49b-8e66-4dda-bd97-f94dba5c7778"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfOC04LTEtMS0w_0ebf8802-adb1-473a-a237-c4f0efae63b6"
      unitRef="usd">141000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtMi0xLTEtMA_ea1c552f-78ca-4a1d-bbb8-929f9da449e9"
      unitRef="usd">12596000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtNC0xLTEtMA_65b52c6a-11e7-4fa6-9729-586556cd540c"
      unitRef="usd">9356000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtNi0xLTEtMA_460f5834-a7df-4a48-bae8-52e2c77a7872"
      unitRef="usd">36614000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTAtOC0xLTEtMA_82a66b48-fd03-4a5e-b6ee-4f5e522c04dc"
      unitRef="usd">27528000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtMi0xLTEtMA_6ea9c481-ba36-4cb5-82e5-fe2729c972c1"
      unitRef="usd">-2157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtNC0xLTEtMA_d24650e9-fff3-4704-b079-68d39e2825c8"
      unitRef="usd">-1133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtNi0xLTEtMA_9b884f58-8d7f-43c4-83af-6d8b1644e172"
      unitRef="usd">-6441000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTEtOC0xLTEtMA_68c84378-5363-4310-88c3-25ac4dcf1e7d"
      unitRef="usd">-4729000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItMi0xLTEtMA_1ddb19ac-c494-4022-a8f5-006714f9e69c"
      unitRef="usd">909000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItNC0xLTEtMA_2a46c5cf-9321-4c57-aeee-2dbf535a7417"
      unitRef="usd">704000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItNi0xLTEtMA_d8d9adda-8329-408d-9196-eecc2fc3a105"
      unitRef="usd">2720000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTItOC0xLTEtMA_d4744acd-3ead-4954-abd5-b19da3352c6d"
      unitRef="usd">2098000</us-gaap:InterestExpense>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtMi0xLTEtMA_e8d48045-0cca-49a1-9021-0cce663521be"
      unitRef="usd">-200000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtNC0xLTEtMA_73b98443-9074-4045-9491-6996d1384dda"
      unitRef="usd">55000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtNi0xLTEtMA_8cc36ea5-dbd1-434f-8599-3f497fb5cc43"
      unitRef="usd">267000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTQtOC0xLTEtMA_e1412c4a-f4e4-4f72-8827-1fdb50618cff"
      unitRef="usd">55000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtMi0xLTEtMA_acd2c5d3-92b9-4d90-aa0f-7aee91e64f3c"
      unitRef="usd">125000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtNC0xLTEtMA_5d7b4720-8628-4eb0-bfe4-9295f8d324a4"
      unitRef="usd">26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtNi0xLTEtMA_c10a2d6c-dbca-4f6f-8742-80d36fe6d1e1"
      unitRef="usd">264000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTUtOC0xLTEtMA_210f907e-cd9b-4271-ae8e-d9772ebe2107"
      unitRef="usd">77000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtMi0xLTEtMA_64d4d0ac-faa4-4cbe-bd50-17f49d24bd30"
      unitRef="usd">-3141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtNC0xLTEtMA_21676f79-e4c8-4110-8b30-9923ee49d568"
      unitRef="usd">-1756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtNi0xLTEtMA_b67f621a-f2c3-4dc2-8254-b6ddc26789dd"
      unitRef="usd">-8630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTYtOC0xLTEtMA_d9203870-9135-4339-a733-c2bd53754772"
      unitRef="usd">-6695000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctMi0xLTEtNzcyNA_b810634e-e566-4852-abf6-27c69f950ec9"
      unitRef="usd">-338000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctNC0xLTEtNzczMw_444283a8-c2ab-4876-834a-21db13ca2e5f"
      unitRef="usd">-2768000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctNi0xLTEtNzc0Mg_3a80ab05-d278-4db6-868f-2594a8fd2163"
      unitRef="usd">-4640000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTctOC0xLTEtNzc1Mg_34784d88-cc3d-4c59-8b99-e44ce70d70c6"
      unitRef="usd">-6462000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtMi0xLTEtNzcyNA_9fd9f5fd-e1be-41a7-93c1-f52e7b435c9c"
      unitRef="usd">13601000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtNC0xLTEtNzczMw_c29a6b83-22d1-406d-9e8a-489d698b6e6f"
      unitRef="usd">0</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtNi0xLTEtNzc0Mg_cb7d9d61-8eed-49d6-9601-d8aaf55589cb"
      unitRef="usd">13601000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTgtOC0xLTEtNzc1Mg_b508a1d2-a891-49d3-bfd4-a55acee0d887"
      unitRef="usd">1152000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktMi0xLTEtNzcyNA_181dc7c5-edaa-4eae-8981-935f8fefa6da"
      unitRef="usd">-17080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktMi0xLTEtNzcyNA_cbd7e9b5-0135-4b64-b979-8cc1747302ff"
      unitRef="usd">-17080000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNC0xLTEtNzczMw_4b1e9849-4ee5-4dcf-83df-6094a1b0a5c4"
      unitRef="usd">-4524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNC0xLTEtNzczMw_5f849cd8-84a9-488e-a974-16ae0c5e4527"
      unitRef="usd">-4524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNi0xLTEtNzc0Mg_82f8f703-a13d-484f-8d8e-3c2dbd3e1b4e"
      unitRef="usd">-26871000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktNi0xLTEtNzc0Mg_e2002487-8a70-4cb7-9319-28364ef321a9"
      unitRef="usd">-26871000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktOC0xLTEtNzc1Mg_3e80886f-c16a-4365-8328-732d6b8789db"
      unitRef="usd">-14309000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMTktOC0xLTEtNzc1Mg_90654e60-da46-4300-9c0e-145112c66735"
      unitRef="usd">-14309000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItMi0xLTEtMA_4953527d-740c-480c-9c7e-5757ac56502d"
      unitRef="usdPerShare">-11.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItNC0xLTEtMA_94d1339a-a346-4728-9110-6ecd00d5e4b2"
      unitRef="usdPerShare">-71.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItNi0xLTEtMA_8e13b226-631b-4a3a-9678-efe93344a1aa"
      unitRef="usdPerShare">-48.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjItOC0xLTEtMA_fea77e01-5f91-45aa-a78f-5ce6239cf9e4"
      unitRef="usdPerShare">-227.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtMi0xLTEtMA_872b2a12-90e3-4d6e-813a-8217656a8b2f"
      unitRef="shares">1513189</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtNC0xLTEtMA_c76f355f-bc6f-430f-b4cf-86102a83d0ec"
      unitRef="shares">63005</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtNi0xLTEtMA_6c12c11e-612e-4e10-b6e2-35f572b974cb"
      unitRef="shares">551730</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8yOC9mcmFnOjA5Mjk4ZWVjZDU3MTQzMGU4OTYyOGEyM2Q2ZjI3ZTg1L3RhYmxlOmRlYWE1NThiOTJjZTRkNDE5MTY5NWM1ZWNiNDE1NTliL3RhYmxlcmFuZ2U6ZGVhYTU1OGI5MmNlNGQ0MTkxNjk1YzVlY2I0MTU1OWJfMjMtOC0xLTEtMA_58e8e734-ea22-4df1-86af-9e27effe8570"
      unitRef="shares">63005</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMi0xLTEtMA_e5b579bb-56aa-4a3a-a55b-133d234fcc58"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctNC0xLTEtMA_72a36863-588a-44f5-90da-25d7f8d9adcd"
      unitRef="usd">105232000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia29630b56e3742939a0bdba1189a6cbc_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctNi0xLTEtMA_2a84dea4-857b-4d30-9394-95117527450d"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia29630b56e3742939a0bdba1189a6cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctOC0xLTEtMA_ef7eeccb-fcc9-45bc-8ef0-15b042f89199"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a482197c34d44c3ae90623f48d4b912_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTAtMS0xLTA_bbff4071-2ac2-4fa0-8099-68c403002053"
      unitRef="usd">40598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b5aac5ad5ae438abb53532ed876958a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTItMS0xLTA_c6d52c80-1590-45a2-a134-4679fcb6fcfc"
      unitRef="usd">-152564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMTQtMS0xLTA_50894b7e-b5cd-452f-9070-30c7302e67e3"
      unitRef="usd">-111966000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMA_45ab147b-3216-42f0-91b5-2d4dbc3c93aa"
      unitRef="usd">2114000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTA_f6152f23-ea18-418c-8e80-731df06f5da0"
      unitRef="usd">2114000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTA_ba2f39eb-c4fc-402f-8f2c-e55884b0eb0c"
      unitRef="usd">2114000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktNi0xLTEtMA_85d77469-29ad-4e11-9e5f-9ef6b61eafdf"
      unitRef="shares">24</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2c013698125444e4b15598f33cadc1d3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktOC0xLTEtMA_28ff4586-3237-4eac-a7ac-79aeb38b25f3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTktMTQtMS0xLTA_20971da1-d829-426f-8127-3db55f909236"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a2831af63f84a0eb1802ebf117b29bd_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjAtMTAtMS0xLTA_47240be0-1395-4f79-8168-b037cc9bbbfd"
      unitRef="usd">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjAtMTQtMS0xLTA_10242731-7460-46f0-b29f-3e03f897bafd"
      unitRef="usd">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfNi0wLTEtMS0xMjA5My90ZXh0cmVnaW9uOmQxMzllMTA0NGNiNzQyMmVhMGY2MTA5ZWI3MjViYjBkXzE5MjQxNDUzNDg3MDY3_bc99a97e-0822-4a67-a338-3ec1c4aa9f25"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="ia9ebdcb60bde4e66b1e6465cf454868e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfNi0wLTEtMS0xMjA5My90ZXh0cmVnaW9uOmQxMzllMTA0NGNiNzQyMmVhMGY2MTA5ZWI3MjViYjBkXzE5MjQxNDUzNDg3MDcy_b4f79016-0f38-48de-a2a4-16fb894c5680"
      unitRef="usd">96000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjEtMi0xLTEtMA_68ab703a-b086-402d-a6cf-c45c43373da4"
      unitRef="shares">97646289</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjEtNC0xLTEtMA_808a63d0-937b-49ff-b5b6-21e858a97cf5"
      unitRef="usd">7520000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="i64c8f49f4ea54bc58629c4cf906e85ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjItMTItMS0xLTA_e185cbd6-1a63-4e41-af6e-749da6cc4064"
      unitRef="usd">-2704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a531ff562be481daec4c48baa08acc8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjItMTQtMS0xLTA_64691d8e-886c-4a2b-aaae-045cce868796"
      unitRef="usd">-2704000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMi0xLTEtMA_e61b02de-076a-4be1-98c1-664a3a3f2eac"
      unitRef="shares">630252373</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtNC0xLTEtMA_c5f68f04-24eb-47f7-b919-b16e913dc822"
      unitRef="usd">114866000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i594311f90cd64628a3d0aa29e07f0898_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtNi0xLTEtMA_4f167beb-576c-44c6-abfe-a92d9861d4c8"
      unitRef="shares">63029</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i594311f90cd64628a3d0aa29e07f0898_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtOC0xLTEtMA_ca15f2b5-7d5a-4af4-9711-0db9136d92e1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20a1c50a126f4905ba75a973e1a3e682_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTAtMS0xLTA_0af00cd4-f20f-49f3-8826-6b6e82432d10"
      unitRef="usd">38496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e681c5c446e4f03a7abffd537dd5352_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTItMS0xLTA_27cbd050-3feb-4863-851f-090bfc866aa5"
      unitRef="usd">-155268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjMtMTQtMS0xLTA_07b87e35-243e-4d86-8f65-0b98d0b77db5"
      unitRef="usd">-116772000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtNC0xLTEtMA_320c5665-e3c9-493f-b413-740bf834839e"
      unitRef="usd">2188000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtMTAtMS0xLTA_7f2f31d5-b5d8-477b-9253-ce1c166e5432"
      unitRef="usd">2188000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjUtMTQtMS0xLTA_8bb33174-fc26-4fdf-9d4a-e17feaa4d795"
      unitRef="usd">2188000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtNi0xLTEtMTAyMjM_ce862728-aeee-4480-80a1-fb693e095d26"
      unitRef="shares">26</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib4408902a20a43d5b6e5384736f9ea33_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtOC0xLTEtMTAyMjM_eced59e2-465c-4ae2-aab4-93daf943f087"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTQtMS0xLTEwMjIz_bc68caab-1cf3-4fc5-bc73-8c18b423300a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e3e7b53d500427db76ec8945fb285c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTAtMS0xLTA_7a44620b-210d-4dd1-aeb0-ad837994c258"
      unitRef="usd">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjYtMTQtMS0xLTA_b046af1d-2124-4059-a58b-81cdd9595f07"
      unitRef="usd">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTItMC0xLTEtMTIxMDYvdGV4dHJlZ2lvbjozMzMxOTg0Mjk2OTA0M2IyYWVlYmJhN2JiMWRiMWMzNl8xOTI0MTQ1MzQ4NzA1MQ_f9192df9-f12b-47e1-8ea0-83a19ca8d9fd"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="ibb9d1effa6a5434fbfeeb49cae0d8a73_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTItMC0xLTEtMTIxMDYvdGV4dHJlZ2lvbjozMzMxOTg0Mjk2OTA0M2IyYWVlYmJhN2JiMWRiMWMzNl8xOTI0MTQ1MzQ4NzA1Ng_e2b11e3a-9bc9-4de2-9899-fc86cd29dae0"
      unitRef="usd">28000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjctMi0xLTEtMA_877a2590-7272-4582-bc5b-8dc3417e9fc6"
      unitRef="shares">51282048</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjctNC0xLTEtMA_9928c8a9-c695-4e76-9b87-5758f7f0aa46"
      unitRef="usd">3972000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="i3229df7dacf74fca997f4b0f45d5bb9b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjgtMTItMS0xLTA_b0fb038d-6866-41b3-92a1-d0217063d705"
      unitRef="usd">-2785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i451b27c088ef42b885c58a55a626cd87_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjgtMTQtMS0xLTA_bad3457a-38cc-4835-a1e8-a94fa2a3f6ba"
      unitRef="usd">-2785000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ia414d6d243b647818871ad407f657257_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMi0xLTEtMA_fffdd48f-1867-4e73-8d2d-ee7cc172ed54"
      unitRef="shares">681534421</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ia414d6d243b647818871ad407f657257_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktNC0xLTEtMA_f08a72d2-5c0f-4b5f-ac4b-86a61172fa98"
      unitRef="usd">121026000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i23ae889f40dd442a96d1fcd4f3335f02_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktNi0xLTEtMA_a47ee016-2b80-4507-b33d-ce25657d42f2"
      unitRef="shares">63055</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i23ae889f40dd442a96d1fcd4f3335f02_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktOC0xLTEtMA_5e25db9b-fcd7-4944-a155-03d9351645c9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i822fcb2995c1470cb62140417fcb6f90_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTAtMS0xLTA_c6545230-e270-40ce-9c59-0865237a99a9"
      unitRef="usd">36319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iececa9bd8c374f448e2c8c12d96a1d37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTItMS0xLTA_d6a3de22-8446-4caf-8e29-1fa200521501"
      unitRef="usd">-158053000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia414d6d243b647818871ad407f657257_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMjktMTQtMS0xLTA_e6a91d69-b762-4f2f-8ace-2c538aaa0ef2"
      unitRef="usd">-121734000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtNC0xLTEtMTAyNzI_ff9ea939-4876-4f20-b54c-b2aa4828c4df"
      unitRef="usd">338000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtMTAtMS0xLTEwMjc0_4c7324b4-469e-42bc-9084-ee00048bb91e"
      unitRef="usd">338000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTUtMTQtMS0xLTEwMjc0_09e622c7-403c-4d8b-961f-eb93dbef7161"
      unitRef="usd">338000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzItMTAtMS0xLTgxNw_288a4146-194f-488c-a0ad-582b4d28ece5"
      unitRef="usd">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzItMTQtMS0xLTgyMw_d0ac2d39-5057-47a9-81d6-68ae0d4142d5"
      unitRef="usd">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMC0xLTEtMTIwOTAvdGV4dHJlZ2lvbjo4YmExYTY2YjhmMjM0Y2I0ODhjODE3NTA3ZjMzNDM1Zl8xOTI0MTQ1MzQ4NjIzMg_5b7c59c2-5f25-4f16-8dbf-bd3f13b3ec34"
      unitRef="usdPerShare">0.047</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTctMC0xLTEtMTIwOTAvdGV4dHJlZ2lvbjo4YmExYTY2YjhmMjM0Y2I0ODhjODE3NTA3ZjMzNDM1Zl8xOTI0MTQ1MzQ4NjIzOA_71733499-97d7-408a-b5dd-a377889d4316"
      unitRef="usd">318000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMi0xLTEtODQx_c1ffec1b-b53b-483d-8237-9443e22e9215"
      unitRef="shares">233446519</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNC0xLTEtODQ4_5ebb3e49-70c0-4a80-ab07-cdebe7f1f551"
      unitRef="usd">3941000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTAtMS0xLTg1Nw_91f32a09-4125-4ce8-ab19-cc182dbeb88f"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTQtMS0xLTg2Mw_2228671d-c0f8-4c07-96b8-a1cce94a7151"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMTIwNTU_b94751f8-691f-4889-834f-2f86657fccd0"
      unitRef="usd">6741000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTEyMDY0_ead279b3-1992-4204-873c-84f0943dd803"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTEyMDcw_2635f8d4-a75e-44ae-82b1-7ef3a6f8225d"
      unitRef="usd">6741000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividendSharesIssued
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMi0xLTEtMTAzMTg_1d90bd93-a052-4f81-bf54-60299bf387b6"
      unitRef="shares">97592739</exdx:TemporaryEquityDeemedDividendSharesIssued>
    <exdx:TemporaryEquityDeemedDividend
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtNC0xLTEtMTAzMTg_6888fd43-29fa-4501-9384-276c67feb5d5"
      unitRef="usd">6860000</exdx:TemporaryEquityDeemedDividend>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTAtMS0xLTEwMzI2_5e8d3c7e-41ef-41e4-8473-c801bb4fd110"
      unitRef="usd">6860000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMTgtMTQtMS0xLTEwMzI2_42502f57-3fa2-46ce-bf35-5c410a2d6961"
      unitRef="usd">6860000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends>
    <exdx:TemporaryEquitySharesRedeemedUponConversion
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMi0xLTEtODA2_2b7c3eb8-c80d-43ab-9c97-53b10f122575"
      unitRef="shares">1012573679</exdx:TemporaryEquitySharesRedeemedUponConversion>
    <exdx:TemporaryEquitySharesRedeemedUponConversionAmount
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNC0xLTEtODA4_c6a28de7-a6ed-40cb-aa71-6860cf008d0a"
      unitRef="usd">138906000</exdx:TemporaryEquitySharesRedeemedUponConversionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtNi0xLTEtODEx_277e8f64-6240-4c9e-89ca-43d8763b20d4"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtOC0xLTEtODE0_c12aa759-293a-4cef-8f33-35511fe088a0"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTAtMS0xLTgxNw_ff218580-5672-488a-87b2-4624c57726f7"
      unitRef="usd">138898000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzMtMTQtMS0xLTgyMw_21c42f2c-de06-476c-8ac8-8b3ca8856c7f"
      unitRef="usd">138906000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtNi0xLTEtODEx_27543035-9719-4ace-be40-947aacb3be71"
      unitRef="shares">4140000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtOC0xLTEtODE0_a44f5072-fee6-40ef-b040-9a39bde9a47c"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtMTAtMS0xLTgxNw_a0ca11a0-d4cb-4588-b8b3-93a4679fc597"
      unitRef="usd">50514000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzQtMTQtMS0xLTgyMw_b169358f-25a4-4b9c-93cb-b62c47dfe286"
      unitRef="usd">50518000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtNi0xLTEtODEx_f2adf6a1-4644-4c71-aee3-10dcaf0c5d14"
      unitRef="shares">539794</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i4f9b75d34a7a4da29a877c5d9cc9a3af_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtOC0xLTEtODE0_8170e140-e652-4a4c-afd4-7a7cdfe7dbdd"
      unitRef="usd">1000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtMTAtMS0xLTgxNw_fe93595f-ae5e-4da2-be8b-4545e48a6175"
      unitRef="usd">510000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzUtMTQtMS0xLTgyMw_51c004e6-63b7-46e3-b807-8abe8893b32b"
      unitRef="usd">511000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability
      contextRef="i38f0be662b5b4e89a2ae8a04fb90a971_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzYtMTAtMS0xLTgxNw_dc8b6530-fec6-4193-a0cf-d3ecedb11f94"
      unitRef="usd">726000</exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability>
    <exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzYtMTQtMS0xLTgyMw_326e1f41-c3e7-45b4-b0f2-3af4d9d6082f"
      unitRef="usd">726000</exdx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability>
    <us-gaap:NetIncomeLoss
      contextRef="i25e5197af80646e69a15779b9738a368_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzctMTItMS0xLTgyMA_0ae360ce-5135-4b34-a572-871ee8470499"
      unitRef="usd">-3141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzctMTQtMS0xLTgyMw_1769eb95-98db-4579-8b0d-49b6155b9f7a"
      unitRef="usd">-3141000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMi0xLTEtODA2_5188fbdc-fb7d-4904-a0ba-c2ee1491c5c4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtNC0xLTEtODA4_07f91d40-f4f4-4dce-83f0-fab60fb95cab"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21b9dac09b37446fb247a953a02f8cfd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtNi0xLTEtODEx_a15f7b03-3454-4c70-8702-eff24df3e960"
      unitRef="shares">12559492</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i21b9dac09b37446fb247a953a02f8cfd_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtOC0xLTEtODE0_04c2fc3c-618a-4966-9d53-7a013bde5b37"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a5c654aa4fe4cd2af17f3785df2fe7b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTAtMS0xLTgxNw_371a0507-f87f-4af0-b33c-1b753d945570"
      unitRef="usd">219831000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f4bdb7e8bdd41f98f110e1f34540e3e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTItMS0xLTgyMA_a2ab7b04-df52-45fb-8aa0-6d33732cff39"
      unitRef="usd">-161194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOmFhOGUyNTJkMjBjNzRmZTliODhkZDk0MWE5NzYxMDY0L3RhYmxlcmFuZ2U6YWE4ZTI1MmQyMGM3NGZlOWI4OGRkOTQxYTk3NjEwNjRfMzgtMTQtMS0xLTgyMw_323a8fa4-7457-4b8e-9010-db1d1bd932df"
      unitRef="usd">58650000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0yLTEtMS0w_1cc042f1-18c1-47d5-85b2-d9d3eeac9fa6"
      unitRef="shares">497691757</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi00LTEtMS0w_d057e8ff-006e-4366-bd21-8b625534b481"
      unitRef="usd">92046000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i15c321aea67a4b76bb1d06797b32516f_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi02LTEtMS0w_ac7f8146-4c67-4196-b9aa-942a9ebb9cd8"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i15c321aea67a4b76bb1d06797b32516f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi04LTEtMS0w_a32f8eb0-3c1f-4514-8454-8f35637f8e84"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i355fab1a4851405d964d3ce01c25e0cb_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xMC0xLTEtMA_0d1ab52c-f33a-4f4e-8630-572e9ab2fa35"
      unitRef="usd">50954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40961c268efa4e669f1ab85e0e151e85_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xMi0xLTEtMA_69ec55e6-7e65-4a61-9b2d-7ce35cdfca56"
      unitRef="usd">-147638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMi0xNC0xLTEtMA_b3ed39eb-e0ae-4364-9eff-9cee2ecca36d"
      unitRef="usd">-96684000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i5e60ced97b104c0abfde5ea44bf688d1_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMy0xMi0xLTEtMA_41750987-ba09-464a-a2ad-92a4d8af818f"
      unitRef="usd">3086000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i7b4c6d0140a2430f9e5cc852e998ada7_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMy0xNC0xLTEtMA_fbae0162-be07-4eac-825c-619d3a5b2c6b"
      unitRef="usd">3086000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC00LTEtMS0w_210032cc-8418-46a4-b84a-2dd24c0d1585"
      unitRef="usd">1382000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC0xMC0xLTEtMA_6738e017-e1c4-4677-9651-8860a5c2e0c3"
      unitRef="usd">1382000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNC0xNC0xLTEtMA_ac921ea6-48e2-4316-98ab-671a671ce247"
      unitRef="usd">1382000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNS0xMC0xLTEtMA_3ed851ed-ab7d-4c50-9b03-f6865bfa0c90"
      unitRef="usd">46000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNS0xNC0xLTEtMA_1e2df2c5-e715-4dbb-8dc6-a8634aa083b8"
      unitRef="usd">46000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0wLTEtMS0xMjExMi90ZXh0cmVnaW9uOmI1NThjZTMyZTgxNDRhMzJhYjZjOTM1OWY1ODk5MjQxXzE5MjQxNDUzNDg2Mjc3_4dc0e620-4b38-42c8-a64b-0b4b73b663d1"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityIssuanceCosts
      contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0wLTEtMS0xMjExMi90ZXh0cmVnaW9uOmI1NThjZTMyZTgxNDRhMzJhYjZjOTM1OWY1ODk5MjQxXzE5MjQxNDUzNDg2Mjgx_3e333982-9979-4c20-857d-59ef03745bfd"
      unitRef="usd">7000</exdx:TemporaryEquityIssuanceCosts>
    <exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0yLTEtMS0w_13ab34f9-de69-4e46-a2c6-fcc2a1183567"
      unitRef="shares">34914327</exdx:TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock>
    <exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi00LTEtMS0w_cadcc049-7fcf-4255-87fc-3716856edf55"
      unitRef="usd">3868000</exdx:TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="ice03cdba22334e48a533d94a025d010e_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0xMC0xLTEtMA_192e454d-1bfb-41d7-bc78-e7d0af3f8ce9"
      unitRef="usd">-1152000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNi0xNC0xLTEtMA_936f3cb0-f78e-4e09-8998-c91752db651c"
      unitRef="usd">-1152000</exdx:AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibdf8495c14984c22b8ce5f6c41ee86e8_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNy0xMi0xLTEtMA_0deadfbb-2771-49aa-aa9f-36d4e655d8a6"
      unitRef="usd">-2793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfNy0xNC0xLTEtMA_89b747e6-5d28-4756-8b1f-43256345899c"
      unitRef="usd">-2793000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0yLTEtMS0w_6fcd6341-6ace-462e-80fa-c25ea6487b79"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC00LTEtMS0w_bf1045df-c01e-4b09-b887-60f25fd6ca71"
      unitRef="usd">97296000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC02LTEtMS0w_50e3302b-15ab-47cc-afe8-bc453f708491"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6bf289f7c0ec49b79f6f9ed0e1c464f4_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC04LTEtMS0w_31b5118d-782a-4c1b-87c2-5fcfb13b42fa"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0f39641f06e425987e31b75e8435957_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xMC0xLTEtMA_6aaafa89-e2fd-4a0f-9ede-ad0cc8516577"
      unitRef="usd">48466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5dd86c6fc3a247958775687c6c9081f7_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xMi0xLTEtMA_fa3eeb48-a957-4ebc-b6f6-dd9c06e36317"
      unitRef="usd">-147345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ad03575f3844523a836225bd6a1ff75_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOC0xNC0xLTEtMA_afc3d9cb-a7b8-4b27-b10b-d67bf8b33bf2"
      unitRef="usd">-98879000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS00LTEtMS0w_9d2319c7-e66e-4257-adf2-e4a2bd1395bd"
      unitRef="usd">2312000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i15803c46e4214e129bb899b341202df8_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS0xMC0xLTEtMA_8a855c73-56c2-4847-9064-dfd74624fd83"
      unitRef="usd">2312000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfOS0xNC0xLTEtMA_1c15454b-8a12-4d8b-a836-2a804c68d0c6"
      unitRef="usd">2312000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15803c46e4214e129bb899b341202df8_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTAtMTAtMS0xLTA_37b432b2-7656-4385-8570-38874d78d414"
      unitRef="usd">44000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTAtMTQtMS0xLTA_bbd87140-8863-4586-8df5-ead52707c835"
      unitRef="usd">44000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0ce8694d9ba647108d4ea5ab8b905c1b_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTEtMTItMS0xLTA_35fc10f4-277f-4221-a94a-375138f7e629"
      unitRef="usd">-2146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86162f3100254a16a5a5b013e44b3eb7_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTEtMTQtMS0xLTA_8a129509-7d90-4d28-8a55-41c06d87e128"
      unitRef="usd">-2146000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i337919a6832e4104bc0864899a13424e_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMi0xLTEtMA_df6d53dd-3600-4358-bd70-0d7052ce17c4"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i337919a6832e4104bc0864899a13424e_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItNC0xLTEtMA_5c2e366c-f63f-4e2a-9878-5dc411ed6e0d"
      unitRef="usd">99608000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItNi0xLTEtMA_a29c3bb5-164a-45b5-b9c1-40ef090b6aa7"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id96c3ca5da7142e3aa6f8c12ae2ad580_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItOC0xLTEtMA_1ca5fcf0-2236-4b6b-b9ac-7c1f35b7fba1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f88d3ad0c564ab193266b222933588d_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTAtMS0xLTA_b503de28-8985-45fb-b606-8537d327e5f0"
      unitRef="usd">46198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9a450e5a552453fa6bac61e4872ceba_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTItMS0xLTA_735c33e4-faef-4694-a23e-593651d6b3a5"
      unitRef="usd">-149491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i337919a6832e4104bc0864899a13424e_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTItMTQtMS0xLTA_26be3c9c-bfa4-43f8-8cd7-a88fd69c2a2e"
      unitRef="usd">-103293000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtNC0xLTEtNjAz_09c172b6-6cc8-471c-a051-f2f6a0ef1f41"
      unitRef="usd">2768000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtMTAtMS0xLTY1NQ_76f122eb-35ea-4b6e-9ae7-184c72879f3a"
      unitRef="usd">2768000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTMtMTQtMS0xLTY4MQ_73c05e23-3a63-4a9d-bf50-74312734f0c6"
      unitRef="usd">2768000</exdx:AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1b612e88b3e0478487b5fe0f7548f7ac_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTQtMTAtMS0xLTY1OA_c6902723-af59-4657-ac74-53552ecc30ea"
      unitRef="usd">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTQtMTQtMS0xLTY4NA_bc147af5-cc92-4f06-ab19-6a84409d5dc5"
      unitRef="usd">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ifee63a714e044b14bee48842ecfb743b_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTUtMTItMS0xLTY3NQ_11ffdb71-14af-4bb8-8cda-54e363a123da"
      unitRef="usd">-1756000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTUtMTQtMS0xLTY4Nw_aea94060-a64e-43fd-9fd1-b5332ebb4f8c"
      unitRef="usd">-1756000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMi0xLTEtNjE1_e810d1fc-1668-475b-9b28-ad3d37bef819"
      unitRef="shares">532606084</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtNC0xLTEtNjI4_cc54d8e1-1f85-4234-aab1-fd8dc8ae61be"
      unitRef="usd">102376000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idcd81548cfe74374b9b0ab13f94caa0a_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtNi0xLTEtNjQw_8bcf8b43-a527-41aa-bd05-58b9f668d578"
      unitRef="shares">63005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idcd81548cfe74374b9b0ab13f94caa0a_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtOC0xLTEtNjUy_69c2683d-2c32-4047-9d21-683b62efd243"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d80c008209c426a814d7dd70f19e32f_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTAtMS0xLTY2Ng_49c7277f-d9d9-4843-958e-066f6567f474"
      unitRef="usd">43440000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30025f8cbc5f45baa8876d50bde62fe7_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTItMS0xLTY3OA_3b67f36a-c0e6-4521-bb02-5edc12a85bb6"
      unitRef="usd">-151247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNC9mcmFnOjlhZGZiZTc5ZjBhNzQ5YTdiYmRkOWVhNTU0MDEwYzVhL3RhYmxlOjk4NDE2MDNlNjdjNzQ4ZjdiZTdjNDM2NGRiNGNiZGQzL3RhYmxlcmFuZ2U6OTg0MTYwM2U2N2M3NDhmN2JlN2M0MzY0ZGI0Y2JkZDNfMTYtMTQtMS0xLTY5MA_e84c2687-f5ca-4bb5-8c01-b622b01fbe79"
      unitRef="usd">-107807000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNC02LTEtMS0w_b4604c2f-c887-4255-a3d7-c56abb79e747"
      unitRef="usd">-8630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNC04LTEtMS0w_763f2b18-df5e-4d44-82fb-edc1dd0f41b8"
      unitRef="usd">-6695000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNy02LTEtMS0w_1de55166-d190-44b4-bff0-bffd43d79067"
      unitRef="usd">480000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNy04LTEtMS0w_ee606bad-2b99-45d4-b9d3-cc1f4641b868"
      unitRef="usd">576000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOC02LTEtMS0w_e976cc14-7b5e-4dac-a8d6-49378e65a724"
      unitRef="usd">575000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOC04LTEtMS0w_2000c69a-7869-4741-ad5b-cc4ad15f1be0"
      unitRef="usd">425000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOS02LTEtMS0w_22d5d2c9-bd12-42e9-a3fe-e7a819ed4d44"
      unitRef="usd">484000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfOS04LTEtMS0w_361e767b-6664-47f1-971f-e9051a849eac"
      unitRef="usd">380000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTAtNi0xLTEtMA_f790f476-fab7-4784-b9da-77239e8a52fd"
      unitRef="usd">-267000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTAtOC0xLTEtMA_0ddd0ec7-0b86-405f-b79e-26dd60a251e7"
      unitRef="usd">-55000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTQtNi0xLTEtMA_549487f6-15d0-4d6f-a528-e45f86407618"
      unitRef="usd">-20000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTQtOC0xLTEtMA_223e6c4b-316b-4451-84eb-215c39b68323"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTUtNi0xLTEtMA_079a0391-f05c-4e69-bb5d-dada96b34c57"
      unitRef="usd">85000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTUtOC0xLTEtMA_30de543d-ae01-4e23-8ef7-5fceb95eea26"
      unitRef="usd">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTctNi0xLTEtMA_83352eb8-5ab1-4988-8093-9b43c35fee76"
      unitRef="usd">286000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTctOC0xLTEtMA_af5224a2-cdaf-4ff2-acb7-aad045d6d9f1"
      unitRef="usd">1168000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTgtNi0xLTEtMA_5adf8750-fa99-4595-9b47-056bdac5e851"
      unitRef="usd">-510000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTgtOC0xLTEtMA_f329a4e8-460e-4bab-8ebd-167398387a4b"
      unitRef="usd">590000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTktNi0xLTEtMA_523321f4-b75a-4063-b46c-630e958c4d2a"
      unitRef="usd">24000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMTktOC0xLTEtMA_016f55ff-aa72-4441-bae1-b1a48c60e5f6"
      unitRef="usd">8000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjAtNi0xLTEtMA_4bfbbcc9-b55b-4fac-9f01-058e4b1bd53e"
      unitRef="usd">174000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjAtOC0xLTEtMA_6e6c4a7f-d4f5-4ef4-b82f-8b15fd323a29"
      unitRef="usd">-392000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjEtNi0xLTEtMA_6e34744f-021c-4713-9f9e-707f538003fb"
      unitRef="usd">1095000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjEtOC0xLTEtMA_92edf028-841e-4a9f-8b64-982f3768bed2"
      unitRef="usd">-5000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjMtNi0xLTEtMA_54e8d784-c569-49ce-b052-3225e78a7d14"
      unitRef="usd">-5784000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjMtOC0xLTEtMA_228a8085-34b6-4f9f-b6fd-4852bd8a1eac"
      unitRef="usd">-7432000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjUtNi0xLTEtMA_6c9a99eb-0d11-4a40-a042-9e5c99c559d2"
      unitRef="usd">377000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjUtOC0xLTEtMA_0423d888-a862-4e69-b5e1-55ce11cdd4b6"
      unitRef="usd">128000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjYtNi0xLTEtMA_ddc21455-01ae-4766-bdb8-58b196b4add6"
      unitRef="usd">300000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjYtOC0xLTEtMA_2e44ff01-ae59-442d-912b-c6ee326b8e21"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjctNi0xLTEtMA_61aa537d-0c80-4fd9-9a21-003227e64d65"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjctOC0xLTEtMA_d820b6a6-2153-4ff1-b92b-9b76aa5ed851"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjgtNi0xLTEtMA_4d689497-06ec-4e4e-8059-9a0ff455f0a3"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjgtOC0xLTEtMA_62f82e08-e9de-40d8-a15d-3d2e2c95b354"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjktNi0xLTEtMA_7bf2028f-81b0-4deb-83b1-6557fe67cbb0"
      unitRef="usd">-77000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMjktOC0xLTEtMA_0f538156-92c6-4710-8c51-946996a15fdf"
      unitRef="usd">-1128000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzEtNi0xLTEtMA_a6a12dbd-f553-49bb-8474-5a61155f3c25"
      unitRef="usd">94000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzEtOC0xLTEtMA_ef2594a5-7b8b-42ca-91d2-8c0478decd09"
      unitRef="usd">17000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtNi0xLTEtODgw_acb656d5-3887-4827-8aa7-4917bb9b3048"
      unitRef="usd">52195000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtOC0xLTEtODgz_d97669db-318b-40b5-bec9-06010f65bd76"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtNi0xLTEtMA_51524781-7782-4e62-bded-32c72d0a6df1"
      unitRef="usd">0</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzUtOC0xLTEtMA_c2febd6d-c9be-4caf-80cc-14dc8dcebe4d"
      unitRef="usd">2716000</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzYtNi0xLTEtMA_229aae6f-60a4-4812-9f6f-2fdbf9f88330"
      unitRef="usd">7742000</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzYtOC0xLTEtMA_b86ba959-fc4c-4056-9a87-260e0a6f1b64"
      unitRef="usd">0</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzctNi0xLTEtODcy_3f2346a8-f795-471a-9d9d-a190111bf8c9"
      unitRef="usd">10682000</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity
      contextRef="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzctOC0xLTEtODc1_905804f2-8236-4ad5-ad8b-81e099d2158d"
      unitRef="usd">0</exdx:ProceedsFromIssuanceOrSaleOfTemporaryEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzgtNi0xLTEtMA_46c8f352-863b-44d2-9896-719d3ff7cc74"
      unitRef="usd">70525000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzgtOC0xLTEtMA_fcf49680-07e4-49f0-b624-561e0fa71cc3"
      unitRef="usd">2699000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzktNi0xLTEtMA_b329d939-feaa-4090-a2a9-f23f5071d0e8"
      unitRef="usd">64664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfMzktOC0xLTEtMA_68e2e55b-9625-4748-9bf8-0fbf8bc7df21"
      unitRef="usd">-5861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDAtNi0xLTEtMA_a28e00d1-4b04-46dc-add7-fa36c10c469d"
      unitRef="usd">13264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDAtOC0xLTEtMA_e9a3b39b-5812-44a7-ae64-0c7f7f394d61"
      unitRef="usd">11341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDEtNi0xLTEtMA_31e50641-df0b-4502-93e6-938146c6e2ac"
      unitRef="usd">77928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iae2f6600a9cd41b7908364073cd2f4b1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDEtOC0xLTEtMA_9338cd2e-931e-4952-96cc-38f090099489"
      unitRef="usd">5480000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDMtNi0xLTEtMA_7843ddb2-48f9-4d6f-8eb0-72a4824b5460"
      unitRef="usd">1661000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDMtOC0xLTEtMA_0a0709f8-fdf3-4894-b904-2bfe6f7caf0f"
      unitRef="usd">1293000</us-gaap:InterestPaidNet>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDUtNi0xLTEtMA_74d08688-b7e7-4045-a109-f5c4238d0111"
      unitRef="usd">4640000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDUtOC0xLTEtMA_802197dc-71fd-4883-be99-21d2c0e487d1"
      unitRef="usd">6462000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDYtNi0xLTEtMA_0dd0f6d9-cc10-43d5-abc1-92ab37e04b63"
      unitRef="usd">412000</exdx:EquipmentPurchasedUnderCapitalLease>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDYtOC0xLTEtMA_a2901b11-3103-405c-8bcd-be036a5d6f86"
      unitRef="usd">289000</exdx:EquipmentPurchasedUnderCapitalLease>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDgtNi0xLTEtMA_89e8838c-45d9-474d-8308-3242c005201d"
      unitRef="usd">71000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDgtOC0xLTEtMA_25b6fc66-45a0-44f0-addb-b8e3f1c867de"
      unitRef="usd">207000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTEtNi0xLTEtODk0_745c8f49-ba4f-46df-b1ac-27e0e964edef"
      unitRef="usd">138906000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTEtOC0xLTEtODk3_e645aaf5-5c69-4a1f-9016-295b608408cc"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <exdx:NoncashExerciseOfStockPurchaseWarrants
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtOTE0_53677b33-764f-4692-8555-e7d5efd081ea"
      unitRef="usd">511000</exdx:NoncashExerciseOfStockPurchaseWarrants>
    <exdx:NoncashExerciseOfStockPurchaseWarrants
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtOTE3_9af7d675-35b1-4e8b-9780-ae178c1fffd7"
      unitRef="usd">0</exdx:NoncashExerciseOfStockPurchaseWarrants>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDktNi0xLTEtMA_f826d6dd-7b7f-46b0-8228-8e7e9d637ea3"
      unitRef="usd">1677000</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNDktOC0xLTEtMA_d1ad5c5b-da40-40ee-873f-0f1d41b93d4f"
      unitRef="usd">0</exdx:DeferredOfferingCostsIncludedWithinCurrentLiabilities>
    <exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtNi0xLTEtMTAxNTE_b9634752-cc25-4fe7-90bd-279056671b64"
      unitRef="usd">726000</exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity>
    <exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtOC0xLTEtMTAxNTY_89fc7ca9-591e-4bde-9ed0-d3d31df089b7"
      unitRef="usd">0</exdx:ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="iea8b76a57cc54883929d0d90bc4595be_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtMA_0c3e6589-d274-4369-a8a3-60db08cd2a2f"
      unitRef="usd">6741000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i0dfa20d5f8ab40b493c71c503b0f5015_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtMA_06951f5d-aa5f-4910-a8ff-81184d88e2cb"
      unitRef="usd">0</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtNi0xLTEtMA_fc525851-9fe5-4a5e-b103-1ce8ace317d5"
      unitRef="usd">6860000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtOC0xLTEtMA_6d86f9fb-96e5-4d9a-ba89-4b96fb8c4830"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionOfDividends>
    <exdx:ConversionOfTemporaryEquityAmountConverted
      contextRef="ibc05fc54af544eb6af35145f94c5ddba_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItNi0xLTEtMTAzNTY_815d30b9-5b32-4623-8557-8d7e2b8501a3"
      unitRef="usd">11875000</exdx:ConversionOfTemporaryEquityAmountConverted>
    <exdx:ConversionOfTemporaryEquityAmountConverted
      contextRef="i3b49b48cb2c04fa2a9d3ccdb084ae63b_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTItOC0xLTEtMTAzNjM_348596b5-8423-4ab8-acb0-ac28a5f1260a"
      unitRef="usd">0</exdx:ConversionOfTemporaryEquityAmountConverted>
    <exdx:DeemedDividend
      contextRef="i83a7fb7a4ca54f6fa1b3536703a72193_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtNi0xLTEtMTIyMjY_0734d0fe-d0a1-4046-b9cd-0173be985607"
      unitRef="usd">0</exdx:DeemedDividend>
    <exdx:DeemedDividend
      contextRef="i82834ce037a340c0b764beb37d248f7d_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTMtOC0xLTEtMTIyMzU_73179499-8db4-4a92-9f8c-5621086e2238"
      unitRef="usd">1152000</exdx:DeemedDividend>
    <exdx:OtherNoncashTransactionChangeInAccountingPrinciple
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtNi0xLTEtMA_d7f6fe41-5377-448f-a4de-7cd770dd10b6"
      unitRef="usd">0</exdx:OtherNoncashTransactionChangeInAccountingPrinciple>
    <exdx:OtherNoncashTransactionChangeInAccountingPrinciple
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zMS9mcmFnOjg1YmJkMzQ2ODZiZDQ3NTg5MDJjZjIxMzkwM2NlODRkL3RhYmxlOjMyOTMwMzBkNDU4OTRhZmNiOGU0ZGRkNjM1OTdkOTcyL3RhYmxlcmFuZ2U6MzI5MzAzMGQ0NTg5NGFmY2I4ZTRkZGQ2MzU5N2Q5NzJfNTQtOC0xLTEtMA_e9359f91-c4ad-41e9-b086-eedd69cb714a"
      unitRef="usd">3086000</exdx:OtherNoncashTransactionChangeInAccountingPrinciple>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMTQyOTM2NTExODM5NTI_af5709fa-311b-48a2-ab1e-363e5556b248">Organization&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Exagen Inc. (the Company) was incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, Exagen Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the Company changed its name to Exagen Diagnostics, Inc. In January 2019, the Company changed its name to Exagen Inc. The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 23, 2019, the Company closed its initial public offering (the IPO) of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying condensed financial statements and notes to the condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has suffered recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2019, the Company had cash and cash equivalents of $77.8 million and had an accumulated deficit of $161.2 million, respectively. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIwMA_b8321d76-8995-4279-a50a-73c1a113baa3"
      unitRef="shares">4140000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIxNw_3209b701-bb95-48c2-81c4-ee5613ad1f19"
      unitRef="usdPerShare">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIwOQ_77f6876f-b2ee-4618-9a3b-45939a8cb794"
      unitRef="shares">540000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIyNA_364a8089-7538-4213-82d3-06878d33c6e3"
      unitRef="usd">50500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjIzMA_38d94116-98ba-41f4-9d8a-fc03f372f8ca"
      unitRef="usd">7500000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcxNjI5MQ_caee41ab-e6c5-409e-9933-5421f380e683"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMTA4Ng_2fdd5b0b-10b8-479d-b3be-dacf95ff633e"
      unitRef="usd">77800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF8zNy9mcmFnOjJmMThkODUyYjQ1NjQyMDk5ZmIxZmNmZWJkMzU1ZmY2L3RleHRyZWdpb246MmYxOGQ4NTJiNDU2NDIwOTlmYjFmY2ZlYmQzNTVmZjZfMzg0ODI5MDcwNDkwMw_566eb885-a069-4a17-a3d0-ce6bb51f166d"
      unitRef="usd">-161200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTY_8cc66151-f680-4681-8f24-32bb2aa61ba7">Note 2. Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim condensed balance sheet as of September&#160;30, 2019, the condensed statements of operations and the condensed statements of redeemable convertible preferred stock and stockholders' equity (deficit) for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2019 and its results of operations for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 in accordance with GAAP. The results for the nine months ended September&#160;30, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended December 31, 2018, included in its Prospectus dated September 18, 2019 filed with the SEC on September 20, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Significant payers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.147877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.491228%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.450292%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended September&#160;30, 2019 and 2018, approximately 83%, and 86%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; CTD test. For the nine months ended September&#160;30, 2019 and 2018, approximately 83% and 86%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is dependent on key suppliers for certain laboratory materials. An interruption in the supply of these materials would temporarily impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes the Company's revenues as disaggregated by payer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.374449%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Client&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt;"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying value of the Company's cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 -&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 -&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 -&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099415%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of December 31, 2018, the Company deferred offering costs of $0.4 million consisting of legal, accounting and other fees and costs directly attributable to its IPO, which are recorded within other assets in the accompanying condensed balance sheet. As of September&#160;30, 2019, the deferred offering costs were offset against the proceeds received upon the completion of the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying condensed balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of 7,816,643 shares of common stock, excluding warrant conversions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 5 for further discussion on the remaining warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Payers are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payer (i.e. each individual third-party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Collection of the Company's net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company early adopted Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; (Topic 606) as of January&#160;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, the Company entered into a co-promotion agreement with Janssen (the Janssen agreement) to co-promote SIMPONI&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; in the United States. The Company recognized revenue of approximately $0.4 million and $0.8 million during the three and nine months ended September&#160;30, 2019, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt; are included in selling, general and administrative expenses and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million for the three months ended September&#160;30, 2019 and 2018, and $1.1 million for the nine months ended September&#160;30, 2019 and 2018, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.4 million and $0.3 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $1.1 million and $0.9 million for the nine months ended September&#160;30, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;period) on a straight-line basis. The fair value of stock options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and options outstanding under the Company's stock option plans. For the three and nine months ended September&#160;30, 2019 and 2018, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.647059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,202,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,202,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;934,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;934,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,936,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,411,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,936,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,411,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement: Disclosure Framework--Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&#160;2018-13 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTc_656dbc4b-fe27-4981-87ea-64e37492ba99">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzI_12f83e59-5c88-487e-8754-96a601a22efb">For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.147877%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532064%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.980966%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.491228%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.450292%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy0yLTEtMS0w_5f391e68-0971-46bd-8cf8-b59d94e55a00"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9cfb3b43b3d643db9c0aa9a4cf494dc2_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy00LTEtMS0w_852adbac-5f15-4167-9b46-d70173538eab"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1f0a93f41a20455ebdd1ecf05f3d71f1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy02LTEtMS0w_305586f7-9ec6-4bf8-b439-76448d32e6cc"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5f42ba8fdddf43508fe432039d3bea83_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfMy04LTEtMS0w_8ab7bc4d-d31c-4d55-9880-fa59d2433439"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3a5a1b65ea2e4772af6730adb19a219b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC0yLTEtMS0w_ca70529f-cb12-425d-bd89-79c234d0553b"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id6c397043b0a4757a1ab205b9203c35c_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC00LTEtMS0w_67a7777b-937b-451f-aa26-3e068cd11aad"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie6bf1ae302d841fc97de1f33e7991b73_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC02LTEtMS0w_34352076-90ff-4c1f-8a0b-12dc9ae08c45"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84325f36965b4db489f07aff6f65377b_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNC04LTEtMS0w_7d3f4fd5-f3ab-441d-8f0c-776c4ddcceef"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i48533d3983e8456cbeabafad30dbeb68_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS0yLTEtMS0w_cd3361e9-9823-4c63-9603-ad0823f2f3a3"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9910315e8ba4f9ebdbc616cfe66741f_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS00LTEtMS0w_2650dae6-d152-4302-a2c0-99553798fd21"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8d86bef637f5439da150d6607648998b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS02LTEtMS0w_6e4754f6-e885-47b6-9e73-67a63549fbb6"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec2569645c6b438594320c445bd2f7df_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNS04LTEtMS0w_2c9091b5-f4d2-4b6d-b0cd-5c0c9c1e8b45"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i42b6a2a4f7464d0c962375e478a9a57f_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi0yLTEtMS0w_bcff1661-b16b-4880-8e34-82d968942e12"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f4b9180e4b54309b12c8bde22fbd406_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi00LTEtMS0w_d695f6f6-5d92-4b99-907f-2bf774c99a73"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idbf3daa4d6ce48df96adce7481138367_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi02LTEtMS0w_3d6fc591-fe75-4c02-b3cf-41f2a07dbbb1"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ife08467e105c4ca290a3a0fa3636d3ea_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjI2ZjVlNTExOTUyNzQwZDZiYmQ0ZTgwOTE1NzQ3YzU5L3RhYmxlcmFuZ2U6MjZmNWU1MTE5NTI3NDBkNmJiZDRlODA5MTU3NDdjNTlfNi04LTEtMS0w_a90fbff6-eac2-46b3-b809-4ee66bf5ee14"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i412a4bc0981e429bb2c3c5e64c8588b0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfMy00LTEtMS0w_e05346fc-03a7-4a32-b64a-12aa2b9959a4"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4fe4f91b3fec4fef9d89209d8df0145a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfMy02LTEtMS0w_32a486fb-8842-4ac6-8a58-7a96eaed193e"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2bb9a3f35ed44889b3becb647aad758d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNC00LTEtMS0w_bdbf9da7-4b1e-42c1-9def-d42a189254d7"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc18586b25674689a55653cbc6ba01fd_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNC02LTEtMS0w_908db973-d948-455e-b5aa-e1a8e7f1709f"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4a849e120d8a4d0e8a2192315f7f1d31_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNS00LTEtMS0w_f68f3325-25fa-44c4-a302-21148e3b746a"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icab7fdcf6ea44e4196147db770e82818_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNS02LTEtMS0w_c90c0467-4e28-4ec5-a037-94f48c63e2b1"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6bfbb7c25a64494dbfebb530261307a8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNi00LTEtMS0w_587e6c84-25f4-40e6-920c-0712eb5ab0bf"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5ead417360294b46b273d3316cc3ac11_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjVlMWNiNzliNDNlZDRhYmRhYWZhN2FkZWE2YTlkZmEyL3RhYmxlcmFuZ2U6NWUxY2I3OWI0M2VkNGFiZGFhZmE3YWRlYTZhOWRmYTJfNi02LTEtMS0w_18d9de0a-6ec5-41ce-81d7-f06f07eb4c38"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e2db87ab7524a10b5714856382436dc_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU4NQ_a2369ada-282c-433f-bbac-0754a4689145"
      unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i82e71d7bdf8b4e58ab63f9e4492e3a24_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5MA_771092da-1c87-44a8-9653-45b2f0e2cc66"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if7491bc1715c402c87c11f837d462f25_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5Mg_7994eb01-e453-4bee-a6c0-e8c4f8915e95"
      unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0d50576626ca4bb09058ce09556f99f6_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMTU5OQ_61786279-5de9-48b4-bd44-1e2db04d309e"
      unitRef="number">0.86</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMQ_a8041187-c819-45d1-baa5-8ee948dc5fbc">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes the Company's revenues as disaggregated by payer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.374449%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.922173%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Client&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:31.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt;"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac7d07ac43134c56bd65c32a20842780_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy0yLTEtMS0yODA4_d8fa5cd1-ac54-4f8b-8482-3ee037576995"
      unitRef="usd">6188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b3c7dcf56ca41a4b105284483e7e373_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy00LTEtMS0yODA4_47409f9c-e0ed-4545-8c80-5c308ecd2153"
      unitRef="usd">5408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i117917342465407baf079c005b0dfcb3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy02LTEtMS0yODA4_ee41354e-d7fc-4709-b3b5-eaf140a5a7da"
      unitRef="usd">17716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0986e73045a14160ba73146b0023d069_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfMy04LTEtMS0yODA4_e82e17d8-58c7-4055-af8c-3b5e00ba38f4"
      unitRef="usd">15023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a60fb4a5d5d4f5289b1f4c0113fe3e8_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC0yLTEtMS0yODA4_18ebab2e-dbe5-4b58-b573-451528763a90"
      unitRef="usd">2665000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d1f81cc6e84b5494d096638cfd9d83_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC00LTEtMS0yODA4_ad3b7f64-f156-47f5-b30d-5fb3463bbe05"
      unitRef="usd">2524000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24e975d35170436cab761c1a79d6a68f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC02LTEtMS0yODA4_86a94e7d-38df-4093-a203-16aee5405437"
      unitRef="usd">7964000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92d1b13bd06f4289b57c9968d5a5034f_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNC04LTEtMS0yODA4_5945d73e-7ae2-4c34-b632-e0793a2aa48d"
      unitRef="usd">7013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9d710d634904421a501a1631a9070fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS0yLTEtMS0yODA4_c6192efe-282a-43c0-af74-3948259fec27"
      unitRef="usd">1007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7e26ceee4414fc2ab3a53e749e41b4a_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS00LTEtMS0yODA4_0de4960d-706a-4a45-82d9-b7f310d29c70"
      unitRef="usd">171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35ae2ebb8e184bd395a0b6b0997eb389_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS02LTEtMS0yODA4_533ea587-ed15-47ef-b6a2-3d9295631c53"
      unitRef="usd">3200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebc7396f4e6249ecafc16cddc8b813e2_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNS04LTEtMS0yODA4_fb208e19-042e-47f7-a700-62dd12fc8262"
      unitRef="usd">428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05cd8526aa4f4a2897a2f2d8cdd90fa4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi0yLTEtMS0yODA4_163ae80b-f8e8-467d-9591-471be1b836c5"
      unitRef="usd">148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9774db8f05cb4b99b9d4806cbefe7bbe_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi00LTEtMS0yODA4_af99fa29-e940-49cc-bb1d-ad1ebf52be72"
      unitRef="usd">120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0717d7c677d6448da99afc8400886103_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi02LTEtMS0yODA4_98801171-d8e7-4ff1-8c8f-a5b34cc4fa9f"
      unitRef="usd">458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2036583b6802432094a2445756a97d97_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNi04LTEtMS0yODA4_34feb2bd-8077-402a-a7c5-885aba2d1442"
      unitRef="usd">335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy0yLTEtMS0yODA4_a5f89a9c-4c8f-490b-b849-1190a9573e91"
      unitRef="usd">431000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0d3ee1297444fc9aa08f456ef2c9c7_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy00LTEtMS0yODA4_9ed39587-7a94-4ec2-b8ad-5710d8ae7950"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy02LTEtMS0yODA4_732fa9b8-ef69-4ca3-9fc3-fbd27b60f159"
      unitRef="usd">835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50eedc9033db402abed9620d44e35700_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfNy04LTEtMS0yODA4_cef17009-421e-4fc2-a5c4-7eb5e008a5e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC0yLTEtMS0yODA4_213c0832-a7a0-4511-9584-53789095fff8"
      unitRef="usd">10439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC00LTEtMS0yODA4_563cf0bf-08e8-4946-bc8d-35d929aea3ed"
      unitRef="usd">8223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC02LTEtMS0yODA4_409c7967-a29f-4131-9705-b5fc03ae2d3a"
      unitRef="usd">30173000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmQ3NDQzZjdjN2JjNzQ5YjViZGMzM2QxMzg4YThhZjI0L3RhYmxlcmFuZ2U6ZDc0NDNmN2M3YmM3NDliNWJkYzMzZDEzODhhOGFmMjRfOC04LTEtMS0yODA4_a61a18c3-3e49-4639-85e8-657f9a45f4cb"
      unitRef="usd">22799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTg_0858a99c-acbf-447a-b94b-c370751a5e7f">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying value of the Company's cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 -&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 -&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 -&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNTk_13a561dd-2ca3-4daf-a0c5-9f036dc5cf7f">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i6c30c3ce04a84e4d874b74595bca6d56_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDc5NDA5NQ_c193bd11-63a0-4d7f-8966-43cf356ccd41"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMg_5e97c874-c7d1-467e-8129-57b740282013">&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099415%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwMg_b93c812d-7ff9-4f45-92ce-3fd64c30a0eb">&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.099415%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719298%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMi00LTEtMS0w_8f338b8d-9997-4cb9-b463-2132d0587d8f"
      unitRef="usd">77828000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMi02LTEtMS0w_cc52f9fb-9290-4242-90cd-0e2347229cca"
      unitRef="usd">13164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMy00LTEtMS0w_be95251e-1b58-4619-8087-b551a627829f"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfMy02LTEtMS0w_22cbd258-94df-4f5f-a8f3-0e73e8d1d3b7"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfNC00LTEtMS0w_22594496-0bda-4030-a844-07a20290ed65"
      unitRef="usd">77928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOmRhNGYxMDY3ODNjMzQ2ZjY5ODFkMmI3OThmNzgxNjJhL3RhYmxlcmFuZ2U6ZGE0ZjEwNjc4M2MzNDZmNjk4MWQyYjc5OGY3ODE2MmFfNC02LTEtMS0w_a9f5901c-e1d0-47d7-ae90-2b35074558f9"
      unitRef="usd">13264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DeferredOfferingCosts
      contextRef="i9c143e96ac9b4806bef7c462dd041d9e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfNTQ5NzU1ODIxMTE0Ng_8642ce5d-2069-4caa-9ce1-26924c2c4e37"
      unitRef="usd">400000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjI_28ed81ac-c992-4615-b336-c8c730a1dcbb">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying condensed balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfNTQ5NzU1ODIxMjA4OQ_caee41ab-e6c5-409e-9933-5421f380e683"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjM_a395a152-372f-4922-a3b8-cd0ea3df9dc7">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Payers are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payer (i.e. each individual third-party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Collection of the Company's net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company early adopted Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt; (Topic 606) as of January&#160;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i199eae29222f49ccbbc2f5f8369952de_I20180101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTY4MDM_43bb16fb-9dcc-4d7a-8bf7-4aaf5082777f"
      unitRef="usd">3100000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if02ac8015cd741d79fac73f26cf3a679_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTkzNzM_385d9723-dc75-4413-b59d-ee70a27f9341"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia78219d227ee4753b01fa415dee42ddc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczMzg1MA_fa371903-3029-446c-95c8-4197be8c5513"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjQ_195e2b5c-22d7-4063-ac43-daeccc4189ce">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjU_b8c25b19-306c-4559-9f75-b274850807c5">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million for the three months ended September&#160;30, 2019 and 2018, and $1.1 million for the nine months ended September&#160;30, 2019 and 2018, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzI4Nw_768e1949-04ec-4706-b6e6-f85d95af7815"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzI4Nw_fa4e4aff-2dec-467e-aabb-352627ff339b"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzM4Mw_08258d60-10b6-40f9-8b55-a92e5c931727"
      unitRef="usd">1100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzg0ODI5MDczNzM4Mw_a04bfe38-0575-460e-af96-c4195f8ce12b"
      unitRef="usd">1100000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfRevenue
      contextRef="ic77e882cd1974313a78b7279282ccfd2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1Mzg_6930372f-5a80-445f-ab78-277d6a099770"
      unitRef="usd">400000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i717f3fbc203143a2b2caad2a58d2a79d_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NDI_2e7202c6-6722-4834-ad79-d5493c5b3398"
      unitRef="usd">300000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i4c29ece949cf4a19a46b6de69ea06eb8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NDY_65364ec7-132b-4634-a187-2f4c87be05fb"
      unitRef="usd">1100000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i67896f9ab6ed4543aecbdd23e5c897fc_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMjA1NTQ_856fce7e-21f2-4a45-9050-072092dc3889"
      unitRef="usd">900000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjY_a060e9c2-9db5-42d2-a229-7af17a4466c6">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;period) on a straight-line basis. The fair value of stock options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors).</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjc_29fd5c82-6523-47fe-88f4-8fc57c5ac0aa">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNjk_9561fa53-d8d3-4d0b-afcb-8deceb749c05">&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and options outstanding under the Company's stock option plans. For the three and nine months ended September&#160;30, 2019 and 2018, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMzI5ODUzNDk4MDIwNA_e0dd30b5-1da4-48c0-8f8b-e6dd688d55cd">&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.647059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.852941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,202,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,202,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;934,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;934,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,936,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,411,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,936,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,411,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica3ed9cee3e94243840bca963f193791_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi0yLTEtMS0w_859a22ce-2770-4902-9a58-6550753ef9bb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1c087d67dc248d6a8b02fc4a43f742c_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi00LTEtMS0w_637642bc-6aeb-4e29-a68f-5978a4caa231"
      unitRef="shares">5202940</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6060eadd8f24bc1be3eb453cc22ca19_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi02LTEtMS0w_34551175-56f9-401d-89f2-7af9e3ccd5bb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8542a7dabeb54160bf0ca8be742e9212_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMi04LTEtMS0w_c11a8112-a403-445e-83e5-50fe939028a6"
      unitRef="shares">5202940</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i349270c037f94e44af2351837279531e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy0yLTEtMS0w_e36dad0d-0c12-4434-833d-c18f21591433"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1efe7f934c0047d1bd2ce2d9c861261e_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy00LTEtMS0w_f9af6606-d846-4c80-8734-8fbf6f4f13a8"
      unitRef="shares">203549</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5fbce37a02d245539b9bcdbbdeea57b7_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy02LTEtMS0w_ff51e5fd-2d92-4ec6-b1a5-0b09b5bdd50d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0f1132f9c16d4dc1af50508da38762d4_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfMy04LTEtMS0w_01461da0-9a60-465e-99f9-868fc8886edb"
      unitRef="shares">203549</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i260086f6c68e4de8b8f8f51fc380212a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC0yLTEtMS0w_7f22147e-3d2b-4bdd-ada6-47bebbad9cd1"
      unitRef="shares">461273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec80ab26441a4e79a659a24f2e383d48_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC00LTEtMS0w_209ebcc5-f978-4abd-a5d6-339b1142b3a4"
      unitRef="shares">934789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i621ecaf0fe824109be7c5edd830fcf40_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC02LTEtMS0w_c7ce0bca-d064-40af-a723-9658b55c9805"
      unitRef="shares">461273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85a81e346b614153977eb22e41d41635_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNC04LTEtMS0w_09ce97a2-e88d-4220-9b35-dee89b0830b8"
      unitRef="shares">934789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i25ef04b2fcfa49d582c1daa128336b09_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS0yLTEtMS0w_747862ce-ba05-4dc2-b92c-4147a1c8b605"
      unitRef="shares">1475006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i705ad45db6ea4e2195c730551dac08dc_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS00LTEtMS0w_465584ca-cd51-4f16-86e6-eecd5a2ff9ae"
      unitRef="shares">69885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife9c9599bc1a428cac54f6b6233b42a7_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS02LTEtMS0w_9a0a76ba-c15f-4f37-b09a-ad90b5fac0b1"
      unitRef="shares">1475006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib99b30654d864c038634ae1e2765c0e4_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNS04LTEtMS0w_24a36c2a-5e90-475e-a9ab-fdd58317871c"
      unitRef="shares">69885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi0yLTEtMS0w_b02fae05-2496-493d-b7e4-2084c0565b62"
      unitRef="shares">1936279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi00LTEtMS0w_965ea2b6-3460-4424-a4dd-a4fbbc644713"
      unitRef="shares">6411163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi02LTEtMS0w_55df4d4d-22fb-4089-8f37-82a9c8877022"
      unitRef="shares">1936279</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RhYmxlOjIxMjFkYTRjZmZkYjQ4NWE4Y2E5NDZjZDBkNGE1ZDQ0L3RhYmxlcmFuZ2U6MjEyMWRhNGNmZmRiNDg1YThjYTk0NmNkMGQ0YTVkNDRfNi04LTEtMS0w_dc08f489-43af-4e21-a9ea-b43896462658"
      unitRef="shares">6411163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzA_0c87d0a7-71c6-405b-be78-47a3a9c70828">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80MC9mcmFnOmE0YzgwYWJkYzE5NjQ4MmU5MjcwMDhhZmY5NjM0YjY0L3RleHRyZWdpb246YTRjODBhYmRjMTk2NDgyZTkyNzAwOGFmZjk2MzRiNjRfMTM3NDM4OTU0NDQwNzE_ae53b77c-bd38-482f-b084-16bf5ec867f9">Recent Accounting Pronouncements&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement: Disclosure Framework--Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&#160;2018-13 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQwNg_52625434-6f8f-4111-a40d-6f0832b74141">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;"&gt;Note 3. Other Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation and amortization expense for the three months ended September&#160;30, 2019 and 2018 was approximately $0.1 million and $0.2 million, respectively, and for the nine months ended September&#160;30, 2019 and 2018, was approximately $0.5 million and $0.4 million, respectively. At September&#160;30, 2019 and December 31, 2018, the gross book value of assets under capital lease was $0.8 million and $0.4 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQwOQ_3bbb71f6-8b02-47f5-9d68-b8fbd6157e2d">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMi0yLTEtMS0w_395d1867-1c49-4475-82b6-78cc22c704d3"
      unitRef="usd">916000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMi00LTEtMS0w_dc0e4483-6f7d-4e82-8b46-1e9c830401da"
      unitRef="usd">1174000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMy0yLTEtMS0w_5d2b6566-6da3-4cc8-b922-3e514465f769"
      unitRef="usd">137000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfMy00LTEtMS0w_da89948b-136c-4dc3-bba7-1ff42e6e11e9"
      unitRef="usd">176000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNC0yLTEtMS0w_22ab521c-a17d-44e9-9200-11de162aa8fb"
      unitRef="usd">619000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNC00LTEtMS0w_ab159bab-3b3a-4078-b348-3a2d7c111345"
      unitRef="usd">698000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNS0yLTEtMS0w_14d263be-e73d-4092-bbcb-b8dcd6f297dd"
      unitRef="usd">14000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNS00LTEtMS0w_008c81cf-1a2d-4f97-aaaa-95d9bd610981"
      unitRef="usd">148000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNi0yLTEtMS0w_a3cb1f59-ce45-421b-b6da-aa062961063d"
      unitRef="usd">1686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmJjY2EyZjIzODIwNjQ3ZWJiYmM1NmIzZWIxMTRhZDQ4L3RhYmxlcmFuZ2U6YmNjYTJmMjM4MjA2NDdlYmJiYzU2YjNlYjExNGFkNDhfNi00LTEtMS0w_a54bb4ab-314c-458c-b525-50507aabc8a5"
      unitRef="usd">2196000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQxMA_9fb62717-3768-4502-a4ee-94978e4606d3">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i40e030b64dea4330b9962390e9b32038_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMi0yLTEtMS0w_a832d563-376d-4713-9a7f-a68e7aae52b1"
      unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i167c8bf3e14242d4b6b0b5533837f6e1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMi00LTEtMS0w_879b14cc-4225-4dea-94fe-4b2e14cf4a08"
      unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ice1fa1729eb34b299178d8caf2161699_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMy0yLTEtMS0w_17d7c008-751e-4c10-b2e4-cad533a3b928"
      unitRef="usd">2228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i321e9cae976c4953b8b700e620bfb3ce_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfMy00LTEtMS0w_1620fd23-3e4b-4cff-abdb-cdeed719068a"
      unitRef="usd">1855000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i69188b3f953943e8857feda39af6a513_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNC0yLTEtMS0w_692847fa-71c3-47c3-bb82-b7b08f3502c0"
      unitRef="usd">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i879c70b4b5494742ae2de43311dee3aa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNC00LTEtMS0w_88a359e5-064f-44c7-97e2-afd1341391fb"
      unitRef="usd">796000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib83471b6a9094305b6ad8430295ff5cc_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNS0yLTEtMS0w_7898111e-a384-4892-8c31-de8ef40b98cd"
      unitRef="usd">423000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7547ba12aab74508ae6730cee6b11777_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNS00LTEtMS0w_a114f605-2e26-4e18-acaf-57220ec715f9"
      unitRef="usd">399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib3f8b0aeca3d46d185477b020a4cad1f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNi0yLTEtMS0w_7814ac8f-2240-497f-917a-95841352ade1"
      unitRef="usd">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c9982c73979435b8b18653fef66b69e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNi00LTEtMS0w_1dca02c9-83ee-4c45-ba51-91bcc053e237"
      unitRef="usd">310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNy0yLTEtMS0w_5a642cd1-cb6c-41b0-b54e-b6d71b057f02"
      unitRef="usd">3598000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfNy00LTEtMS0w_f4a41bee-6c8f-4c25-888d-c75c32a24dbf"
      unitRef="usd">3385000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOC0yLTEtMS0w_d342c9f6-77be-40c8-8107-5852f010eefb"
      unitRef="usd">2284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOC00LTEtMS0w_b619ea02-91a2-47d1-8e78-2d9e482d8cfb"
      unitRef="usd">1819000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOS0yLTEtMS0w_cd92a837-b9b7-40d5-94ec-4a09a2e6fd2b"
      unitRef="usd">1314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOmVlNmJlYTIzYTJhNDQ4MTY4MDM2YTA5Y2NkNDhjMTg0L3RhYmxlcmFuZ2U6ZWU2YmVhMjNhMmE0NDgxNjgwMzZhMDljY2Q0OGMxODRfOS00LTEtMS0w_1fbb230d-c445-47fe-bdde-7a7676a77423"
      unitRef="usd">1566000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5NzkzNg_37c3ba03-d147-4a52-8f04-8948988c38f0"
      unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5Nzk0Mw_a164068f-c77c-4059-9e8d-4b2512876c3e"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODAyNw_654b3c4f-03b4-44df-97db-d43db163230a"
      unitRef="usd">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODAzNA_6c93327d-2cf0-41b4-8626-010e6815bbbc"
      unitRef="usd">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie67a92bb4ee44f42b31178b35355abc0_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODIxMQ_7cbb2c88-6a2f-460c-9f88-8e0789f42822"
      unitRef="usd">800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i52ca50f81cf04570bc17e8f427844a2e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzg0ODI5MDY5ODIyNw_b558ad34-a26b-4d08-b51a-5b70f34630f4"
      unitRef="usd">400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RleHRyZWdpb246Mzc3ZmI2NGU2ZTI1NDk0NDk5NTI3MGRmNDU5NDlhMmRfMzI5ODUzNDg4NDQxMQ_c04401e8-af62-45b1-88a7-72f207580dbe">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.520468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643275%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued deferred offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMi0yLTEtMS0w_8d43d4c3-af47-4c40-b148-c6c895f9d507"
      unitRef="usd">2850000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMi00LTEtMS0w_079a4011-772f-4e43-8ca5-208f0d0c98d9"
      unitRef="usd">2111000</us-gaap:AccruedSalariesCurrent>
    <exdx:AccruedFinancingCostsCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMy0yLTEtMS0w_7ff43376-66d4-431c-b792-7af8464a29d5"
      unitRef="usd">1598000</exdx:AccruedFinancingCostsCurrent>
    <exdx:AccruedFinancingCostsCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMy00LTEtMS0w_4656ffd3-10d3-41cc-a8bc-a64317e8c8da"
      unitRef="usd">355000</exdx:AccruedFinancingCostsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNC0yLTEtMS0w_b2aeda82-0fde-43c6-88fa-c572a48a77f2"
      unitRef="usd">182000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNC00LTEtMS0w_09ecb0dd-2104-4888-b934-98f34be4548b"
      unitRef="usd">178000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNS0yLTEtMS0w_c574f947-489f-44c0-b105-001cf4c97207"
      unitRef="usd">292000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNS00LTEtMS0w_9773d6c2-ae92-460f-8673-019e14b7d060"
      unitRef="usd">243000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNi0yLTEtMS0w_7cdc6290-3e05-4944-9c34-a5fb7dd7b70c"
      unitRef="usd">708000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNi00LTEtMS0w_03d0e924-65d3-48dd-9004-01c10b41aa1c"
      unitRef="usd">602000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNy0yLTEtMS0w_5436f410-16c2-4317-9f35-1254c38692bb"
      unitRef="usd">43000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfNy00LTEtMS0w_e0bf1a07-00f0-4350-82d5-db11dd202854"
      unitRef="usd">146000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOC0yLTEtMS0w_50bea0c1-ba73-4cb2-a57c-d436d7904fe1"
      unitRef="usd">179000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOC00LTEtMS0w_4343cbcf-1586-484c-ab6b-6254d9dc5d9d"
      unitRef="usd">81000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOS0yLTEtMS0w_041965c6-e88e-4017-aa92-c3d21bbbf9f2"
      unitRef="usd">597000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfOS00LTEtMS0w_2adce198-0f05-4800-a82d-1088be8185ff"
      unitRef="usd">207000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMTAtMi0xLTEtMA_cf9c45fe-1246-4e22-83da-32c3fbe340ac"
      unitRef="usd">6449000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF80Ni9mcmFnOjM3N2ZiNjRlNmUyNTQ5NDQ5OTUyNzBkZjQ1OTQ5YTJkL3RhYmxlOjlkYjliYTRlZDdhODRhMjBhNDc3OTNjODViNWU1ZWIzL3RhYmxlcmFuZ2U6OWRiOWJhNGVkN2E4NGEyMGE0Nzc5M2M4NWI1ZTVlYjNfMTAtNC0xLTEtMA_90820848-8f12-4fdc-b463-f26be1d2eb0c"
      unitRef="usd">3923000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzI5ODUzNDg5NTcyOA_84e29150-e683-4752-a925-620ce1a07924">Borrowings&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At September&#160;30, 2019, no additional amounts remain available to borrow under the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The interest rate on all borrowings under the 2017 Term Loan is 11.0%, of which 2.5% is paid in-kind in the form of additional term loans, or PIK Loans, until September of 2019, after which interest accrues at an annual rate of 11.0%. The Company has estimated the effective interest rate of this loan to be approximately 14%. Accrued interest is due and payable monthly, unless the Company elects to pay PIK interest. The outstanding principal and accrued interest on the 2017 Term Loan will be repaid in twenty-four equal monthly installments commencing in October 2020. Upon repayment of the final installment under the 2017 Term Loan, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of 2017 Term Loan using the effective interest method. For the three months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $0.2 million and $0.1 million, respectively. For the nine months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;If the 2017 Term Loan is prepaid after September&#160;7, 2019, but before September&#160;7, 2020, the 2017 Term Loan requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after September&#160;7, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The 2017 Term Loan is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Term Loan require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, and either (i)&#160;gross margins, or (ii)&#160;gross profits (collectively referred to as the Interest Only Milestones), as measured quarterly on a rolling twelve month basis, and commencing with the quarter ending December 31, 2017 (1)&#160;the interest rate on the 2017 Term Loan will increase by 8%  and (2)&#160;repayment will commence on the date it is determined the Interest Only Milestones have not been met and over the following eighteen months in equal monthly installments. The consequences of failing to achieve the Interest Only Milestones will be waived if, within sixty days of failing to achieve the Interest Only Milestones, the Company issues additional equity securities or subordinated debt with net proceeds of at least $9.5 million. In addition, the 2017 Term Loan requires that the Company maintain certain levels of minimum liquidity. If the Company has achieved the Interest Only Milestones, the Company is required to maintain an unrestricted cash balance of $2.0 million. If the Interest Only Milestones are not met, the Company must maintain unrestricted cash balances totaling at least the trailing four months cash used to fund operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The 2017 Term Loan agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;At September&#160;30, 2019, the Company was in compliance with all covenants of the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon an event of default in any of the 2017 Term Loan covenants, the repayment of the 2017 Term Loan may be accelerated and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Term Loan due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the 2017 Term Loan, the Company paid issuance costs of $0.4 million to Innovatus and an additional $0.1 million to third parties. These fees were recorded as discounts to the carrying value of the 2017 Term Loan. The Company also issued Innovatus warrants (i)&#160;on the closing date of the 2017 Term Loan, to purchase 15,384,615 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share and (ii) on December 7, 2018, to purchase 3,846,154 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share (Note 5). These warrants are immediately exercisable and will expire if unexercised seven years after their issuance. The fair value of the warrants on each of their dates of issuance, determined using BSM option pricing model, was recorded as a discount to long-term debt and an offsetting amount recognized as a liability. The resulting debt discount is being amortized to interest expense using the effective interest method over the term of the 2017 Term Loan. In connection with the completion of the IPO in September 2019, the Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:81.333333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.935673%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia55d1a24be2548af9b0dd677741eb14f_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTk1_b9dfde4b-070f-4787-abd8-3e17ab89b72b"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie724734be96b41eb9f3acb00203b7563_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTk5_7036c096-0322-40f1-af00-30d8a980c265"
      unitRef="usd">17800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i784c198f85794d068e262abe227f7399_D20181207-20181207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzgz_ffada748-0bb7-47c9-9cae-5451dc491e9f"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTY1_ba2cb247-9819-477e-980e-85616d4127e1"
      unitRef="number">11.0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTc4_255ca4cd-99b4-4308-8061-a91a379ef83c"
      unitRef="number">2.5</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNzI0_ba2cb247-9819-477e-980e-85616d4127e1"
      unitRef="number">11.0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfODE1_6c5758fb-0916-4c63-b985-7e2dec4a4490"
      unitRef="number">14</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMTE4Mw_96c2f5a8-336d-4821-9248-fe8900df3bd1"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="id19b52fc68724d4c9866d0bbfa02eb24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNjk0Ng_f739926d-ec72-44cd-8c07-d702f37c6e21"
      unitRef="usd">200000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i593387046d9c4d19baf524fd531f341c_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNjk2MQ_763ce2c4-f00b-41c1-8b06-874f85c3191c"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="ic84146f62f914258a7de7f505ec8dae3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNzA2OA_858ea220-33b3-4ee8-a033-aadd7e73ea9d"
      unitRef="usd">500000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i9f42b4e0da004e11a3d759fb51a524c2_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwNzA4Mw_2aac5aa0-73a2-4024-8123-50fee9b4e90e"
      unitRef="usd">400000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjA0NzMxMzk2NTE3NA_b9a477c0-cc79-49af-b733-c3960e01be97"
      unitRef="number">0.03</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMjAxMw_1d09830a-b580-434c-9130-f242a2ff7407"
      unitRef="number">1</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzAzNQ_7bce2709-e0c7-4ed5-b8a3-5799ebe7b107"
      unitRef="number">8</exdx:DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease>
    <exdx:DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzQ3Mg_68622a63-cce5-41f4-8898-74989e1c9587"
      unitRef="usd">9500000</exdx:DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzcwNg_6d973030-e262-45f1-994e-4f4e78cefe35"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="ida1326b9e5734d61880de0e289e849bb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTI1NQ_5efdf222-d271-4942-bf81-98e6f2e84bbe"
      unitRef="number">4.0</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if57cc12cbbd74a1ca2bdcab1be975050_I20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTY5OA_d8f841aa-821a-40fa-bf23-731dfd3910b5"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id95d3234e4504a759f6d486b2d115f8d_I20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTczMg_a5ced481-f8a7-4085-9dfd-8f8cf9e43810"
      unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNTkzOA_8bf4326e-74da-4188-a1ba-02179bda9b9c"
      unitRef="shares">15384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjAyMw_d07fb4be-a931-4de0-8cb8-e0cdb98e22fd"
      unitRef="usdPerShare">0.078</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4f9edfc62e2b4d1bad85e451eacf5407_I20181207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjA3OA_a17bfe43-0acb-4c10-8e8b-22a0cbbb57c2"
      unitRef="shares">3846154</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfNjE2Mw_d07fb4be-a931-4de0-8cb8-e0cdb98e22fd"
      unitRef="usdPerShare">0.078</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic3dc0027db4d4c89b9e31c4154ad56cc_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzg0ODI5MDcwOTU2NA_63dd8fdd-32f3-465e-9036-aed16ccc0022"
      unitRef="shares">104722</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RleHRyZWdpb246ZDVmMGY3NzhlYzBiNDFkNzgzMjdjNGU1NWM5ZGIyNzFfMzI5ODUzNDg5NTcyOQ_e0f7fab8-8ceb-4617-a9d9-cb5648ce805b">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:81.333333%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.935673%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMS00LTEtMS0w_7f82b452-0c9a-4b66-8003-d5803c11fa54"
      unitRef="usd">725000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMi00LTEtMS0w_475f52f5-a087-48cb-863d-2639e3cc8c11"
      unitRef="usd">6125000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfMy00LTEtMS0w_ec9af286-f992-494b-af36-c0adb606e2cb"
      unitRef="usd">14937000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNC00LTEtMS0w_7e1b6234-9a33-4ca7-b862-1db15481e438"
      unitRef="usd">11250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNS00LTEtMS0w_8c6a0c66-8694-43f9-ba93-8dfcbdcf0780"
      unitRef="usd">33037000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfNy00LTEtMS0w_fd4f4dae-367f-4cee-aa24-e946c13c1546"
      unitRef="usd">484000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfOC00LTEtMS0w_0f5a537b-f3e5-4336-baa6-8462853b5cf4"
      unitRef="usd">6876000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81Mi9mcmFnOmQ1ZjBmNzc4ZWMwYjQxZDc4MzI3YzRlNTVjOWRiMjcxL3RhYmxlOmIxODg4MWU0MTBhYTRlMzZiMDU0YjU4N2M0NTQ1NGEyL3RhYmxlcmFuZ2U6YjE4ODgxZTQxMGFhNGUzNmIwNTRiNTg3YzQ1NDU0YTJfOS00LTEtMS0w_56d1e1dd-a54b-45e3-b7ec-34309b7499ff"
      unitRef="usd">25677000</us-gaap:LongTermDebt>
    <us-gaap:PreferredStockTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzI5ODUzNDkyNTk5NQ_e15b51a3-9f40-4dee-8548-44dcc7c09d24">Warrants to Purchase Common or Preferred Stock&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the completion of the Company's IPO in September 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;The remaining outstanding Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate 104,722 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Warrants to purchase common stock for 569,184 shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of 512,363 shares of common stock. Unexercised warrants to purchase common stock for 9,054 shares were terminated prior to the completion of the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Warrants to purchase Series D and Series E redeemable convertible preferred stock for 119,771 shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of 27,431 shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following warrants to purchase common stock were outstanding as of September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.532164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 8, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 8, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"&gt;(1) Prior to the conversion upon IPO, the remaining warrants were for the purchase of Series F redeemable convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The outstanding warrants to purchase shares of common stock are equity classified at September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iece3f21b80234006a7c103426a2665ce_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzg0ODI5MDcyNzk3Mw_02e8203f-48ee-45ba-98f4-5a47c533f223"
      unitRef="shares">104722</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <exdx:ClassOfWarrantOrRightExercised
      contextRef="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1Nzk4OQ_8ed4d768-f15f-4948-ab4d-e647751da403"
      unitRef="shares">569184</exdx:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODEwMw_5df86fba-59e4-4a27-adfd-6da0c1853053"
      unitRef="shares">512363</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <exdx:ClassOfWarrantOrRightUnexercisedAndTerminated
      contextRef="i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzg0ODI5MDcyNzQ5NA_8e3b5bad-d02a-48a2-9ff4-d395682db0ae"
      unitRef="shares">9054</exdx:ClassOfWarrantOrRightUnexercisedAndTerminated>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia15176551c5942c6996c700737062eb7_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODIwNQ_ed22cc0e-fa1d-467c-8444-d0753e0fa4fe"
      unitRef="shares">119771</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i7d71efa9a85b42ea9b589b656b2491e8_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfNTQ5NzU1ODE1ODMxMQ_3cb7eb22-e02c-46f6-811a-5d372e462f70"
      unitRef="shares">27431</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RleHRyZWdpb246MzFiZGZmYmI1Zjk1NDY4OGE2YzMxMWQ5NmY4MTVmNjhfMzI5ODUzNDkyNTk5Ng_4cde7125-620a-4f17-8c90-ad13c82a8a07">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following warrants to purchase common stock were outstanding as of September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.532164%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,402&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 8, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 8, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;461,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;"&gt;(1) Prior to the conversion upon IPO, the remaining warrants were for the purchase of Series F redeemable convertible preferred stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id6b232544b0e4c3982a50c01fa3beedd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMS0xLTEtMS03Njgy_2c08f99f-33a9-4505-95c5-48abef22ec97"
      unitRef="shares">282402</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id6b232544b0e4c3982a50c01fa3beedd_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMS0zLTEtMS0xMjYxMA_230448cd-a729-4242-a567-0210aa371fa8"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia072d734c1074dffafc2727ff7d43637_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMi0xLTEtMS03Njgy_096ef89b-c065-4913-bb32-3d643488465a"
      unitRef="shares">74018</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia072d734c1074dffafc2727ff7d43637_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMi0zLTEtMS0xMjYxMA_890e50f2-5409-4681-895a-ca6a82507e42"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icbbd59a27b684af7ad1433a642355d7b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMy0xLTEtMS03Njgy_85d2cb42-6ba5-494e-a754-d9e3894baf02"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icbbd59a27b684af7ad1433a642355d7b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfMy0zLTEtMS0xMjYxMQ_b7bb9948-ad74-40e0-a5f6-7e7ab540127d"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if49e177a5bc240e58f5c1feec55322b0_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNC0xLTEtMS03Njgy_8660d6fc-34cf-4fca-9e6a-db6c9f0b8549"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if49e177a5bc240e58f5c1feec55322b0_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNC0zLTEtMS0xMjYxMg_784442ea-65a7-4093-b369-9ff4ae156830"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2dbe833388254c769b6515006ac2d21a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNS0xLTEtMS03Njgy_c4abe3e5-a4a2-4e32-81cb-819381d74bbd"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2dbe833388254c769b6515006ac2d21a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNS0zLTEtMS0xMjYxMw_f2a4f14c-cfaf-4497-a3c6-32966227e791"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81NS9mcmFnOjMxYmRmZmJiNWY5NTQ2ODhhNmMzMTFkOTZmODE1ZjY4L3RhYmxlOmU2OGEzNzQwNjU1YjRmMTc5MDkzNjhkOTlkMWEyMDQzL3RhYmxlcmFuZ2U6ZTY4YTM3NDA2NTViNGYxNzkwOTM2OGQ5OWQxYTIwNDNfNi0xLTEtMS03Njgy_c28ca174-2a44-4f7c-888a-72f5eebc29c4"
      unitRef="shares">461273</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzI5ODUzNDg5ODUzNw_41c06ae7-9020-4bd7-8667-dcf00a9a2146">Commitments and Contingencies&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company leases approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in January 2021, with options to extend the lease for two additional 36-month periods. In addition, the Company also leases approximately 19,500 square feet of office space in Vista, California, under a lease that expires in January 2021 with an option to extend the lease for an additional 24-month period. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended September&#160;30, 2019 and 2018, rent expense was $0.1 million. For the nine months ended September&#160;30, 2019 and 2018, rent expense was $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. All milestone payments other than one have been paid as of December 31, 2017. The remaining milestone obligation is for an additional $2.0 million payment due to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at September&#160;30, 2019 and December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, the Company has ongoing royalty payment obligations on net sales of products which incorporate certain acquired technologies ranging from 2.5% to 7.5%. Future royalties payable under these arrangements are limited to the lesser of an aggregate of $4.2 million (including an upfront payment of $100,000) or the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments on net sales of products which incorporate licensed technology, as defined, ranging from 3.0% to 20.0%. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2018, the Company entered into a supply agreement with one supplier for reagents which includes a minimum annual purchase commitment of $3.25 million for each of the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjEwMDA_c43a2b30-47ae-46c0-8186-19be08bba125"&gt;three&lt;/span&gt; years covered by the agreement, which terminates in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Litigation&lt;/span&gt;&lt;/div&gt;The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk4Ng_7735bdd5-03d3-437b-b3b1-466ce783b25c"
      unitRef="sqft">14000</us-gaap:NetRentableArea>
    <exdx:NumberOfOperatingLeaseExtensions
      contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5ODc_61ca4be9-908e-44f2-8eea-b65bf8175c80"
      unitRef="leaseextention">2</exdx:NumberOfOperatingLeaseExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i0b712c3e3658431f99e266dbcbea25a3_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk5OA_6f9226d5-d271-41a6-a73e-6537edc5578f">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:NetRentableArea
      contextRef="i049fe228926f4c9398df1295ac08300c_I20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2Nzk5NA_b99cf219-0f2e-4013-843d-bfafbd9c2743"
      unitRef="sqft">19500</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i049fe228926f4c9398df1295ac08300c_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNjA0NzMxMzk2ODAwMg_2569ace1-3181-4ace-a1ef-2e6273a75aa3">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzg0ODI5MDcwMjg2NA_f417e9d8-c01d-4840-86ea-e6fcad8071c1"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMzg0ODI5MDcwMjg2NA_f9887a2f-5e89-4463-abb8-9dc6d8be3c78"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNzgx_479bd037-e70a-4c23-a343-6d6eccf13c01"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNzgx_b3317b01-1641-4b2f-9b51-590d9d39b03b"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <exdx:MilestoneObligation
      contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODE0MA_2eef1817-e61f-462d-bc16-0e1d9dab1c4a"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5OTM_92b2015b-097a-415b-9f63-8cca0153636e"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="icba0cb4c451d417dbe3f4f8dfab39b44_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfMTU5NDI5MTg2MjA5OTM_afb8680a-c9d2-4910-bf24-e9553e9fbf46"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i7ec9d6e18a8246b99def6548100abbca_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODQzNA_85b4c558-50fd-4304-8477-9bf252d79d40"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i97157708442344caa00fafca0fbb5704_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNTQ5NzU1ODE0ODQ0MA_64c24cdf-f721-4b61-9977-0c7734a31b2c"
      unitRef="number">0.075</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="i97157708442344caa00fafca0fbb5704_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDM5ODA0NjUyMzI4NA_6ec1ae53-750d-4bbd-a7e5-aca8ee8b83d9"
      unitRef="usd">4200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="ib88479b12a8647d596f63546f0bbdd6e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDM5ODA0NjUyMzI5Ng_165e1f93-0e7a-46b1-a014-7a34147c418c"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i9cdbf37439b04f6980d34a5eb0f08877_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDQ2MQ_830bb94e-b103-4573-9a81-18ce2cdaa4c9"
      unitRef="number">0.030</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i4d2cf5de0966423685b89de08ef5d10f_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDQ2Nw_52734ee5-ba03-41ee-86f4-091984f256e7"
      unitRef="number">0.200</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF81OC9mcmFnOjFmODhlYjEwZjUxYzQzMzViOTY2NTI1ZjNhZjgwZDIwL3RleHRyZWdpb246MWY4OGViMTBmNTFjNDMzNWI5NjY1MjVmM2FmODBkMjBfNDc0OQ_86be8b13-2784-47cf-b750-7381685ff23e"
      unitRef="usd">3250000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3MA_8a4130a9-ec8a-48da-926b-5bd705388fd6">Fair Value Measurements&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970760%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.385965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Company's money market funds is based on quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes a roll-forward of the financial instruments measured on a recurring basis and classified within Level&#160;3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.941520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&lt;br/&gt;Classified&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances at December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remeasurement of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remeasurement of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net exercise of preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclassification of liability classified warrants to stockholders' equity (deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Changes in the fair value of the Company's liability classified warrants are recorded in the line item change in fair value of financial instruments in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3MQ_ab503b78-df80-4db5-9492-54ae853248f6">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.970760%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.526316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.385965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9aeb522a5a804c1ab10f04b766c6d235_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy0yLTEtMS0zMTQ2_43bc48ef-cbe1-4b66-8132-17fe7c65b384"
      unitRef="usd">71950000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8cdfd7d55d447c6a6ba587c0fb72778_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy00LTEtMS0zMTQ2_b9606bf0-20c4-4872-af4f-122b0daae0c9"
      unitRef="usd">71950000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia8396f778183403a8b3d18137e1d7154_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy02LTEtMS0zMTQ2_633b4763-8094-484c-a14e-163e2891076c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia5b7d6be4807402181770f969bd3b3c8_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjFiNDdkNjczMjg0YzRiMGI4ZjZlNjdjMTFkNmE0YThmL3RhYmxlcmFuZ2U6MWI0N2Q2NzMyODRjNGIwYjhmNmU2N2MxMWQ2YTRhOGZfMy04LTEtMS0zMTQ2_abe971d1-bbc2-4788-9dee-ac9d0685232b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9cc77115ea38400ebaa8de4fdf3c7cd9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC0yLTEtMS0w_db749146-3be9-4a75-93f5-4bec3420b172"
      unitRef="usd">8618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib1c4da20970f49bab695c3ca35f9f79a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC00LTEtMS0w_21201df3-a915-45b3-a2a6-e093f4fb704e"
      unitRef="usd">8618000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i202d9a2d99d343aeb330da6b95303d98_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC02LTEtMS0w_4585ac9c-f6bd-46c8-83e2-baa039254853"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i578d8c5006254318b4ecbd98581f9308_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNC04LTEtMS0w_93c582c3-7c94-41ea-8baf-f52e414b1218"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ib206ca9a730640ff880db0ca2948c48f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi0yLTEtMS0w_378200f3-8a54-4182-8e8f-2277ba9b1ca5"
      unitRef="usd">1503000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i48be9f8c11ab46a0a2b04915df9f4383_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi00LTEtMS0w_7e5832f5-e2a4-4a5f-a226-a7985da67021"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ife24fcb5063e4bf2a8ca790bfd29a229_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi02LTEtMS0w_a909122d-41f8-4abc-b425-8cedd4011469"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i08cb01ea319e4dcf9a9ae2d18095b29c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjEyZmM2M2M5YzZmODQ1OWM4MGZhMmE5Yjk0ZjllNDM0L3RhYmxlcmFuZ2U6MTJmYzYzYzljNmY4NDU5YzgwZmEyYTliOTRmOWU0MzRfNi04LTEtMS0w_aae0edc4-0a32-4bf6-9692-952876376589"
      unitRef="usd">1503000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RleHRyZWdpb246ODBhNmJiZjhkZTE0NDI5Nzk5ZTFhNmQ2YjZjYjRiNTVfMzI5ODUzNDg4NjE3Mg_bf6701cf-17ab-4290-9a33-d07ddea0db20">&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table includes a roll-forward of the financial instruments measured on a recurring basis and classified within Level&#160;3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:82.941520%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability&lt;br/&gt;Classified&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(As&#160;Revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances at December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remeasurement of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balances at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remeasurement of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net exercise of preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reclassification of liability classified warrants to stockholders' equity (deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="ib871a4638845441c862fde06e4cc74f2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS02LTEtMS0w_69d80e43-d036-4598-a389-82395e58372e"
      unitRef="usd">-896000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTAtNi0xLTEtMA_a4df30f9-af19-43b2-87d9-ea1377d5a19b"
      unitRef="usd">-289000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="if808a2ea757647c8bd919d180eb2162e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTEtNi0xLTEtMA_317c40dd-c68e-4554-a395-403103e9e42b"
      unitRef="usd">318000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="iab6de603a8d9482782ee114aee3bf819_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfMTItNi0xLTEtMA_a03baf9e-3003-4cf0-9b32-ea3d3a7dd328"
      unitRef="usd">-1503000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOC00LTEtMS0zMTc1_4f80ca8e-f2c2-4779-b0e1-6cad46eb1e5d"
      unitRef="usd">-267000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfNy00LTEtMS0xMzQ3Mg_0cefa240-7823-4a0f-bdf0-6497bebc7ccd"
      unitRef="usd">-510000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
      contextRef="i4d3195e867314fdfacbdc9dbc8b3df75_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS00LTEtMS03Nzk5_77b62f9a-4663-4728-b141-b167c60a4db8"
      unitRef="usd">-726000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i18c74d0be6304b29b0107390ce9abeec_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82MS9mcmFnOjgwYTZiYmY4ZGUxNDQyOTc5OWUxYTZkNmI2Y2I0YjU1L3RhYmxlOjMzODkyNDY0NTA2MTRmMWQ5ZWYyYzlhNzM2NzJhNDhiL3RhYmxlcmFuZ2U6MzM4OTI0NjQ1MDYxNGYxZDllZjJjOWE3MzY3MmE0OGJfOS00LTEtMS0zMTc1_17520d47-ca91-4ff1-902e-d1f7700c60e3"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <exdx:TemporaryEquityTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzOTMxNjI4NTc2MzU_60f48b20-8620-4060-adfe-0be999ae79a2">Redeemable Convertible Preferred Stock&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of convertible preferred stock from 750,300,000 to 955,500,000 shares, of which 205,200,000 shares are designated as Series G convertible preferred stock and set forth the rights, preferences and privileges of the Series G convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 11, 2019, the Company amended and restated its restated certificate of incorporation to among other things, increase its authorized shares of convertible preferred stock from 955,500,000 to 1,038,667,059 shares, of which 479,967,595 shares are designated as Series H redeemable convertible preferred stock and set forth the rights, preferences and privileges of the Series H redeemable convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon completion of the Company's IPO in September 2019, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of redeemable convertible preferred stock remain outstanding at September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Series F Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company's Board of Directors authorized a third tranche closing of the issuance to existing preferred stockholders in connection with the Company's Series F financing, which was completed between December 2017 and January 2018. In December 2017, a group of existing investors of the Company purchased 54,246,756 shares of Series F redeemable convertible preferred stock at a per share price of $0.078 for aggregate gross proceeds of approximately $4.2 million. In early January 2018, a group of existing stockholders of the Company purchased an additional 34,914,327 shares of Series F redeemable convertible preferred stock at a per share price of $0.078 for aggregate gross proceeds of approximately $2.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that the third tranche closing of the Series F preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series F redeemable convertible preferred stock, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;the Company determined there were no embedded features requiring bifurcation in the shares of Series F redeemable convertible preferred stock issued in the third tranche closing. The Company accounted for the difference between the estimated fair value and the $0.078 per share purchase price of shares of Series F redeemable convertible preferred stock issued in the third tranche closing as a deemed dividend since all investors in the third closing are existing preferred stockholders of the Company, and the Company did not identify any elements to the transaction which it believes were compensatory in nature. As a result, the Company recognized a deemed dividend in the amount of $1.2 million in the first quarter of 2018, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#x2019; deficit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Series G Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at per share price of $0.078 in each closing. Shares of Series G redeemable convertible preferred stock were issuable under the Series G preferred stock purchase agreement until the earlier of March 31, 2019 or the issuance of all authorized shares of Series G redeemable convertible preferred stock, as specified in the Company's amended and restated certificate of incorporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2019 and March 2019, the Company sold 88,030,905 and 9,615,384 shares, respectively, of Series G redeemable convertible preferred stock for aggregate gross proceeds of approximately $7.6 million to new and existing investors, of which $3.75 million of gross proceeds were received as of December 31, 2018 and are included in the accompanying December 31, 2018 balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, the Company sold an additional 51,282,048 shares of Series&#160;G redeemable convertible preferred stock for aggregate gross proceeds of approximately $4.0 million to existing investors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, in May 2019, the Series&#160;G preferred stock purchase agreement was amended to include the right of the Company to require certain holders of Series&#160;G redeemable convertible preferred stock to purchase an additional 32,051,280 shares of Series&#160;G redeemable convertible preferred stock at $0.078 per share, for total aggregate proceeds of $2.5&#160;million, at any time after July&#160;31, 2019 and prior to May&#160;31, 2020. This right terminated in connection with the issuance of the Series H redeemable convertible stock in July 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that the closings of the Series G preferred stock purchase agreement in January and March 2019, contained a single freestanding financial instrument, shares of Series G redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company concluded the closing in May 2019 contained two freestanding financial instruments, shares of Series G redeemable convertible preferred stock and the Company call right, and the Company concluded there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company call right was deemed to have nominal value since it was with insiders with knowledge of the imminent closing of Series H redeemable convertible stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Series H Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $0.04712. Pursuant to the terms of the agreement, the new investor purchased 233,446,519 shares of Series H redeemable convertible preferred stock for gross proceeds of approximately $11.0 million. In connection with the Series H financing, the Company converted all of the 148,928,337 outstanding shares of the Company's Series G redeemable convertible preferred stock into 246,521,076 shares of Series H redeemable convertible preferred stock on a dollar-for-dollar basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that the closing of the Series H preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series H redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series H redeemable convertible preferred stock issued at closing. The Company accounted for the difference between the effective conversion price of $0.04712 and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $6.7 million in the third quarter of 2019, that was &lt;/span&gt;&lt;/div&gt;recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit). Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $6.9 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders' equity (deficit).</exdx:TemporaryEquityTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i51991cbb9983403c883bb01e0ecacfe4_I20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMjkz_489e3bde-b127-4d90-b0f0-fec0adf9623a"
      unitRef="shares">750300000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="if76ec7383c01495aa62e382bd4f709f7_I20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMjk5_87c506e7-4b58-479a-8a22-de85da1e3926"
      unitRef="shares">955500000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i6ac11f467d4a414d8b4dc99e134c6b38_I20190102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzE4_3f1f5842-dc67-47b5-909a-9f343327cb60"
      unitRef="shares">205200000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ia414d6d243b647818871ad407f657257_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTM5Mw_a2d0b798-b099-475b-b78d-77e8bacd8b80"
      unitRef="shares">955500000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i9f3012c64b3841629d97963b5c65859a_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTQwOA_77997fcc-00fd-4dd5-8017-9822a1a1c9e3"
      unitRef="shares">1038667059</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ibd111bb967164dd1b749064f44fe4ace_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjUyOTQyMQ_dab42acd-c205-4111-941e-6fca7e7abc16"
      unitRef="shares">479967595</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU1NzY2MQ_caee41ab-e6c5-409e-9933-5421f380e683"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI3Mw_f72200ec-b2d7-4b40-9842-75d4505f72b4"
      unitRef="shares">54246756</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI4MQ_a379d07a-e67e-4da4-80c7-ab07d6708b2e"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODI5NQ_9e2dcbba-86d3-4ac7-b797-65fe8d831799"
      unitRef="usd">4200000</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="i6821094327564f7ba91627dc90eeb669_D20180131-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODMwNw_3285e295-619f-4c92-8fac-eca1c583d833"
      unitRef="shares">34914327</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="id07edc4e5b92475b8e47bad4f0b1c23f_D20180101-20180131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNTQ5NzU1ODIwNzY2Mg_1bbdcd43-3180-45e3-878c-16333b2fdd94"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="i6821094327564f7ba91627dc90eeb669_D20180131-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODMxMw_60cfdcab-ee22-42f0-98fa-3ff11976559a"
      unitRef="usd">2700000</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i6f00742440504aff8408b3b8c3fc98b7_D20171201-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODM2MQ_a379d07a-e67e-4da4-80c7-ab07d6708b2e"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityDeemedDividend
      contextRef="ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDczODM2Nw_945240bc-24a3-4f33-b70c-46e80def7390"
      unitRef="usd">1200000</exdx:TemporaryEquityDeemedDividend>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjExMw_7cccd428-1e4c-4776-a8bc-ada942cedbd2"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzMjg_16566775-7c68-424b-84d5-5d9ff1be349e"
      unitRef="shares">88030905</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="i8b4fe828275f44fdbff0acdc8da1a56f_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzMzU_2f8bc609-982c-4de3-929b-8e5035f6227f"
      unitRef="shares">9615384</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="i3ecfcc3c27f94cccbdb02d3266aed9c6_D20180101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU0NTc_37e04251-6f51-4bd3-bb37-776455c5313a"
      unitRef="usd">7600000</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="i34cec7509c0b444690051ce059a40fc2_D20180101-20181231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU1MDA_485c5b1b-9738-4338-9e9b-21999dc6a738"
      unitRef="usd">3750000</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU2NDk_732b8536-825f-4520-b5bd-275ea2ffbde7"
      unitRef="shares">51282048</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU3NTY_014010da-c715-4845-a003-28f18ace7449"
      unitRef="usd">4000000.0</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:TemporaryEquityRightsForMandatoryPurchase
      contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTU5OTk_2a688f27-48b0-44c8-9cdb-1551bb12dd5a"
      unitRef="shares">32051280</exdx:TemporaryEquityRightsForMandatoryPurchase>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="ied60dbfe28ae45d9b205e711f33a1fb7_D20190101-20190131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjEyMg_7cccd428-1e4c-4776-a8bc-ada942cedbd2"
      unitRef="usdPerShare">0.078</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase
      contextRef="icc7e9a9fed1d4564b3c056fee4e9412e_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjEyOA_cb71d366-4b45-406c-8f18-d3dab504e97c"
      unitRef="usd">2500000</exdx:TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjI3Ng_ee9f048f-4f38-48a3-b9c8-828048f9a239"
      unitRef="usdPerShare">0.04712</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction
      contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjM0Nw_2ddc0804-88e9-4d53-bac7-964715217c95"
      unitRef="shares">233446519</exdx:SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction>
    <exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction
      contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjM5Mw_73c36e0c-5e6e-4bb4-a739-2e5a74894dad"
      unitRef="usd">11000000.0</exdx:SaleOfTemporaryEquityConsiderationReceivedOnTransaction>
    <exdx:TemporaryEquitySharesRedeemedUponConversion
      contextRef="i3a943c5b22a147a0a01ed7c2ddc3799b_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjQ4MQ_94c991e0-35d1-4b18-aabb-c8fa06142f68"
      unitRef="shares">148928337</exdx:TemporaryEquitySharesRedeemedUponConversion>
    <exdx:TemporaryEquitySharesIssuedUponConversion
      contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU0MjU5Nw_9d1055af-d454-4f96-9431-3dd94111500e"
      unitRef="shares">246521076</exdx:TemporaryEquitySharesIssuedUponConversion>
    <exdx:SaleOfTemporaryEquityPricePerShare
      contextRef="i16c9869181a54bfc8ead1acff9c58057_D20190701-20190731"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMTUzOTMxNjI4NTc2MjY_f3845e96-4442-4c1b-9fac-39fa7c1484b8"
      unitRef="usdPerShare">0.04712</exdx:SaleOfTemporaryEquityPricePerShare>
    <exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature
      contextRef="i9e550b05869e40b08c21bb6a2735d299_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfNDM5ODA0NjU3MjM0Mw_4053e420-1d1f-43cc-a5ab-02a0852663c1"
      unitRef="usd">6700000</exdx:TemporaryEquityDeemedDividendsWithBeneficialConversionFeature>
    <exdx:TemporaryEquityDeemedDividend
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82NC9mcmFnOmM2MWQ5MTQ5MjRhMzRjZThiZDZmNDA1Y2M1Nzc3M2Q5L3RleHRyZWdpb246YzYxZDkxNDkyNGEzNGNlOGJkNmY0MDVjYzU3NzczZDlfMzg0ODI5MDc2NjAwMQ_885e405c-b696-488a-ae05-8d1e0203c323"
      unitRef="usd">6900000</exdx:TemporaryEquityDeemedDividend>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTg_8819dbbe-2eb2-412d-8fd9-43cf0edaa1f5">Stockholders' Equity (Deficit)&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things,&#160;increase its authorized shares of common stock from 1,470,000,000 to 1,675,200,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 11, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of common stock from 1,675,200,000 to 1,970,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company filed its amended and restated certificate of incorporation on September 23, 2019, authorizing 200,000,000 shares of common stock and 10,000,000 shares of preferred stock.&lt;/span&gt;&lt;/div&gt;On September 23, 2019, the Company closed its IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTc_93e805e4-4437-43d5-8f0a-3779cd76531a"
      unitRef="shares">1470000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i74d7a070fb6e417cbecca982fcd80243_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMTUzOTMxNjI3OTc3OTY_3b37a05d-4bfb-4343-b64c-d75e609bd177"
      unitRef="shares">1675200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia414d6d243b647818871ad407f657257_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDIzMw_1c8cbf1f-8ad0-4af7-9f7f-6396892c89d8"
      unitRef="shares">1675200000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9f3012c64b3841629d97963b5c65859a_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDI0OA_ae42c846-c67d-4b27-9707-4b600793c81f"
      unitRef="shares">1970000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1936657650f8443fb7d623789b65864b_I20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDMwMg_2ca9b673-9635-4292-af91-8bb586dfbe9a"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1936657650f8443fb7d623789b65864b_I20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMDMxNA_024aaf19-c7f8-42c3-9e35-8f64a2f91e2f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwMzk5Mw_b8321d76-8995-4279-a50a-73c1a113baa3"
      unitRef="shares">4140000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDA1MQ_3209b701-bb95-48c2-81c4-ee5613ad1f19"
      unitRef="usdPerShare">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if6695b6e79b2405283b2097bffd48a55_D20190923-20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDE0NA_77f6876f-b2ee-4618-9a3b-45939a8cb794"
      unitRef="shares">540000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDMwNQ_364a8089-7538-4213-82d3-06878d33c6e3"
      unitRef="usd">50500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="i2cdf719c7a7e4723b6692faeb9eec292_I20190923"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfMzg0ODI5MDcwNDQzOQ_38d94116-98ba-41f4-9d8a-fc03f372f8ca"
      unitRef="usd">7500000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i878b8d661b254efb84e9bae56778e4b4_D20190923-20190923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF82Ny9mcmFnOmY2MzdlODEzODg0ZjRkMGM4MzNlNTZhMGUyY2ZkZDY5L3RleHRyZWdpb246ZjYzN2U4MTM4ODRmNGQwYzgzM2U1NmEwZTJjZmRkNjlfNTQ5NzU1ODE0NTI1NA_caee41ab-e6c5-409e-9933-5421f380e683"
      unitRef="shares">7816643</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTQ_edc7fbfa-b206-44fd-baa0-50ef41efcae2">Stock Option Plan&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2012, the Company's Board of Directors adopted the 2013 Stock Option Plan (the Plan). Pursuant to the Plan, employees, consultants, and directors may be granted either incentive stock options or non-qualified stock options to purchase shares of the Company's common stock. In July 2019, the number of shares reserved for issuance under the Plan was increased from 669,806 to 1,663,681 shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Incentive Award Plan (the 2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. A total of (i) 2,011,832 shares of common stock plus (ii) shares subject to awards granted under the 2013 Plan on or before the effective date of the 2019 Plan became available for issuance under the 2019 Plan and will initially be reserved for issuance under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be increased annually on the first day of each fiscal year during the term of the 2019 Plan, beginning with the 2020 fiscal year, by an amount equal to 4% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year or such smaller amount as the Board of Directors may determine. As of September&#160;30, 2019, 1,199,631 shares remained available for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The options generally expire &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzU_c6825e11-0fc3-4e9f-9041-6ef37ef4651d"&gt;ten&lt;/span&gt; years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODA_bc7e3512-1d71-474f-a1f3-d50463190609"&gt;four&lt;/span&gt; years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Activity under the Company's stock option plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.953216%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;661,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;814,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Outstanding, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Vested and expected to vest, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options exercisable, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.953216%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;2.0%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Total non-cash stock-based compensation expense recorded related to options granted in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.497076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, total unrecognized compensation cost was $6.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2019, the Board of Directors adopted the Employee Stock Purchase Plan (the ESPP). The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 120,000 shares of common stock was initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2020 fiscal year, by an amount equal to 1% of the total number capital stock outstanding on December 31 of the preceding calendar year or such smaller other amount as the Board of Directors may determine. There has been no stock-based compensation expense incurred related to the ESPP for the three and nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6966cf5374bc41b5875121d7c8d99c81_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzY5NQ_69763633-f112-4260-842e-28ffeaa552fc"
      unitRef="shares">669806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ief83568c465c465ab430cf56fab8b518_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzY5Mg_a88945ca-cd08-4666-9b0f-cc0b6881ada5"
      unitRef="shares">1663681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzcwNg_07c4df66-acc0-4acc-98ff-d1e911de008f"
      unitRef="shares">2011832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExNzM_b180136c-fdac-4533-a06a-07713c24c758"
      unitRef="number">4</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie73e694807f84cd394cbd47d74001ce4_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfNjA0NzMxMzk2NTE0NQ_9035e737-e784-4116-bdce-0abb8c47f9c2"
      unitRef="shares">1199631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODc_b1a71e7b-bc14-4108-9521-6df07456b2eb">&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Activity under the Company's stock option plans is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.953216%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.011696%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596491%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;661,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;814,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Outstanding, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Vested and expected to vest, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,475,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;Options exercisable, September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi0yLTEtMS0w_593bdda1-e3f4-47e9-a19b-8dcf9961ec14"
      unitRef="shares">661180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi00LTEtMS0w_c6868840-b620-411b-8ed0-6dd18ab493ce"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi02LTEtMS0w_fe8372ce-8b02-4b46-a9cf-4ad59422ff56">P9Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNi04LTEtMS0w_7f9d76c4-4f54-4c8b-bf51-020d76c84588"
      unitRef="usd">6198000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNy0yLTEtMS0w_356d4ad1-40dc-460b-a856-7672fc0f64ff"
      unitRef="shares">814339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfNy00LTEtMS0w_5f323241-b2a8-4f54-ac54-d4f470d7e590"
      unitRef="usdPerShare">13.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOC0yLTEtMS0w_a060b67f-7752-4423-adbf-6a4fc02feff3"
      unitRef="shares">50</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOC00LTEtMS0w_81d84c5d-db17-45a3-bd3a-847d1f676045"
      unitRef="usdPerShare">1.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOS0yLTEtMS0w_9c468134-4555-4769-90bc-ebb8831d9d77"
      unitRef="shares">310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfOS00LTEtMS0w_88c9a771-d09f-4055-9688-a468d34d9196"
      unitRef="usdPerShare">5.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTAtMi0xLTEtMA_5d55ff91-0d62-4cfa-ba61-c61e6befbb79"
      unitRef="shares">153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTAtNC0xLTEtMA_c8e47e66-d80a-4c56-9a47-9e507d3c788d"
      unitRef="usdPerShare">37.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtMi0xLTEtMA_5baaab90-d896-40ce-855d-dd55e6775b26"
      unitRef="shares">1475006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtNC0xLTEtMA_8229d58d-717a-4759-ba29-a825415ddf6a"
      unitRef="usdPerShare">8.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtNi0xLTEtMA_18897431-ab51-4668-9fd4-99e6b3b1d57f">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTEtOC0xLTEtMA_f8fbbad7-fa94-4eb4-9d38-2286840a49da"
      unitRef="usd">10993000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtMi0xLTEtMA_61024eca-4da9-4570-a774-caf56ad669ea"
      unitRef="shares">1475006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtNC0xLTEtMA_8512ff54-3ef8-4927-b973-8bc9552c5e9d"
      unitRef="usdPerShare">8.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtNi0xLTEtMA_61d7f751-21e3-4fee-8d06-3ffb096bbaaf">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTQtOC0xLTEtMA_b807f8c3-8f33-481a-9113-f8742ad80224"
      unitRef="usd">10993000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtMi0xLTEtMA_315a4c3e-dd56-4c38-a046-6fbeef997046"
      unitRef="shares">20464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtNC0xLTEtMA_2db7bd32-ed4c-4387-9c7c-f23b28cb3055"
      unitRef="usdPerShare">30.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtNi0xLTEtMA_e434adf1-67cd-48e8-8a1a-ee7892a30428">P4Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjljZmY5N2I3NWYzOTQwYjc5ZDhiMjkzMTA2M2FmMGJjL3RhYmxlcmFuZ2U6OWNmZjk3Yjc1ZjM5NDBiNzlkOGIyOTMxMDYzYWYwYmNfMTUtOC0xLTEtMA_6dc55a55-afd3-477d-a436-7d0890811597"
      unitRef="usd">23000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODg_ebb95503-48c3-467d-a8e9-70d2f0a4b6af">&lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.953216%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.280702%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;2.0%-2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;"&gt;5.75-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi0yLTEtMS0w_83701106-3c52-4666-bada-d53c3101ed44"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi00LTEtMS0w_4a9052b4-f418-468b-a971-6519a1869c0c"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi02LTEtMS0w_f77d29c4-6903-4a95-b13c-27257805d39c"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMi04LTEtMS0w_c743858e-0e20-4b4b-85ff-7a80955cca3a"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy0yLTEtMS0w_e9196aff-cde6-4dd4-84fd-58e991d6ffba"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy00LTEtMS0w_c5fbb0d7-1b54-4595-8c13-65518098b07d"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy02LTEtMS0wL3RleHRyZWdpb246YjJjZmY2ODNhYTU1NGRjOGI1NDAzY2Y1Y2E2YmQ0MjBfMTUzOTMxNjI3ODg4Nzk_fa8452c9-5703-4abc-845c-bbb7cd43bc4a"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy02LTEtMS0wL3RleHRyZWdpb246YjJjZmY2ODNhYTU1NGRjOGI1NDAzY2Y1Y2E2YmQ0MjBfMTUzOTMxNjI3ODg4ODU_f27f4d2f-7986-4d7e-95e7-ea4f8745ef67"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy04LTEtMS0wL3RleHRyZWdpb246MjVkMmU4OWI3ZmZiNDU1Mzg4ZjljYTU4MjE5YjE4MWFfMTA5OTUxMTYyNzc4MA_1bfe4600-5c1b-41bc-b657-6780b57297e9"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfMy04LTEtMS0wL3RleHRyZWdpb246MjVkMmU4OWI3ZmZiNDU1Mzg4ZjljYTU4MjE5YjE4MWFfMTA5OTUxMTYyNzc4NQ_fbe19310-3d78-4924-8809-9b20e715f167"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC0yLTEtMS0w_a6db7bf5-6bff-485c-843d-eaf1504b1de0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC00LTEtMS0w_9790f6cc-9fc3-485b-9257-03da1e953398"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC02LTEtMS0w_656889a3-5f9f-4f4f-8839-634881dcdde0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNC04LTEtMS0w_b3f33377-1ea4-4df4-a1b9-2a4e6d3d70ff"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae39458ccf0d427992cbe4b9527b3bf2_D20190701-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS0yLTEtMS0wL3RleHRyZWdpb246NGI0ZjE1MTA5NGU3NGI4NGEwMzI3Y2M5YWJjYzJiODhfMzI5ODUzNDg4MzM0NQ_6ab2c87b-9508-4e0b-9d69-4e0e1a092a67">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iebae713e20d543688dfbdbe7e08cf864_D20190701-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS0yLTEtMS0wL3RleHRyZWdpb246NGI0ZjE1MTA5NGU3NGI4NGEwMzI3Y2M5YWJjYzJiODhfMzI5ODUzNDg4MzM1MA_856be53c-49dd-4e2f-8788-b0f42d91990a">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS00LTEtMS0w_0431d0bd-1044-4dde-be88-90a4d8f77d51">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4c5dcfbeb31e4eb58cbd0c160cec9a94_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS02LTEtMS0wL3RleHRyZWdpb246ODE2MmE0YjVkODdjNGE4NGJhN2YxMTdkMGI5OTdmNGZfMzI5ODUzNDg4MzM0NQ_6e13a166-11d7-4a6a-bb5b-cada12f579bd">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if0c70eba81b941949fd1d670216abba6_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS02LTEtMS0wL3RleHRyZWdpb246ODE2MmE0YjVkODdjNGE4NGJhN2YxMTdkMGI5OTdmNGZfMzI5ODUzNDg4MzM1MQ_e7e6e6e8-a965-40ab-bbc3-685f448b60d4">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOmFiM2U5NDE0MzdlYjRiMWQ4MWIxN2M2OTBhN2EwYmVmL3RhYmxlcmFuZ2U6YWIzZTk0MTQzN2ViNGIxZDgxYjE3YzY5MGE3YTBiZWZfNS04LTEtMS0w_f61fe8d7-8157-46e9-a84b-645845cb939f">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODk_14c75341-20f7-46b6-978f-3bdb12a97170">&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;Total non-cash stock-based compensation expense recorded related to options granted in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.497076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.035088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181287%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ecd63e9c5f4460db504293975df2da0_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi0yLTEtMS0w_d50962a9-f713-4a74-b463-74232248a776"
      unitRef="usd">4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icda4e23b775541d98dd6601b0687861c_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi00LTEtMS0w_cff0139d-26c5-4695-b8db-8db5a805f9a3"
      unitRef="usd">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8317e42cca1547e9993f03b3818b96f3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi02LTEtMS0w_0a215f4c-25c0-47e7-81d7-cc266b339e38"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23dea42dd5f74d579f2d9bf2d1dd0899_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMi04LTEtMS0w_07ab0461-d0ba-4420-b90b-66ed7e07209f"
      unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie58c1033dd94444781da3f845ffefc22_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy0yLTEtMS0w_3cddd339-5418-4b82-8d24-7ec021e9a35c"
      unitRef="usd">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icefda7fbf4b24e1c95147ec5fc5fbd6a_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy00LTEtMS0w_77f7dec2-85c8-47d8-968e-41b642caabf7"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c606ae405a1436dae303d8eb1512adc_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy02LTEtMS0w_8e34afdc-4d90-447e-a70f-76b459ff977b"
      unitRef="usd">73000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99104c1c22ba4f62b010859df135eb14_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfMy04LTEtMS0w_428a01df-7f1e-479b-91e8-48f727302c91"
      unitRef="usd">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39b3ab090ddd4194a42e7530e862e17f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC0yLTEtMS0w_30635c04-d761-4024-b73e-3db00231d079"
      unitRef="usd">3000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i156a4580a77d4e07840641d780bf4cf0_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC00LTEtMS0w_0a9a88e8-630b-41a3-82f2-571499c58b01"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c0fd8531c4e483bb241496bd66cde52_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC02LTEtMS0w_1626c82b-3ec9-42e9-830a-a6ec30236788"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib98b0d24446a4951aa7a1010ab0bfe0a_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNC04LTEtMS0w_f4c14193-8248-44e9-9d5a-95c661389040"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS0yLTEtMS0w_82b8801f-c4c3-4337-8d85-a084ad75d91f"
      unitRef="usd">62000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib32d69081f94475aa4f278d61e8afdcb_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS00LTEtMS0w_f3ffb0f8-7201-44b8-8ee7-c46e6dd042cc"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS02LTEtMS0w_c9b1b24c-82da-4ee1-8fb8-da72c842f1f8"
      unitRef="usd">85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51e871fb34404f9181118c3f2d995264_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RhYmxlOjU3MGEzM2UzZGZkYzQ0OGM4Y2NhMzYyN2IxNWNkOGY5L3RhYmxlcmFuZ2U6NTcwYTMzZTNkZmRjNDQ4YzhjY2EzNjI3YjE1Y2Q4ZjlfNS04LTEtMS0w_0128c1c1-86f9-419c-ac3c-7d7ed58baa06"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9e798451cd564d85a050ce8581db466a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTk0NQ_80dc7e11-e82c-4385-9c6f-4a9a9f0d377a"
      unitRef="usd">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzgxMw_1e88240d-2f2e-4fe1-9bc4-81a13c394bf5">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODU_2cb89625-0456-486c-95f2-f795df54b107"
      unitRef="number">20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMzg0ODI5MDcwNzgyMg_ea220c37-d4c2-433f-ba55-3e6271ea9376"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="i029c39ddb96e43e7add282e21e47eeb1_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExODY_d2f328de-7cf8-4f28-9350-96e2d2ea8657"
      unitRef="number">1</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88c8b9c0ae1445a795a53d86906d1dc1_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTM_52106542-6eb8-4016-83f6-41a74f08c674"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide5daf739bda4ce99c2faed14eefff7e_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83MC9mcmFnOjIxZmZjZmJlYTI0NzQyNzM4YjU2ZmM5YTJhNWI4NmRkL3RleHRyZWdpb246MjFmZmNmYmVhMjQ3NDI3MzhiNTZmYzlhMmE1Yjg2ZGRfMTUzOTMxNjI4MDExOTM_8346be50-9868-4906-93af-94a3b99dafb7"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NTQ_6fc97e77-cb68-4e12-a884-cb13dfe9c9b7">Related PartiesThe Company entered into a consulting services agreement, as amended, with a member of the Company's Board of Directors under which this board member provides certain scientific consulting services to the Company. Under this agreement, as amended in June 2018, this board member is compensated at a bi-weekly rate of $5,000 &lt;div style="margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;(plus reimbursement for certain administrative and travel related expenses) and received options to purchase 544 shares of common stock in November 2017, the commencement date of the agreement. Total amounts paid to this board member under this agreement for the three months ended September&#160;30, 2019 and 2018 and the nine months ended September&#160;30, 2019 and 2018, were $30,000, $30,000, $95,000, and $91,000, respectively, which was recorded in research and development expenses in the accompanying condensed statements of operations. The Company accounted for the grant of options as an award to a non-employee and measures compensation cost for this award based on the value of the award at the date the consulting services are complete. The options granted to this board member were granted at an exercise price of $0.367 (the estimated fair value of share of common stock on the grant date using an OPM model), and vests over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NDg_b98a8d34-8542-45c3-b460-7428b1e5f9cc"&gt;three&lt;/span&gt;-year term expected to coincide with the period the board member is expected to provide consulting services to the Company. The estimated fair value of the awards and related compensation cost recognized during the three and nine months ended September&#160;30, 2019 and 2018 was immaterial. All compensation cost related to these awards is recorded in research and development expenses in the accompanying condensed statements of operations. Effective July 12, 2019, this consultant no longer serves on the Company's Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2011, the Company entered into a license agreement with the Company's Chief Scientific Officer, and a related company, De&#160;Novo Diagnostics, Inc. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by the Company's Chief Scientific Officer prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company's Chief Scientific Officer will be eligible to receive up to $0.6 million upon the achievement of certain sales milestones and an ongoing royalty of 5% on sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The third tranche closing of the Series&#160;F financing and the closings of the Series&#160;G financing described in Note 8 were issued to existing holders of the Company's redeemable convertible preferred stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic5649d541959437c953f9b7daa0a171d_D20180601-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfNTQ5NzU1ODE0NzUxMg_0e23f8cd-012c-4a40-8eea-1954054fa102"
      unitRef="usd">5000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTA3NQ_5c6763fa-0da2-4e15-8235-48ba8ca58fd3"
      unitRef="shares">544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i23243689232c443f8220af8eb34ad150_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM0NA_ba679deb-1295-4d62-9526-b00a31768d85"
      unitRef="usd">30000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i61985dc8dff1424b8c09ade62daae302_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM0OA_b8a52149-c47f-4ddb-9f78-e28eba859326"
      unitRef="usd">30000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i92647d4518404696ab919e985542dc23_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM1Mg_73ef0962-d01d-4db5-b49e-6bc1893531f2"
      unitRef="usd">95000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i2c33b5d4543e4472a07114c686f5e1ba_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTM2MA_394e6665-2c34-490d-ba2c-47bd40b143cb"
      unitRef="usd">91000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8fb1b0ee46b4498aa2028ccebc760f59_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfNDM5ODA0NjUxOTk4MQ_b180f53e-e7c5-4ae2-aa37-18fe44547de4"
      unitRef="usdPerShare">0.367</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <exdx:MilestoneObligation
      contextRef="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMzU5Mg_1b0c1e97-d9b4-4f2c-b8cf-11c0f28e4681"
      unitRef="usd">600000</exdx:MilestoneObligation>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i36b91fe1d85d490aa919ae3f5d1cd16e_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMzY3MA_7f337a03-bbcf-49da-aa78-4b7607cbac9e"
      unitRef="number">0.05</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RleHRyZWdpb246ZGMxYmQ2YmExNDM5NGZiYmI2YTJjNDk0ZjYzOGNjNmVfMTUzOTMxNjI3OTAwMjI_bc0ad587-6f76-423c-988c-9a4699f5efa2">Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018 &lt;div style="text-indent:24.75pt;margin-top:4pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;During 2019, Company management identified immaterial misstatements in the financial statements for the year ended December 31, 2018 related to the carrying value of redeemable convertible preferred stock warrant liabilities. Based on a quantitative and qualitative analysis of the error as required by authoritative guidance, management concluded that the correction, which decreased the carrying value of the redeemable convertible preferred stock warrant liabilities with a corresponding decrease in net loss, had no material impact on the Company's previously issued financial statements as of and for the year ended December 31, 2018. These amounts have been adjusted in the accompanying balance sheet and statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The revision to the Company's previously reported balance sheet are identified in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Previously&lt;br/&gt;Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stockholders' deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A revised rollforward of the Company's warrant liabilities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.239766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.473684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.473684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Previously&lt;br/&gt;Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance of warrants to purchase shares of Series&#160;F redeemable convertible preferred stock in connection with 2017 Term Loan (Note&#160;4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, March&#160;31, 2019 (unaudited) (as revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RleHRyZWdpb246ZGMxYmQ2YmExNDM5NGZiYmI2YTJjNDk0ZjYzOGNjNmVfMTUzOTMxNjI3OTAwMjM_838b7678-be99-45fd-ae8a-f657e26fdaf8">&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;The revision to the Company's previously reported balance sheet are identified in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:55.894737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.304094%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Previously&lt;br/&gt;Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Redeemable convertible preferred stock warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;153,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stockholders' deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"&gt;A revised rollforward of the Company's warrant liabilities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.239766%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.473684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.473684%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Previously&lt;br/&gt;Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As&lt;br/&gt;Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December&#160;31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Issuance of warrants to purchase shares of Series&#160;F redeemable convertible preferred stock in connection with 2017 Term Loan (Note&#160;4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, March&#160;31, 2019 (unaudited) (as revised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <exdx:PreferredStockWarrantLiability
      contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi0yLTEtMS0w_2a065fd8-181c-4043-9b59-edd3f3c98404"
      unitRef="usd">2680000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi00LTEtMS0w_4fab0d68-f1c8-49f4-93b8-b06c6911963e"
      unitRef="usd">-1177000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMi02LTEtMS0w_4056c081-2ba6-4be2-9764-905a52a30b5e"
      unitRef="usd">1503000</exdx:PreferredStockWarrantLiability>
    <us-gaap:Liabilities
      contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy0yLTEtMS0w_c319df53-1a5d-4ea4-9c1a-3afbf0e94540"
      unitRef="usd">36798000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy00LTEtMS0w_c993e047-f433-4590-a49f-20c521b9e968"
      unitRef="usd">-1177000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfMy02LTEtMS0w_8094ba2b-c47b-45d1-b172-a5d99914b394"
      unitRef="usd">35621000</us-gaap:Liabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC0yLTEtMS0w_a91bcba7-80c9-4880-980a-929049e6ab28"
      unitRef="usd">-153741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC00LTEtMS0w_f48f8c19-9e81-4664-a14a-be717e09850b"
      unitRef="usd">1177000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNC02LTEtMS0w_69b7fea1-6281-4357-bed4-22ec3d17f81e"
      unitRef="usd">-152564000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS0yLTEtMS0w_21e18bc2-b4e9-42ff-b4a8-e705f7a8ac54"
      unitRef="usd">-113143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS00LTEtMS0w_b261ca1d-443a-45c1-9829-85bf76ecd602"
      unitRef="usd">1177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOmYxOWJhZWI1YzJjYTRkNzg4NzkwZTIxZWU4ZTQ3YTEwL3RhYmxlcmFuZ2U6ZjE5YmFlYjVjMmNhNGQ3ODg3OTBlMjFlZThlNDdhMTBfNS02LTEtMS0w_c9372c8c-687d-43e7-9bba-3b645adc10a9"
      unitRef="usd">-111966000</us-gaap:StockholdersEquity>
    <exdx:PreferredStockWarrantLiability
      contextRef="i0bb1b252737849b5896adb5e69e39207_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS0yLTEtMS0w_5eed1c13-70e8-44a4-8c5b-70b1966ad861"
      unitRef="usd">896000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="i050d48ebbcd24210b1475a4d33bb14c6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS00LTEtMS0w_79e42fae-6092-48ef-862e-700684c80f13"
      unitRef="usd">0</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMS02LTEtMS0w_3d2a1b82-4b55-403a-8365-a78ec4317dbc"
      unitRef="usd">896000</exdx:PreferredStockWarrantLiability>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi0yLTEtMS0w_9efe6db6-b180-4070-8bd7-38ff47f97c89"
      unitRef="usd">-289000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi00LTEtMS0w_94390932-3ca9-44e2-beeb-e63fc4111f10"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMi02LTEtMS0w_be21fb9d-f2e7-4034-bac0-8726de18e04c"
      unitRef="usd">-289000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy0yLTEtMS0w_3ab793c0-bd87-4134-8115-9f478fa4342b"
      unitRef="usd">1495000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="ie79825e431a24ff99e533f4e0f8393c2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy00LTEtMS0w_a0145611-3bb2-44d4-8847-d6a74c3b260c"
      unitRef="usd">-1177000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:IncreaseDecreaseInFairValueOfFinancialInstruments
      contextRef="ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfMy02LTEtMS0w_ec6a17a0-7b3e-4cb9-a3d3-957deb260eb9"
      unitRef="usd">318000</exdx:IncreaseDecreaseInFairValueOfFinancialInstruments>
    <exdx:PreferredStockWarrantLiability
      contextRef="if36ac713957946c8b6ec9a842cee9f1b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC0yLTEtMS0w_2664fa4a-cbf2-4e95-9246-6fbaed7e43d3"
      unitRef="usd">2680000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="idcaca6cf8313483db51df9c1afdb0e41_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC00LTEtMS0w_d80a524f-63f4-4025-b707-3068dac5b268"
      unitRef="usd">-1177000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="ib1618f264237473e8438081b30871740_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNC02LTEtMS0w_ce031d64-95bd-4b31-92e0-38575bce9638"
      unitRef="usd">1503000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="i6525292a42e544c98b6b7fe58ef7a0b2_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS0yLTEtMS0w_897cb777-e81c-494b-afa4-141aa0f235d3"
      unitRef="usd">2680000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="i84f237a8b0314f22ba9545b209899f19_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS00LTEtMS0w_d8e79362-c118-476a-be67-35f64ca51b41"
      unitRef="usd">-1177000</exdx:PreferredStockWarrantLiability>
    <exdx:PreferredStockWarrantLiability
      contextRef="ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF84Mi9mcmFnOmRjMWJkNmJhMTQzOTRmYmJiNmEyYzQ5NGY2MzhjYzZlL3RhYmxlOjYyNjYyZjQ0MjNmYTRmODBhMjJhNjVkMzcwMTQ1ZmQyL3RhYmxlcmFuZ2U6NjI2NjJmNDQyM2ZhNGY4MGEyMmE2NWQzNzAxNDVmZDJfNS02LTEtMS0w_385cd105-1866-4cbc-a84b-d781621bac72"
      unitRef="usd">1503000</exdx:PreferredStockWarrantLiability>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790626960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">Stockholders' Equity (Deficit)<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things,&#160;increase its authorized shares of common stock from 1,470,000,000 to 1,675,200,000 shares.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On July 11, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of common stock from 1,675,200,000 to 1,970,000,000 shares.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company filed its amended and restated certificate of incorporation on September 23, 2019, authorizing 200,000,000 shares of common stock and 10,000,000 shares of preferred stock.</span></div>On September 23, 2019, the Company closed its IPO of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793401056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Common or Preferred Stock - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Warrants to Purchase Common or Preferred Stock</a></td>
<td class="text">Warrants to Purchase Common or Preferred Stock<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the completion of the Company's IPO in September 2019:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The remaining outstanding Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate 104,722 shares of common stock.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Warrants to purchase common stock for 569,184 shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of 512,363 shares of common stock. Unexercised warrants to purchase common stock for 9,054 shares were terminated prior to the completion of the IPO.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Warrants to purchase Series D and Series E redeemable convertible preferred stock for 119,771 shares of the Company's common stock were exercised via cashless exercise resulting in the issuance of 27,431 shares of common stock. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Outstanding Warrants</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following warrants to purchase common stock were outstanding as of September&#160;30, 2019:</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.532164%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888889%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration date</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">282,402</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">January 19, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">74,018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">131</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">April 1, 2026</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">83,778</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.32</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2017</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 8, 2024</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants (1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,944</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14.32</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1) Prior to the conversion upon IPO, the remaining warrants were for the purchase of Series F redeemable convertible preferred stock.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The outstanding warrants to purchase shares of common stock are equity classified at September&#160;30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6672504528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2019 (remaining)</a></td>
<td class="nump">$ 725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2020</a></td>
<td class="nump">6,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2021</a></td>
<td class="nump">14,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="nump">11,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">33,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="nump">6,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 25,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794741824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 10,439<span></span>
</td>
<td class="nump">$ 8,223<span></span>
</td>
<td class="nump">$ 30,173<span></span>
</td>
<td class="nump">$ 22,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_HealthcareInsurersMember', window );">Healthcare Insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
<td class="nump">17,716<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_GovernmentMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="nump">7,964<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784427936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 1,686<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804238592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Changes and Error Corrections - Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,177)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,177)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrant liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784950848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>41
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20190930.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "contextCount": 258,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20190930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20190930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 498,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 9
   },
   "keyCustom": 58,
   "keyStandard": 304,
   "memberCustom": 28,
   "memberStandard": 43,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Other Financial Information - (Notes)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNotes",
     "shortName": "Other Financial Information - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Borrowings - (Notes)",
     "role": "http://www.exagen.com/role/BorrowingsNotes",
     "shortName": "Borrowings - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Notes)",
     "role": "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes",
     "shortName": "Warrants to Purchase Common or Preferred Stock - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Commitment and Contingencies - (Notes)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNotes",
     "shortName": "Commitment and Contingencies - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Fair Value Measurements - (Notes)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsNotes",
     "shortName": "Fair Value Measurements - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.exagen.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://www.exagen.com/role/StockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Stock Option Plan",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141112 - Disclosure - Related Parties",
     "role": "http://www.exagen.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143113 - Disclosure - Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018",
     "role": "http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018",
     "shortName": "Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://www.exagen.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary Of Significant Accounting Policies - Policies",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary Of Significant Accounting Policies - Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary Of Significant Accounting Policies - (Tables)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary Of Significant Accounting Policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Other Financial Information - (Tables)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Borrowings - (Tables)",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Warrants to Purchase Common or Preferred Stock - (Tables)",
     "role": "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables",
     "shortName": "Warrants to Purchase Common or Preferred Stock - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Fair Value Measures and Disclosures (Tables)",
     "role": "http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables",
     "shortName": "Fair Value Measures and Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock Option Plan (Tables)",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Accounting Changes and Error Corrections (Tables)",
     "role": "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables",
     "shortName": "Accounting Changes and Error Corrections (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Organization - (Details)",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary Of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary Of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003003 - Statement - Unaudited Condensed Statements of Operations",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
     "shortName": "Unaudited Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails",
     "shortName": "Summary Of Significant Accounting Policeies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i3c1a76f2ce7c4af7ad35da5cd1267b00_D20190701-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary Of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "iac7d07ac43134c56bd65c32a20842780_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
     "shortName": "Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Summary Of Significant Accounting Policies - Securities (Details)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary Of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Other Financial Information - Narrative (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414409 - Disclosure - Other Financial Information - Prepaid expenses (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails",
     "shortName": "Other Financial Information - Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415410 - Disclosure - Other Financial Information - Property and equipment (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails",
     "shortName": "Other Financial Information - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416411 - Disclosure - Other Financial Information - Accrued liabilities (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails",
     "shortName": "Other Financial Information - Accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ie724734be96b41eb9f3acb00203b7563_D20170101-20171231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Borrowings - Future minimum payments (Details)",
     "role": "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails",
     "shortName": "Borrowings - Future minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i7d3d2fbb30244e3ea6e4e191b5e96941_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004004 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
     "shortName": "Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ieab38b3b7e664bb5adcb877fbb794408_D20180101-20180331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Warrants to Purchase Common or Preferred Stock - Narrative (Details)",
     "role": "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails",
     "shortName": "Warrants to Purchase Common or Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i1b21b17a27a0472da0a97b3d7df44a66_D20190901-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "exdx:ClassOfWarrantOrRightExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)",
     "role": "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails",
     "shortName": "Warrants to Purchase Common or Preferred Stock - Outstanding warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "id6b232544b0e4c3982a50c01fa3beedd_I20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ib206ca9a730640ff880db0ca2948c48f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Fair Value Measurements - Fair value measurement (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails",
     "shortName": "Fair Value Measurements - Fair value measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ib206ca9a730640ff880db0ca2948c48f_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ibcb6091d19a6405e8226dae5e6b494f6_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - Fair Value Measurements- Fair value level 3 (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
     "shortName": "Fair Value Measurements- Fair value level 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ib871a4638845441c862fde06e4cc74f2_I20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9f3012c64b3841629d97963b5c65859a_I20190731",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9f3012c64b3841629d97963b5c65859a_I20190731",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i1936657650f8443fb7d623789b65864b_I20190923",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Stockholders' Equity (Deficit) (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
     "shortName": "Stockholders' Equity (Deficit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i1936657650f8443fb7d623789b65864b_I20190923",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Stock Option Plan - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ib1618f264237473e8438081b30871740_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006005 - Statement - Unaudited Statements of Cash Flows",
     "role": "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
     "shortName": "Unaudited Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i2ecd63e9c5f4460db504293975df2da0_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Related Parties (Details)",
     "role": "http://www.exagen.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ic5649d541959437c953f9b7daa0a171d_D20180601-20180630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exdx:PreferredStockWarrantLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Accounting Changes and Error Corrections - Balance Sheet (Details)",
     "role": "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
     "shortName": "Accounting Changes and Error Corrections - Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ie4c54be20a5f4f8fa7ba09eecbbb0e7b_I20190331",
      "decimals": "-3",
      "lang": null,
      "name": "exdx:PreferredStockWarrantLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i4b30b91d338e4fe0a8939ab9f3d74c24_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exdx:IncreaseDecreaseInFairValueOfFinancialInstruments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Accounting Changes and Error Corrections - Operations (Details)",
     "role": "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
     "shortName": "Accounting Changes and Error Corrections - Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ib1618f264237473e8438081b30871740_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exdx:PreferredStockWarrantLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Accounting Changes and Error Corrections - Warrant Liabilities (Details)",
     "role": "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails",
     "shortName": "Accounting Changes and Error Corrections - Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i28fffe76d7094196bf00ca25cbf4ce05_D20180101-20181231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exdx:SaleOfTemporaryEquityPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1105101 - Statement - Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ibc0a21e4d49a4bd0ae4a494622418fc7_D20180101-20180331",
      "decimals": "-3",
      "lang": null,
      "name": "exdx:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1402401 - Statement - Condensed Balance Sheets - (Parenthetical)",
     "role": "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets - (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i9e798451cd564d85a050ce8581db466a_I20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101102 - Disclosure - Organization - (Notes)",
     "role": "http://www.exagen.com/role/OrganizationNotes",
     "shortName": "Organization - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103103 - Disclosure - Summary Of Significant Accounting Policies - (Notes)",
     "role": "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes",
     "shortName": "Summary Of Significant Accounting Policies - (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "ia5527ee6d32941c0b7a44cefa02b0afd_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20190930.htm",
      "contextRef": "i5e60ced97b104c0abfde5ea44bf688d1_I20180101",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - exdx-20190930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - exdx-20190930.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 72,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedFinancingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Financing Costs, Current",
        "label": "Accrued Financing Costs, Current",
        "terseLabel": "Accrued deferred offering costs"
       }
      }
     },
     "localname": "AccruedFinancingCostsCurrent",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Issuance of Temporary Equity",
        "label": "Adjustments to Additional Paid In Capital, Issuance of Temporary Equity",
        "terseLabel": "Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 8)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability",
        "label": "Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability",
        "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liabilities as equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value",
        "label": "Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends",
        "label": "Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends",
        "terseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature",
        "label": "Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature",
        "terseLabel": "Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AssetsUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets Under Capital Lease",
        "label": "Assets Under Capital Lease [Member]",
        "terseLabel": "Assets under capital lease"
       }
      }
     },
     "localname": "AssetsUnderCapitalLeaseMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CapitalRoyaltyPartnersIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capital Royalty Partners II LP",
        "label": "Capital Royalty Partners II LP [Member]",
        "terseLabel": "Capital Royalty Partners II LP"
       }
      }
     },
     "localname": "CapitalRoyaltyPartnersIILPMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised",
        "label": "Class of Warrant or Right, Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ClassOfWarrantOrRightUnexercisedAndTerminated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Unexercised and Terminated",
        "label": "Class of Warrant or Right, Unexercised and Terminated",
        "terseLabel": "Number of warrants unexercised and terminated"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnexercisedAndTerminated",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting Services",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ConversionOfTemporaryEquityAmountConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion of Temporary Equity, Amount Converted",
        "label": "Conversion of Temporary Equity, Amount Converted",
        "terseLabel": "Conversion of Series G to Series H redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfTemporaryEquityAmountConverted",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Interest Only Milestones, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Compliance, Interest Only Milestones, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, interest only milestones, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceInterestOnlyMilestonesInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Issuance of Equity Securities or Subordinated Debt",
        "label": "Debt Instrument, Covenant Compliance, Minimum Issuance of Equity Securities or Subordinated Debt",
        "terseLabel": "Term loan covenant, minimum issuance of equity securities and subordinated debt"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumIssuanceOfEquitySecuritiesOrSubordinatedDebt",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deemed dividend from issuance of redeemable convertible preferred stock",
        "label": "Deemed dividend",
        "terseLabel": "Deemed dividend from issuance of Series F redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Offering Costs Included within Current Liabilities",
        "label": "Deferred Offering Costs Included within Current Liabilities",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedWithinCurrentLiabilities",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EquipmentPurchasedUnderCapitalLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment Purchased Under Capital Lease",
        "label": "Equipment Purchased Under Capital Lease",
        "terseLabel": "Equipment Purchased Under Capital Lease"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderCapitalLease",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep82024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Sep 8, 2024",
        "label": "Expiration Sep 8, 2024 [Member]",
        "terseLabel": "Warrant expiration September 8, 2024"
       }
      }
     },
     "localname": "ExpirationSep82024Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare Insurers"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInFairValueOfFinancialInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Fair Value of Financial Instruments",
        "label": "Increase (Decrease) in Fair Value of Financial Instruments",
        "verboseLabel": "Change in fair value of financial instruments"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfFinancialInstruments",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Increase (Decrease) in Prepaid Expense and Current Other Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Janssen (SIMPONI)"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MilestoneContingencyFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Contingency, Fair Value Disclosure",
        "label": "Milestone Contingency, Fair Value Disclosure",
        "terseLabel": "Remaining milestone obligation, fair value"
       }
      }
     },
     "localname": "MilestoneContingencyFairValueDisclosure",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MilestoneObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Obligation",
        "label": "Milestone Obligation",
        "terseLabel": "Remaining milestone obligation",
        "verboseLabel": "Milestone obligation"
       }
      }
     },
     "localname": "MilestoneObligation",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_NoncashExerciseOfStockPurchaseWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Exercise of Stock Purchase Warrants",
        "label": "Noncash Exercise of Stock Purchase Warrants",
        "terseLabel": "Net exercise of common and preferred stock warrants"
       }
      }
     },
     "localname": "NoncashExerciseOfStockPurchaseWarrants",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_NumberOfOperatingLeaseExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Operating Lease Extensions",
        "label": "Number of Operating Lease Extensions",
        "terseLabel": "Number of operating lease extensions"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseExtensions",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20190930",
     "xbrltype": "stringItemType"
    },
    "exdx_OtherNoncashTransactionChangeInAccountingPrinciple": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Noncash Transaction, Change in Accounting Principle",
        "label": "Other Noncash Transaction, Change in Accounting Principle",
        "terseLabel": "Adjustment upon adoption of ASC 606"
       }
      }
     },
     "localname": "OtherNoncashTransactionChangeInAccountingPrinciple",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PreferredStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock warrant liability",
        "label": "Preferred stock warrant liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Redeemable convertible preferred stock warrant liabilities"
       }
      }
     },
     "localname": "PreferredStockWarrantLiability",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails",
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Issuance or Sale of Temporary Equity",
        "label": "Proceeds from Issuance or Sale of Temporary Equity",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfTemporaryEquity",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification of Temporary Equity and Liabilities to Permanent Equity",
        "label": "Reclassification of Temporary Equity and Liabilities to Permanent Equity",
        "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liabilities as equity"
       }
      }
     },
     "localname": "ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_SaleOfTemporaryEquityConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Temporary Equity, Consideration Received on Transaction",
        "label": "Sale of Temporary Equity, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of temporary equity"
       }
      }
     },
     "localname": "SaleOfTemporaryEquityConsiderationReceivedOnTransaction",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Temporary Equity, Number of Shares Issued in Transaction",
        "label": "Sale of Temporary Equity, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold, temporary equity"
       }
      }
     },
     "localname": "SaleOfTemporaryEquityNumberOfSharesIssuedInTransaction",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_SaleOfTemporaryEquityPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Temporary Equity, Price Per Share",
        "label": "Sale of Temporary Equity, Price Per Share",
        "terseLabel": "Sale of temporary equity, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfTemporaryEquityPricePerShare",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "exdx_SeriesDAndSeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series D and Series E Preferred Stock",
        "label": "Series D and Series E Preferred Stock [Member]",
        "terseLabel": "Series D and Series E redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesDAndSeriesEPreferredStockMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "terseLabel": "Annual percentage increase in shares available for issuance under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockOptionPlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Option Plan, 2013",
        "label": "Stock Option Plan, 2013 [Member]",
        "terseLabel": "2013 Stock Option Plan"
       }
      }
     },
     "localname": "StockOptionPlan2013Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Consideration to be Received Under Mandatory Purchase",
        "label": "Temporary Equity, Consideration to be Received Under Mandatory Purchase",
        "terseLabel": "Consideration to be received under mandatory purchase, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityConsiderationToBeReceivedUnderMandatoryPurchase",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityDeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividend",
        "label": "Temporary Equity, Deemed Dividend",
        "terseLabel": "Deemed Dividend"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividend",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityDeemedDividendSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividend, Shares Issued",
        "label": "Temporary Equity, Deemed Dividend, Shares Issued",
        "terseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8) (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividendSharesIssued",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Deemed Dividends with Beneficial Conversion Feature",
        "label": "Temporary Equity, Deemed Dividends with Beneficial Conversion Feature",
        "netLabel": "Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock",
        "terseLabel": "Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)",
        "verboseLabel": "Beneficial conversion feature, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityDeemedDividendsWithBeneficialConversionFeature",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Issuance Costs",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock",
        "terseLabel": "Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock",
        "terseLabel": "Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityProceedsReceivedPriorToIssuance": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Proceeds received prior to issuance",
        "label": "Temporary Equity, Proceeds received prior to issuance",
        "terseLabel": "Proceeds received prior to issuance of Series\u00a0G redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityProceedsReceivedPriorToIssuance",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityRightsForMandatoryPurchase": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Rights for Mandatory Purchase",
        "label": "Temporary Equity, Rights for Mandatory Purchase",
        "terseLabel": "Right to require mandatory purchase, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityRightsForMandatoryPurchase",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquitySharesIssuedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Shares Issued upon Conversion",
        "label": "Temporary Equity, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion, temporary equity (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssuedUponConversion",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquitySharesRedeemedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Shares Redeemed upon Conversion",
        "label": "Temporary Equity, Shares Redeemed upon Conversion",
        "terseLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Note 8) (in shares)",
        "verboseLabel": "Temporary Equity, Shares Redeemed upon Conversion"
       }
      }
     },
     "localname": "TemporaryEquitySharesRedeemedUponConversion",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_TemporaryEquitySharesRedeemedUponConversionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity, Shares Redeemed upon Conversion, Amount",
        "label": "Temporary Equity, Shares Redeemed upon Conversion, Amount",
        "terseLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Note 8)"
       }
      }
     },
     "localname": "TemporaryEquitySharesRedeemedUponConversionAmount",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_WarrantsTemporaryEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants, Temporary Equity",
        "label": "Warrants, Temporary Equity [Member]",
        "terseLabel": "Warrants to purchase redeemable convertible preferred stock"
       }
      }
     },
     "localname": "WarrantsTemporaryEquityMember",
     "nsuri": "http://www.exagen.com/20190930",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board Member"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Chief Scientific Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r128",
      "r192",
      "r195",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r127",
      "r192",
      "r194",
      "r317",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r98",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "As Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.",
        "label": "Accounting Changes and Error Corrections [Text Block]",
        "terseLabel": "Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CorrectionofImmaterialMisstatementsintheFinancialStatementsfortheYearEndedDecember312018"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r23",
      "r130",
      "r131",
      "r193"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r151"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r201",
      "r203",
      "r231",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Cost"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r203",
      "r226",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r75",
      "r268"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r299",
      "r309"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r50"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r204",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Cost incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r31",
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r78",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r83"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r264"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r94",
      "r189",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Warrants issued to purchase redeemable convertible preferred stock, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares to be called upon exercise of warrants",
        "verboseLabel": "Number of common shares called upon exercise of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock",
        "verboseLabel": "Common stock warrants, shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r87",
      "r189",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockOutstandingwarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r158",
      "r303",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r261",
      "r262",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r261",
      "r262",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r114",
      "r115",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue (excluding amortization of purchased technology)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect of changes in accounting principle related to revenue recognition"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r300",
      "r301",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r40",
      "r172",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r91",
      "r181",
      "r184",
      "r185",
      "r186",
      "r266",
      "r267",
      "r269",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r170",
      "r268"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid expenses table"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r34",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Term loan, issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r49",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "verboseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r51",
      "r52",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Redeemable convertible preferred stock warrant liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends, Preferred Stock [Abstract]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r84",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r75",
      "r174"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Revaluation of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r248",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r250",
      "r251",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r248",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r248",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r248",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r252",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instruments Measured on Recurring Basis, Level 3 Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r253",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "terseLabel": "Remeasurement of financial instruments"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "auth_ref": [
      "r254",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues",
        "negatedLabel": "Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails",
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": {
     "auth_ref": [
      "r254",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
        "terseLabel": "Net exercise of preferred stock warrants"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset) out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3",
        "terseLabel": "Reclassification of liability classified warrants to stockholders' equity (deficit)"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r247",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluelevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Capital lease obligations, current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase (Decrease) in Accounts Receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Increase (Decrease) in Other Noncurrent Assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r124",
      "r265",
      "r268",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r70",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r302",
      "r313"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r36",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r171",
      "r301",
      "r310"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r95",
      "r168"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r95",
      "r168"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r95",
      "r168"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year",
        "terseLabel": "2019 (remaining)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Minimum annual purchase commitment"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Purchase commitment, term"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r55",
      "r57",
      "r76",
      "r108",
      "r304",
      "r316"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common stockholders (diluted)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Operating lease, rentable area (square feet)"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPrinciplesEarlyAdoptionMember": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents a group of guidance that has been adopted early.",
        "label": "New Accounting Principles, Early Adoption [Domain]",
        "terseLabel": "New Accounting Principles, Early Adoption [Domain]"
       }
      }
     },
     "localname": "NewAccountingPrinciplesEarlyAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionAxis": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.",
        "label": "New Accounting Pronouncement, Early Adoption [Axis]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Axis]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncement, Early Adoption [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementEarlyAdoptionTable": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing the financial statement line items and the effect of the guidance on financial statement line items by guidance implemented if the entity elects earlier application.",
        "label": "New Accounting Pronouncement, Early Adoption [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementEarlyAdoptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r103",
      "r117",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPreferredStockDividendsAndAdjustments": {
     "auth_ref": [
      "r104",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of preferred stock dividends and adjustments classified as other.",
        "label": "Other Preferred Stock Dividends and Adjustments",
        "negatedLabel": "Deemed dividend recorded in connection with financing transactions"
       }
      }
     },
     "localname": "OtherPreferredStockDividendsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r6"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r204",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Warrants to Purchase Common or Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r4",
      "r6",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r150"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r152",
      "r314"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred\u00a0Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemablePreferredStockMember": {
     "auth_ref": [
      "r11",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.",
        "label": "Redeemable Preferred Stock [Member]",
        "terseLabel": "Redeemable Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemablePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r199",
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses incurred with related party (bi-weekly rate)"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r199",
      "r274",
      "r275",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Repayments of Long-term Capital Lease Obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Loan repayment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r237",
      "r321"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r83",
      "r298",
      "r311"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r187",
      "r312"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in public offering"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliceiesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r203",
      "r225",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsOperationsDetails",
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Correction of Immaterial Misstatements"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasuresandDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r88",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r12",
      "r83",
      "r298",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r204",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r209",
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r90",
      "r175",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r87",
      "r189",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r116",
      "r261",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62",
      "r143"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesFPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum Employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares reserved for issuance under Stock Option Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in Shares)",
        "verboseLabel": "Issued during period (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r211",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, September 30, 2019 (in Shares)",
        "periodStartLabel": "Outstanding, December 31, 2018 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, September 30, 2019, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2018, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, September 30, 2019 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, September 30, 2019, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, September 30, 2019 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, September 30, 2019, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r202",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)",
        "verboseLabel": "Common stock options, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RelatedPartiesDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r220",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r126",
      "r149",
      "r154",
      "r155",
      "r156",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r180",
      "r181",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock issued upon conversion of redeemable convertible preferred shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r180",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r180",
      "r187",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in Shares)",
        "terseLabel": "Exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r48",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock in connection with initial public offering (Note 8)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r180",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r132"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total stockholders' deficit",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/AccountingChangesandErrorCorrectionsBalanceSheetDetails",
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r18",
      "r19",
      "r84",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/StockholdersEquityDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "terseLabel": "Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)",
        "verboseLabel": "Deemed dividend from conversion/issuance of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion of redeemable convertible preferred stock",
        "verboseLabel": "Accretion to redemption value of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Accretion of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r11",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Temporary Equity, Carrying Amount, Attributable to Parent"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails",
      "http://www.exagen.com/role/WarrantstoPurchaseCommonorPreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/RedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsFairvaluemeasurementDetails",
      "http://www.exagen.com/role/SummaryOfSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=116854557&loc=d3e20905-112640"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.Q)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187283-122770"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r322": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r323": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r324": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r325": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r326": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r327": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r328": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6785010896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="nump">$ 0.078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_SaleOfTemporaryEquityPricePerShare', window );">Sale of temporary equity, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfTemporaryEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Temporary Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfTemporaryEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803355792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,828<span></span>
</td>
<td class="nump">$ 13,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,238<span></span>
</td>
<td class="nump">5,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">85,752<span></span>
</td>
<td class="nump">21,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">92,744<span></span>
</td>
<td class="nump">28,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">6,449<span></span>
</td>
<td class="nump">3,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityProceedsReceivedPriorToIssuance', window );">Proceeds received prior to issuance of Series&#160;G redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,662<span></span>
</td>
<td class="nump">8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">25,677<span></span>
</td>
<td class="nump">24,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,094<span></span>
</td>
<td class="nump">35,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">219,831<span></span>
</td>
<td class="nump">40,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(161,194)<span></span>
</td>
<td class="num">(152,564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">58,650<span></span>
</td>
<td class="num">(111,966)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)</a></td>
<td class="nump">92,744<span></span>
</td>
<td class="nump">28,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Carrying Amount, Attributable to Parent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 105,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrant liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityProceedsReceivedPriorToIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Proceeds received prior to issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityProceedsReceivedPriorToIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784993072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair value measurement (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 71,950<span></span>
</td>
<td class="nump">8,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">71,950<span></span>
</td>
<td class="nump">8,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795158800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance under Stock Option Plan</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum Employee payroll deduction percentage</a></td>
<td class="nump">2000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_StockOptionPlan2013Member', window );">2013 Stock Option Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance under Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,663,681<span></span>
</td>
<td class="nump">669,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance under Stock Option Plan</a></td>
<td class="nump">2,011,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,011,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards</a></td>
<td class="nump">1,199,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_StockOptionPlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_StockOptionPlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790600960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Activity under the Company's stock option plans is set forth below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:45.953216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.011696%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257310%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial MT Std Black';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">661,180&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">814,339&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13.99&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(50)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1.84&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(153)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">37.20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Outstanding, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.89</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Vested and expected to vest, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8.89</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Options exercisable, September&#160;30, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">20,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30.74&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4.56</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:45.953216%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.280702%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">59%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">59%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">70%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2.6%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">2.0%-2.6%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">5.75-6.08</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6.08</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">5.75-6.08</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6.08</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Total non-cash stock-based compensation expense recorded related to options granted in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:38.497076%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.035088%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181287%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">55&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790512928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid expenses table</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid product royalties</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">399&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,819)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued liabilities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued deferred offering costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical study activity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6785037888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">1,936,279<span></span>
</td>
<td class="nump">6,411,163<span></span>
</td>
<td class="nump">1,936,279<span></span>
</td>
<td class="nump">6,411,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,202,940<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,202,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exdx_WarrantsTemporaryEquityMember', window );">Warrants to purchase redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">203,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">203,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">461,273<span></span>
</td>
<td class="nump">934,789<span></span>
</td>
<td class="nump">461,273<span></span>
</td>
<td class="nump">934,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation</a></td>
<td class="nump">1,475,006<span></span>
</td>
<td class="nump">69,885<span></span>
</td>
<td class="nump">1,475,006<span></span>
</td>
<td class="nump">69,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exdx_WarrantsTemporaryEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exdx_WarrantsTemporaryEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6736919760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedFinancingCostsCurrent', window );">Accrued deferred offering costs</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 6,449<span></span>
</td>
<td class="nump">$ 3,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedFinancingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedFinancingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790525232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related PartiesThe Company entered into a consulting services agreement, as amended, with a member of the Company's Board of Directors under which this board member provides certain scientific consulting services to the Company. Under this agreement, as amended in June 2018, this board member is compensated at a bi-weekly rate of $5,000 <div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(plus reimbursement for certain administrative and travel related expenses) and received options to purchase 544 shares of common stock in November 2017, the commencement date of the agreement. Total amounts paid to this board member under this agreement for the three months ended September&#160;30, 2019 and 2018 and the nine months ended September&#160;30, 2019 and 2018, were $30,000, $30,000, $95,000, and $91,000, respectively, which was recorded in research and development expenses in the accompanying condensed statements of operations. The Company accounted for the grant of options as an award to a non-employee and measures compensation cost for this award based on the value of the award at the date the consulting services are complete. The options granted to this board member were granted at an exercise price of $0.367 (the estimated fair value of share of common stock on the grant date using an OPM model), and vests over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI1NjU0NTJhNDdlZjRkNDNhOWFkNDU2MWJjZjVlZGQ4L3NlYzoyNTY1NDUyYTQ3ZWY0ZDQzYTlhZDQ1NjFiY2Y1ZWRkOF83Ni9mcmFnOjg0YjVhNWUzNzgwMTQxOTg4YWVjNThhYTZlMjBkMGVkL3RleHRyZWdpb246ODRiNWE1ZTM3ODAxNDE5ODhhZWM1OGFhNmUyMGQwZWRfMTY0OTI2NzQ0MjU4NDg_b98a8d34-8542-45c3-b460-7428b1e5f9cc">three</span>-year term expected to coincide with the period the board member is expected to provide consulting services to the Company. The estimated fair value of the awards and related compensation cost recognized during the three and nine months ended September&#160;30, 2019 and 2018 was immaterial. All compensation cost related to these awards is recorded in research and development expenses in the accompanying condensed statements of operations. Effective July 12, 2019, this consultant no longer serves on the Company's Board of Directors.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2011, the Company entered into a license agreement with the Company's Chief Scientific Officer, and a related company, De&#160;Novo Diagnostics, Inc. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by the Company's Chief Scientific Officer prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company's Chief Scientific Officer will be eligible to receive up to $0.6 million upon the achievement of certain sales milestones and an ongoing royalty of 5% on sales.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The third tranche closing of the Series&#160;F financing and the closings of the Series&#160;G financing described in Note 8 were issued to existing holders of the Company's redeemable convertible preferred stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793384096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.970760%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.526316%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.385965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company's money market funds is based on quoted market prices.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes a roll-forward of the financial instruments measured on a recurring basis and classified within Level&#160;3 of the fair value hierarchy (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:82.941520%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Liability<br/>Classified<br/>Warrants</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(As&#160;Revised)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series F redeemable convertible preferred stock in connection with 2017 Term Loan (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Remeasurement of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(267)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Net exercise of preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(510)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Reclassification of liability classified warrants to stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(726)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Changes in the fair value of the Company's liability classified warrants are recorded in the line item change in fair value of financial instruments in the accompanying condensed statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793401056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Note 3. Other Financial Information</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid Expenses and Other Current Assets</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid product royalties</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,686&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,855&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">399&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(2,284)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,819)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense for the three months ended September&#160;30, 2019 and 2018 was approximately $0.1 million and $0.2 million, respectively, and for the nine months ended September&#160;30, 2019 and 2018, was approximately $0.5 million and $0.4 million, respectively. At September&#160;30, 2019 and December 31, 2018, the gross book value of assets under capital lease was $0.8 million and $0.4 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Liabilities</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:64.520468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643275%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,111&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued deferred offering costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued interest</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical study activity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">146&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">207&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,449&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6807068832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">497,691,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 92,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</a></td>
<td class="nump">34,914,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</a></td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">$ 97,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">(96,684)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,954<span></span>
</td>
<td class="num">$ (147,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity', window );">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 8)</a></td>
<td class="num">(1,152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,793)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="num">$ (98,879)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">48,466<span></span>
</td>
<td class="num">(147,345)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">497,691,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 92,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">$ 102,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">(96,684)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50,954<span></span>
</td>
<td class="num">(147,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="num">$ (107,807)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43,440<span></span>
</td>
<td class="num">(151,247)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">$ 97,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">$ 99,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="num">(98,879)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">48,466<span></span>
</td>
<td class="num">(147,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="num">(103,293)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">46,198<span></span>
</td>
<td class="num">(149,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">$ 102,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="num">$ (107,807)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43,440<span></span>
</td>
<td class="num">(151,247)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 2,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</a></td>
<td class="nump">97,646,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</a></td>
<td class="nump">$ 7,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">630,252,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 114,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">63,005<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (111,966)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,598<span></span>
</td>
<td class="num">(152,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="num">$ (116,772)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,496<span></span>
</td>
<td class="num">(155,268)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">532,606,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 105,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 4,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">63,005<span></span>
</td>
<td class="nump">63,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (111,966)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,598<span></span>
</td>
<td class="num">(152,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">12,559,492<span></span>
</td>
<td class="nump">12,559,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 58,650<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">219,831<span></span>
</td>
<td class="num">(161,194)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">630,252,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">$ 114,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</a></td>
<td class="nump">51,282,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</a></td>
<td class="nump">$ 3,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">681,534,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 121,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="num">(116,772)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,496<span></span>
</td>
<td class="num">(155,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,785)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="num">(121,734)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,319<span></span>
</td>
<td class="num">(158,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs (in shares)</a></td>
<td class="nump">233,446,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock', window );">Issuance of Series G redeemable convertible preferred stock for aggregate proceeds, net of issuance costs</a></td>
<td class="nump">$ 3,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)</a></td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendSharesIssued', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8) (in shares)</a></td>
<td class="nump">97,592,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversion', window );">Conversion of preferred stock to common stock in connection with initial public offering (Note 8) (in shares)</a></td>
<td class="nump">1,012,573,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquitySharesRedeemedUponConversionAmount', window );">Conversion of preferred stock to common stock in connection with initial public offering (Note 8)</a></td>
<td class="nump">$ 138,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity', window );">Issuance of Series H redeemable convertible preferred stock for aggregate proceeds of $0.047 per share, net of issuance costs of $318 (Note 8)</a></td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature', window );">Deemed dividend recognized on beneficial conversion features of Series H redeemable convertible preferred stock (Note 8)</a></td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividend', window );">Deemed Dividend</a></td>
<td class="nump">6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends', window );">Deemed dividend from conversion of Series G to Series H redeemable convertible preferred stock (Note 8)</a></td>
<td class="nump">6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock in connection with initial public offering (Note 8)</a></td>
<td class="nump">138,906<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">138,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net of underwriting discount, commissions and issuance costs (Note 9)</a></td>
<td class="nump">50,518<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">50,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability', window );">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</a></td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,141)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">12,559,492<span></span>
</td>
<td class="nump">12,559,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 58,650<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 219,831<span></span>
</td>
<td class="num">$ (161,194)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Issuance of Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Reclassification of Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Temporary Equity, Accretion to Redemption Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Temporary Equity, Deemed Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Temporary Equity with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividend, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issued During the Period, Shares, Redeemable Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuedDuringThePeriodSharesRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issued During the Period, Value, Redeemable Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityIssuedDuringThePeriodValueRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesRedeemedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Redeemed upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesRedeemedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquitySharesRedeemedUponConversionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares Redeemed upon Conversion, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquitySharesRedeemedUponConversionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793377904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Exagen Inc. (the Company) was incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, Exagen Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the Company changed its name to Exagen Diagnostics, Inc. In January 2019, the Company changed its name to Exagen Inc. The Company is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On September 23, 2019, the Company closed its initial public offering (the IPO) of 4,140,000 shares of its common stock at a price to the public of $14.00 per share, including the exercise in full by the underwriters of their option to purchase 540,000 additional shares of the Company's common stock. Including the exercise of the option to purchase additional shares, the aggregate net proceeds to the Company from the offering was approximately $50.5 million, net of underwriting discounts, commissions and other estimated offering expenses, for aggregate expenses of approximately $7.5 million. In addition, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On September 6, 2019, the Company effected a one-for-183.635 reverse stock split of its common stock (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock and the conversion ratio of the redeemable convertible preferred stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented in the accompanying condensed financial statements and notes to the condensed financial statements.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company has suffered recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At September&#160;30, 2019, the Company had cash and cash equivalents of $77.8 million and had an accumulated deficit of $161.2 million, respectively. Since inception, the Company has financed its operations primarily through private placements of preferred securities, the sale of common stock through its IPO and debt financing arrangements. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least the next twelve months.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6805952624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting Changes and Error Corrections - Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(161,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="nump">$ 58,650<span></span>
</td>
<td class="num">$ (121,734)<span></span>
</td>
<td class="num">(116,772)<span></span>
</td>
<td class="num">(111,966)<span></span>
</td>
<td class="num">$ (107,807)<span></span>
</td>
<td class="num">$ (103,293)<span></span>
</td>
<td class="num">$ (98,879)<span></span>
</td>
<td class="num">(96,684)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,177)<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrant liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6668329360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,828<span></span>
</td>
<td class="nump">$ 13,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 77,928<span></span>
</td>
<td class="nump">$ 13,264<span></span>
</td>
<td class="nump">$ 5,480<span></span>
</td>
<td class="nump">$ 11,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784891808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,598<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,284)<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,228<span></span>
</td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790557968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred Stock<div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On January 2, 2019, the Company amended and restated its restated certificate of incorporation to, among other things, increase its authorized shares of convertible preferred stock from 750,300,000 to 955,500,000 shares, of which 205,200,000 shares are designated as Series G convertible preferred stock and set forth the rights, preferences and privileges of the Series G convertible preferred stock.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">On July 11, 2019, the Company amended and restated its restated certificate of incorporation to among other things, increase its authorized shares of convertible preferred stock from 955,500,000 to 1,038,667,059 shares, of which 479,967,595 shares are designated as Series H redeemable convertible preferred stock and set forth the rights, preferences and privileges of the Series H redeemable convertible preferred stock.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon completion of the Company's IPO in September 2019, an aggregate of 7,816,643 shares of common stock, excluding warrant conversions, were issued to the holders of the Company's Series A-3, Series B-3, Series C, Series D, Series E, Series F and Series H redeemable convertible preferred stockholders upon the automatic conversion of all shares of redeemable convertible preferred stock to common stock. As a result, no shares of redeemable convertible preferred stock remain outstanding at September&#160;30, 2019.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series F Financing</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company's Board of Directors authorized a third tranche closing of the issuance to existing preferred stockholders in connection with the Company's Series F financing, which was completed between December 2017 and January 2018. In December 2017, a group of existing investors of the Company purchased 54,246,756 shares of Series F redeemable convertible preferred stock at a per share price of $0.078 for aggregate gross proceeds of approximately $4.2 million. In early January 2018, a group of existing stockholders of the Company purchased an additional 34,914,327 shares of Series F redeemable convertible preferred stock at a per share price of $0.078 for aggregate gross proceeds of approximately $2.7 million.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the third tranche closing of the Series F preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series F redeemable convertible preferred stock, and </span></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">the Company determined there were no embedded features requiring bifurcation in the shares of Series F redeemable convertible preferred stock issued in the third tranche closing. The Company accounted for the difference between the estimated fair value and the $0.078 per share purchase price of shares of Series F redeemable convertible preferred stock issued in the third tranche closing as a deemed dividend since all investors in the third closing are existing preferred stockholders of the Company, and the Company did not identify any elements to the transaction which it believes were compensatory in nature. As a result, the Company recognized a deemed dividend in the amount of $1.2 million in the first quarter of 2018, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#8217; deficit.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series G Financing</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, the Company entered into an agreement with new and certain existing preferred stockholders to issue shares of Series G redeemable convertible preferred stock in multiple separate closings at per share price of $0.078 in each closing. Shares of Series G redeemable convertible preferred stock were issuable under the Series G preferred stock purchase agreement until the earlier of March 31, 2019 or the issuance of all authorized shares of Series G redeemable convertible preferred stock, as specified in the Company's amended and restated certificate of incorporation.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In January 2019 and March 2019, the Company sold 88,030,905 and 9,615,384 shares, respectively, of Series G redeemable convertible preferred stock for aggregate gross proceeds of approximately $7.6 million to new and existing investors, of which $3.75 million of gross proceeds were received as of December 31, 2018 and are included in the accompanying December 31, 2018 balance sheet.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company sold an additional 51,282,048 shares of Series&#160;G redeemable convertible preferred stock for aggregate gross proceeds of approximately $4.0 million to existing investors.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In addition, in May 2019, the Series&#160;G preferred stock purchase agreement was amended to include the right of the Company to require certain holders of Series&#160;G redeemable convertible preferred stock to purchase an additional 32,051,280 shares of Series&#160;G redeemable convertible preferred stock at $0.078 per share, for total aggregate proceeds of $2.5&#160;million, at any time after July&#160;31, 2019 and prior to May&#160;31, 2020. This right terminated in connection with the issuance of the Series H redeemable convertible stock in July 2019.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the closings of the Series G preferred stock purchase agreement in January and March 2019, contained a single freestanding financial instrument, shares of Series G redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company concluded the closing in May 2019 contained two freestanding financial instruments, shares of Series G redeemable convertible preferred stock and the Company call right, and the Company concluded there were no embedded features requiring bifurcation in the shares of Series G redeemable convertible preferred stock issued. The Company call right was deemed to have nominal value since it was with insiders with knowledge of the imminent closing of Series H redeemable convertible stock.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Series H Financing</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In July 2019, the Company entered into an agreement with a new investor to issue shares of Series H redeemable convertible preferred stock at a per share price of $0.04712. Pursuant to the terms of the agreement, the new investor purchased 233,446,519 shares of Series H redeemable convertible preferred stock for gross proceeds of approximately $11.0 million. In connection with the Series H financing, the Company converted all of the 148,928,337 outstanding shares of the Company's Series G redeemable convertible preferred stock into 246,521,076 shares of Series H redeemable convertible preferred stock on a dollar-for-dollar basis.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the closing of the Series H preferred stock purchase agreement contained a single freestanding financial instrument, shares of Series H redeemable convertible preferred stock, and the Company determined there were no embedded features requiring bifurcation in the shares of Series H redeemable convertible preferred stock issued at closing. The Company accounted for the difference between the effective conversion price of $0.04712 and the fair value of the underlying common stock at the commitment date as a beneficial conversion feature, which was immediately accreted as a deemed dividend. As a result, the Company recognized a beneficial conversion feature in the amount of $6.7 million in the third quarter of 2019, that was </span></div>recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders&#8217; equity (deficit). Additionally, the Company concluded that the conversion of shares of Series G into shares of Series H redeemable convertible preferred stock in connection with the issuance of Series H redeemable convertible preferred stock represented an extinguishment of the Series G shares. As a result, the Company recognized a deemed dividend for the extinguishment charge in the amount of $6.9 million in the third quarter of 2019, that was recorded as additional paid-in capital (in the absence of retained earnings) in the accompanying condensed statement of redeemable convertible preferred stock and stockholders' equity (deficit).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790557968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2017 Term Loan</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At September&#160;30, 2019, no additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The interest rate on all borrowings under the 2017 Term Loan is 11.0%, of which 2.5% is paid in-kind in the form of additional term loans, or PIK Loans, until September of 2019, after which interest accrues at an annual rate of 11.0%. The Company has estimated the effective interest rate of this loan to be approximately 14%. Accrued interest is due and payable monthly, unless the Company elects to pay PIK interest. The outstanding principal and accrued interest on the 2017 Term Loan will be repaid in twenty-four equal monthly installments commencing in October 2020. Upon repayment of the final installment under the 2017 Term Loan, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of 2017 Term Loan using the effective interest method. For the three months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $0.2 million and $0.1 million, respectively. For the nine months ended September&#160;30, 2019 and 2018, the Company issued PIK Loans totaling $0.5 million and $0.4 million, respectively.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">If the 2017 Term Loan is prepaid after September&#160;7, 2019, but before September&#160;7, 2020, the 2017 Term Loan requires a prepayment premium of 3% of the aggregate outstanding principal. The prepayment premium decreases by 1% during each subsequent twelve-month period after September&#160;7, 2020.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The 2017 Term Loan is collateralized by a first priority security interest on substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Term Loan require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The affirmative covenants require that the Company achieve a specified level of revenue, and either (i)&#160;gross margins, or (ii)&#160;gross profits (collectively referred to as the Interest Only Milestones), as measured quarterly on a rolling twelve month basis, and commencing with the quarter ending December 31, 2017 (1)&#160;the interest rate on the 2017 Term Loan will increase by 8%  and (2)&#160;repayment will commence on the date it is determined the Interest Only Milestones have not been met and over the following eighteen months in equal monthly installments. The consequences of failing to achieve the Interest Only Milestones will be waived if, within sixty days of failing to achieve the Interest Only Milestones, the Company issues additional equity securities or subordinated debt with net proceeds of at least $9.5 million. In addition, the 2017 Term Loan requires that the Company maintain certain levels of minimum liquidity. If the Company has achieved the Interest Only Milestones, the Company is required to maintain an unrestricted cash balance of $2.0 million. If the Interest Only Milestones are not met, the Company must maintain unrestricted cash balances totaling at least the trailing four months cash used to fund operating activities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The 2017 Term Loan agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">At September&#160;30, 2019, the Company was in compliance with all covenants of the 2017 Term Loan.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon an event of default in any of the 2017 Term Loan covenants, the repayment of the 2017 Term Loan may be accelerated and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Term Loan due beyond twelve months of the balance sheet date as non-current.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the 2017 Term Loan, the Company paid issuance costs of $0.4 million to Innovatus and an additional $0.1 million to third parties. These fees were recorded as discounts to the carrying value of the 2017 Term Loan. The Company also issued Innovatus warrants (i)&#160;on the closing date of the 2017 Term Loan, to purchase 15,384,615 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share and (ii) on December 7, 2018, to purchase 3,846,154 shares of Series F redeemable convertible preferred stock at an exercise price of $0.078 per share (Note 5). These warrants are immediately exercisable and will expire if unexercised seven years after their issuance. The fair value of the warrants on each of their dates of issuance, determined using BSM option pricing model, was recorded as a discount to long-term debt and an offsetting amount recognized as a liability. The resulting debt discount is being amortized to interest expense using the effective interest method over the term of the 2017 Term Loan. In connection with the completion of the IPO in September 2019, the Series F redeemable convertible preferred stock warrants automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:81.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935673%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(484)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,876)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793400624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018</a></td>
<td class="text">Correction of Immaterial Misstatements in the Financial Statements for the Year Ended December 31, 2018 <div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">During 2019, Company management identified immaterial misstatements in the financial statements for the year ended December 31, 2018 related to the carrying value of redeemable convertible preferred stock warrant liabilities. Based on a quantitative and qualitative analysis of the error as required by authoritative guidance, management concluded that the correction, which decreased the carrying value of the redeemable convertible preferred stock warrant liabilities with a corresponding decrease in net loss, had no material impact on the Company's previously issued financial statements as of and for the year ended December 31, 2018. These amounts have been adjusted in the accompanying balance sheet and statement of operations.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The revision to the Company's previously reported balance sheet are identified in the table below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:55.894737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">35,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">153,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">152,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">111,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A revised rollforward of the Company's warrant liabilities is as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.239766%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.473684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.473684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series&#160;F redeemable convertible preferred stock in connection with 2017 Term Loan (Note&#160;4)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March&#160;31, 2019 (unaudited) (as revised)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790626960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text">Note 2. Summary of Significant Accounting Policies<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Use of Estimates</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim condensed balance sheet as of September&#160;30, 2019, the condensed statements of operations and the condensed statements of redeemable convertible preferred stock and stockholders' equity (deficit) for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial position as of September&#160;30, 2019 and its results of operations for the three and nine months ended September&#160;30, 2019 and 2018 and cash flows for the nine months ended September&#160;30, 2019 and 2018 in accordance with GAAP. The results for the nine months ended September&#160;30, 2019 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2018, included in its Prospectus dated September 18, 2019 filed with the SEC on September 20, 2019.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill), net deferred tax assets (and related valuation allowance), and for periods prior to the IPO, the fair value of the Company's common stock and redeemable convertible preferred stock. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Significant payers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"/><td style="width:51.147877%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532064%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.980966%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:69.491228%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.450292%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Blue Shield</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">United Healthcare</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Medicare Advantage</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September&#160;30, 2019 and 2018, approximately 83%, and 86%, respectively, of the Company's revenue was related to the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test. For the nine months ended September&#160;30, 2019 and 2018, approximately 83% and 86%, respectively, of the Company's revenue was related to the AVISE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> CTD test.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company is dependent on key suppliers for certain laboratory materials. An interruption in the supply of these materials would temporarily impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disaggregation of Revenue</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The following table includes the Company's revenues as disaggregated by payer category (in&#160;thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:43.374449%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.922173%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Healthcare insurers</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,408&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">17,716&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">15,023&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Government</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">7,013&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Client</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,007&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">3,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Other(1)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">458&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">Janssen (SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:100%;">)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">835&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">10,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">8,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">30,173&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">22,799&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt;">Includes patient self-pay that is immaterial</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The carrying value of the Company's cash and cash equivalents, other assets and accrued liabilities approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 1 -&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 2 -&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="text-indent:-72pt;padding-left:94.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Level 3 -&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company's redeemable convertible preferred stock warrant liabilities were measured at fair value on a recurring basis and were classified as Level&#160;3 liabilities. The Company recorded subsequent adjustments to reflect the increase or decrease in estimated fair value at each reporting date in current period earnings.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:71.099415%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719298%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,164&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">77,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">13,264&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Offering Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2018, the Company deferred offering costs of $0.4 million consisting of legal, accounting and other fees and costs directly attributable to its IPO, which are recorded within other assets in the accompanying condensed balance sheet. As of September&#160;30, 2019, the deferred offering costs were offset against the proceeds received upon the completion of the IPO.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of the IPO, the Company had multiple classes of redeemable convertible preferred stock, all of which were classified as temporary equity in the accompanying condensed balance sheet as the redemption of the shares were outside of the Company's control. Redeemable convertible preferred stock which was redeemable on or after a certain date at the option of the holder was accreted to its redemption value from the date of issuance to the earliest redemption date.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In connection with the completion of the IPO in September 2019, all outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of 7,816,643 shares of common stock, excluding warrant conversions. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Redeemable Convertible Preferred Stock Warrants</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Prior to the completion of the IPO, the Company accounted for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of each instrument. The redeemable convertible preferred stock warrants were recorded at their fair value on the date of issuance and were revalued on each subsequent balance sheet date, with fair value changes recognized as increases or reductions in the statements of operations. Upon the completion of the IPO, all remaining outstanding warrants to purchase shares of redeemable convertible preferred stock were automatically converted into warrants to purchase shares of common stock. As such, the warrants no longer require liability accounting and the then fair value of the warrant liability was reclassified into stockholders&#8217; equity.</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company performed the final remeasurement of the warrant liabilities as of the IPO closing date. See Note 7 for the amounts associated with the fair value measurements and Note 5 for further discussion on the remaining warrants.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (the Payers) consist of healthcare insurers, government payers (primarily Medicare and Medicaid), client payers (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Payers are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payer (i.e. each individual third-party insurance, Medicare, client payers, patient self-pay, etc.) and per test basis.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Collection of the Company's net revenues from payers is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company early adopted Accounting Standards Codification (ASC) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> (Topic 606) as of January&#160;1, 2018 using a cumulative-effect adjustment to the opening balance of accumulated deficit and accounts receivable of $3.1 million. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Janssen Promotion Agreement</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company entered into a co-promotion agreement with Janssen (the Janssen agreement) to co-promote SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> in the United States. The Company recognized revenue of approximately $0.4 million and $0.8 million during the three and nine months ended September&#160;30, 2019, respectively. The related expenses for marketing SIMPONI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Advertising and Marketing Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million for the three months ended September&#160;30, 2019 and 2018, and $1.1 million for the nine months ended September&#160;30, 2019 and 2018, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Shipping and Handling Costs</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.4 million and $0.3 million for the three months ended September&#160;30, 2019 and 2018, respectively, and $1.1 million and $0.9 million for the nine months ended September&#160;30, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting </span></div><div style="margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">period) on a straight-line basis. The fair value of stock options is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. This decision was based on the lack of relevant historical data due to the Company's limited historical experience. In addition, due to the Company's limited historical data, the estimated volatility incorporates the historical volatility over the expected term of the award of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Upon the effective date of the IPO, the Company began using the closing price of its common stock as the fair value of its common stock on the corresponding date. Prior to the completion of the IPO in September 2019, due to the absence of a public market for the Company's common stock, it was necessary to estimate the fair value of the common stock underlying the Company's stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company's stock-based awards was assessed on each grant date by the Company's board of directors (Board of Directors). </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comprehensive Loss</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Potentially dilutive common stock equivalents are comprised of redeemable convertible preferred stock, warrants for the purchase of redeemable convertible preferred and common stock and options outstanding under the Company's stock option plans. For the three and nine months ended September&#160;30, 2019 and 2018, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:35.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.852941%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,202,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">5,202,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">203,549&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">203,549&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">934,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">461,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">934,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">69,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,475,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">69,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,936,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,411,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,936,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,411,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Reporting</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;Leases&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Codification Improvements to Topic 842</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases: Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU No.&#160;2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement: Disclosure Framework--Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy, or valuation processes for Level&#160;3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective for annual periods beginning after December&#160;15, 2019, and interim periods within those periods, and early adoption is permitted. The Company is currently evaluating the impact of ASU&#160;2018-13 on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795080352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,630)<span></span>
</td>
<td class="num">$ (6,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Revaluation of warrant liabilities</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase (Decrease) in Accounts Receivable</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Increase (Decrease) in Prepaid Expense and Current Other Assets</a></td>
<td class="nump">510<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase (Decrease) in Other Noncurrent Assets</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">174<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,784)<span></span>
</td>
<td class="num">(7,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayments of Long-term Capital Lease Obligations</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">52,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">70,525<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">64,664<span></span>
</td>
<td class="num">(5,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">13,264<span></span>
</td>
<td class="nump">11,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">77,928<span></span>
</td>
<td class="nump">5,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to redemption value of redeemable convertible preferred stock</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">6,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderCapitalLease', window );">Equipment Purchased Under Capital Lease</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Cost incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock</a></td>
<td class="nump">138,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_NoncashExerciseOfStockPurchaseWarrants', window );">Net exercise of common and preferred stock warrants</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities', window );">Deferred offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity', window );">Reclassification of redeemable convertible preferred stock warrant liabilities as equity</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherNoncashTransactionChangeInAccountingPrinciple', window );">Adjustment upon adoption of ASC 606</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeemedDividend', window );">Deemed dividend from issuance of Series F redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series G redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Deemed dividend from conversion/issuance of redeemable convertible preferred stock</a></td>
<td class="nump">6,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ConversionOfTemporaryEquityAmountConverted', window );">Conversion of Series G to Series H redeemable convertible preferred stock</a></td>
<td class="nump">11,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">10,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividend recognized for beneficial conversion features of Series H redeemable convertible preferred stock</a></td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ConversionOfTemporaryEquityAmountConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary Equity, Amount Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ConversionOfTemporaryEquityAmountConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend from issuance of redeemable convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Included within Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsIncludedWithinCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Capital Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NoncashExerciseOfStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Exercise of Stock Purchase Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NoncashExerciseOfStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherNoncashTransactionChangeInAccountingPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Transaction, Change in Accounting Principle</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherNoncashTransactionChangeInAccountingPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance or Sale of Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ProceedsFromIssuanceOrSaleOfTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Temporary Equity and Liabilities to Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Deemed Dividends with Beneficial Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_TemporaryEquityDeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6803090112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 08, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784878512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Changes and Error Corrections - Operations (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,141)<span></span>
</td>
<td class="num">$ (2,785)<span></span>
</td>
<td class="num">$ (2,704)<span></span>
</td>
<td class="num">(1,756)<span></span>
</td>
<td class="num">$ (2,146)<span></span>
</td>
<td class="num">$ (2,793)<span></span>
</td>
<td class="num">(8,630)<span></span>
</td>
<td class="num">(6,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income (Loss) Available to Common Stockholders, Basic</a></td>
<td class="num">(17,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,871)<span></span>
</td>
<td class="num">(14,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders (diluted)</a></td>
<td class="num">$ (17,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,871)<span></span>
</td>
<td class="num">$ (14,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (USD per share)</a></td>
<td class="num">$ (11.29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48.70)<span></span>
</td>
<td class="num">$ (227.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,177)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794916336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>leaseExtention</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>leaseExtention</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Minimum annual purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneObligation', window );">Remaining milestone obligation</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneContingencyFairValueDisclosure', window );">Remaining milestone obligation, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Operating lease, rentable area (square feet) | ft&#178;</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_NumberOfOperatingLeaseExtensions', window );">Number of operating lease extensions | leaseExtention</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Operating lease, rentable area (square feet) | ft&#178;</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneContingencyFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contingency, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneContingencyFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NumberOfOperatingLeaseExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Lease Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NumberOfOperatingLeaseExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795273792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">1,970,000,000<span></span>
</td>
<td class="nump">1,675,200,000<span></span>
</td>
<td class="nump">1,675,200,000<span></span>
</td>
<td class="nump">1,470,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering</a></td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of redeemable convertible preferred shares (in shares)</a></td>
<td class="nump">7,816,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in public offering</a></td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]5V/?6[=T_-KX(Z@9^W87^ E!+ P04    " "CB6Q/F5R<(Q &  "<)P
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M5UE9>#<3J[%3E7:_T>ZBC:J'*G8J=?':'\O&'6_]G2P;:)C !P)_)[#_$L1
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M^YSF6LP\%829!U1P]CG-M5CX*@"S#*C@['.:Z\QW'V%"GP8X^YSF.O/=1YB
M^QQGG]-<9[[["!-R'V>?TUQGQ'V ";F/L\]IKC/B/L"$W,?9YS37.7$?8$+N
MX^QSFNN<N \P(?=Q]CG-=4[<IYC 7[+ T1<TUKF_O0!,2 0G7]!4Y_X;!C"A
M_WV!DR]HJG-_#T.8@/<B\-%.4YW[[S' !->"DR_ Q[VW4VX'3.XPS:"2S]+E
MTO]:2B8]52W;HVL_=;13E\;UOI/1L<6]YZXG>X?W_?&WHCV6C8Z>E;&=G>N_
M#DH9:2>4?K!3.=F6?+RHY,%TIW-[WO9]:7]AU'GHN9.Q\=_\!5!+ P04
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MHCF]'Z"0BMSB$2P,P@[M[;L@%(L.=N"&#MQM!TG*9N&B20?-<=#,LM2RN2J
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MVH?C)SS;:<PFPYM^_D%L^<;%7U!+ P04    " "CB6Q/*ROM9+@!  #2 P
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M/AQO\6RG,9L,;_KY!['E&Q=_ 5!+ P04    " "CB6Q/\^$RPK4!  #2 P
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M-WBVTYA-AC?]_(/8\HV+OU!+ P04    " "CB6Q/#JX6JK<!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6QM4]MNVS ,_15!'U E2M($@6V@
MZ3!TP 8$+;8]*S9]075Q)3GN_KZ4[+INYQ=)I'@.#RDJZ8U]=C6 )Z]*:I?2
MVOOVR)C+:U#"W9@6--Z4QBKAT;05<ZT%4420DHRO5K=,B4;3+(F^L\T2TWG9
M:#A;XCJEA/UW FGZE*[IN^.QJ6H?'"Q+6E'!$_C?[=FBQ2:6HE&@76,TL5"F
M]&Y]/&U#? SXTT#O9F<2*KD8\QR,'T5*5T$02,A]8!"X7>$>I Q$*.-EY*13
MR@"<G]_9O\?:L9:+<'!OY-^F\'5*#Y044(I.^D?3/\!8SXZ2L?B?< 6)X4$)
MYLB-='$E>>>\42,+2E'B==@;'?=^N-GM1]@R@(\ /@$.,0\;$D7EWX0766)-
M3^S0^U:$)UX?.?8F#\[8BGB'XAUZKQG?[!)V#41CS&F(X;.8]13!D'U*P9=2
MG/A_<+X,WRPJW$3XYI/"VV6"[2+!-A)L/Q'LOY2X%'/XDH3->JK 5G&:',E-
MI^,DS[S3P-[Q^"8?X<.T_Q*V:K0C%^/Q96/_2V,\H)35#8Y0C1]L,B24/ASW
M>+;#F V&-^WX@]CTC;,W4$L#!!0    ( *.);$_F/4!RM@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;&U386_<( S]*X@?4!(NW;I3$JG7
M:=JD33IU6O>92YP$%4(&Y-+]^QF29EF7+X"-W_.S,?ED[+/K #QYT:IW!>V\
M'XZ,N:H#+=R-&:#'F\98+3R:MF5NL"#J"-**\21YQ[20/2WSZ#O;,C>C5[*'
MLR5NU%K8WR=09BIH2E\=C[+M?'"P,A]$"]_!_QC.%BVVLM120^^DZ8F%IJ#W
MZ?&4A?@8\"1A<ILS"95<C'D.QI>ZH$D0! HJ'Q@$;E=X *4"$<KXM7#2-64
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MB/J#5$EIP)82/=A^&_M2S &'RKCIUL[5>%_&P,A^>@K(_![E?P%02P,$%
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MEYG96=N;8E+ZU?0 %KT)+DV)>VN' R&F[D%0<Z<&D.Y+J[2@UH6Z(V;00)M
M$IQD2?*!",HDKHJ0.^FJ4*/E3,))(S,*0?6?(W UE3C%U\0SZWKK$Z0J!MK!
M#[ _AY-V$5E5&B9 &J8DTM"6^#$]'/<>'P O#":SV2/?R5FI5Q]\;4J<>$/
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M!UL,!;4+QR_^;*8QFPR'_?R#V/*-BW]02P,$%     @ HXEL3_.=Y\!L @
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MQDE%3U(/$S7F_8G:3R1KA]M",%Y9\K]02P,$%     @ HXEL3Y.LOT,L P
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M<2IJ=Q_$VCZ*&U77R.B>-Z^A>*_::T7;X*Q45R:GN[?-_P-02P,$%     @
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M?^H "K5ZFGH^'3LG351C9A6&7F!" [)H0\@U8M5&>+[78!SE9.,I19[.:(O
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MF<M?\?H[M.\I_8235K=+,/3L_!]02P,$%     @ HXEL3T9WB @* @  ]@4
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M9.;N IKTR>XD($@"@*0&2&(%"7(3!-!$(0R2@B I &(L^RZU@J2FIK(UB1_
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MXZ,P!46^9ZK_)MY$J>&=$IUC(\NV__4VKZV2E6'14JK\SW LZOYX-/SO83B
MF@!Z"B#\;  S >S: &X"^+4!D0F(K@V(34!\;4!B I)K U(3D%H!P? X^N=[
MGZM\M6CDT6N&*7K(NTX@MZF>09ON9C]A^O_T(V[UW;<5)W01O'5$!G,W8.@$
MPZ:8-<+P*>;>Q5B9/KN(S$KT<)'DRV621Q?"DOB$"?2(G8:-PF&C/0&;E!MA
M @8)6$_ )P2Q-5X#)NHQ]8")"4WL$;D(F\CA4 X'<A)+#G?R1(2RV)9S$3:1
M$T$YD2.'9 DFB"%!?/WS22!!<GE UHE3*0EY0BG.D\(\*<B38H(,$F375TI"
M; $AT)#9'3. XG&Q21J&,YEFS(:XF>@<!6X\\H'.([CU".@]2FP_8VZ]L]7B
MGB*@J>8F!\%]0*(/5(L[@<1 !;,=/G:JC<)1N69,8F?"ZTW2[*C@QB*@LZBS
M4B!09*\$YT%3,;C["&@_:MLP!"6VF/.@J1C<R20#%*DM!H$R6\QYT'1]PZ9
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MI.H8IJYKQB0H2>])1=VHSKTL*-123Q,UYU/[FA:2#7-K1LO_H?@/4$L#!!0
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MADE%CU(/$S7F_0FEGTC6VM.7-QP!\W]02P,$%     @ HXEL3R#P1T&2 P
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M68 "/OR8 FKS  5\_'%V,XO^:Y5Y/LWQA*+KJF1>5<89'@?R@=V$?3M1%**
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M#N][[1==\":8I[S6IV7QSVK1+(^GZ72RT"_Y6]$\E+M+;0-2TXF-_D:_Z\+
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MZ;."P:S@ED^N(LY@ 0(*D%8@NPP$T4%:.PQM,;4/UO\&R9V,? B1Z):!T$<
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M"*+SK"*,/41@@]\C#! Y0C."AKS>F4A4>.H:P9V."$#%;"H"4$4L]3#!DH
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M$2*L]R(O^=P^"5'-'(?O3J3 _(E6I)1O#I056,@I.SJ\8@3O-:G('<]U(Z?
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MWD#?X =*!9'>W2?I_23;QG:2DX-0PXD<L[IWJB>"5DU?Z+3-:?H/4$L#!!0
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MN"$(WQ\1/$WPW@G^AP1?$_RAA$ 3@J$$H@ED*"'4A' H(=*$:&B68DV(AWI
M[G7EW'<*4555+[FJH?N$)[-)R2Y667\&QT1^;6B,9)ENY*RJ2O6GJ*-*S)YG
M!*.)<Y:6-&9>8W +$^-;R+(+,8RLNPC/]QJ,(Z)L0L5@J'/<L6!$L0 0+KG%
MW$.8\!;ST,7$WBWDL0LAIJLGR%5D).Y34:O/@UD#P2 XM1Y<!9XRX-T8"&$+
M/FS!5Q;\=@&XOE%'-88H3*$P7\1.;N2^"PH"(V=="";&$JX^-[/N0CP4P:(#
M6'0 B#:*8%YC@K9H#_G&U[$(@-2$D1'Q/8@RT_P >$1A8,3U"-E"OEG"H$>S
M_I: QXAXQLJN !0A<0!GG, 9)T#&8R/C!-+O1F:A 3 _P$8REP *DR@TUF\%
M^?2]5F@WXD)87-@5AXRHYV%W02!Q  P0!Z @<9#/?G$1+"X"Q!E;W;S&A#>.
MT @;"_P P$(T,G=6 .5'(W.? % 8AR/4LW_&L+BX(XZ@GO3(C@TV8G?X'HSZ
MFCGZ?!=>:U"[5I'?]QDBN!??(=Q5C-T>&SU-!_U'UT$];0<-Z#MK!#0>A$+3
ME=,Z-.6TW*N#>V5MV*G@,LS6;',YN,/RT&7,S]'X"0'S2S1>U4?_=_/U3>1;
M4N[3HK)>&1>'/74>VS'&J8C>'8F5.HC+3S/(Z([+UU"\E_4-H!YP=M2W&Z>Y
M8LW^ 5!+ P04    " "CB6Q/[FDN<!4#  #$#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6R55]N.FS 0_17$>Q?,Q4"41-I<4"NUTFI7;9_9Q$G0
M J;@)-N_KVV\+-B32U\"=L[,G!F/CX;IF39O[8$09KV71=7.[ -C]<1QVLV!
ME%G[0&M2\7]VM"DSQI?-WFGKAF1;:506CN>ZV"FSO++G4[GWU,RG],B*O")/
MC=4>RS)K_BY(0<\S&]D?&\_Y_L#$AC.?UMF>O!#VLWYJ^,KIO6SSDE1M3BNK
M(;N9_8@F*4J$@43\RLFY';Q;(I572M_$XMMV9KN"$2G(A@D7&7^<R)(4A?#$
M>?Q13NT^IC <OG]X3V7R/)G7K"5+6OS.M^PPLV/;VI)==BS8,SU_)2JAT+94
M]M_)B10<+ICP&!M:M/+7VAQ;1DOEA5,IL_?NF5?R>5;^/\Q@ T\9>+T!CWW-
MP%<&_J=!<-4@4 ;!O1%"91#>&P$K _QI@.5Y=,62U5]E+)M/&WJVFJZ!ZDST
M*9I@?KX;L2F/4_['#Z#ENZ<Y]KRI<Q*.%&;18;P!)M$@*Q."QHC41/B!WV,<
M3K)GZD%,%Y[A0".Q-!&)K_&\Z61]VTEJ0C"",_'!FOO2WA_91["# '002 ?!
MP$&(0BW3#H,EINI.)'2U3-8F*$ZPENUUS(AM"+(- ;9Z23M,. CBQ0D<!(-!
ML!$$N8'6Q]C(Y N78*V)3%"HEQ:;9'&D5=;$Z&Y2$^*C&,XY G..@,(F6LZ1
MD8Z6\"HR:&B(U$2,6FG$- :9Q@93C"X<;P(Z2.Z_,LB%A<Z]X](HT/AH8ZT>
M:P!E7IL;H#'E"]J,[K@Y"G37U4&@LCXB[_;E215HU 5!$EX(! L?\F]W;*I
M%\]@' @62&0J)/8NN8!5"X7_T7*P)B%3E("6 U0)H4C7$P"F7U-D"LJEE&$]
M09"@&/UV32_&46 M0*88 -T6&U'&51E'@D4#)?>T6W*C_ETD9S!0E:39RW&X
MM3;T6#'1)8/=?N1^],1 INTOT&2)@/T5FJR[@?K3?3??_\B:?5ZUUBME? R4
MP]J.4D8X>_>!5^C /RGZ14%V3+Q&_+WIYNINP6BMOAF<_L-E_@]02P,$%
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MH-?IC8:CV632T-(Y-%(D*QC>,OT:_>_TH;XPO?Y@.IH.IS4:VQ<%;LGKK%Q
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M;7;A5WHPHTOC"?B$ HE/L"$7 UJRD<,M8<?V.QC_CM8A#HFWXJKB98$+?!\
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M9AB!V_S! ;Y,RT61F>M(L7V@%26WZ09=O=WH!(A(@72G<(/2K2@89[3XD."
MSZR2>SK<^+EDN.E-]"Z]C]ZF7[-%CF0WZ/4&L?/*)EFGVMFYQ4UWH6=\=A@'
M?HP82PEW,JR!Z2=S<=?,ZYVN@26_3&%\>/! &E:,(HDI9&?9P!/2U<LLN=W
M:<L694PK$"-@ H_A#MNYO\L6=Y&S)MYX:$('VL*)_5>RV2-G0.82MVV)7O[H
M/)N5H.XOT?3"'F5RVZ/(2CY\>'"!DV7,TWZ_)LZ_A=4ATBGW*N?02BU3$EY$
MMT2HU%V1;] )O=_EV7J]WZ0HN*:DL\'ZI1LX0=1/MDY7#_#;#1T'TEJ6/.=,
M (5 7.OL;S*H(MFF>U@-EIF_X!N\VZSP7++"\UX']WZ#-GZ@=W2B#X9Q:,E
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MV/)7-(K#H4!2PSA8')@WE(;];'XQ^'!!+]SDR%_*YY%$S\-!1[G1C=>/WJ&
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MA /--T1/UZYG=?>PI:,DA(FK@P%FRHD\_GQC+Z/*D6/@J&5)%5A?4E",:TZ
M8B?8Y$H.>XEUR&S&RI.SJ_/3Z&,.(\,\3+&1AFAW[,1)!#N'<Y*OZ<(R;YR*
M?*<Y'=0D)<0=23@F,,>.Q!G9\Z8[A=4F76LD\[Q:'&<39 I-2D-KWNT:E, E
MS"&G:9ZA19BZO-A8RU7=:N5;O&&A.UO31F+:H,4P4 1\7_\PSYQR)+B\GD85
MO$*S(.6Z1^2:,^BU6E"_:TC#U8$O;%2L@^H]+HZ@&A[[T?&2&<PPWF4L71)U
M^=/C,V<AX.41I52,!T.^4*61DJZAM.Y45GGI5%9AVV15:RB:"K$X =!-G;DQ
M)4T Y1B/;8DVF%6GND9N8HRR(7&^/AQ;<%+L@IP$!47)(38H?!FC8BRVQ>J,
M\1+"A_9;Q5Z0BHVOP1X0 RIW,"A=:;CJ.(4*BK%W'">@HRY4F-COC _O;$D:
M<JEJZ%M#!+P#X7U(*F]9TFFQ$5U!\30WXIA9#QP1/ZSF"%@<'JV^XT#ZIH":
MV%#V-Q^-8YP-KNGDZB[;;G75_@#_K*K[96B>//;NXW?Z>'7DBVK!I6\;G2A^
ML+^XZ8_RM^&3=]-',M;V5OJ9/W6S*RD&Z/PST.K</?]!GE\&>83)1N$R$TSI
MQ+EI4A"/\@=UDK![!/'WG@QRBT:/#MG\0I[SDKB F$K8!VW48E=NP6WFCD_V
MY=X .S2[+#]YRB(LDC&Z$#LK7$!'C/7M5GZI!8)@L?/02,K8PXM5 E._6MSE
MJ[3LO 5V@$+,BZNWIVJ!1T&;W.HYJ*^QP8LWA_NH-=^-0T![M2@83@DCED"_
M<BSK7L.580K MT$0@6E)=CY:&]RNFY2S?OI>*'9HB/S):P$S"$[ 33564D^(
M S-:3#7W4MNPD=C1.7(4SU:4HL]\2> <<GQFY>?.#1XPXS<MK+!R7RWWY#=
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M-,*J>B6N5X4G=VELZM@*KS(\$&^];B5,[>@4$GZV)^LXT5NTN:ZG'I! %<\
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MA8XQ?R9S=X-M'<P'T6 T-,];SCKMS:));V!^\<!K#S:-![S<'TU,W5;>7:<
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M;?%@["6:=&YON8E]^>U"TJ]0LFQT:!8L1%LO9&U6)4_*!B"1P=12CKA&!6U
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MHUW_4&_<@TQG11@@E93&2@EXVV)V;-, PX8D#I<8E- @N8EL:O\-\3:WE$>
M6=.K]OJ0,O2B4@TY!6T/X71NV8 N57;@B@S+G.X<+<+@'C[KVL6!YANB)P^S
ML7O8TE&RV$_*>J*<R.//-PYFPS]R!)YP6))_NCFOH4(S'0OSE1SV$AY=VG31
M)V=7YUB2%$8637J3.%)IB';'3IPT@7,X)_D:UK$N0CEXFY<6;]/V.8(/E[4J
M2(TP'M&PM5J)H'KHK!L,'_$0-FMP502U1M@Z-S&N>8GNB56G"MMR2]8^!AR,
MC4L07G/KK7$)$AL=R-11[NB;T(RU,/)^JU9-PKOB:T"*1#WE#@:E, ;@4PMZ
M&V40(/BE,^I";X+]3K7CFD=^23)_J=B%MR0NDH,>AG?<TV7#)B:5M];FK1:[
M:&!LC8WP.G+U+3^7A5N'_=OP;((\ZSM%VK6A(Q%NH<1:90M$_%/Q:L'0V4!L
M2=OG:N85DL3*X*E@6_5JY1T?&_=HPALKT;(>RR1(6(>TP) 5IK2%NPEY4,+!
M-K*OPV85(P>2]K[<&R.A#\8_Y1L7UQY!^QW*/>_<NH?"83*ON)B-M'FQ2F#J
M5PM0?M.R\Q9H&'GNBZNWITT%U4D"$QA%Z;J<T!J>?':J@CFA.Q@T)O*0@SWG
M"_.KU&(A7QS2%-8-0AD2 P[8\L#XP1N.!-MK'F\WS23,1:Y+7HNFBO!.##JT
M@CVA3\$(72Y3W=66M&JD\/-GUR*"G"_)T$LPVW!0D.Q@+1K#;\#!;5("91L&
M9C>T)+&4;#@LIDD:LF6Z8-P$ONF1,%* */$I^ED\H1H-V(X?S55_^))R'K:R
M=B7BH&T#V%M<T6Z< "MOZTB LJ\ZCYD35UL\<\R4^)(BT5",9$.6W[M<T03J
M,^#LM*".+ESWGX!1&D*\2,WG,J*N/5P+9Y&$ZXQ)"#6K;,RG[A5T4Y =^D&B
MP5!#H, 754A)0LMOF!'QJ)9^ !EN.-81C-4H9PV(*/#B:IE$'F2>R)9N=A)H
MAQ[,)6@4H_#RB&H[\A')40I*.5:$HE9#Y6Y!$[_#(GEPO-_D9:C4;.6)R/\*
M\4T5GV3BE-P0"R79IK2 &0-KR6JE@2:)[$H<V?+5;,ISXQCHFTV.Q:\P<5:^
M+[343345"OF.V:%^\R!IA:4267WTL))$W 6%F,?F]E%"D0IIFC/ 8S35MNYE
M*TN*0"_%2"DF*,6#U?8!S12TMI<P0DIO\?@3Z!@'T5O;='*));M=D8'<JM[P
M12#KC1^L>OW A*6\RC3:IBE!\-98I'>=T%N"!7+">YPX(ZU_^S);[=W%^H:)
MP;;L?\-IT7WN>B?<&9IRV"Q3!._ZG;"2CHWYS6XZ-AF:8+R[T:6#D5GB.G&>
MJH9A*&3?F(?;.B ,DBM4R_O11EC]J,0PFQPESM*T"X:OEBUN&S_ER-!TMME2
MX 9D"Y^LA=PIA, <$)+E%B)M,G4&:%E./LDII6/$V(8VK41'I3@U%:J!7@-]
MH"Y_IVR@^Z!>PT<?B-ZS-$]1'+>V6JL#M)1B#V)R($BIRYQ!'P7MEP5+DZP:
M80KH@_&<S-:$@G9C+T0QM<YF.5(+PN_G9G0J 7502BT8"_#9_<$54V'5B>^K
M!HOMDOJ#7K929'*UAO@6#BP'R1S9B7A.!!S&\C+_;"ZJ#&0D*D%<7<F MVB1
M5H!Y!5Q4>PFU"M@]#C\?O:;;#V4(%-#@OS&G<[8O;/T7$AL!(.MLP79!:P['
MX9V\/KMZ<>H@+(QM5RT*U[FU&@0#=P6.3->>2<CM)VG!N [RYU(?]W3S QWM
M8=/D5E5$] V920G2);,IS8@]: C&D=A.*/0#OR8Q('D<:6VIEV!V&3LEU4WA
M1\6SMWK)7(E$Z-?I=:&)PB<\ 5Q''7)PO3]M21L].;OZ=$KO=7J#.'K#U=M/
MV) V&PTDHAHW>T??E7NT-:48 *D/]<Q[L5JK"OZ;Y"4XJ<#@'I03DS3-(KAD
M)//JI%Y;?9PBAPB\X #[^ L7AJ%@O!I W&B?2Z=V)JSEY_3!8Q+,6+!A8IQ.
M/6DOZ=0LL+)7G^B7#I9E]^R1%VM*[&2L\69!(]6-31SI)D%H'H=_FN=1T,9J
M#W?Y/07<475@JS*SPT;('#>'ET6)D_?!CJZO._0\^I@4M^0=\T;H974T@3M:
M:[= E.B-B":B I'TRQG<U%:<B+%')-5JLC'@Q3"BV.#WC%E#:=D[Q>8(29:X
M4 ]6%HZD-K8U)84B%9B60PF;8&P:V,%:&6ERSG2EUKM%R>@0;/@Y0P@,2+L_
M-O$.9N^QQ#"II0F:&9@UP>U5Y!H*RB>&&8#5R]TBN3M2MY D<-4:]E]=,I'@
M_\D$Q_H@OAD("S YIU(#(P).]3FYE>*-5*I8E/=EQJ!;@;?4T@IR0^1[JF&F
M$; ::8P [IBCG/,<_#J0E>F[&%N]RD5LM2S;KG?>CBK@D)_M;Q&/V7S,W^5=
M.4S#. JCF)^[%1)?%W"@[_/B<Z>C06)BVW >^L <RH9-A1LVQS-9BJHMU&.#
MT!VX9E%MM &\Z48W(@G9R"9*N<DQ170("4><%@S@E< HRO])?3(DU69E9=:+
ME9%%9!<0K_55*U+4@A4'RLM"R%42!ZS<)EY>\84K>*YQDG_([]%X$=?/M 9H
M-LZ)+@)![;'>%:G>A?*YXS0+('&-X"X.G\=&&LO"242N=?5B@I=D14 !*IO-
MUV!>EB[>%<O$!2P*: M;IV+;V_.5C[Y;PP(9A\TEXUMRM+G>\BC3K.L&+%P]
M^9*?='QY(I-S\I1=-7=[N^-MK[5ARP/^I#B6DX]D9*ZE KY:W*7+_8I(H1:&
M\H$@^B#+4.3):X()T%JX_1%ZI!8@@4H*)<1UGB3O<FP@*&35@C7$/H48.8&)
M>2 <7]+\8O#A(O7PW>I1#>1=JF=:"N56,ABBP3CZ$=W4/T:#"7[JPS\O\#Q<
MW9$I$C;VQZ@_PG_,)\%J_<$ZP_O80'^ __3T4=/%F<8"R!/T3U__.=/I?K#3
M#>CL]8 K.X6ACMX;.'Y!_]2'.]?. V.<R6]58H"K0FN/*&'Q)M1J]=X=J*\=
MQ/L1=G]IVV<]BL$6 N*N5\7^55)NR92>NXME@ Z4#'"&5=''\:B'_^U/XVF?
MDG&-XQYLPR\6MC:()Y,Q_#L>C*)I/)_@OYBX\YQ1()AX8PKO]Z,AIB^.1H,9
MQX>=]$\QKS^F5(I&XUDT'(XQNS1PV$UT<G7Q]O+]NXOHW_^M/QW]')U&(Z!7
MC>^;P9/Z^:-W!"F[WXC2%L[BP6!(:?OB_A0_# ;Q=#Z/L-L+W:0J-,7@V9P0
M[#HC<WA0%3&-/* *K6X7AAX,6C,9FZ4/^MV3OUO[=>G5&P)O.<BWG4?"5<IK
M=3K/&Z/CGD73:3P;$/T,XSY0QH?*5##5&OZ?GISKDP-X\B#C;[G2WDMGCF4-
M)F9,;Z^^RF4NF!6T&YN#_TK@]XU&^?!F!FVTCKF/2@M6JF2II5$CT)I-X)AC
M#6.1C+/'LQYV3(?^54*;VV G%E/FK\=K6@'%]4ACFO-!/!_U M_\*11@W#*:
MQ(0']X;Q>#2O_1ULVUNQT:0?#X"9S(>C>#J;U_X^]_+2B+G;YB'%?->S<?T+
MYF']>#Z<0'-S8+ZC?A_.RS#X797(.=C6&OHN'"-+LR!U"4HU.A,-1H2NKW;4
M77W50C,5/2FFH^_+:&QZ'(/_5HP4\(TY7T_ [$>1CE"PVY*E!9_K#_$NFI@G
M,#0%SBJ9(%B^5ACJPJ#7)C":R5QN+:0J>E.F"&(27F+:7N-2X- F,TH=&_?G
MD]HN7A9H;-RQP0Y/9@@"U[0?H5>_\^*_W@,GY+3'F'(B^\I0CV<H5M(_;RQR
MS8YA )<PW/#Q;#P6U@IMVI\)6Y+?[.Z15<W&_6@**T,V,_3 H?9AC64CN,V'
M<SQC%,ZVT)(Q\ C(4L @4<( F90/TS:\)G#082.'\1!.W1MXZ7G%+..D9R=I
M?HUV)XFJ.X')S$:G&*\_Z\]/H_"RQ\2Q<;>'_1'']$]JNQW>Q[- ]/3WW43M
M01-BNKJO.<U(H;-QCRFUWS<O+96;YN@]L^BY/J\I[+ ^:? 6_=D 3IO3KW!5
M$DAN\USL*@:L.I@/HL%H:)ZWYW:*J7%[ _.+!VA\L$&3\')_- '!@)-)LG'+
MQBL@=%(!WKBUL*U]8*ZSOASN4 #[>#Z%U9M&H>U!07DT0G%S".)+G3>_L '@
M[73:UYQ:_"W&'>_73DIO*7+!YA<GDW9DNVA%9-+!6CIPBBQ*!R[*2C>2\1"N
MH].);/?2U;NY.0+RQR,4RRDS3, @YL28 FNAS**@D?#'/NPP7(NX*8,!%FX9
MC/74#X=Q#W[@D_UI(\>7:/=Z1U8FS@)* 502$\9$?#+"HWVAA'LRB6?3R:DT
M:R<;:VR(MB7X0VR^TB(RQ7@RG=9HPA4S3$9=D1Q@E:N1A^WHQJ4([>"PNAI,
MU>(GL]4P0,>[G8>2(C_7,L2:)![#)6$A3&88LH!14OC$!-OYPI(9#=9S'?4&
MFF!>RPVA_0O]994O!I.&9J:C&!D>M>&E9)EX?S:^WP=UDUX^VQ89RF;\KO-7
MXZNH8,Z&\13X7G_4'0Z<!9M)&IW*-Z X-S<UZ('@.Y*F#$N?JDSD?0$'1$52
M?+42M&I*>Y$OTX2L.OFFM5_:^1#PX\@$/BT2D? !>NGX"ENQ2=-.[$F^)M#]
MK0:($RKW@PD)1\!4.T89,NZ4DCRAEO(QG%6(LW <&Z_N8!*#&25:\%%F6VKP
M5V._FL+/2")]CEI<^F!2=NS1PP7\%E0.NOSE0S6C?5VH.-S9":7CDJ1'WA\'
MAS&+)_V9^6]U$&_L%?S\:<F^..52M?W&5$Q'D&#IT6"% F.S/G_0??UFHC06
MQX12@74JN<#"I+GVSD<H98(3;^ZE]1@><AK5B/.-2?SB[;VDRZ)J]TU9QOYY
M\HI]2-W$,XU)Q)RT8<&)S82J6C9W,IA,3REZU63+S6N5TYR[8HP%6#ZDOB<7
M7[')=]P]=5;4SS\G<-V3I99//)D.)F;+<&(!CO/,G)W'ZZVU8?#>6UHZIZ46
M]:\Z._^_JK/3C@GC=:(1+;%'/F$Y^%\5</Z9*^ <VO-W6A;GRHD,"Y4Z:G>C
M_JO4SC^XU,XW)WINAQ%HD]VYM>SUKP2W_TIP^Z\$M]\YP>U[!XJ,YJZ7Z2[)
M5G!%=*)/5R^CDV?XZD^ZRC!AA'G )?\,/W]4AEF/A=AV3>7B.A9)BID^@*R0
MN"+GG]\@4[W V+%:I9QSMX[XW]&"4@O1JL:1")81_10,A%/C>;"@\8'G8TW2
M:=S >%UP,B?'.1SP\^68*U839E0;W:2U0/W*+-\#\7;.X"CQ\6&9ZDG8KG=X
MAN@>"6_UH5W]+ZRTVFLH$? NO6^,IHC1EP_,^4P!<8<VN@)3.)3*("QK_/Z\
M!@%&"(:%%WHQ')12=96Z(D4@[U%M%%>?,.E&8(4\"$W]>KS+MEM-A? '^&<5
M(,>*F%#].4#Z+Y6SO5?W$&5T^$9*29E4%/UV_0!\YR]H'9>45THXU>;[ T\@
MJOYL4&!_-TV_2#>+.[0^P7>:HJ0"+411N35(["!A73(*L(8=K#XW&'=[O1HP
M#32CP+>#2?#9?NA;9_XA--Y1*S 8AGIP@7E/7N1^L(O^Z/&.GSR[?G!5ZP##
MI\\QN*G]0=ONGSS3>;#_P^1C091/GG^PS2=/:A8:_MD?+ZY>1><?7X)\!>PM
M//1+P8RTZ"-(G;,@X1QU03;SEN,O3(=6+@3>67W$8CEKMP!!.(. HR=-\ BP
MX_$S!GFV:P3ZFNV'N.ZW)\\]:IH.RM"=!HN&];5.RK*=''KFP?P<7&'J81D7
M%LMX(.MMU=_\Y[>D#=0Z?0+RKE53KNNY023U3&C'P>">(G,JT"<F\S7#!UX9
M2-'!Z[X!(G1;!-)LL#],S-8+%\!RW%1K\+SC9_P^@&!K A#6,'9-#[: VH7'
MX2/NFIIO0MX=NWA!W-CQ2W@(AE9]]D@D6LVIKM"\?_^W_J3W,SS.'Q2D5^LN
M@-0+Y7PY -:KSR"$V:LW&H;N';=%(1S6\?O3!@K7]$X#$J[I<;6O-P[A,"JN
MZ;7& _<(1JZV*ZVQ<N%]"F#F#L+@'F/%1UMZZ,+O3<,V 3(#B3&\)@V\1-R6
M@QHYQ,O-I>5$:C_M&GS7D!Q'\]U32F'"ZK@.X/L&=!=9"X&:55:67?T@!2JQ
MNO,&5>>+B^C-9?!E9*0/(69@39(K?.[OD=M7C?'I<W$%$7=4JVA>VVSR+\EN
M7T9OLIN4:WVB9_U-RFBTUW!3-G;N8/8.#=#U?-55H%Y0-7/>IXLGVW0^9Y@^
MZF!K@_%CC=GPT,/#&CTZK)O4J49.!*1IS<4^S+9A(+#0;KOS,R2!']?9?NW$
M,=8L#H^,2@)>84SN#6 [ -$ ";6Y@\?V@\KBPIVQ<[8BWV >>U.^-;9E.K!Z
MP*%UGK7O3<&TF>,H$!2%(YQ+(D5*/2V7_'7SX@>:QY!D7SD2!U.[%6DY[P;R
M^AZG%1X[TD'R_9EP7*T]W<Z,7IO^I7/T,9[KR1S+YR;TE4[SX'5: 70KC-NY
M7%OX2=1;++=P8/8>+KO^^Z 7^*X?^&Y0MVFUAVG7S- -DM6WP[8/J:JMP-IA
MZ2:L\O</VJH_FA(ODFCUD'32)$L<*T78=HRG4U^K#3#P['YCGN:Z! 2'06Y7
M)SMB!"\Y/I__>/4=[ FM-LE%RUL 79-/P3LA5CY]Q(PC@\(!?$#D6!O/H@_I
MBQO(1EM.+:"^BHJOOE(!YO_=$;-;M.XCYEN\X,'D6SQ?P\.W>*>*? \M:;8S
MFBLFHX?M!H;<Z(1LPQEO=AB1/ON9E*577RG,-^ .==Z<-?!4UTS9](SD6G5'
M?MAMR4L4<DAJ1)&F'7'-;KQ,-<-*_9&8#G1-\&-(5U./("H S6W(6WH&^GY#
M,CS14ZS^&:LHB*<)^3=51:KU@K4<][4Q#8)"S&618WZG%&]HISA.?1U-Q3*5
M')UQ'?=T[, S:HHZ>CRPXHD)<VM0P!K&#4LKBUR;?G?<>O;82G@1IZ%6*O)&
M(?O63$?O;VXR,?E9RU/M(9-=D4Y63/4'-"%*$IV4?]VC"P,TF]TI#%B/8?.5
ME/L-PK'8(0TB;NSOT>'3&QI+>B]IH6O$/Y$DI.%IUS9FU/!X4XG>CEOWU<6-
MN^*%C2YH:_YJBA%S(ROJ1KXOZ8I-BWU8Q,8F[&.#=H\-#SQ6CPX)V\UKHPV$
ME?P]<J=P[ LUR?6Q%X8M]]C;XI7&S1QMT70#4C!JX"56E.,KCI8H.C'!&*>'
M8U.\ J94_)7*V\$%M!*3])\_H,WT-8/R:O?0/P5@[A"]U10JDWRK0:-N%[)1
MXT8M8S?JO7WW((Z:0"AAO$W3;544\SO9;PG3-6S =/W7?F5^K,'XWB8/C;^Y
MK89_Q-2KS3\VO%G5RF*-?>4U4UWKW$1;UFEM0WL"I..$9-ZD5/D\KA7V;+[A
M9)5+V/+'7_-A@*5 'A][BQ47@J-1LCY)I8F>(SW+CW=][I? R[V*Y.SM_)9F
M?< D+;I=S_KK9.>1-#>UIKRC(]HV$+?&/WT?,K^X?(]V>0==&1S'(P:)(!RS
M5;MN"-8C7IC@6H<B+<YLVE[$Z+G/2<*"Z(QPVX?4EBO7K1^3F=,ITNCTM@B4
ME:J\C(^8U-"VG=B-<JYFE?0+^31H-U&3G'?U2,1(C?-JK)$4%M8[$?>E@<8E
M!&')==N5//CHU/:V)AZ9/).:?]"8@LV)J*1KKW2!@/M0RZ(U1&9&ZDM=&A-_
MLS%_T O;F:\.83PJF^U8 \)[U^^%5=-*.X<)8!1N8X Y[NHGZ^_1P1F0)?6"
MD&4DF-'A:/.BD *%E#,M5S:-R[M(I:HV'" 88OG=T/=/Y1BQ1N_%GK7NL.#Y
M2#PF7@%7X2M PS$//.)$9C8_Y 1J'FI)PC:;'WDLAO/ J[_2TL<F C8Z$\99
ML2K^^>RZ)!S/D?OR>,OM?#2RA]^K.;/?WZM!0QO?;X1$1]^KN4=H[GMUX\7F
MQM&95"*#.\K- M*2F&I#LM:X<Z>@U\> Y68F%SM<$E)&9L#56ZL/SBL20#0-
M/G8P;OH)XPP&4#^AO5%U.H-^<#[>.MN8]PMH'73>;,&VAJ-6H74KP3E_GS$<
MQTR/;.J['<660?.';A"_"603O\V95ODB')O?[&X)!*U7'QD'8Q6F04&R(;Z]
M;BD/@1VZD]8-&GQ&3?CLCHYI)&R"]Z/MJ[\&)]X4<5]];B)\8# /'O\&S\)8
MWIH?4H="DF:H'JP$SWV#L;-%E'K=J!6.5*\_QRA01,PU8TN/MW+M-]8G6+/J
MY%^:48KN@!ZBCTY9^$-:]04;1J2ZGM1].< O0AC[;P3+<%4ICB,@TX0I7]V$
M:7UE*Q4+;$U*>//,N=;\R776N4_3SQAB#U_79T UQ0AU@S'VBXA=,(7Q0*;6
M_U@CZV"X4POO7^ML!1V30>>*T@$<3_/U-K$G3O)VR?MKX]Q+BF31M!.'".5
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MJ)QMFOZLN*,_"7KPSRV7R@5=#0X,\NI" NLDV1_#!6^TUU>ZT>%^DO3?&Y7
MKQBAG]''X>ES&\0C]W_":)=+7:F9K;I6F;"-HU--[-WXM=[X1!C9JDDRM3?*
M16+HX+3>T@>(RPN2<$<:=KC3.HUXG"BF5L:K6AS+1II*B3ZJ'M%E!%W&2_?=
MR*[6 >A>.!>1)9[G!8+,"<A\AY _,@19$)#%6T&B^-FEF$J_%B<-@BP)R'*7
MD<P1Y#X!N;^;.T;LB7=SB6_K P+R@!?RW*VDT0_]C@AV!AG;_X[8#@FV0UZV
M1=>VTMV+\Z58Z)71<)HT07RJ*MN9H!'D>P+R/7, PUHY<:(-C+"6C3@UV\L\
MQA,G[S&5O<>\F,?6.7L+*O6OCG)*FH59+7]+YV1,,\&*>>>JM?0*;NRVA1!:
MAY-W2BDF979,)-(A'B2DZ3-/@'@J&'85@XHQ*<FDS)8YD=J)2]ET2GQ5TG?N
M,8<_#CO&I#23,GOF0M4*+@*=QDC>Q'HL?I\[M53.#3 IT:3,IED$6UVO;5,K
MYW\3G__IH" 4[V8*3M=A< =1IDF95=-3BO--GW7F(!L,1MDE9=;+16P$ X+O
M MPF&(L22\ILEBEDP^W$))8VIZ 9F'#$[/U5>X#"F)1:4F:WD (<%(P9Y9:,
MV2TT)J[&,DHS&;-F2%,/HTG.9)@U,S3UMY@A!ZK.*+EDS'(A53V,(267C%DN
M/SO0]\Z>:5\U=C!GI>22O85<<-I^=;PIL63,8GFJM<U*3-<2JIUM'#_#7]3!
MN&-,2C/9&\]B9BI(W0S#2/DFV^5,YD>!,2G?9#OU38E742C?Y#OUS3[&I'R3
M,_N&QCS F)1O<F;?T)B'&)-<.V,V#SW//L.8E'ER9O/0F'.,29DG9S8/70OA
MDBVG]),SZX>.YB>,2>DG9];/H&0[BR52?*3QK"&,25DH9[;0 /.D"U 6;9^B
M=*W8R'N,25DH9[8076/B_V9!6:A@MA"-B9U>4!8JV)_;$*M6PX<.E(4*9@O]
M>M6JWX,Q*0L5NUE<>Z2\P9CD,YQ=+JX-!YVR4+'3Q;7!H%,6*MYZ=6V8Y3$F
M9:&"V4*O8:(VC$E9J.">"[V"B6XKC$E9J.">"_TJFGO'D.AK_!R4LE#);*'_
M++"^.O4M*?^4S/XA5Q &J:BD_%,R^X?&Q$5'2?FG9/8/C8F+CI+R3\G^$D$%
M/:_B^SCPWSP-JHTF5W?UW5XV[I?4GS')MPAZ_XR>WK.I00Q&U6?0A8?V2C;5
MW(GXL7TV6)3QTLNN::;0=FZ^6-F_,Q.O\?3*T<=_ 5!+ P04    " "CB6Q/
M+9Y.-_D!  !Z(0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSQ=K-
M;MI %(;A6T&^@ SG9TA2A:RRR;;I#5@P8!2P+<]43>Z^#ILZ4N*O"_2Q 2'0
M.>_&CZPQ#S_3L2Z'KLW-H<^+M].QS>NJ*:7_$4+>-.E4YYNN3^WXS:X;3G49
M/P[[T->;UWJ?@BZ7JS!,9U2/#].9B^?MNAJ>MU(M?M7#/I5U%=Z.X4\WO.8F
MI9+#^4UNQ@7C3][[]#_KN]WNL$E/W>;W*;7EBXI_"ZKP=9#.!RD]R.:#C![D
M\T%.#XKS09$>M)H/6M&#;N>#;NE!=_-!=_2@^_F@>WJ0+(&,2WX2PIJOM0"N
MA>^U +"%+[8 LH5OM@"TA:^V +:%[[8 N(4OMP"ZA6^W +R%K[<"O96OMP*]
M]0KWVNAFFZ^W KV5K[<"O96OMP*]E:^W KV5K[<"O96OMP*]E:^W KV5K[<!
MO8VOMP&]C:^W ;WM"F<EZ+"$K[<!O8VOMP&]C:^W ;V-K[<!O8VOMP&]C:^W
M ;V-K[<#O9VOMP.]G:^W [V=K[<#O?T*9]WHL)NOMP.]G:^W [V=K[<#O9VO
MMP.]G:^W [V=KW<$>D>^WA'H'?EZ1Z!WY.L=@=Z1KW<$>L<K/*M$#ROY>L>)
MWKFIA[1]*<.AW>=+EWP:_FW-!.Y<WH_I\AGGJ=_NGRA=QBTIG%\O?HF?IWY$
MA$]_M7C\"U!+ P04    " "CB6Q/=[\36]8!   U(0  $P   %M#;VYT96YT
M7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.G'_(IXH]ZJB?Z!NAW8PM8V;4'\
M]W833#288(#DO6%LISOGW6B>*VY>/QR%T;IK39AF=8SNFK%0UM3ID%M')E5F
MUG<ZIE,_9TZ7"STG)B:3<U9:$\G$<>Q[9+<W]S33RS:.[KZN]ZVGF7:N;4H=
M&VO8RE2_FHXW#7-/[; FU(T+9VE!-GI8IRXA79MFJ1HRML>$WS?VY^F^IQ5Y
MWU3TKVAV-FM*JFRY[-(M>7">=!5JHMBU>:BUI^HE^L;,-WF?M8^/NDN-V;IE
M/Q;DI\L1/UK:'6"H''-R3-N"=HT:"E^?_*"!V]U06D]CYU/5QV;'XZ5(SZD:
M6+_PF(](_=:IJ-IK>&I]NA_VW?K%\'W7"_\N!C8<#GOKQ\LA0')(D!P*)$<!
MDN,<),<%2(Y+D!Q7(#GX!"4(BJ@<A52.8BI'096CJ,I16.4HKG(46#F*K )%
M5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625*+)*%%DEBJP2
M15:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D52BR%BBR%BBR
M%BBR%BBR%BBR%B>4=3CFG6[,7TG>K%ULY[/AWQ*WGU!+ 0(4 Q0    ( *.)
M;$\?(\\#P    !,"   +              "  0    !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( *.);$\GZ(<.@@   +$    0              "  >D   !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ HXEL3\PMGZ7N    *P(  !$
M             ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MHXEL3YE<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "CB6Q/D[$X$$8#   $$   &
M    @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MHXEL3][-LI;" P  B1$  !@              ( !<PP  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *.);$_B$A'!200   04   8
M          "  6L0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "CB6Q/NS?W&U(*  "<0@  &               @ 'J%   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ HXEL3Z;AO-IS!0  R1T
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M965T.2YX;6Q02P$"% ,4    " "CB6Q/*ROM9+@!  #2 P  &0
M    @ %[+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M *.);$_SX3+"M0$  -(#   9              "  6HP  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ HXEL3PZN%JJW 0  T@,  !D
M             ( !5C(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "CB6Q/YCU <K8!  #2 P  &0              @ %$-   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *.);$_)$49KM@$
M -(#   9              "  3$V  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ HXEL3RALLB2U 0  T@,  !D              ( !
M'C@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "CB6Q/
MLC[[@[,!  #2 P  &0              @ $*.@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( *.);$\;ZH1+M0$  -(#   9
M      "  ?0[  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ HXEL3YSWNMVV 0  T@,  !D              ( !X#T  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "CB6Q/LY,DBK$!  #2 P
M&0              @ '-/P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( *.);$\#S)A/3@(  #P(   9              "  ;5!  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ HXEL3[GMF?OH
M 0  9@4  !D              ( !.D0  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "CB6Q/P)I$_M4!  ";!   &0
M@ %91@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *.)
M;$]E^4* M@$  -(#   9              "  65(  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ HXEL3VJ?2K6V 0  T@,  !D
M         ( !4DH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "CB6Q/]1RV5,,!   W!   &0              @ $_3   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *.);$]S>,O@T0$  )P$
M   9              "  3E.  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ HXEL3ZTG W"V 0  T@,  !D              ( !05
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "CB6Q/\YWG
MP&P"  "^"   &0              @ $N4@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( *.);$^3K+]#+ ,  ,,-   9
M  "  =%4  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MHXEL3VG6-2Q% P  _ \  !D              ( !-%@  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "CB6Q/4Q9/B0<#  !9#   &0
M            @ &P6P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( *.);$^?82DQ# (  -T%   9              "  >Y>  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ HXEL3_[P-ZC& @
M(0L  !D              ( !,6$  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "CB6Q/^4C91%<"  "_!P  &0              @ $N
M9   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *.);$]&
M=X@("@(  /8%   9              "  ;QF  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ HXEL3_XU+?Z; @  /@H  !D
M     ( !_6@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *.);$])4:P1?@(   X*   9              "
M 3-W  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ HXEL
M3R#P1T&2 P  QA$  !D              ( !Z'D  'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "CB6Q/G%!>9)L"  #Q"@  &0
M        @ &Q?0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( *.);$^.37UL6 (  *0'   9              "  8.   !X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ HXEL3\GK00*\!   "1@
M !D              ( !$H,  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "CB6Q/R/LG0[0"   ""P  &0              @ $%B
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( *.);$]HX\4Y
M20,  )<.   9              "  ?"*  !X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ HXEL3W:D8895 P  !0X  !D
M ( !<(X  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "C
MB6Q/1UOGN*H"  "H"@  &0              @ '\D0  >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *.);$]<#"\DD0(  '\)   9
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M970U-"YX;6Q02P$"% ,4    " "CB6Q/=P=3!+(!  #7 P  &0
M    @ ';I   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M *.);$_^P[6L8&@  )JN 0 4              "  <2F  !X;"]S:&%R9613
M=')I;F=S+GAM;%!+ 0(4 Q0    ( *.);$]BG#,P20(  (8+   -
M      "  58/ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ HXEL3Y; >!Z8
M!   ]B0   \              ( !RA$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *.);$\MGDXW^0$  'HA   :              "  8\6 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *.);$]WOQ-;U@$
M #4A   3              "  < 8 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !  $  <A$  ,<: 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6793356880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Changes and Error Corrections (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Correction of Immaterial Misstatements</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The revision to the Company's previously reported balance sheet are identified in the table below:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:55.894737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.304094%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As of December&#160;31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable convertible preferred stock warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">36,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">35,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">153,741&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">152,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">113,143&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">111,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">A revised rollforward of the Company's warrant liabilities is as follows:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:52.239766%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.473684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.473684%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Previously<br/>Reported</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">As<br/>Revised</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">896&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of warrants to purchase shares of Series&#160;F redeemable convertible preferred stock in connection with 2017 Term Loan (Note&#160;4)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of financial instruments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December&#160;31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March&#160;31, 2019 (unaudited) (as revised)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,177)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">1,503&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6788723696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Term Loan are as follows (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:81.333333%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.935673%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7pt;font-weight:700;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2019 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">6,125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">14,937&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">11,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">33,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Less:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(484)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,876)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">25,677&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
